

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 August 2001 (30.08.2001)

PCT

(10) International Publication Number
WO 01/62928 A2

(51) International Patent Classification⁷: C12N 15/12,
15/54, C07K 14/47, 14/81, C12N 9/12, C07K 16/18,
16/40, C12Q 1/68, G01N 33/53, 33/68, A61K 38/17, 48/00

(21) International Application Number: PCT/US01/06151

(22) International Filing Date: 26 February 2001 (26.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/184,951 25 February 2000 (25.02.2000) US
60/185,548 28 February 2000 (28.02.2000) US
60/185,967 1 March 2000 (01.03.2000) US
60/197,723 18 April 2000 (18.04.2000) US
60/199,957 27 April 2000 (27.04.2000) US
09/789,390 23 February 2001 (23.02.2001) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US 60/184,951 (CIP)
Filed on 25 February 2000 (25.02.2000)
US 60/185,548 (CIP)
Filed on 28 February 2000 (28.02.2000)
US 60/185,967 (CIP)
Filed on 1 March 2000 (01.03.2000)
US 60/197,723 (CIP)
Filed on 18 April 2000 (18.04.2000)
US 60/199,957 (CIP)
Filed on 27 April 2000 (27.04.2000)
US 09/789,390 (CIP)
Filed on 23 February 2001 (23.02.2001)

(71) Applicant (for all designated States except US): CURA-
GEN CORPORATION [US/US]; 555 Long Wharf Drive,
11th Floor, New Haven, CT 06511 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): VERNET, Corine,
A., M. [FR/US]; 4830 NW 43rd Street P#253, Gainesville,
FL 32060 (US). FERNANDES, Elma [IN/US]; 77 Flo-
rence Road, #2, Branford, CT 06405 (US). SHIMKETS,
Richard, A. [US/US]; 191 Leete Street, West Haven, CT
06516 (US). MACDOUGALL, John [US/US]; 117 Russell
Street, Hamden, CT 06517 (US). SPADERNA, Steven, K.
[US/US]; 261 Deerfield Drive, Berlin, CT 06037 (US).

(74) Agent: ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris,
Glovsky, and Popeo, P.C., One Financial Center, Boston,
MA 02111 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: NOVEL POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME

(57) Abstract: The present invention provides novel isolated NOVX polynucleotides and polypeptides encoded by the NOVX polynucleotides. Also provided are the antibodies that immunospecifically bind to a NOVX polypeptide or any derivative, variant, mutant or fragment of the NOVX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the NOVX polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.

WO 01/62928 A2

NOVEL POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME

BACKGROUND OF THE INVENTION

The invention relates generally to nucleic acids and polypeptides.

5

SUMMARY OF THE INVENTION

The present invention is based, in part, upon the discovery of novel human nucleic acid sequences encoding polypeptides. The NOV-X nucleic acids, polynucleotides, proteins, and polypeptides or fragments thereof described herein collectively include NOV-1, NOV-2a, and NOV-2b, which are novel KIAA1233-like polypeptides; NOV-3a, NOV-3b, NOV-3c, and NOV-3d, which are novel STE20-like polypeptides; NOV-4a, NOV-4b, NOV-4c, NOV-4d, and NOV-4e, which are novel trypsin inhibitor-like polypeptides.

In one aspect, the invention includes an isolated NOV-X nucleic acid molecule which includes a nucleotide sequence encoding a polypeptide that includes the amino acid sequence of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23. For example, in various embodiments, the nucleic acid can include a nucleotide sequence that includes SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57. Alternatively, the encoded NOV-X polypeptide may have a variant amino acid sequence, *e.g.*, have an identity or similarity less than 100% to the disclosed amino acid sequences, as described herein.

The invention also includes an isolated polypeptide that includes the amino acid sequence of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23, or a fragment having at least 6 amino acids of these amino acid sequences. Also included is a naturally occurring polypeptide variant of a NOV-X polypeptide, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule consisting of a NOV-X nucleic acid molecule.

Also included in the invention is an antibody that selectively binds to a NOV-X polypeptide. The antibody is preferably a monoclonal antibody, and most preferably is a human antibody. Such antibodies are useful, for example, in the treatment of a pathological state in a subject wherein the treatment includes administering the antibody to the subject.

The invention further includes a method for producing a NOV-X polypeptide by culturing a host cell expressing one of the herein described NOV-X nucleic acids under conditions in which the nucleic acid molecule is expressed.

The invention also includes methods for detecting the presence of a NOV-X polypeptide or nucleic acid in a sample from a mammal, *e.g.*, a human, by contacting a sample from the mammal with an antibody which selectively binds to one of the herein described polypeptides, and detecting the formation of reaction complexes including the antibody and the polypeptide in the sample. Detecting the formation of complexes in the sample indicates the presence of the polypeptide in the sample.

The invention further includes a method for detecting or diagnosing the presence of a disease, *e.g.*, a pathological condition, associated with altered levels of a polypeptide having an amino acid sequence at least 80% identical to a NOV-X polypeptide in a sample. The method includes measuring the level of the polypeptide in a biological sample from the mammalian subject, *e.g.*, a human, and comparing the level detected to a level of the polypeptide present in normal subjects, or in the same subject at a different time, *e.g.*, prior to onset of a condition. An increase or decrease in the level of the polypeptide as compared to normal levels indicates a disease condition.

Also included in the invention is a method of detecting the presence of a NOV-X nucleic acid molecule in a sample from a mammal, *e.g.*, a human. The method includes contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule and determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample. Binding of the nucleic acid probe or primer indicates the nucleic acid molecule is present in the sample.

The invention further includes a method for detecting or diagnosing the presence of a disease associated with altered levels of a NOV-X nucleic acid in a sample from a mammal, *e.g.*, a human. The method includes measuring the level of the nucleic acid in a biological sample from the mammalian subject and comparing the level detected to a level of the nucleic acid present in normal subjects, or in the same subject at a different time. An increase or decrease in the level of the nucleic acid as compared to normal levels indicates a disease condition.

The invention also includes a method of treating a pathological state in a mammal, *e.g.*, a human, by administering to the subject a NOV-X polypeptide to the subject in an amount sufficient to alleviate the pathological condition. The polypeptide has an amino acid sequence at least 80% identical to a NOV-X polypeptide.

5 Alternatively, the mammal may be treated by administering an antibody as herein described in an amount sufficient to alleviate the pathological condition.

Pathological states for which the methods of treatment of the invention are envisioned include hematopoietic, immunological, tumor, cancer, neurodegenerative (*e.g.* Alzheimer's and Parkinson's disease) and fertility disorders.

10 Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references
15 mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

20

DETAILED DESCRIPTION OF THE INVENTION

The present invention is based, in part, upon the discovery of novel human nucleic acid sequences and of polypeptides encoded by these nucleic acids. The nucleic acids have been named "NOV 1-4", or collectively, "NOV-X". Representative NOV-X sequences, and
25 representative examples of uses of these sequences, are briefly discussed below.

Table 1 provides a summary of the NOV-X nucleic acids, their encoded polypeptides and homology.

TABLE 1. Sequences and Corresponding SEQ ID Numbers

NOVX Assignment	Internal Identification	SEQ ID NO (nucleic acid)	SEQ ID NO (polypeptide)	Homology
1	10132038.0.67	1	2	KIAA1233 protein
2a	10132038.0.139	3	4	KIAA1233 protein
2b	10132038.0.136	57	5	KIAA1233 protein

3a	18552586_EXT1	6	7	STE20 protein kinase
3b	18552586_EXT2	8	9	STE20 protein kinase
3c	18552586_EXT3	10	11	STE20 protein kinase
3d	18552586_EXT4	12	13	STE20 protein kinase
4a	10093872.0.107	14	15	Trypsin inhibitor
4b	10093872.1	16	17	Trypsin inhibitor
4c	10093872.0.38	18	19	Trypsin inhibitor
4d	10093872.2	20	21	Trypsin inhibitor
4e	10093872.3	22	23	Trypsin inhibitor

NOV-1: A Novel KIAA1233-like Polypeptide

A NOV-1 sequence according to the invention is a nucleotide sequence encoding a polypeptide related to KIAA1233 proteins, which bear sequence similarity to lacunin, thrombospondins, proteinases, semaphorins, ADAM-TS, and properdin family members. This invention maps to Unigene cluster Hs.18705. This cluster has been mapped to Chromosome 15 Marker stSG35204, Interval D15S115-D15S152. By integrating information from the Online Mendelian Inheritance in Man (OMIM), this region is identified as 15q22-qter. Therefore, the chromosomal location of the invention is Chromosome 15 Marker stSG35204, Interval D15S115-D15S152, which corresponds to 15q22-qter.

The nucleic acid of the invention, NOV-1, encoding a KIAA1233-like protein originating from chromosome 15, is shown in TABLE 2. The disclosed nucleic acid (SEQ ID NO: 1) is a full-length clone of 1281 nucleotides and contains an open reading frame (ORF) that begins with an ATG initiation codon at nucleotide 416 and ends with a TAA stop codon at nucleotides 4259. A representative ORF encodes a 1281 amino acid polypeptide (SEQ ID NO: 2). The initiation and stop codons of SEQ ID NO: 1 are shown in bold font. Putative untranslated regions are upstream of the initiation codon and downstream of the stop codon in SEQ ID NO: 1.

TABLE 2

TAATAGAGACCTTTCAAAGGACAAATTCTGTGAAATAAAGTGGTTTTCTGAAGAGCCTAC
 TAATAGGACAGTGTGTTAATATCACTAATAAGAGAGTAATGATTATAAAAAGGAATAAAT
 TTATTGAAATTGCAAGATACTTTTCTCCTTTGATTAATATACTGCTAGTTTAGTTTTCTA
 CATTTTCAAATAGAACTGGGGAATTTGTGTCGTAGATATTCTTGACAACATAAAGAGATGG
 TGGCTGAATTTTTGGGAATGGTTGATAACACTTGATATTTTAGTTTCCAATTTGGAAGA
 GCTCTGTCTCTTGGGATGTCAAATATTATATTCGTCAATTAATGAATGTGTTAATTTATT
 ATAGAAATGATATTCACAAATGATTTGATTTGTAGTGATGGATTTAAAGAGATAATGCC
 CTATGACCACTTCCAACCTCTTCCTCGCTGGGAACATAATCCTTGGACTGCATGTTCCGT
 GTCCTGTGGAGGAGGATTGAGAGACGAGCTTTGTGTGTGTAGAGGAATCCATGCATGG
 AGAGATATTGCAGGTGGAAGAATGGAAGTGCATGTACGCACCCAAACCAAGGTTATGCA

AACTTGTAACTCTGTTTGATTGCCCCAAGTGGATTGCCATGGAGTGGTCTCAGTGCACAGT
GACTTGTGGCCGAGGGTTACGGTACCGGGTTGTTCTGTGTATTAAACCACCGGAGAGCA
TGTGGGGGCTGCAATCCACAAGTGAAGTTACACATCAAAGAAGAATGTGTCATTCCCAT
CCCGTGTATAAACCAAAAGAAAAAGTCCAGTGAAGCAAAATTGCCTTGGCTGAAACA
5 AGCACAAGAAGTCTAGAGAGACCAGAATAGCAACAGAAGAACCAACGTTTATTCCAGAACC
CTGGTCAGCCTGCAGTACCACGTGTGGCCGGGTGTGCAGGTCCGTGAGGTGAAGTCCCG
TGTGCTCCTCACATTCACGCAGACTGAGACTGAGCTGCCCCGAGGAAGAGTGTGAAGGCCC
CAAGCTGCCCCACCGAACGGCCCTGCCTCCTGGAAGCATGTGATGAGAGCCCCGGCCTCCCG
AGAGCTAGACATCCCTCTCCCTGAGGACAGTGAAGACGACTTACGACTGGGAGTACGCTGG
10 GTTACCCCCCTTGACAGCAACATGCGTGGGAGGCCATCAAGAAGCCATAGCAGTGTGCTT
ACATATCCAGACCCAGCAGACAGTCAATGACAGCTTGTGTGATATGGTCCACCGTCCCTCC
AGCCATGAGCCAGGCCGTGAACACAGAGCCCTGTCCCCCAGGTGGCATGTGGGCTCTTG
GGGGCCCTGCTCAGCTACCTGTGGAGTTGGAATTCAGACCCGAGATGTGTACTGCCTGCA
CCCAGGGGAGACCCCTGCCCTCCTGAGGAGTGCCGAGATGAAAAGCCCCATGCTTTACA
15 AGCATGCAATCAGTTTGACTGCCCTCCTGGCTGGCACATTGAAGAATGGCAGCAGTGTTC
CAGGACTTGTGGCGGGGAACTCAGAACAGAAGAGTCACCTGTCCGCAGCTGCTAACGGA
TGGCAGCTTTTTGAATCTCTCAGATGAATTGTGCCAAGGACCCAAGGCATCGTCTCACAA
GTCTGTGCCAGGACAGACTGTCTCCACATTTAGCTGTGGGAGACTGGTCAAGTGTTC
TGTCAGTTGTGGTGTGGAATCCAGAGAAGAAAGCAGGTGTGTCAAAGGCTGGCAGCCAA
20 AGGTCCGGCGCATCCCCCTCAGTGAGATGATGTGCAGGGATCTACCAGGGCTCCCTCTTGT
AAGATCTTGCCAGATGCCTGAGTGCAGTAAATCAAATCAGAGATGAAGACAAAACCTTGG
TGAGCAGGGTCCGCAGATCCTCAGTGTCCAGAGAGTCTACATTCAGACAAGGGAAGAGAA
GCGTATTAACCTGACCATTTGGTAGCAGAGCCTATTTGCTGCCCAACACATCCGTGATTAT
TAAGTGCCAGTGGCAGATTCCAGAAATCTCTGATCCAGTGGGAGAAGGATGGCCGTTG
25 CCTGCAGAACTCCAAACGGCTTGGCATCACCAAGTCAGGCTCACTAAAAATCCACGGTCT
TGCTGCCCCGACATCGGCGTGTACCGGTGCATTGCAGGCTCTGCACAGGAAACAGTTGT
GCTCAAGCTCATTGGTACTGACAACCGGCTCATCGCACGCCAGCCCTCAGGGAGCCTAT
GAGGGAATATCCTGGGATGGACCACAGCGAAGCCAATAGTTTGGGAGTCACATGGCACAA
AATGAGGCAAATGTGGAATAACAAAAATGACCTTTATCTGGATGATGACCACATTAGTAA
30 CCAGCCTTTCTTGAGAGCTCTGTTAGGCCACTGCAGCAATTCTGCAGGAAGCACCAACTC
CTGGGAGTTGAAGAATAAGCAGTTTGAAGCAGCAGTTAAACAAGGAGCATATAGCATGGA
TACAGCCCAGTTTGATGAGCTGATAAGAAACATGAGTCAGCTCATGGAACCCGAGAGGT
CAGCGATGATCTTGCGTCCCAGCTGATATATCAGCTGGTGGCCGAATTAGCCAAGGCACA
GCCAACACACATGCAGTGGCGGGGCATCCAGGAAGAGACACCTCCTGCTGCTCAGCTCAG
35 AGGGGAAACAGGGAGTGTGTCCCAAAGCTCGCATGCAAAAACTCAGGCAAGCTGACATT
CAAGCCGAAAGGACCTGTTCTCATGAGGCAAAGCCAACCTCCCTCAATTTTCAATTAATAA
AACAATAAATCCAGGATTGGAATACAGTATACATTACAAAAAGGACAGAGGTATCAA
TATACTGTGTGACCTTATTACCCCCAGTGAGGCCACATATACATGGACCAAGGATGGAAC
CTTGTTACAGCCCTCAGTAAAAATAATTTTGGATGGAACGGGAAGATACAGATACAGAA
40 TCCTACAAGGAAGAACAAGGCATATATGAATGTTCTGTAGCTAATCATCTTGGTTCAGA
TGTGGAAGTTCTTCTGTGCTGTATGCAGAGGCACCTGTCATCTTGTCTGTTGAAAGAAA
TATCACCAACCAGAGCACAAACATCTGTCTGTTGTGGTGGAGGCATCGTGGAGGCAGC

CCTTGGAGCAAACGTGACAATCCGATGTCTGTAAAAGGTGTCCCTCAGCCTAATATAAC
TTGGTTGAAGAGAGGAGGATCTCTGAGTGGCAATGTTTCCTTGCTTTTCAATGGATCCCT
GTTGTTGCAGAATGTTTCCCTTGAAAATGAAGGAACCTACGTCTGCATAGCCACCAATGC
TCTTGGAAAGGCAGTGGCAACATCTGTACTCCACTTGCTGGAACGAAGATGGCCAGAGAG
5 TAGAATCGTATTTCTGCAAGGACATAAAAAGTACATTCTCCAGGCAACCAACACTAGAAC
CAACAGCAATGACCCAACAGGAGAACCCCGCCTCAAGAGCCTTTTGGGAGCCTGGTAA
CTGGTCACATTGTTCTGCCACCTGTGGTCATTGGGAGCCCGCATTGAGAGACCCAGTG
TGTGATGGCCAATGGGCAGGAAGTGAGTGAGGCCCTGTGTGATCACCTCCAGAAGCCACT
GGCTGGGTTTGAGCCCTGTAACATCCGGGACTGCCAGCGAGGTGGTTCACAAGTGTGTG
10 GTCACAGTGTCTGTGTCTTGCGGTGAAGGATACCACAGTCGGCAGGTGACGTGCAAGCG
GACAAAAGCCAATGGAAGTGTGCAGGTGGTGTCTCCAAGAGCATGTGCCCTAAAGACCG
GCCTCTGGGAAGAAAACCATGTTTGGTTCATCCATGTGTTGAGTGGGAACCAGGGAACCG
GTGTCTGGACGTTGCATGGGCCGTGCTGTGAGGATGCAGCAGCGTCACACAGCTTGTC
ACACAACAGCTCTGACTCCAACCTGTGATGACAGAAAGAGACCCACCTTAAGAAGGAACTG
15 CACATCAGGGGCTGTGATGTGTGTTGGCACACAGGCCCTTGAAGCCCTGTACAGCAGC
CTGTGGCAGGGGTTTCCAGTCTCGGAAAGTCGACTGTATCCACACAAGGAGTTGCAAACC
TGTGGCCAAGAGACACTGTGTACAGAAAAAGAAACCAATTTCTGGCGGCACGTGCTTGG
GCCCTCTGTGATAGAGACTGCACAGACACAACCTCACTACTGTATGTTTGTAAACATCT
TAATTTGTGTTCTCTAGACCGCTACAAACAAAGGTGCTGCCAGTCATGTCAAGAGGGATA
20 AACCTTTGGAGGGGTGATGATGCTGCTGTGAAGATAAAAGTAGAATATAAAGCTCTTTT
CCCCATGTCGCTGATTCAAAAACATGTATTTCTTAAAGACTAGATTCTATGGATCAAAC
AGAGGTTGATGCAAAAACACCACTGTTAAGGTGTAAAGTGAAATTTTCCAATGGTAGTTT
TATATTCCAATTTTTTAAATGATGTATTCAAGGATGAACAAAATACTATAGCATGCATG
CCACTGCACCTTGGGACCTCATCATGTGAGTGAATCGAGAAATCACCAAGATTATGAGTG
25 CATCCTCACGTGCTGCCCTTTTCTGTGATATGTAGACTAGCACAGAGTGGTACATCCTA
AAAACCTTGGGAACACAGCAACCCATGACTTCCTCTTCTCTCAAGTTGCAGGTTTTCAAC
AGTTTTATAAGGTATTTGCATTTTAGAAGCTCTGGCCAGTAGTTGTTAAGATGTTGGCAT
TAATGGCATTTTCATAGATCCTTGGTTAGTCTGTGAAAAAGAAACCATCTCTCTGGATA
GGCTGTCACACTGACTGACCTAAGGGTTCATGGAAGCATGGCATCTTGTCCTTGCTTTTA
30 GAACACCCATGGAAGAAAACACAGAGTAGATATTGCTGTCATTTATACAACTACAGAAAT
TTATCTATGACCTAATGAGGCATCTCGGAAGTCAAAGAAGAGGGAAAGTTAACCTTTTCT
ACTGATTTCTAGTATATTGAGAGCTTCTTTTAAGAGCTGTGAATGAACTTTTTCTAA
GCACTATTCTATTGCACACAAACAGAAAACCAAGCCTTATTAGACCTAATTTATGCATA
AAGTAGTATTCCTGAGAACTTTATTTTGGAAAATTTATAAGAAAGTAATCCAAATAAGAA
35 ACACGATAGTTGAAAATAATTTTTATAGTAAATAATTGTTTTGGGCTGATTTTCAGTAA
ATCCAAAGTGACTTAGGTTAGAAGTTACACTAAGGACCAGGGGTGGAATCAGAATTTAG
TTTAAGATTGAGGAAAAGGTAAGGGTTAGTTTCAGTTTATAGATTAGAGCTAGAATTG
GGTTAGGTGAGAAAGAAAGTTAAGGTTAAGGCTAGAGTTGTCTTTAAGGGTTAGGGTTAG
GACCAGGTTAGGTCAGGGTTGGATTGGGTTTAGATTGGGGCCAGTGCTGGTGTAGTGAT
40 AGTGTGAGGATGGAGGTTAGGTTTGGAGTAAGCGTTGTGCTGAAGTGAGTTCAGGCTAG
CATTAAATTGTAAGTTCTGAAGCTGATTGGTTATGGGGTCTTTCCCTGTATACTACCA
GTTGTGTCTTTAGATGGCACACAAGTCCAAATAAGTGGTCATACTTCTTTATTGAGGTC

TCAGCTGCCTGTACACCTGCTGCCTACATCTTCTTGGCAACAAAGTTACCTGCCACAGGC
 TCTGCTGAGCCTAGTTCCCTGGTCAGTAATAACTGAACAGTGCATTTTGGCTTTGGATGTG
 TCTGTGGACAAGCTTGCTGAGTTTCTCTACCATATTCTGAGCACACGGTCTCTTTTGTTC
 TAATTTAGCTTCACTGACACTGGGTTGAGCACTACTGTATGTGGAGGGTTTGGTGATTG
 5 GGAATGGATGGGGGACAGTGAGGAGGACACACCAGCCCATTAGTTGTTAATCATCAATCA
 CATCTGATTGTTGAAGGTTATTAAATTAAGAAAGATCATTTGTAACATACTCTTTGTA
 TATATTTATTATATGAAAGGTGCAATATTTTATTTTGTACAGTATGTAATAAGACATGG
 GACATATATTTTTCTTATTAACAAAATTTTATTTTGTACAGTATGTAATAAGACATGG
 TAAAAGTTACTATTTTCTTATTTGCTATTGTACTTTTATTGTTGTCATTCAATTGACATT
 10 CCTGTGTACTGTATTTTACTACTGTTTTTATAACATGAGAGTTAATGTTTCTGTTTCATG
 ATCCTTATGTAATTCAGAAATAAATTTACTTTGATTATTTCAGTGGCATCCTTAT (SEQ ID NO: 1)

MPYDHFQPLPRWEHNPWTACSVSCGGGIQRRSFVCVEESMHGEILQVEEWKCMYAPKPKVMQTCNLFDCPKWIAME
 WSQCTVTTCGRGLRYRVVLCINHRGEHVGGCNPQLKHLHIKEECVIRIPCYKPKEKSPVEAKLPWLKQAQEELEETRIA
 15 TEEPTFIPEPWSACSTTCGPGVQVREVKCRVLLTFTQTETELPEEECEGPKLPPTERPCLEACDESPASRELDIPL
 PEDSETTYDWEYAGFTPCATATCVGGHQAIAVCLHIQTQQTVDNSLCDMVHRPPAMSQACNTEPCPPRWHVGSWGP
 CSATCGVGIQTRDVYCLHPGETPAPPEECRDEKPHALQACNQFDCPPGWHIEEWQCSRTC GGGTQNRRTVTCRQLL
 TDGSFLNLSDELCOGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQRRKQVCQRLAAKGRIPLSEMMCRDL
 PGLPLVRSCOMPECSKIKSEMKTCLGEQGPQILSVQRVYIQTREEKRINLTIGSRAYLLPNTSVIICKPVRRFQKS
 20 LIQWEKDGRCLQNSKRLGITKSGSLKIHGLAAPDIGVYRCIAGSAQETVVVLKLGTDNRILIARPALREPMREYPM
 DHSEANSLGVTWHKMRQMWNNKNDLYLDDDHISNQPFRLALLGHCSNSAGSTNSWELKNKQFEAAVKQAGYSMDTA
 QFDELIRNMSQLMETGEVSDDLASQLIYQLVAELAKAQPTHMQRGIEETPPAAQLRGETGSVSQSSHAKNSGKL
 TFKPKGPVLMRQSOPPSISFNKTINSRIGNTVYITKRTEVINILCDLITPSEATYTWTKDGTLLQPSVKIILDGTG
 KIQIQNPTRKEQGIYECSVANHLGSDVESSSVLYAEAPVILSVERNITKPEHNHLSVVVGIVEAALGANVTIRCP
 25 VKGVPQPNITWLKRGGSLSGNVSLLFNGSLLLQNVSLLENEGTYVCIATNALGKAVATSVLHLLERRWPESRIVFLQ
 GHKKYILQATNTRTNSNDPTGEPFPQEPFWEFGNWSHCSATCGHLGARIQRPQCMANGQEVSEALCDHLQKPLAG
 FEPCNIRDCPARWFTSVWSQCSVSCGEGYHSRQVTCRRTKANGTVQVVS PRACAPKDRPLGRKPCFGHPCVQWEPG
 NRCPPGRCMGRAVRMQQRHTACQHNSSDSNCDRKRPTLRNCTSGACDVCWHTGPWKPCACGRGFQSRKVDCHI
 TRSCKPVAKRHCVCQKKKPISWRHCLGPSCDRDCTDTTHYCMFVKHLNLCSLDRYKQRCQSCQEG (SEQ ID
 30 NO: 2)

In a search of sequence databases, it was found, for example, that the disclosed NOV-1
 nucleotide sequence has 5106 of 5107 bases (99%) identical to a human mRNA for a
 KIAA1233 protein (SECR) (GenBank Accession No: ABO33059), as shown in Table 3. In all
 35 sequence alignments, identical residues are depicted as “|”. As indicated by the “Expect”
 value, the probability of this alignment occurring by chance alone is 0.0, the lowest
 probability.

Furthermore, the encoded amino acid sequence has 1023 of 1023 amino acid residues
 (100%) identical to, and 1023 of 1023 residues (100 %) positive with, a 1023 amino acid

residue human KIAA1233 protein (GenBank Accession No: BAA86547), as shown in Table 4. As indicated by the "Expect" value, the probability of this alignment occurring by chance alone is 0, the lowest probability.

5 TABLE 3

Score = 1.012e+04 bits (5103), Expect = 0.0

Identities = 5106/5107 (99%)

Strand = Plus / Plus

10	NOV1: 1188 tagcagtgtgcttacatatccagacccagcagacagtcaatgacagcttgtgtgatatgg 1247		
15	SECR : 1 tagcagtgtgcttacatatccagacccagcagacagtcaatgacagcttgtgtgatatgg 60		
20	NOV1: 1248 tccaccgtcctccagccatgagccaggcctgtaacacagagccctgtccccccaggtggc 1307		
25	SECR : 61 tccaccgtcctccagccatgagccaggcctgtaacacagagccctgtccccccaggtggc 120		
30	NOV1: 1308 atgtgggctcttggggccctgtcagctacctgtggagttggaattcagacccgagatg 1367		
35	SECR : 121 atgtgggctcttggggccctgtcagctacctgtggagttggaattcagacccgagatg 180		
40	NOV1: 1368 tgtactgcctgcacccaggggagacccctgccctcctgaggagtgccgagatgaaaagc 1427		
45	SECR : 181 tgtactgcctgcacccaggggagacccctgccctcctgaggagtgccgagatgaaaagc 240		
50	NOV1: 1428 cccatgctttacaagcatgcaatcagtttgactgccctcctggctggcacattgaagaat 1487		
55	SECR : 241 cccatgctttacaagcatgcaatcagtttgactgccctcctggctggcacattgaagaat 300		
60	NOV1: 1488 ggcagcagtgttccaggacttgtggcgggggaactcagaacagaagagtacactgtcggc 1547		
65	SECR : 301 ggcagcagtgttccaggacttgtggcgggggaactcagaacagaagagtacactgtcggc 360		
70	NOV1: 1548 agctgctaacggatggcagctttttgaatctctcagatgaattgtgccaaggacccaagg 1607		
75	SECR : 361 agctgctaacggatggcagctttttgaatctctcagatgaattgtgccaaggacccaagg 420		
80	NOV1: 1608 catcgtctcacaagtcctgtgccaggacagactgtcctccacatttagctgtgggagact 1667		
85	SECR : 421 catcgtctcacaagtcctgtgccaggacagactgtcctccacatttagctgtgggagact 480		

NOV1: 1668 ggtcgaagtgttctgtcagttgtggtgttgaatccagagaagaaagcaggtgtgtcaaa
1727
5 SECR : 481 ggtcgaagtgttctgtcagttgtggtgttgaatccagagaagaaagcaggtgtgtcaaa 540
|||

NOV1: 1728 ggctggcagccaaaggtcggcgcatccccctcagtgagatgatgtgcagggatctaccag
1787
10 SECR : 541 ggctggcagccaaaggtcggcgcatccccctcagtgagatgatgtgcagggatctaccag 600
|||

NOV1: 1788 ggctccctcttgtaagatcttgccagatgcctgagtgagtaaaatcaaatacagagatga
1847
15 SECR : 601 ggctccctcttgtaagatcttgccagatgcctgagtgagtaaaatcaaatacagagatga 660
|||

NOV1: 1848 agacaaaacttggtgagcaggggtccgcagatcctcagtggtccagagagtctacattcaga
1907
20 SECR : 661 agacaaaacttggtgagcaggggtccgcagatcctcagtggtccagagagtctacattcaga 720
|||

NOV1: 1908 caaggggaagagaagcgtattaacctgaccattggtagcagagcctatttgctgccaaca
1967
25 SECR : 721 caaggggaagagaagcgtattaacctgaccattggtagcagagcctatttgctgccaaca 780
|||

NOV1: 1968 catccgtgattattaagtgccagtgcgacgattccagaaatctctgatccagtgggaga
2027
30 SECR : 781 catccgtgattattaagtgcccggtgacgattccagaaatctctgatccagtgggaga 840
|||

NOV1: 2028 aggatggccgttgctgcagaactccaaacggcttggcatcaccaagtccaggtcactaa
2087
35 SECR : 841 aggatggccgttgctgcagaactccaaacggcttggcatcaccaagtccaggtcactaa 900
|||

NOV1: 2088 aaatccacggtcttgctgcccccgacatcggcggtgtaccggtgcattgcaggtctgcac
2147
40 SECR : 901 aaatccacggtcttgctgcccccgacatcggcggtgtaccggtgcattgcaggtctgcac 960
|||

NOV1: 2148 aggaacagttgtgctcaagctcattggtactgacaaccggctcatcgacgccagccc
2207
45 SECR : 961 aggaacagttgtgctcaagctcattggtactgacaaccggctcatcgacgccagccc
1020
|||

NOV1: 2208 tcaggagcctatgagggaaatatcctgggatggaccacagcgaagccaatagtttgggag
2267
50 SECR : 1021 tcaggagcctatgagggaaatatcctgggatggaccacagcgaagccaatagtttgggag
1080
55
60

NOV1: 2268 tcacatggcacaaaatgaggcaaagtgtgaataacaaaaatgacctttatctggatgatg
2327
|||||
5 SECR : 1081 tcacatggcacaaaatgaggcaaagtgtgaataacaaaaatgacctttatctggatgatg
1140
NOV1: 2328 accacattagtaaccagcctttcttgagagctctgttaggccactgcagcaattctgcag
2387
10 SECR : 1141 accacattagtaaccagcctttcttgagagctctgttaggccactgcagcaattctgcag
1200
NOV1: 2388 gaagcaccaactcctgggagttgaagaataagcagtttgaagcagcagttaaacaaggag
2447
|||||
20 SECR : 1201 gaagcaccaactcctgggagttgaagaataagcagtttgaagcagcagttaaacaaggag
1260
NOV1: 2448 catatagcatggatacagcccagtttgatgagctgataaagaacatgagtcagctcatgg
2507
|||||
25 SECR : 1261 catatagcatggatacagcccagtttgatgagctgataaagaacatgagtcagctcatgg
1320
NOV1: 2508 aaaccggagaggtcagcgatgatcttgcgctccagctgatatatcagctggtggccgaat
30 2567
|||||
SECR : 1321 aaaccggagaggtcagcgatgatcttgcgctccagctgatatatcagctggtggccgaat
1380
35
NOV1: 2568 tagccaaggcacagccaacacacatgcagtgggcgggcatccaggaagagacacctcctg
2627
|||||
40 SECR : 1381 tagccaaggcacagccaacacacatgcagtgggcgggcatccaggaagagacacctcctg
1440
NOV1: 2628 ctgctcagctcagaggggaaacaggagtggtgtcccaaagctcgcatgcaaaaaactcag
2687
45 SECR : 1441 ctgctcagctcagaggggaaacaggagtggtgtcccaaagctcgcatgcaaaaaactcag
1500
NOV1: 2688 gcaagctgacattcaagccgaaaggacctgttctcatgaggcaaagccaacctccctcaa
2747
|||||
50 SECR : 1501 gcaagctgacattcaagccgaaaggacctgttctcatgaggcaaagccaacctccctcaa
1560
55
NOV1: 2748 ttctatttaataaaaacaataaattccaggattggaaatacagtatacattacaaaaagga
2807
|||||
60 SECR : 1561 ttctatttaataaaaacaataaattccaggattggaaatacagtatacattacaaaaagga
1620

NOV1: 2808 cagaggtcatcaatatactgtgtgaccttattacccccagtgaggccacatatacatgga
2867
|||||
5 SECR : 1621 cagaggtcatcaatatactgtgtgaccttattacccccagtgaggccacatatacatgga
1680

NOV1: 2868 ccaaggatggaaccttgttacagccctcagtaaaaaataattttggatggaactgggaaga
2927
|||||
10 SECR : 1681 ccaaggatggaaccttgttacagccctcagtaaaaaataattttggatggaactgggaaga
1740
1740

NOV1: 2928 tacagatacagaatcctacaaggaaagaacaaggcatatatgaatgttctgtagctaate
2987
|||||
15 SECR : 1741 tacagatacagaatcctacaaggaaagaacaaggcatatatgaatgttctgtagctaate
1800
1800

NOV1: 2988 atcttggttcagatgtggaaagtcttctgtgctgtatgcagaggcacctgtcatcttgt
3047
|||||
25 SECR : 1801 atcttggttcagatgtggaaagtcttctgtgctgtatgcagaggcacctgtcatcttgt
1860
1860

NOV1: 3048 ctggttgaaagaaatatcaccaaaccagagcacaaccatctgtctgttggttgaggga
3107
|||||
30 SECR : 1861 ctggttgaaagaaatatcaccaaaccagagcacaaccatctgtctgttggttgaggga
1920
1920

NOV1: 3108 tcgtggaggcagcccttgagcaaacgtgacaatccgatgtcctgtaaaagggtgtccctc
3167
|||||
35 SECR : 1921 tcgtggaggcagcccttgagcaaacgtgacaatccgatgtcctgtaaaagggtgtccctc
1980
1980

NOV1: 3168 agcctaataataacttggttgaagagaggaggatctctgagtggcaatgtttccttgcttt
3227
|||||
40 SECR : 1981 agcctaataataacttggttgaagagaggaggatctctgagtggcaatgtttccttgcttt
2040
2040

NOV1: 3228 tcaatggatccctgttggttcagaatgtttcccttgaaaatgaaggaaacctacgtctgca
3287
|||||
45 SECR : 2041 tcaatggatccctgttggttcagaatgtttcccttgaaaatgaaggaaacctacgtctgca
2100
2100

NOV1: 3288 tagccaccaatgctcttgaaaggcagtggaacatctgtactccacttgctggaacgaa
3347
|||||
50 SECR : 2101 tagccaccaatgctcttgaaaggcagtggaacatctgtactccacttgctggaacgaa
2160
2160

NOV1: 3348 gatggccagagagtagaatcgtattttctgcaaggacataaaaaagtagattctccaggcaa
3407
|||||
5 SECR : 2161 gatggccagagagtagaatcgtattttctgcaaggacataaaaaagtagattctccaggcaa
2220

NOV1: 3408 ccaacactagaaccaacagcaatgaccaacaggagaacccccgcctcaagagccttttt
3467
10 |||||
SECR : 2221 ccaacactagaaccaacagcaatgaccaacaggagaacccccgcctcaagagccttttt
2280

NOV1: 3468 gggagcctggtaactgggtcacattgttctgccacctgtggtcatttgggagcccgcatte
3527
15 |||||
SECR : 2281 gggagcctggtaactgggtcacattgttctgccacctgtggtcatttgggagcccgcatte
2340
20

NOV1: 3528 agagaccccagtggtgatggccaatgggcaggaagtgagtgaggccctgtgtgatcacc
3587
25 |||||
SECR : 2341 agagaccccagtggtgatggccaatgggcaggaagtgagtgaggccctgtgtgatcacc
2400

NOV1: 3588 tccagaagccactggctgggtttgagccctgtaacatccgggactgccagcgaggtggt
3647
30 |||||
SECR : 2401 tccagaagccactggctgggtttgagccctgtaacatccgggactgccagcgaggtggt
2460

NOV1: 3648 tcacaagtgtgtggtcacagtgtctgtgtcttgcggtgaaggataccacagtcggcagg
3707
35 |||||
SECR : 2461 tcacaagtgtgtggtcacagtgtctgtgtcttgcggtgaaggataccacagtcggcagg
40 2520

NOV1: 3708 tgacgtgcaagcgggacaaaagccaatggaactgtgcaggtggtgtctccaagagcatgtg
3767
45 |||||
SECR : 2521 tgacgtgcaagcgggacaaaagccaatggaactgtgcaggtggtgtctccaagagcatgtg
2580

NOV1: 3768 cccctaaagaccggcctctgggaagaaaaccatgttttggatccatgtgttcagtgagg
3827
50 |||||
SECR : 2581 cccctaaagaccggcctctgggaagaaaaccatgttttggatccatgtgttcagtgagg
2640
55

NOV1: 3828 aaccagggaaaccggtgtcctggacgttgcatgggcccgtgctgtgaggatgcagcagcgtc
3887
60 |||||
SECR : 2641 aaccagggaaaccggtgtcctggacgttgcatgggcccgtgctgtgaggatgcagcagcgtc
2700

NOV1: 3888 acacagcttgtcaacacaacagctctgactccaactgtgatgacagaaagagacccacct
3947
|||||
5 SECR : 2701 acacagcttgtcaacacaacagctctgactccaactgtgatgacagaaagagacccacct
2760

NOV1: 3948 taagaaggaaactgcacatcaggggcctgtgatgtgtgttggcacacaggcccttggaagc
4007
|||||
10 SECR : 2761 taagaaggaaactgcacatcaggggcctgtgatgtgtgttggcacacaggcccttggaagc
2820

NOV1: 4008 cctgtacagcagcctgtggcaggggtttccagtctcggaagtcgactgtatccacacaa
4067
|||||
15 SECR : 2821 cctgtacagcagcctgtggcaggggtttccagtctcggaagtcgactgtatccacacaa
2880

NOV1: 4068 ggagttgcaaaccctgtggccaagagacactgtgtacagaaaaagaaaccaatttcctggc
4127
|||||
25 SECR : 2881 ggagttgcaaaccctgtggccaagagacactgtgtacagaaaaagaaaccaatttcctggc
2940

NOV1: 4128 ggcactgtcttgggccctcctgtgatagagactgcacagacacaactcactactgtatgt
4187
|||||
30 SECR : 2941 ggcactgtcttgggccctcctgtgatagagactgcacagacacaactcactactgtatgt
3000

NOV1: 4188 ttgtaaaacatcttaatttgtgttctctagaccgctacaaacaaaggtgctgccagtcac
4247
|||||
35 SECR : 3001 ttgtaaaacatcttaatttgtgttctctagaccgctacaaacaaaggtgctgccagtcac
3060

NOV1: 4248 gtcaagagggataaacctttggaggggtcatgatgctgctgtgaagataaaagtagaata
4307
|||||
45 SECR : 3061 gtcaagagggataaacctttggaggggtcatgatgctgctgtgaagataaaagtagaata
3120

NOV1: 4308 taaaagctcttttcccatgtcgctgattcaaaaacatgtatttcttaaaagactagatt
4367
|||||
50 SECR : 3121 taaaagctcttttcccatgtcgctgattcaaaaacatgtatttcttaaaagactagatt
3180

NOV1: 4368 ctatggatcaaacagaggttgatgcaaaaacaccactgttaaggtgtaaagtgaatttt
4427
|||||
55 SECR : 3181 ctatggatcaaacagaggttgatgcaaaaacaccactgttaaggtgtaaagtgaatttt
3240

60

NOV1: 4428 ccaatggtagttttatattccaattttttaaaatgatgtattcaaggatgaacaaaatac
4487
|||||
5 SECR : 3241 ccaatggtagttttatattccaattttttaaaatgatgtattcaaggatgaacaaaatac
3300

NOV1: 4488 tatagcatgcatgccactgcacttgggacctcatcatgtcagttgaatcgagaaatcacc
4547
|||||
10 SECR : 3301 tatagcatgcatgccactgcacttgggacctcatcatgtcagttgaatcgagaaatcacc
3360

NOV1: 4548 aagattatgagtgcacacctcacgtgctgcctctttcctgtgatatgtagactagcacaga
4607
|||||
15 SECR : 3361 aagattatgagtgcacacctcacgtgctgcctctttcctgtgatatgtagactagcacaga
3420

NOV1: 4608 gtggtacatcctaaaaacttgggaaacacagcaacccatgacttcctcttctctcaagtt
4667
|||||
20 SECR : 3421 gtggtacatcctaaaaacttgggaaacacagcaacccatgacttcctcttctctcaagtt
3480

NOV1: 4668 gcaggttttcaacagttttataaggtatttgcattttagaagctctggccagtagttggt
4727
|||||
25 SECR : 3481 gcaggttttcaacagttttataaggtatttgcattttagaagctctggccagtagttggt
3540

NOV1: 4728 aagatgttggcattaatggcattttcatagatccttggtttagtctgtgaaaaagaaacc
4787
|||||
30 SECR : 3541 aagatgttggcattaatggcattttcatagatccttggtttagtctgtgaaaaagaaacc
3600

NOV1: 4788 atctctctggataggctgtcacactgactgacctaaaggttcatggaagcatggcatctt
4847
|||||
35 SECR : 3601 atctctctggataggctgtcacactgactgacctaaaggttcatggaagcatggcatctt
3660

NOV1: 4848 gtccttgcttttagaacacccatggaagaaaacacagagtagatattgctgtcatttata
4907
|||||
40 SECR : 3661 gtccttgcttttagaacacccatggaagaaaacacagagtagatattgctgtcatttata
3720

NOV1: 4908 caactacagaaatttatctatgacctaatgaggcatctcggaagtcaaagaagagggaaa
4967
|||||
45 SECR : 3721 caactacagaaatttatctatgacctaatgaggcatctcggaagtcaaagaagagggaaa
3780

NOV1: 4968 gttaaccttttctactgatttcgtagtatattcagagctttcttttaagagctgtgaatg
5027
|||||
5 SECR : 3781 gttaaccttttctactgatttcgtagtatattcagagctttcttttaagagctgtgaatg
3840
|||||

NOV1: 5028 aaacttttttctaagcactattctattgcacacaaacagaaaaccaaagccttattagacc
5087
|||||
10 SECR : 3841 aaacttttttctaagcactattctattgcacacaaacagaaaaccaaagccttattagacc
3900
|||||

NOV1: 5088 taatttatgcataaagtagtattcctgagaactttattttgaaaatttataagaaagta
5147
|||||
15 SECR : 3901 taatttatgcataaagtagtattcctgagaactttattttgaaaatttataagaaagta
3960
20
|||||

NOV1: 5148 atccaaataagaaacacgatagttgaaaataatttttatagtaaataattgttttgggct
5207
|||||
25 SECR : 3961 atccaaataagaaacacgatagttgaaaataatttttatagtaaataattgttttgggct
4020
|||||

NOV1: 5208 gatttttccagtaaatccaaagtgacttaggttagaagttacactaaggaccaggggttg
5267
|||||
30 SECR : 4021 gatttttccagtaaatccaaagtgacttaggttagaagttacactaaggaccaggggttg
4080
|||||

NOV1: 5268 aatcagaatttagtttaagatttgaggaaaagggttaagggttagtttcagttttaggatt
5327
|||||
35 SECR : 4081 aatcagaatttagtttaagatttgaggaaaagggttaagggttagtttcagttttaggatt
4140
40
|||||

NOV1: 5328 agagctagaattgggttaggtgagaaagaaagtttaagggttaaggctagagttgtcttta
5387
|||||
45 SECR : 4141 agagctagaattgggttaggtgagaaagaaagtttaagggttaaggctagagttgtcttta
4200
|||||

NOV1: 5388 ggggttagggtaggaccaggttaggtcaggggttgattgggttagattggggccagtgc
5447
|||||
50 SECR : 4201 ggggttagggtaggaccaggttaggtcaggggttgattgggttagattggggccagtgc
4260
55
|||||

NOV1: 5448 tgggttagtgatagtgatgcaggatggagggttaggtttggagtaagcgttggtgctgaagt
5507
|||||
60 SECR : 4261 tgggttagtgatagtgatgcaggatggagggttaggtttggagtaagcgttggtgctgaagt
4320
|||||

NOV1: 5508 gagttcaggctagcattaaattgtaagttctgaagctgatttgggtatggggctttccc
5567
|||||
5 SECR : 4321 gagttcaggctagcattaaattgtaagttctgaagctgatttgggtatggggctttccc
4380
|||||
10 NOV1: 5568 ctgtatactaccagttgtgtcttttagatggcacacaagtccaaataagtggtcatacttc
5627
|||||
SECR : 4381 ctgtatactaccagttgtgtcttttagatggcacacaagtccaaataagtggtcatacttc
4440
|||||
15 NOV1: 5628 tttattcagggtctcagctgcctgtacacctgctgcctacatcttcttggcaacaaagtt
5687
|||||
SECR : 4441 tttattcagggtctcagctgcctgtacacctgctgcctacatcttcttggcaacaaagtt
4500
20
NOV1: 5688 acctgccacaggctctgctgagcctagttcctggtcagtaataactgaacagtgcattht
5747
|||||
25 SECR : 4501 acctgccacaggctctgctgagcctagttcctggtcagtaataactgaacagtgcattht
4560
|||||
30 NOV1: 5748 ggctttggatgtgtctgtggacaagcttgctgagtttctctaccatattctgagcacacg
5807
|||||
SECR : 4561 ggctttggatgtgtctgtggacaagcttgctgagtttctctaccatattctgagcacacg
4620
35
NOV1: 5808 gtctcttttgttctaatttcagcttcactgacactgggttgagcactactgtatgtggag
5867
|||||
40 SECR : 4621 gtctcttttgttctaatttcagcttcactgacactgggttgagcactactgtatgtggag
4680
|||||
45 NOV1: 5868 ggtttggtgattgggaatggatgggggacagtgaggaggacacaccagcccattagttgt
5927
|||||
SECR : 4681 ggtttggtgattgggaatggatgggggacagtgaggaggacacaccagcccattagttgt
4740
50 NOV1: 5928 taatcatcaatcacatctgattgttgaaggttattaaattaaaagaaagatcatttgtaa
5987
|||||
SECR : 4741 taatcatcaatcacatctgattgttgaaggttattaaattaaaagaaagatcatttgtaa
4800
55
NOV1: 5988 catactctttgtatatatttatttatatgaaagggtgcaatattttattttgtacagtatgt
6047
|||||
60 SECR : 4801 catactctttgtatatatttatttatatgaaagggtgcaatattttattttgtacagtatgt
4860
|||||

NOV1: 6048 aataaagacatgggacatatatcttatttaacaaaatttcattataaattgcttcac
6107

|||||
SECR : 4861 aataaagacatgggacatatatcttatttaacaaaatttcattataaattgcttcac
4920

NOV1: 6108 tttgtattttaagttaaaagttactatcttatttgcatttgctattgtactttcattgttgtca
6167

|||||
SECR : 4921 tttgtattttaagttaaaagttactatcttatttgcatttgctattgtactttcattgttgtca
4980

NOV1: 6168 ttcaattgacattcctgtgtactgtattttactactgtttttataacatgagagttaatg
6227

|||||
SECR : 4981 ttcaattgacattcctgtgtactgtattttactactgtttttataacatgagagttaatg
5040

NOV1: 6228 tttctgtttcatgatccttatgtaattcagaaataaatttactttgattattcagtgggca
6287

|||||
SECR : 5041 tttctgtttcatgatccttatgtaattcagaaataaatttactttgattattcagtgggca
5100

NOV1: 6288 tccttat 6294 (SEQ ID NO: 58)

|||||
SECR : 5101 tccttat 5107 (SEQ ID NO: 24)

Table 4

Score = 2027 bits (5253), Expect = 0.0

Identities = 1023/1023 (100%), Positives = 1023/1023 (100%)

NOV1: 259 AVCLHIQTQOTVNDLSLDCMVHRPPAMSQACNTEPCPPRWHVGSWGPCSATCGVGITQTRDV 318
40 AVCLHIQTQOTVNDLSLDCMVHRPPAMSQACNTEPCPPRWHVGSWGPCSATCGVGITQTRDV
SECR : 1 AVCLHIQTQOTVNDLSLDCMVHRPPAMSQACNTEPCPPRWHVGSWGPCSATCGVGITQTRDV 60

NOV1: 319 YCLHPGETPAPPEECRDEKPHALQACNQFDCPPGWHIEEWQCSRTC GGGTQNRVTCRQ 378
45 YCLHPGETPAPPEECRDEKPHALQACNQFDCPPGWHIEEWQCSRTC GGGTQNRVTCRQ
SECR : 61 YCLHPGETPAPPEECRDEKPHALQACNQFDCPPGWHIEEWQCSRTC GGGTQNRVTCRQ 120

NOV1: 379 LLTDGSFLNLSDELQCGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQRRKQVCQR 438
50 LLTDGSFLNLSDELQCGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQRRKQVCQR
SECR : 121 LLTDGSFLNLSDELQCGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQRRKQVCQR 180

NOV1: 439 LAAKGRRIPLEMMCRDLPGLPLVRSCOMPECSKIKSEMKTGLGEQGPQILSVQRVYIQT 498
55 LAAKGRRIPLEMMCRDLPGLPLVRSCOMPECSKIKSEMKTGLGEQGPQILSVQRVYIQT
SECR : 181 LAAKGRRIPLEMMCRDLPGLPLVRSCOMPECSKIKSEMKTGLGEQGPQILSVQRVYIQT 240

NOV1: 499 REEKRLNTIGSRAYLLPNTSVIIKCPVRRFQKSLIQWEKDGRCLQNSKRLGITKSGSLK 558
55 REEKRLNTIGSRAYLLPNTSVIIKCPVRRFQKSLIQWEKDGRCLQNSKRLGITKSGSLK
SECR : 241 REEKRLNTIGSRAYLLPNTSVIIKCPVRRFQKSLIQWEKDGRCLQNSKRLGITKSGSLK 300

NOV1: 559 IHGLAAPDIGVYRCIAGSAQETVVLKLGTDNRLIARPALREPMREYPGMDHSEANSLGV 618
60 IHGLAAPDIGVYRCIAGSAQETVVLKLGTDNRLIARPALREPMREYPGMDHSEANSLGV
SECR : 301 IHGLAAPDIGVYRCIAGSAQETVVLKLGTDNRLIARPALREPMREYPGMDHSEANSLGV 360

	NOV1: 619	TWHKMRQMWNNKNDLYLDDDDHISNQPFLLRALLGHCSNSAGSTNSWELKNKQFEAAVKQGA	678
		TWHKMRQMWNNKNDLYLDDDDHISNQPFLLRALLGHCSNSAGSTNSWELKNKQFEAAVKQGA	
	SECR : 361	TWHKMRQMWNNKNDLYLDDDDHISNQPFLLRALLGHCSNSAGSTNSWELKNKQFEAAVKQGA	420
5	NOV1: 679	YSMDTAQFDELIRNMSQLMETGEVSDDLASQLIYQLVAELAKAQPTHMQWRGIEETPPA	738
		YSMDTAQFDELIRNMSQLMETGEVSDDLASQLIYQLVAELAKAQPTHMQWRGIEETPPA	
	SECR : 421	YSMDTAQFDELIRNMSQLMETGEVSDDLASQLIYQLVAELAKAQPTHMQWRGIEETPPA	480
10	NOV1: 739	AQLRGETGSVSQSSSHAKNSGKLTFKPKGPVLMRQSQPPSISFNKTINSRIGNTVYITKRT	798
		AQLRGETGSVSQSSSHAKNSGKLTFKPKGPVLMRQSQPPSISFNKTINSRIGNTVYITKRT	
	SECR : 481	AQLRGETGSVSQSSSHAKNSGKLTFKPKGPVLMRQSQPPSISFNKTINSRIGNTVYITKRT	540
	NOV1: 799	EVINILCDLITPSEATYTWTKDGTLLQPSVKIILDGTGKIQIQNPTRKEQGIYECSVANH	858
		EVINILCDLITPSEATYTWTKDGTLLQPSVKIILDGTGKIQIQNPTRKEQGIYECSVANH	
15	SECR : 541	EVINILCDLITPSEATYTWTKDGTLLQPSVKIILDGTGKIQIQNPTRKEQGIYECSVANH	600
	NOV1: 859	LGSDVESSSVLYAEAPVILSVERNITKPEHNHLSVVVGGIVEAALGANVTIRCPVKGVPO	918
		LGSDVESSSVLYAEAPVILSVERNITKPEHNHLSVVVGGIVEAALGANVTIRCPVKGVPO	
20	SECR : 601	LGSDVESSSVLYAEAPVILSVERNITKPEHNHLSVVVGGIVEAALGANVTIRCPVKGVPO	660
	NOV1: 919	PNITWLKRGGSLSGNVSLLFNGSLLLQNVSLNEGTYVCIATNALGKAVATSVLHLLERR	978
		PNITWLKRGGSLSGNVSLLFNGSLLLQNVSLNEGTYVCIATNALGKAVATSVLHLLERR	
	SECR : 661	PNITWLKRGGSLSGNVSLLFNGSLLLQNVSLNEGTYVCIATNALGKAVATSVLHLLERR	720
25	NOV1: 979	WPESRIVFLQGHKKYILQATNTRTNSNDPTGEPPPQEPFWEFGNWSHCSATCGHLGARIQ	1038
		WPESRIVFLQGHKKYILQATNTRTNSNDPTGEPPPQEPFWEFGNWSHCSATCGHLGARIQ	
	SECR : 721	WPESRIVFLQGHKKYILQATNTRTNSNDPTGEPPPQEPFWEFGNWSHCSATCGHLGARIQ	780
30	NOV1: 1039	RPQCVMANQGEVSEALCDHLQKPLAGFEPNIRDCPARWFTSVWSQCSVSCGEGYHSRQV	1098
		RPQCVMANQGEVSEALCDHLQKPLAGFEPNIRDCPARWFTSVWSQCSVSCGEGYHSRQV	
	SECR : 781	RPQCVMANQGEVSEALCDHLQKPLAGFEPNIRDCPARWFTSVWSQCSVSCGEGYHSRQV	840
35	NOV1: 1099	TCKRTKANGTVQVVS PRACAPKDRPLGRKPCFGHPVQWEPGNRCPGRCMGRAVRMQQRH	1158
		TCKRTKANGTVQVVS PRACAPKDRPLGRKPCFGHPVQWEPGNRCPGRCMGRAVRMQQRH	
	SECR : 841	TCKRTKANGTVQVVS PRACAPKDRPLGRKPCFGHPVQWEPGNRCPGRCMGRAVRMQQRH	900
40	NOV1: 1159	TACQHNSSDSNCDRKRPTLRRNCTSGACDVCWHTGPWKPCTAACGRGFQSRKVDCHIHR	1218
		TACQHNSSDSNCDRKRPTLRRNCTSGACDVCWHTGPWKPCTAACGRGFQSRKVDCHIHR	
	SECR : 901	TACQHNSSDSNCDRKRPTLRRNCTSGACDVCWHTGPWKPCTAACGRGFQSRKVDCHIHR	960
45	NOV1: 1219	SCKPVAKRHC VQKKKPISWRHCLGPSCDRDCTDTTHYCMFVKHLNLCSLD RYKQRCQSC	1278
		SCKPVAKRHC VQKKKPISWRHCLGPSCDRDCTDTTHYCMFVKHLNLCSLD RYKQRCQSC	
	SECR : 961	SCKPVAKRHC VQKKKPISWRHCLGPSCDRDCTDTTHYCMFVKHLNLCSLD RYKQRCQSC	1020
50	NOV1: 1279	QEG 1281 (SEQ ID NO: 59)	
		QEG	
	SECR : 1021	QEG 1023 (SEQ ID NO: 25)	

55

Based the relatedness of NOV-1 to KIAA1233 sequences, which are related to lacunin, thrombospondins, proteinases, semaphorins, ADAM-TS and properdin family members, nucleic acids and proteins according to the invention likely have similar functions as proteins belonging to these families. Thus, the NOV-1 of the invention is implicated in the following

diseases and processes and has therapeutic uses in these diseases and processes: (i) inflammation, (ii) cancer, (iii) neuronal development and axonal guidance, (iv) angiogenesis and vasculogenesis – in cancer as well as for ischemia, and (v) tissue regeneration *in vivo* and *in vitro*, (vi) and other diseases and disorders.

5 Functional roles attributed to this family of proteins include cell attachment, spreading, motility, and proliferation, cytoskeletal organization, wound healing, and angiogenesis. Moreover, these proteins are expressed in the nervous systems during development and are thought to play roles in neuronal growth and patterning. In particular, the thrombospondin, METH-1 and ADAMTS families of proteins are potent inhibitors of angiogenesis. The
10 ADAMTS proteins have also been implicated in cleavage of proteoglycans and the control of organ shape during development. In addition, the thrombospondins have been implicated in the activation of both transforming growth factor-beta (TGF- β) precursors and TGF- β in a variety of disease states. Furthermore, semaphorin proteins have shown expression in undifferentiated neuroepithelium, suggesting that these proteins are actors in axonal guidance.

15 **NOV 2: A Novel KIAA1233-like Protein**

 The NOV-2 sequences according to the invention include nucleotide sequences encoding a polypeptide related to KIAA1233 proteins, which bear sequence similarity to lacunin, thrombospondins, proteinases, semaphorins, ADAM-TS, and properdin family
20 members.

 NOV2a and NOV2b are splice variants. Splice variants are sequences that occur naturally within the cells and tissues of individuals. The physiological activity of splice variant products and the original protein, from which they are varied, may be the same (although perhaps at a different level), opposite, or completely different and unrelated. In addition,
25 variants may have no activity at all. When a variant and the original sequence have the same or opposite activity, they may differ in various properties not directly connected to biological activity, such as stability, clearance rate, tissue and cellular localization, temporal pattern of expression, up or down regulation mechanisms, and responses to agonists or antagonists. The presence or level of specific splice variants may be the cause, and/or indicative of, a disease,
30 disorder, pathological or normal condition.

 Because a drug may be effective against one variant but not another, or may cause side effects because it targets all splice variants, an effective drug needs to target the particular splice variant. Because soluble variants with therapeutic or disease-related functions may be naturally occurring in specific tissues, they may be optimal candidates for drug targets or

protein therapeutics. Variants may have no activity at all and may thus serve as dominant negative natural inhibitors. Thus, splice variants useful in generating new drug targets, protein therapeutics and markers for diagnostics.

NOV-2 maps to Unigene cluster Hs.18705. This cluster has been mapped to Chromosome 15 Marker stSG35204, Interval D15S115-D15S152. By integrating information from the Online Mendelian Inheritance in Man (OMIM), this region is identified as 15q22-qter. Therefore, the chromosomal location of the invention is Chromosome 15 Marker stSG35204, Interval D15S115-D15S152 which corresponds to 15q22-qter.

NOV-2a

A NOV-2a nucleic acid of the invention, encoding a KIAA1233-like protein originating from chromosome 15 is shown in TABLE 5. The disclosed nucleic acid (SEQ ID NO: 3) is 7260 nucleotides and contains an open reading frame (ORF) that begins with an ATG initiation codon at nucleotide 136 and ends with a TAA stop codon at nucleotides 5209.

The representative ORF encodes a 1691 amino acid polypeptide (SEQ ID NO: 4). The initiation and stop codons of SEQ ID NO: 3 are shown in bold font. The protein has a predicted molecular weight of 188743.8 daltons. Putative untranslated regions are upstream of the initiation codon and downstream of the stop codon in SEQ ID NO: 3.

TABLE 5

CGCACGAGGTGTTGACGGGCGGCTTCTGCCAACTTCTCCCCAGCGCGCGCGAGCCCGCGCGGCCCCGGGGCTGCACGTC
CCAGATACTTCTGCGGCGCAAGGCTACAACTGAGACCCGGAGGAGACTAGACCCCATGGCTTCTTGGACGAGCCCCCTGGT
GGGTGCTGATAGGGATGGTCTTCATGCACTCTCCCTCCCGCAGACCACAGCTGAGAAATCTCTGGAGCCTATTTCCTT
CCCGAGTTTGCACTTCTCTCAGGGAAGTTTCTGGAAGACACAACAGGGGAGCAGTTCTCCTCATTATCGCTATGATGA
CCAGACCTCAAGAACTCGTTGAGATGAAGACAAAGATGGCACTGGGATGCTTGGGGCGACTGGAGTGACTGCTCCC
GGACCTGTGGGGGAGGAGCATCATATTCTCTGCGGAGATGTTTACTGGAAGGAATTGTGAAGGCAGAACATTCCGTAC
AAGACATGCAGCAATCATGACTGCCCTCCAGATGCAGAAGATTTGAGAGCCAGCAGTGCTCAGCCTACAATGATGTCCA
GTATCAGGGGCATTACTATGAATGGCTTCCACGATATAATGATCTGCTGCCCGGTGCACTCAAGTGTATGCACAAG
GACAAAACCTTGGTGGTGGAGCTGGCACCTAAGGTACTGGATGGAACCTCGTTGCAACACGGACTCCTTGGACATGTGTATC
AGTGGCATCTGTGAGCAGTGGGCTGCGATCGGCAACTGGGAAGCAATGCCAAGGAGGACAACGTGGAGTCTGTGCCGG
CGATGGCTCCACCTGCAGGCTTGTACGGGGACAATCAAAGTCACACGTTTCTCCTGAAAAAGAGAAGAAATGTAATTG
CTGTTCTTTGGGAAGTCGAAGTGTGAGAATTACAGTGAAAGGACCTGCCACCTCTTTATTGAATCAAAAACACTTCAA
GGAAGCAAAGGAGAACAACAGCTTAAACAGCCCCGCGCTTCTGTGCTAGAAAACACAACAGTGGAATTTGAGAGGGGCTC
CGAGAGGCAAACTTTTAAGATTCCAGGACCTCTGATGGCTGATTTTCATCTTCAAGACCAGGTACACTGCAGCCAAAGACA
GCGTGGTTCAGTTCCTTTTACCAGCCCATCAGTCATCAGTGGAGACAACTGACTTCTTTCCCTGCACTGTGACGTGT
GGAGGAGTTATCAGCTCAATTCTGCTGAATGTGTGGATATCCGCTTGAAGAGGGTAGTTCCTGACCATTATTGTCACTA
CTACCCTGAAAATGTAAACCAAAACCAAACTGAAGGAATGCAGCATGGATCCCTGCCCATCAAGTGATGGATTTAAAG
AGATAATGCCCTATGACCACTTCCAACCTCTTCTGCTGGGAACATAATCCTTGGACTGCATGTTCCGTGCTCTGTGGA

GGAGGGATT CAGAGACGGAGCTTTGTGTGTGTAGAGGAATCCATGCATGGAGAGATATTGCAGGTGGAAGAAATGGAAGTG
CATGTACGCACCCAAACCCAAAGGTTATGCAAACCTTGTAATCTGTTTGATTGCCCCAAGTGGATTGCCATGGAGTGGTCTC
AGTGACACAGTGACTTGTGGCCGAGGGTTACGGTACCGGGTTGTCTGTGTATTAAACCACCGCGAGAGCATGTTGGGGGC
TGCAATCCACAACGAAGTTACACATCAAAGAAGAAATGTGTCAATCCCATCCCGTGTATAAACCAAAAGAAAAAGTCC
5 AGTGAAGCAAAATTCCTTGGCTGAAACAAGCACAAGAACTAGAAGAGACCAGAATAGCAACAGAAGAACCAACGTTCA
TTCCAGAACCCTGGTCAGCTGCAGTACCACTGTGTGGGCCGGGTGTGCAGGTCCGTGAGGTGAAGTGCCGTGTGTCTCCTC
ACATTCACGCAGACTGAGACTGAGCTGCCCGAGGAAGAGTGTGAAGGCCCAAGCTGCCACCGAACGGCCCTGCCTCCT
GGAAGCATGTGATGAGAGCCCGCCCTCCCGAGAGCTAGACATCCCTCTCCCTGAGGACAGTGAGACGACTTACGACTGGG
AGTACGCTGGGTTACCCCTTGACAGCAACATGCGTGGGAGGCCATCAAGAAGCCATAGCAGTGTGCTTACATATCCAG
10 ACCCAGCAGACAGTCAATGACAGCTTGTGTGATATGGTCCACCGTCTCCAGCCATGAGCCAGGCCTGTAACACAGAGCC
CTGTCCCCCAGGTGGCATGTGGGCTCTTGGGGGCCCTGCTCAGCTACCTGTGGAGTTGGAATTACAGCCGAGATGTGT
ACTGCCTGCAACCCAGGGAGACCCCTGCCCTCTGAGGAGTGCCGAGATGAAAAGCCCCATGCTTTACAAGCATGCAAT
CAGTTTGAAGTGCCTCTGGCTGGCACATTGAAGAATGGCAGCAGTGTCCAGGACTTGTGGCGGGGGAAGTCAAGACAG
AAGAGTCACTGTGCGCAGCTGCTAACGGATGGCAGCTTTTGAATCTCTCAGATGAATTGTGCCAAGGACCCAAAGGCAT
15 CGTCTCACAAGTCTGTGCCAGGACAGACTGTCTCCACATTTAGCTGTGGGAGACTGGTGAAGTGTCTGTGAGTGTGT
GGTGTGGAATCCAGAGAAGAAAGCAGGTGTGTCAAAGGCTGGCAGCCAAAGGTCCGCGCATCCCCCTCAGTGAGATGAT
GTGCAGGGATCTACCAGGGTTCCCTCTTGTAAAGATCTTGCCAGATGCCTGAGTGAGTAAATCAAATCAGAGATGAAGA
CAAAACTTGGTGAGCAGGGTCCGAGATCCTCAGTGTCCAGAGACTTACATTCAGACAAGGGAAGAGAAGCGTATTAAAC
CTGACCATTGGTAGCAGAGCCTATTGTCTGCCAACACATCCGTGATTATTAAGTGCCCCGTGCGACGATTCCAGAAATC
20 TCTGATCCAGTGGGAGAAGGATGGCCGTTGCCCTGCAGAACTCCAAACGGCTTGGCATCACCAGTCAAGCTCACTAAAA
TCCACGGTCTGTGCTGCCCCGACATCGGCGTGTACCGGTGCATTGCAGGCTCTGCACAGGAAACAGTTGTGCTCAAGCTC
ATTGGTACTGACAACCGGCTCATCGCACGCCCAGCCCTCAGGGAGCCTATGAGGGAATATCCTGGGATGGACCACAGCGA
AGCCAATAGTTTGGGAGTCACATGGCACAAAATGAGGCAAAATGTGAATAACAAAATGACCTTTATCTGGATGATGACC
ACATTAGTAACAGCCTTTCTTGAGAGCTCTGTTAGGCCACTGCAGCAATTCTGCAGGAAGCACCAACTCCTGGGAGTTG
25 AAGAATAAGCAGTTTGAAGCAGCAGTTAAACAAGGAGCATATAGCATGGATACAGCCAGTTTGATGAGCTGATAAGAAA
CATGAGTCAGCTCATGGAACCGGAGAGGTGTCAGCGATGATCTTGGTCCCAGCTGATATATCAGCTGGTGGCCGAATTAG
CCAAGGCACAGCCAACACATGCAGTGGCGGGGCATCCAGGAAGAGACACCTCCTGCTGCTCAGCTCAGAGGGGAAACA
GGGAGTGTGTCCAAAGCTCGCATGCAAAAACTCAGGCAAGCTGACATTCAAGCCGAAAGGACCTGTTCTCATGAGGCA
AAGCCAACCTCCCTCAATTTTCAATTAATAAAACAATAAATTCAGGATTGGAAATACAGTATACATTACAAAAGGACAG
30 AGGTCATCAATATATCTGTGTGACCTTATTTACCCCAAGTGAAGGCCACATATACATGGACCAAGGATGGAACCTTGTACAG
CCCTCAGTAAAAATAATTTTGGATGGAACCTGGGAAGATACAGATACAGAATCCTACAAGGAAAGAAACAAGGCATATATGA
ATGTTCTGTAGTAATCATCTTGGTTCAGATGTGGAAGTTCTTCTGTGCTGTATGCAGAGGCACCTGTCTATCTGTCTG
TTGAAAGAAATATACCAAACAGAGCACAAACCATCTGTCTGTTGTTGGTTGGAGGCATCGTGGAGGCAGCCCTTGGAGCA
AACGTGACAAATCCGATGTCTGTAAAAGGTGTCCCTCAGCCTAATATAACCTGGTTGAAGAGAGGAGGATCTCTGAGTGG
35 CAATGTTTCCTGTCTTTTCAATGGATCCCTGTTGTGCAAGTGTTCCTTGAAGTGAAGGAACCTACGTCTGCATAG
CCACCAATGCTCTTGGAAAGGCAGTGGCAACATCTGTATTCCACTTGTGGAACGAAGATGGCCAGAGAGTAGAATCGTA
TTTCTGCAAGGACATAAAAAGTACATTCTCCAGGCAACCAACACTAGAACCAACAGCAATGACCCAACAGGAGAACCCCT
GCCTCAAGAGCCTTTTGGGAGCCTGGTAAGTGGTCACTTGTCTGCCACCTGTGGTCAATTTGGGAGCCCGCAATCAGA
GACCCCAAGTGTGTGATGGCCAATGGGCAGGAAGTGAAGTGAAGCCCTGTGTGATCACCTCCAGAAGCCACTGGCTGGGTTT
40 GAGCCCTGTAACATCCGGGACTGCCAGCGAGGTGGTTCACAAGTGTGTGGTCAAGTGTCTGTGCTTGTGGTGAAGG
ATACCACAGTCCGCGAGGTGACGTGCAAGCGGACAAAAGCCAATGGAAGTGTGCAGGTGGTGTCTCAAGAGCATGTGCCC
CTAAAGACCGGCCTCTGGGAAGAAAACATGTTTGGTTCATCCATGTGTTCAAGTGGGAACAGGGAACCGGTGTCTGGGA
CGTTGATGAGGCGGTGTGTGAGGATGCAGCAGCGTCACACAGCTTGTCAACACAACAGCTCTGACTCCAAGTGTGATGA
CAGAAAGAGACCCACCTTAAGAAGGAATGCACATCAGGGGCTGTGATGTGTGTGGCACACAGGCCCTTGAAGCCCT

GTACAGCAGCCTGTGGCAGGGGTTTCCAGTCTCGAAAGTCGACTGTATCCACACAAGGAGTTGCAAACCTGTGGCCAAG
AGCACTGTGTACAGAAAAAGAAACCAATTTCTGGCGGCACGTCTTGGGCCCTCCTGTGATAGAGACTGCACAGACAC
AACTCACTACTGTATGTTTGTAAAACATCTTAATTTGTGTTCTCTAGACCGCTACAAACAAAGGTGCTGCCAGTCATGTC
AAGAGGGATAAACCTTTGGAGGGGTCATGATGCTGTGTGAAGATAAAAGTAGAATATAAAAGCTCTTTTCCCCATGTGCG
5 CTGATTCAAAAACATGTATTTCTTAAAGACTAGATTCTATGGATCAAACAGAGGTTGATGCAAAAACACCACTGTTAAG
GTGTAAAGTGAAATTTTCCAATGGTAGTTTATATTTCCAATTTTAAATGATGTATTCAAGGATGAACAAAATACTAT
AGCATGCATGCCACTGCCTTGGGACCTCATCATGTGAGTTGAATCGAGAAATCACCAGATTATGAGTGCATCCTCAGC
TGCTGCCTCTTCTGTGATATGTAGACTAGCACAGAGTGGTACATCTTAAAACTTGGGAAACACAGCAACCCATGACT
TCCTCTTCTCTCAAGTTCAGGTTTCAACAGTTTATAAGGTATTTGCATTTTAGAAGCTCTGGCCAGTAGTTGTTAAG
10 ATGTTGGCATTAAATGGCATTTCATAGATCCTTGGTTTGTCTGTGAAAAAGAAACCATCTCTCTGGATAGGCTGTCA
CTGACTGACCTAAGGGTTCATGGAAGCATGGCATCTTGTCTTGTCTTTAGAACACCCATGGAAGAAAACACAGAGTAGA
TATTGCTGTCAATTTATACAACTACAGAAATTTATCTATGACCTAATGAGGCATCTCGGAAGTCAAAGAAGAGGGAAGTT
AACCTTTTCTACTGATTTCTAGTATATTCAGAGCTTCTTTTAAAGAGCTGTGAATGAACTTTTCTAAGCACTATTTCT
ATTGCACACAAAACAGAAAACCAAAGCCTTATTAGACCTAATTTATGCATAAAGTAGTATTCCTGAGAACTTTATTTTGG
15 AAATTTATAAGAAAGTAATCCAAATAAGAAACACGATAGTTGAAAATAATTTTATAGTAAATAATTGTTTGGGCTGAT
TTTTCAAGTAAATCCAAAGTGACTTAGGTTAGAAGTTACACTAAGGACCAGGGGTTGGAATCAGAATTTAGTTTAAGATTT
GAGGAAAAGGGTAAGGGTTAGTTTCAAGTTTATAGGATTAGAGCTAGAATTGGGTTAGGTGAGAAAGAAAGTTAAGGTTAAG
GCTAGAGTTGTCTTTAAGGGTTAGGGTTAGGACCAGGTTAGGTGAGGTTGGATTGGGTTTAGATTGGGGCCAGTGTCTGG
TGTTAGTGTATAGTGTGAGGATGGAGGTTAGGTTTGGAGTAAGCGTTGTTGCTGAAGTGAGTTGAGGCTAGCATTAAATTG
20 TAAGTTCTGAAGCTGATTTGGTTATGGGGTCTTTCCCTGTATACTACCAGTTGTGTCTTTAGATGGCACACAAGTCCAA
ATAAGTGGTCATACCTCTTTATTCAGGGTCTCAGCTGCCTGTACACCTGCTGCCTACATCTTCTTGGCAACAAAGTTACC
TGCCACAGGCTCTGCTGAGCCTAGTTCCTGGTCAAGTAATAACTGAACAGTGCATTTTGGCTTTGGATGTGTCTGTGGACA
AGCTTGTCTGAGTTTCTCTACCATATTCTGAGCACAGGCTCTTTTGTCTTAACCTCAGCTTCAGTGCAGCTGGGTTGAG
CACTACTGTATGTGGAGGGTTTGGTGATGGGAATGGATGGGGACAGTGAGGAGGACACACCAGCCATTAGTTGTGTTAA
25 TCATCAATCACATCTGATTGTTGAAGGTTATTAAATTAAGAAAGATCATTTGTAACATACTCTTGTATATATTTATT
ATATGAAAGGTGCAATATTTTATTTTGTACAGTATGTAATAAGACATGGGACATATATTTTCTTATTAACAAAATTTT
ATATTAATGCTTCACCTTTGTATTTAAAGTTAAAGTTACTATTTTCAATTTGCTATTTGACCTTCATTGTTGTCAATC
AATTGACATTCCTGTGTACTGTATTTTACTACTGTTTTTATAACATGAGAGTTAATGTTTCTGTTTCATGATCCTTATGT
AATTGAGAAATAAATTTACTTTGATTATTCAGTGGCATCCTTATAAAAAAAAAAAAAAAAAA (SEQ ID NO: 3)

MASWTSPPWWVLIGMVFMHSPLPQTAEKSPGAYFLPEFALSPQGSFLEDTTGEQFLTYRYDDQTSRNRSDKDG
NWDAGWDWSDCSRTCGGGASYSLRRCLTGRNCEGQNIYKTCNSHDCPPDAEDFRAQQCSAYNDVQYQGHYYEWLP
RYNDPAAPCALCKHAQGNLVELAPKVLDGTRCNTDSLDMCISGICQAVGCDRQLGSSNAKEDNCGVCAGDGSTCR
35 LVRGQSKSHVSPEKREENVIAVPLGSRSVRITVKGPAHLFIESKTLQSGKGEHSFNSPGVFVVENTTVEFQRGSER
QTFKIPGPLMADFIFKTRYTAAKDSVVQFFFYQPIHQWRQTDFFPCTVTCGGGYQLNSAECVDIRLKRVPDHYC
HYYPENVKPKPKLKECSMDPCPSSDGFKIMPYDHFQPLPRWEHNPTACSVSCGGGIQRRSFVCEESMHGEILQ
VEEWKCMYAPKPKVMQTCNLFDCPKWIAMEWSQCTVTCGRGLRYRVVLCINHRGEHVGGCNPQLKLIKEECVPI
PCYKPKESPVAKLPWLKQAQEELEETRIATEEPTFPIPEWSACSTTCGPGVQVREVKCRVLLTFTQTETELPEEE
40 CEGPKLPTEPCLLEACDESPASRELDIPLPEDSETTYDWEYAGFTPCTATCVGGHQEALAVCLHIQTQOTVNDL
CDMVHRPPAMSQACNTEPCPPRWHVGSWGPCSATCGVGIQTRDVYCLHPGETPAPPEECRDEKPHALQACNQFDCP
PGWHIEEWQQCSRTCGGGTQNRRTCRQLLTDGSFLNLSDELCOGPKASSHKSCARTDCPHLAVGDWSKCSVSCG

10

15

20

25

30

35

35

40

40

NOV2a : 2258 atgtgggctcttgggggccctgctcagctacctgtggagttggaattcagacccgagatg
2317
5 SECR : 121 atgtgggctcttgggggccctgctcagctacctgtggagttggaattcagacccgagatg
180
|||||

NOV2a : 2318 tgtactgcctgcacccaggggagaccctgccctcctgaggagtgccgagatgaaaagc
2377
10 SECR : 181 tgtactgcctgcacccaggggagaccctgccctcctgaggagtgccgagatgaaaagc
240
|||||

NOV2a : 2378 cccatgctttacaagcatgcaatcagtttgactgccctcctggctggcacattgaagaat
2437
15 SECR : 241 cccatgctttacaagcatgcaatcagtttgactgccctcctggctggcacattgaagaat
300
20 |||||

NOV2a : 2438 ggcagcagtgttccaggacttgtggcgggggaactcagaacagaagagtcacctgtcggc
2497
25 SECR : 301 ggcagcagtgttccaggacttgtggcgggggaactcagaacagaagagtcacctgtcggc
360
|||||

NOV2a : 2498 agctgctaacggatggcagctttttgaatctctcagatgaattgtgccaaggacccaagg
2557
30 SECR : 361 agctgctaacggatggcagctttttgaatctctcagatgaattgtgccaaggacccaagg
420
|||||

NOV2a : 2558 catcgtctcacaagtcctgtgccaggacagactgtcctccacatttagctgtgggagact
2617
35 SECR : 421 catcgtctcacaagtcctgtgccaggacagactgtcctccacatttagctgtgggagact
480
40 |||||

NOV2a : 2618 ggtcgaagtgttctgtcagttgtggtgttggaatccagagaagaaagcaggtgtgtcaaa
2677
45 SECR : 481 ggtcgaagtgttctgtcagttgtggtgttggaatccagagaagaaagcaggtgtgtcaaa
540
|||||

NOV2a : 2678 ggctggcagccaaaggctcgcgcatccccctcagtgagatgatgtgcagggatctaccag
2737
50 SECR : 541 ggctggcagccaaaggctcgcgcatccccctcagtgagatgatgtgcagggatctaccag
600
55 |||||

NOV2a : 2738 ggctccctcttgaagatcttgccagatgcctgagtgagtaaaatcaaatacagagatga
2797
60 SECR : 601 ggctccctcttgaagatcttgccagatgcctgagtgagtaaaatcaaatacagagatga
660
|| |||||

NOV2a : 2798 agacaaaacttggtgagcaggggtccgcagatcctcagtggtccagagagtctacattcaga
2857
5 SECR : 661 agacaaaacttggtgagcaggggtccgcagatcctcagtggtccagagagtctacattcaga
720
|||

NOV2a : 2858 caaggaagagaagcgtattaacctgaccattggttagcagagcctatttgctgcccaca
2917
10 SECR : 721 caaggaagagaagcgtattaacctgaccattggttagcagagcctatttgctgcccaca
780
|||

NOV2a : 2918 catccgtgattattaagtgtcccggtgcgacgattccagaaatctctgatccagtgggaga
2977
15 SECR : 781 catccgtgattattaagtgtcccggtgcgacgattccagaaatctctgatccagtgggaga
840
20 |||

NOV2a : 2978 aggatggccgttgctgcagaactccaaacggcttggcatcaccaagtccaggctcactaa
3037
25 SECR : 841 aggatggccgttgctgcagaactccaaacggcttggcatcaccaagtccaggctcactaa
900
|||

NOV2a : 3038 aaatccacggtcttgctgccccgacatcggcgtgtaccggtgcattgcaggctctgcac
3097
30 SECR : 901 aaatccacggtcttgctgccccgacatcggcgtgtaccggtgcattgcaggctctgcac
960
|||

NOV2a : 3098 aggaaacagttgtgctcaagctcattggtactgacaaccggctcatcgacgcccagccc
3157
35 SECR : 961 aggaaacagttgtgctcaagctcattggtactgacaaccggctcatcgacgcccagccc
1020
40 |||

NOV2a : 3158 tcagggagcctatgaggggaatatcctgggatggaccacagcgaagccaatagtttgggag
3217
45 SECR : 1021 tcagggagcctatgaggggaatatcctgggatggaccacagcgaagccaatagtttgggag
1080
|||

NOV2a : 3218 tcacatggcacaaaatgaggcaaatgtggaataacaaaaatgacctttatctggatgatg
3277
50 SECR : 1081 tcacatggcacaaaatgaggcaaatgtggaataacaaaaatgacctttatctggatgatg
1140
55 |||

NOV2a : 3278 accacattagtaaccagcctttcttgagagctctgttaggccactgcagcaattctgcag
3337
60 SECR : 1141 accacattagtaaccagcctttcttgagagctctgttaggccactgcagcaattctgcag
1200
|||

NOV2a : 3338 gaagcaccaactcctgggagttgaagaataagcagtttgaagcagcagttaaacaaggag
3397
5 SECR : 1201 gaagcaccaactcctgggagttgaagaataagcagtttgaagcagcagttaaacaaggag
1260
|||||

NOV2a : 3398 catatagcatggatacagcccagtttgatgagctgataagaaacatgagtcagctcatgg
3457
10 SECR : 1261 catatagcatggatacagcccagtttgatgagctgataagaaacatgagtcagctcatgg
1320
|||||

NOV2a : 3458 aaaccggagaggtcagcgatgatcttgctgccagctgatatatcagctggtggccgaat
3517
15 SECR : 1321 aaaccggagaggtcagcgatgatcttgctgccagctgatatatcagctggtggccgaat
1380
20 |||||

NOV2a : 3518 tagccaaggcacagccaacacacatgcagtgccggggcatccaggaagagacacctctg
3577
25 SECR : 1381 tagccaaggcacagccaacacacatgcagtgccggggcatccaggaagagacacctctg
1440
|||||

NOV2a : 3578 ctgctcagctcagaggggaaacagggagtggtgtccaaagctcgcatgcaaaaaactcag
3637
30 SECR : 1441 ctgctcagctcagaggggaaacagggagtggtgtccaaagctcgcatgcaaaaaactcag
1500
|||||

NOV2a : 3638 gcaagctgacattcaagccgaaaggacctgttctcatgaggcaaagccaacctccctcaa
3697
35 SECR : 1501 gcaagctgacattcaagccgaaaggacctgttctcatgaggcaaagccaacctccctcaa
1560
40 |||||

NOV2a : 3698 tttcatttaataaaaacaataaattccaggattggaaatacagtatacattacaaaaagga
3757
45 SECR : 1561 tttcatttaataaaaacaataaattccaggattggaaatacagtatacattacaaaaagga
1620
|||||

NOV2a : 3758 cagaggtcatcaatatactgtgtgaccttattacccccagtgaggccacatatacatgga
3817
50 SECR : 1621 cagaggtcatcaatatactgtgtgaccttattacccccagtgaggccacatatacatgga
1680
55 |||||

NOV2a : 3818 ccaaggatggaaccttggttacagccctcagtaaaaataattttggatggaactgggaaga
3877
60 SECR : 1681 ccaaggatggaaccttggttacagccctcagtaaaaataattttggatggaactgggaaga
1740
|||||

NOV2a : 3878 tacagatacagaatcctacaaggaaagaacaaggcatatatgaatgttctgtagctaatac
3937
|||||
5 SECR : 1741 tacagatacagaatcctacaaggaaagaacaaggcatatatgaatgttctgtagctaatac
1800
NOV2a : 3938 atcttggttcagatgtggaaagttcttctgtgctgtatgcagaggcacctgtcatcttgt
3997
10 SECR : 1801 atcttggttcagatgtggaaagttcttctgtgctgtatgcagaggcacctgtcatcttgt
1860
NOV2a : 3998 ctggtgaaagaaatatcaccaaaccagagcacaaccatctgtctgttggttgaggga
4057
20 SECR : 1861 ctggtgaaagaaatatcaccaaaccagagcacaaccatctgtctgttggttgaggga
1920
NOV2a : 4058 tcgtggaggcagcccttgaggcaaacgtgacaatccgatgtcctgtaaaaggtgtccctc
4117
25 SECR : 1921 tcgtggaggcagcccttgaggcaaacgtgacaatccgatgtcctgtaaaaggtgtccctc
1980
NOV2a : 4118 agcctaataataacttggttgaagagaggaggatctctgagtggcaatgtttccttgcttt
4177
30 SECR : 1981 agcctaataataacttggttgaagagaggaggatctctgagtggcaatgtttccttgcttt
2040
NOV2a : 4178 tcaatggatccctgttgttcagaatgtttcccttgaaaatgaaggaaacctacgtctgca
4237
35 SECR : 2041 tcaatggatccctgttgttcagaatgtttcccttgaaaatgaaggaaacctacgtctgca
40 2100
NOV2a : 4238 tagccaccaatgctcttgaaaggcagtggaacatctgtattccacttgctggaacgaa
4297
45 SECR : 2101 tagccaccaatgctcttgaaaggcagtggaacatctgtattccacttgctggaacgaa
2160
NOV2a : 4298 gatggccagagagtagaatcgtatttctgcaaggacataaaaagtacattctccaggcaa
4357
50 SECR : 2161 gatggccagagagtagaatcgtatttctgcaaggacataaaaagtacattctccaggcaa
2220
55 NOV2a : 4358 ccaacactagaaccaacagcaatgaccaacaggagaacccccgcctcaagagccttttt
4417
60 SECR : 2221 ccaacactagaaccaacagcaatgaccaacaggagaacccccgcctcaagagccttttt
2280

NOV2a : 4418 gggagcctggtaactggtcacattgttctgccacctgtggtcatttgggagcccgcatte
4477
5 SECR : 2281 gggagcctggtaactggtcacattgttctgccacctgtggtcatttgggagcccgcatte
2340
NOV2a : 4478 agagacccccagtggtgatggccaatgggcaggaagtgagtgaggccctgtgtgatcacc
4537
10 SECR : 2341 agagacccccagtggtgatggccaatgggcaggaagtgagtgaggccctgtgtgatcacc
2400
NOV2a : 4538 tccagaagccactggctgggtttgagccctgtaacatccgggactgccagcgaggtggt
4597
15 SECR : 2401 tccagaagccactggctgggtttgagccctgtaacatccgggactgccagcgaggtggt
2460
20 NOV2a : 4598 tcacaagtgtgtggtcacagtgtctgtgtcttgccgtgaaggataccacagtcggcagg
4657
25 SECR : 2461 tcacaagtgtgtggtcacagtgtctgtgtcttgccgtgaaggataccacagtcggcagg
2520
NOV2a : 4658 tgacgtgcaagcggacaaaagccaatggaactgtgcaggtggtgtctccaagagcatgtg
4717
30 SECR : 2521 tgacgtgcaagcggacaaaagccaatggaactgtgcaggtggtgtctccaagagcatgtg
2580
35 NOV2a : 4718 cccctaaagaccggcctctgggaagaaaaccatgttttggatcatccatgtgttcagtggg
4777
40 SECR : 2581 cccctaaagaccggcctctgggaagaaaaccatgttttggatcatccatgtgttcagtggg
2640
NOV2a : 4778 aaccaggaaccgggtgtcctggacgttgcatgggccgtgctgtgaggatgcagcagcgtc
4837
45 SECR : 2641 aaccaggaaccgggtgtcctggacgttgcatgggccgtgctgtgaggatgcagcagcgtc
2700
NOV2a : 4838 acacagcttgtcaacacaacagctctgactccaactgtgatgacagaaagagaccacct
4897
50 SECR : 2701 acacagcttgtcaacacaacagctctgactccaactgtgatgacagaaagagaccacct
2760
55 NOV2a : 4898 taagaaggaactgcacatcaggggcctgtgatgtgtgttggcacacagggcccttgaagc
4957
60 SECR : 2761 taagaaggaactgcacatcaggggcctgtgatgtgtgttggcacacagggcccttgaagc
2820

NOV2a : 4958 cctgtacagcagcctgtggcaggggtttccagtctcgaaagtcgactgtatccacacaa
5017
5 SECR : 2821 cctgtacagcagcctgtggcaggggtttccagtctcgaaagtcgactgtatccacacaa
2880
NOV2a : 5018 ggagttgcaaaccctgtggccaagagacactgtgtacagaaaaagaaaccaatttcctggc
5077
10 SECR : 2881 ggagttgcaaaccctgtggccaagagacactgtgtacagaaaaagaaaccaatttcctggc
2940
NOV2a : 5078 ggactgtcttgggccctcctgtgatagagactgcacagacacaactcactactgtatgt
5137
15 SECR : 2941 ggactgtcttgggccctcctgtgatagagactgcacagacacaactcactactgtatgt
3000
20
NOV2a : 5138 ttgtaaaacatcttaatttgtgttctctagaccgctacaaacaaggtgctgccagtc
5197
25 SECR : 3001 ttgtaaaacatcttaatttgtgttctctagaccgctacaaacaaggtgctgccagtc
3060
NOV2a : 5198 gtcaagagggataaacctttggaggggtcatgatgctgctgtgaagataaaagtagaata
5257
30 SECR : 3061 gtcaagagggataaacctttggaggggtcatgatgctgctgtgaagataaaagtagaata
3120
35
NOV2a : 5258 taaaagctcttttcccatgtcgctgattcaaaaacatgtatttcttaaaagactagatt
5317
40 SECR : 3121 taaaagctcttttcccatgtcgctgattcaaaaacatgtatttcttaaaagactagatt
3180
NOV2a : 5318 ctatggatcaaacagaggttgatgcaaaaacaccactgttaaggtgtaaagtgaatttt
5377
45 SECR : 3181 ctatggatcaaacagaggttgatgcaaaaacaccactgttaaggtgtaaagtgaatttt
3240
NOV2a : 5378 ccaatggtagttttatattccaattttttaaatgatgtattcaaggatgaacaaaatac
5437
50 SECR : 3241 ccaatggtagttttatattccaattttttaaatgatgtattcaaggatgaacaaaatac
3300
55
NOV2a : 5438 tatagcatgcatgccactgcacttgggacctcatcatgtcagttgaatcgagaaatcacc
5497
60 SECR : 3301 tatagcatgcatgccactgcacttgggacctcatcatgtcagttgaatcgagaaatcacc
3360

NOV2a : 5498 aagattatgagtgcatcctcacgtgctgcctctttcctgtgatatgtagactagcacaga
5557
5 SECR : 3361 aagattatgagtgcatcctcacgtgctgcctctttcctgtgatatgtagactagcacaga
3420
|||||

NOV2a : 5558 gtggtacatcctaaaaacttgggaaacacagcaacccatgacttcctcttctctcaagtt
5617
10 SECR : 3421 gtggtacatcctaaaaacttgggaaacacagcaacccatgacttcctcttctctcaagtt
3480
|||||

NOV2a : 5618 gcaggttttcaacagttttataaggtatttgcattttagaagctctggccagtagttgtt
5677
15 SECR : 3481 gcaggttttcaacagttttataaggtatttgcattttagaagctctggccagtagttgtt
3540
20 |||||

NOV2a : 5678 aagatgttggcattaatggcattttcatagatccttggtttagtctgtgaaaaagaaacc
5737
25 SECR : 3541 aagatgttggcattaatggcattttcatagatccttggtttagtctgtgaaaaagaaacc
3600
|||||

NOV2a : 5738 atctctctggataggtgtcacactgactgacctaagggttcatggaagcatggcatctt
5797
30 SECR : 3601 atctctctggataggtgtcacactgactgacctaagggttcatggaagcatggcatctt
3660
|||||

NOV2a : 5798 gtccttgcttttagaacacccatggaagaaaacacagagtagatattgctgtcatttata
5857
35 SECR : 3661 gtccttgcttttagaacacccatggaagaaaacacagagtagatattgctgtcatttata
3720
40 |||||

NOV2a : 5858 caactacagaaatttatctatgacctaataaggcatctcggaagtcaaagaagagggaaa
5917
45 SECR : 3721 caactacagaaatttatctatgacctaataaggcatctcggaagtcaaagaagagggaaa
3780
|||||

NOV2a : 5918 gttaaccttttctactgatttcgtagtatattcagagctttcttttaagagctgtgaatg
5977
50 SECR : 3781 gttaaccttttctactgatttcgtagtatattcagagctttcttttaagagctgtgaatg
3840
55 |||||

NOV2a : 5978 aaactttttctaagcactattctattgcacacaaacagaaaaccaagccttattagacc
6037
60 SECR : 3841 aaactttttctaagcactattctattgcacacaaacagaaaaccaagccttattagacc
3900
|||||

NOV2a : 6038 taatttatgcataaagtagtattcctgagaactttattttgaaaatttataagaaagta
6097
|||||
5 SECR : 3901 taatttatgcataaagtagtattcctgagaactttattttgaaaatttataagaaagta
3960
NOV2a : 6098 atccaaataagaaacacgatagttgaaaataatttttatagtaaataattgttttgggct
6157
10 SECR : 3961 atccaaataagaaacacgatagttgaaaataatttttatagtaaataattgttttgggct
4020
NOV2a : 6158 gatttttcagtaaataccaaagtgacttaggttagaagttacactaaggaccaggggttgg
6217
|||||
15 SECR : 4021 gatttttcagtaaataccaaagtgacttaggttagaagttacactaaggaccaggggttgg
4080
20
NOV2a : 6218 aatcagaatttagtttaagatttgaggaaaagggttaagggttagtttcagttttaggatt
6277
|||||
25 SECR : 4081 aatcagaatttagtttaagatttgaggaaaagggttaagggttagtttcagttttaggatt
4140
NOV2a : 6278 agagctagaattgggttaggtgagaaagaaagtttaagggttaaggctagagttgtctttaa
6337
30 SECR : 4141 agagctagaattgggttaggtgagaaagaaagtttaagggttaaggctagagttgtctttaa
4200
35
NOV2a : 6338 ggggttagggtaggaccaggttaggtcagggttggttaggttttagattggggccagtgc
6397
|||||
40 SECR : 4201 ggggttagggtaggaccaggttaggtcagggttggttaggttttagattggggccagtgc
4260
NOV2a : 6398 tgggtgtagtgatagtgtcaggatggaggttaggtttggagtaagcgttggtgctgaagt
6457
45 SECR : 4261 tgggtgtagtgatagtgtcaggatggaggttaggtttggagtaagcgttggtgctgaagt
4320
50
NOV2a : 6458 gagttcaggctagcattaaattgtaagttctgaagctgatttggttatggggctttccc
6517
|||||
55 SECR : 4321 gagttcaggctagcattaaattgtaagttctgaagctgatttggttatggggctttccc
4380
NOV2a : 6518 ctgtatactaccagttgtgtcttttagatggcacacaagtccaaataagtgggtcatacttc
6577
60 SECR : 4381 ctgtatactaccagttgtgtcttttagatggcacacaagtccaaataagtgggtcatacttc
4440

NOV2a : 6578 tttattcaggggtctcagctgcctgtacacctgctgcctacatcttcttggcaacaaagtt
6637
|||||
5 SECR : 4441 tttattcaggggtctcagctgcctgtacacctgctgcctacatcttcttggcaacaaagtt
4500

NOV2a : 6638 acctgccacagggtctgctgagcctagttcctggtcagtaataactgaacagtgcatttt
6697
|||||
10 SECR : 4501 acctgccacagggtctgctgagcctagttcctggtcagtaataactgaacagtgcatttt
4560

NOV2a : 6698 ggctttggatgtgtctgtggacaagcttgctgagtttctctaccatattctgagcacacg
6757
|||||
15 SECR : 4561 ggctttggatgtgtctgtggacaagcttgctgagtttctctaccatattctgagcacacg
4620

NOV2a : 6758 gtctcttttgttctaacttcagcttcactgacactggggttgagcactactgtatgtggag
6817
|||||
20 SECR : 4621 gtctcttttgttctaatttcagcttcactgacactggggttgagcactactgtatgtggag
4680

NOV2a : 6818 ggtttggtgattgggaatggatgggggacagtgaggaggacacaccagcccattagttgt
6877
|||||
25 SECR : 4681 ggtttggtgattgggaatggatgggggacagtgaggaggacacaccagcccattagttgt
4740

NOV2a : 6878 taatcatcaatcacatctgattgttgaaggttattaaattaaaagaaagatcatttgtaa
6937
|||||
30 SECR : 4741 taatcatcaatcacatctgattgttgaaggttattaaattaaaagaaagatcatttgtaa
4800

NOV2a : 6938 catactctttgtatatatttatttatatgaaaggtgcaatattttattttgtacagtatgt
6997
|||||
35 SECR : 4801 catactctttgtatatatttatttatatgaaaggtgcaatattttattttgtacagtatgt
4860

NOV2a : 6998 aataaagacatgggacatatatttttcttattaacaaaatttcattataaattgcttcac
7057
|||||
40 SECR : 4861 aataaagacatgggacatatatttttcttattaacaaaatttcattataaattgcttcac
4920

NOV2a : 7058 tttgtatttaaagttaaaagttactatttttcatttgctattgtactttcattgttgca
7117
|||||
45 SECR : 4921 tttgtatttaaagttaaaagttactatttttcatttgctattgtactttcattgttgca
4980

50
55
60

NOV2a : 7118 ttcaattgacattcctgtgtactgtattttactactgtttttataacatgagagttaatg
7177

|||||
5 SECR : 4981 ttcaattgacattcctgtgtactgtattttactactgtttttataacatgagagttaatg
5040

NOV2a : 7178 tttctgtttcatgatccttatgtaattcagaaataaatttactttgattattcagtgggca
7237

|||||
10 SECR : 5041 tttctgtttcatgatccttatgtaattcagaaataaatttactttgattattcagtgggca
5100

15 NOV2a : 7238 tccttat 7244 (SEQ ID NO: 60)

|||||
SECR : 5101 tccttat 5107 (SEQ ID NO: 26)

TABLE 7

20 Score = 2045 bits (5300), Expect = 0.0
Identities = 1021/1023 (99%), Positives = 1021/1023 (99%)

NOV2A: 669 AVCLHIQTQQTVNDSLCDMVHRPPAMSQACNTEPCPPRWHVGSWGPCSATCGVGIQTRDV 728
AVCLHIQTQQTVNDSLCDMVHRPPAMSQACNTEPCPPRWHVGSWGPCSATCGVGIQTRDV
25 SECR : 1 AVCLHIQTQQTVNDSLCDMVHRPPAMSQACNTEPCPPRWHVGSWGPCSATCGVGIQTRDV 60

NOV2A: 729 YCLHPGETPAPPEECRDEKPHALQACNQFDCPPGWHIEEWQQCSRTC GGGTQNRRTVC RQ 788
YCLHPGETPAPPEECRDEKPHALQACNQFDCPPGWHIEEWQQCSRTC GGGTQNRRTVC RQ
30 SECR : 61 YCLHPGETPAPPEECRDEKPHALQACNQFDCPPGWHIEEWQQCSRTC GGGTQNRRTVC RQ 120

NOV2A: 789 LLTDGSLNLSDELCOGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQRRKQVCQR 848
LLTDGSLNLSDELCOGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQRRKQVCQR
SECR : 121 LLTDGSLNLSDELCOGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQRRKQVCQR 180

NOV2A: 849 LAAKGRRIPLSEMMCRDLPGFPLVRSCQMPESKIKSEMKT KLGEQGPQILSVQRVYIQT 908
LAAKGRRIPLSEMMCRDLPG PLVRSCQMPESKIKSEMKT KLGEQGPQILSVQRVYIQT
35 SECR : 181 LAAKGRRIPLSEMMCRDLPGFPLVRSCQMPESKIKSEMKT KLGEQGPQILSVQRVYIQT 240

NOV2A: 909 REEKRINLTIGSRAYLLPNTSVIIKCPVRRFQKSLIQWEKDGRCLQNSKRLGITKSGSLK 968
REEKRINLTIGSRAYLLPNTSVIIKCPVRRFQKSLIQWEKDGRCLQNSKRLGITKSGSLK
40 SECR : 241 REEKRINLTIGSRAYLLPNTSVIIKCPVRRFQKSLIQWEKDGRCLQNSKRLGITKSGSLK 300

NOV2A: 969 IHGLAAPDIGVYRCIAGSAQETVVLKLIGTDNRLIARPALREPMREYPGMDHSEANSLGV
1028

45 IHGLAAPDIGVYRCIAGSAQETVVLKLIGTDNRLIARPALREPMREYPGMDHSEANSLGV
SECR : 301 IHGLAAPDIGVYRCIAGSAQETVVLKLIGTDNRLIARPALREPMREYPGMDHSEANSLGV 360

NOV2A: 1029 TWHKMRQMWNKNNDLYLDDDHISNQPFRLALLGHCSNSAGSTNSWELKNKQFEAAVKQGA
1088

50 TWHKMRQMWNKNNDLYLDDDHISNQPFRLALLGHCSNSAGSTNSWELKNKQFEAAVKQGA
SECR : 361 TWHKMRQMWNKNNDLYLDDDHISNQPFRLALLGHCSNSAGSTNSWELKNKQFEAAVKQGA 420

NOV2A: 1089 YSMDTAQFDELIRNMSQLMETGEVSDDLASQLIYQLVAELAKAQPTHMQWRGIQEETPPA
1148

55 YSMDTAQFDELIRNMSQLMETGEVSDDLASQLIYQLVAELAKAQPTHMQWRGIQEETPPA
SEC : 421 YSMDTAQFDELIRNMSQLMETGEVSDDLASQLIYQLVAELAKAQPTHMQWRGIQEETPPA 480

NOV2A: 1149 AQLRGETGSVSQSSSHAKNSGKLTFFKPKGPVLMRQSQPPSISFNKTINSRIGNTVYITKRT
1208

60 AQLRGETGSVSQSSSHAKNSGKLTFFKPKGPVLMRQSQPPSISFNKTINSRIGNTVYITKRT

SECR : 481 AQLRGETGSVSQSSHAKNSGKLTfKPKGPVLMRQSQPPSISFNKTINSRIGNTVYITKRT 540
 NOV2A: 1209 EVINILCDLITPSEATYTTWKDGTLLQPSVKIILDGTGKIQIQNPTRKEQGIYECSVANH
 1268
 5 EVINILCDLITPSEATYTTWKDGTLLQPSVKIILDGTGKIQIQNPTRKEQGIYECSVANH
 SECR : 541 EVINILCDLITPSEATYTTWKDGTLLQPSVKIILDGTGKIQIQNPTRKEQGIYECSVANH 600
 NOV2A: 1269 LGSDVESSSVLYAEAPVILSVERNITKPEHNHLSVVVGGIVEAALGANVTIRCPVKGVPO
 1328
 10 LGSDVESSSVLYAEAPVILSVERNITKPEHNHLSVVVGGIVEAALGANVTIRCPVKGVPO
 SECR : 601 LGSDVESSSVLYAEAPVILSVERNITKPEHNHLSVVVGGIVEAALGANVTIRCPVKGVPO 660
 NOV2A: 1329 PNITWLKRGGSLSGNVSLLFNGSLLLQNVSLNEGTIVCIATNALGKAVATSVFHLLERR
 1388
 15 PNITWLKRGGSLSGNVSLLFNGSLLLQNVSLNEGTIVCIATNALGKAVATSV HLLERR
 SECR : 661 PNITWLKRGGSLSGNVSLLFNGSLLLQNVSLNEGTIVCIATNALGKAVATSVLHLLERR 720
 NOV2A: 1389 WPESRIVFLQGHKKYILQATNTRTNSNDPTGEPPPQEPFWEPEGNWSHCSATCGHLGARIQ
 1448
 20 WPESRIVFLQGHKKYILQATNTRTNSNDPTGEPPPQEPFWEPEGNWSHCSATCGHLGARIQ
 SECR : 721 WPESRIVFLQGHKKYILQATNTRTNSNDPTGEPPPQEPFWEPEGNWSHCSATCGHLGARIQ 780
 NOV2A: 1449 RPQCVMANQEVSEALCDHLQKPLAGFEPNIRDPCARWFTSVWSQCSVSCGEGYHSRQV
 1508
 25 RPQCVMANQEVSEALCDHLQKPLAGFEPNIRDPCARWFTSVWSQCSVSCGEGYHSRQV
 SECR : 781 RPQCVMANQEVSEALCDHLQKPLAGFEPNIRDPCARWFTSVWSQCSVSCGEGYHSRQV 840
 NOV2A: 1509 TCKRTKANGTVQVVSPRACAPKDRPLGRKPCFGHPCVQWEPGNRCPGRCMGRAVRMQRH
 1568
 30 TCKRTKANGTVQVVSPRACAPKDRPLGRKPCFGHPCVQWEPGNRCPGRCMGRAVRMQRH
 SECR : 841 TCKRTKANGTVQVVSPRACAPKDRPLGRKPCFGHPCVQWEPGNRCPGRCMGRAVRMQRH 900
 NOV2A: 1569 TACQHNSSDSNCDDRKRPTLRRNCTSGACDVCWHTGWPWKPTAACGRGFQSRKVDCIHTR
 1628
 35 TACQHNSSDSNCDDRKRPTLRRNCTSGACDVCWHTGWPWKPTAACGRGFQSRKVDCIHTR
 SECR : 901 TACQHNSSDSNCDDRKRPTLRRNCTSGACDVCWHTGWPWKPTAACGRGFQSRKVDCIHTR 960
 NOV2A: 1629 SCKPVAKRHCVQKKKPISWRHCLGPSCDRDCTDTTHYCMFVKHLNLCSLDTRYKQRCCQSC
 1688
 40 SCKPVAKRHCVQKKKPISWRHCLGPSCDRDCTDTTHYCMFVKHLNLCSLDTRYKQRCCQSC
 SECR : 961 SCKPVAKRHCVQKKKPISWRHCLGPSCDRDCTDTTHYCMFVKHLNLCSLDTRYKQRCCQSC
 1020
 NOV2A: 1689 QEG 1691 (SEQ ID NO: 61)
 45 QEG
 SECR : 1021 QEG 1023 (SEQ ID NO: 27)

SignalP and PSORT analysis indicate that NOV-2 may be localized in the endoplasmic
 reticulum, with likely cleavage sites between positions 26 and 27. Thus, it is likely that NOV-
 50 2a protein is available at the appropriate sub-cellular localization for the therapeutic uses
 described in this application.

Based the relatedness of the disclosed NOV-2a to KIAA1233 sequences, which are
 related to lacunin, thrombospondins, proteinases, semaphorins, ADAM-TS and properdin
 family members, the nucleic acids and proteins of the invention can have similar functions as
 55 proteins belonging to these families.

Functional roles attributed to this family of proteins include cell attachment, spreading, motility, and proliferation, cytoskeletal organization, wound healing, and angiogenesis. Moreover, these proteins are expressed in the nervous systems during development and are thought to play roles in neuronal growth and patterning. In particular, the thrombospondin, METH-1 and ADAMTS families of proteins are potent inhibitors of angiogenesis. The ADAMTS proteins have also been implicated in cleavage of proteoglycans and the control of organ shape during development. In addition, the thrombospondins have been implicated in the activation of both transforming growth factor- beta (TGF- β) precursors and TGF- β in a variety of disease states. Furthermore, semaphorin proteins have shown expression in undifferentiated neuroepithelium, suggesting that these proteins are actors in axonal guidance. Thus, the NOV-2a sequences of the invention is implicated in the following diseases and processes and has therapeutic uses in these diseases and processes: (i) inflammation, (ii) cancer, (iii) neuronal development and axonal guidance, (iv) angiogenesis and vasculogenesis – in cancer as well as for ischemia, and (v) tissue regeneration *in vivo* and *in vitro*, (vi) and other diseases and disorders.

NOV 2b:

A NOV-2b nucleic acid of the invention, encoding a KIAA1233-like protein, is found within the nucleotide sequence of NOV-2a (SEQ ID NO: 3) in Table 5. The disclosed nucleic acid is 6303 nucleotides in length and contains an open reading frame (ORF) that begins with an ATG initiation codon at nucleotide 425 and ends with a TAA stop codon at nucleotides 4268 (SEQ ID NO: 57). The initiation and stop codons of NOV-2b are shown in bold font in SEQ ID NO: 4. The representative ORF encodes a 406 amino acid polypeptide (SEQ ID NO: 5), which is shown below in Table 8. Putative untranslated regions are upstream of the initiation codon and downstream of the stop codon in SEQ ID NO: 57.

TABLE 8

TATAATTATTAAATAGAGACCTTTCAAAGGACAAATCTGTGAAATAAAGTGGTTTTCTGA
AGAGCCTACTAATAGGACAGTGTGTTAATATCACTAATAAGAGAGTAATGATTATAAAAA
GGAATAAATTTATTGAAATTGCAAGATACCTTTCTCCTTTGATTAAATATACTGCTAGTTT
AGTTTTCTACATTTTCAAATAGAACTGGGGAATTTGTGTCGTAGATATTCTTGACAATA
AAGAGATGGTGGCTGAATTTTGGGAATGGTTGATAACACTTGATATTTTAGTTTCCAA
TTTGAAGAGCTCTGTCTCTTGGGATGTCAAATATTATATTCGTCAATTAATGAATGTGT
TAATTTATTATAGAAATGATATTCTCACAATGATTTTCATTTGTAGTGATGGATTTAAAGA
GATAATGCCCTATGACCACTTCCAACCTCTTCTCGCTGGGAACATAATCCTTGGACTGC
ATGTTCCGTGTCTGTGGAGGAGGGATTGAGAGACGGAGCTTTGTGTGTGTAGAGGAATC
CATGCATGGAGAGATATTGCAGGTGGAAGAATGGAAGTGCATGTACGCACCCAAACCCAA
GGTTATGCAAACTTGTAATCTGTTTGATTGCCCAAGTGGATTGCCATGGAGTGGTCTCA
GTGCACAGTGACTTGTGGCCGAGGGTTACGGTACCGGGTTGTTCTGTGTATTAAACACCG
CGGAGAGCATGTTGGGGCTGCAATCCACAACCTGAAGTTACACATCAAAGAAGAATGTGT
CATTTCCATCCCGTGTATAAACCAAAAGAAAAAGTCCAGTGGGAAGCAAAATTGCCTTG
GCTGAAACAAGCACAAGAAGTAGAAGAGACCAGAATAGCAACAGAGAACAACGTTTCAT

5
10
15
20
25
30
35
40
45
50
55
60
65
70

TCCAGAACCCTGGTGCAGCTGCAGTACCACGTGTGGGCCGGGTGTGCAGGTCCGTGAGGT
GAAGTGCCGTGTGCTCCTCACATTCCAGCAGACTGAGACTGAGCTGCCCGAGGAAGAGTG
TGAAGGCCCAAGCTGCCACCAGACGGCCCTGCCTCCTGGAAGCATGTGATGAGAGCCC
GGCCTCCCAGAGCTAGACATCCCTCTCCCTGAGGACAGTGAGACGACTTACGACTGGGA
GTACCGTGGGTTCACCCCTGCACAGCAACATGCGTGGGAGGCCATCAAGAAGCCATAGC
AGTGTGCTTACATATCCAGACCCAGCAGACAGTCAATGACAGCTTGTGTGATATGGTCCA
CCGTCTCCAGCCATGAGCCAGGCCGTGAACACAGAGCCCTGTCCCCCAGGTGGCATGT
GGGCTCTTGGGGGCCCTGCTCAGCTACCTGTGGAGTTGGAATTGAGACCCGAGATGTGTA
CTGCCTGCACCCAGGGGAGACCCCTGCCCTCCTGAGGAGTCCGAGATGAAAAGCCCCA
TGCTTTACAAGCATGCAATCAGTTTGAAGTGCCTCCTGGCTGGCACATTGAAGAAATGGCA
GCAGTGTTCCAGGACTTGTGGCGGGGGAACCTCAGAACAGAAGAGTCACTGTCCGAGCT
GCTAACGGATGGCAGCTTTTTGAATCTCTCAGATGAATTGTGCCAAGGACCCCAAGGCATC
GTCTCACAAGTCTGTGCCAGGACAGACTGTCTCCACATTTAGCTGTGGGAGACTGGTC
GAAGTGTTCTGTGAGTTGTGGTGTGGAATCCAGAGAGAAAGCAGGTGTGTCAAAGGCT
GGCAGCCAAAGGTCCGGCCATCCCCCTCAGTGAGATGATGTGCAGGGATCTACCAGGGTT
CCCTCTTGAAGATCTTGCCAGATGCCTGAGTGCAAGTAAAATCAAATCAGAGATGAAGAC
AAAAGTGGTGAGCAGGGTCCGAGATCCTCAGTGTCCAGAGAGTCTACATTGAGACAAG
GGAAGAGAGCGTATTAACTGACCATTTGGTAGCAGAGCCTATTTGCTGCCCAACACATC
CGTGATTATTAAGTGCCCCGTGCGAGGATCCAGAAATCTCTGATCCAGTGGGAGAAAGGA
TGGCCGTTGCCTGCAGAACTCAAACGGCTTGGCATCACCAGTCAGGCTCACTAAAAAT
CCACGGTCTTGTGCCCCCCGACATCGGCGTGTACCGGTGCATTGCAGGCTCTGCACAGGA
AACAGTTGTGCTCAAGCTCATTGGTACTGACAACCGGCTCATCGCACGCCCCAGCCCTCAG
GGAGCCTATGAGGGAATATCCTGGGATGGACCACAGCGAAGCCAAATAGTTTGGGAGTCAC
ATGGCACAAAATGAGGCCAAATGTGGAATAACAAAAATGACCTTTATCTGGATGATGACCA
CATTAGTAAACAGCTTTCTGTGAGAGCTCTGTAGGCCATGCAGCAATTTCTGCAGGAAG
CACCACCTCCTGGGAGTTGAAGAATAAGCAGTTTGAAGCAGCAGTTAAACAAGGAGCATA
TAGCATGGATACAGCCAGTTTGTGAGCTGATAAGAAACATGAGTCAGCTCATGGAAC
CGGAGAGGTGAGGATGATCTTGCCTCCAGCTGATATATCAGCTGGTGGCCGAATTAGC
CAAGGCACAGCCAAACACATGCAGTGGCGGGGCATCCAGGAAGAGACACCTCCTGCTGC
TCAGCTCAGAGGGGGAACAGGGAGTGTGTCCAAAGCTCGCATGCAAAAACTCAGGCAA
GCTGACATTCAAGCCGAAAGGACCTGTTCTCATGAGGCAAAGCCAACCTCCCTCAATTTTC
ATTTAATAAAACAATAAATCCAGGATTGGAATAACAGTATACATTACAAAAAGGACAGA
GGTCATCAATATACTGTGTGACCTTATTACCCCAAGTGAGGCCACATATACATGGACCAA
GGATGGAACCTTTTACAGCCCTCAGTAAAAATAATTTGGATGGAAGTGGGAAGATACA
GATACAGAACTCTACAGGAAAGAAACAAGGCATATATGAATGTTCTGTAGCTAATCATCT
TGGTTGAGATGTGGAAGTTCTTCTGTGCTGTATGCAGAGGCACCTGTCTCTTGTCTGT
TGAAAGAAATATACCAAACCCAGAGCACAACCATCTGTCTGTTGTGGTTGGAGGCATCGT
GGAGGCAGCCCTTGGAGCAAACGTGACAATCCGATGTCTGTAAAAGGTGTCCCTCAGCC
TAATATAACTTGGTTGAAGAGAGGAGGATCTCTGAGTGGCAATGTTTCTTGTCTTCAA
TGGATCCCTGTTGTTGCAGAAATGTTTCCCTTGAAGAAAGGAACCTACGCTGTGCATAGC
CACCAGTCTCTTGGAAAGGCAGTGGCAACATCTGTACTCCACTGTCTGGAACGAAGATG
GCCAGAGAGTAGAATCGTATTTCTGCAAGGACATAAAAGTACATTCTCCAGGCAACCAA
CACTAGAACCAACAGCAATGACCCAAAGGAGAACCCCGCCTCAAGAGCCTTTTGGGA
GCCTGGTAACCTGGTCACATTGTTCTGCCACCTGTGGTCATTGGGAGCCCGCATTGAGAG
ACCCAGTGTGTGATGGCCAAATGGGCAGGAAGTGAGTGAGGCCCTGTGTGATCACCTCCA
GAAGCCACTGGCTGGGTTTGGGCCCTGTAAACATCCGGGACTGCCAGCGAGGTGGTTTAC
AAGTGTGTGGTCACAGTGCTCTGTGTCTTGGCGTGAAGGATACCACAGTGGCAGGTGAC
GTGCAAGCGCACAAAGCCCAATGGAACGTGTGAGGTGGTGTCTCCAAGAGCATGTGCCCC
TAAAGACCGGCTCTGGGAAGAAAACCATGTTTGGTCATCCATGTGTTTCAAGTGGGAACC
AGGGAACCGGTGTCTGACGTTGCATGGGCGTGTGTGAGGATGCAGAGCGTCACAC
AGCTTGTCAACACAACAGCTCTGACTCCAACGTGTGATGACAGAAAGAGACCCACCTTAAG
AAGGAATGCACATCAGGGGCTGTGATGTGTGTTGGCACACAGGCCCTTGAAGCCCTG
TACAGCAGCCTGTGGCAGGGGTTTCCAGTCTCGGAAAGTCGACTGTATCCACACAAGGAG
TTGCAAACTGTGGCAAGAGACACTGTGTACAGAAAAGAAACCAATTTCTGGCGGCA
CTGTCTTGGGCCCTCCTGTGATAGAGACTGCACAGACAACTCACTACTGTATGTTGT
AAAACATCTTAATTTGTGTTCTCTAGACCGCTACAAACAAAGGTGCTGCCAGTCATGTCA
AGAGGATAAAACCTTTGGAGGGGTGATGCTGTGTGAAGATAAAAGTAGAATATAAA
AGCTCTTTTCCCATGTGCGTGATTCAAAAACATGTATTTCTTAAAAGACTAGATTCTAT
GGATCAACAGAGGTGATGCAAAAACACCACTGTTAAGGTGTAAAGTGAATTTTCCAA
TGGTAGTTTATATTTCAATTTTTTAAAATGATGTATCAAGGATGAACAAAATACATATA
GCATGCATGCCACTGCACCTGGGACCTCATCATGTGCTGATGAAATCGAGAAATCACCAGA
TTATGAGTGCATCCTCAGCTGCCTCTTCTCCTGTGATATGTAGACTAGCACAGGTGG
TACATCCTAAAACTTGGGAAACACAGCAACCCATGACTTCTCTCTCAAGTTGCAG
GTTTTCAACAGTTTTATAAGGTATTTGCATTTTGAAGCTCTGGCCAGTAGTTGTTAAGA
TGTGGCATTAATGCAATTTTATAGATCCTTGGTTTAGTCTGTGAAAAGAAACCATCT
CTCTGGATAGGCTGCACACTGACTGACCTAAGGGTTCATGGAAGCATGGCATCTTGTCC
TTGCTTTTGAACACCCATGGAAGAAAACACAGAGTAGATATTGCTGTCAATTTATACAAC
TACAGAAATTTATCTATGACCTAATGAGGCATCTCGGAAGTCAAGAAGAGGGAAAGTTA
ACCTTTTCTACTGATTTCTGATATATTGAGAGCTTTCTTTAAGAGCTGTGAATGAAAC
TTTTTCTAAGCACTATTCTATGACACAAACAGAAAACCAAGCCTTATTAGACCTAAT

TTATGCATAAAGTAGTATTCTGAGAACTTTATTTTGGAAAAATTTATAAGAAAGTAATCC
 AAATAAGAAACACGATAGTTGAAAATAATTTTTATAGTAAATAATGTTTTGGGCTGATT
 TTTTCAGTAAATCCAAAGTGACTTAGGTTAGAGTTACACTAAGGACCAGGGGTGGAATC
 5 AGAATTTAGTTTAAGATTTGAGGAAAAGGGTAAGGGTTAGTTTCAGTTTTAGGATTAGAG
 CTAGAATTGGGTTAGGTGAGAAAGAAAGTTAAGGTTAAGGCTAGAGTTGTCTTTAAGGGT
 TAGGGTTAGGACCAGGTTAGGTCAGGGTTGGATTGGGTTTAGATTGGGGCCAGTGCTGGT
 GTTAGTGATAGTGTCAGGATGGAGGTTAGGTTTGGAGTAAGCGTTGTGTCTGAAGTGAGT
 TCAGGCTAGCATTAAATTGTAAGTTCTGAAGCTGATTTGGTTATGGGGTCTTTCCCCTGT
 10 ATACTACCAGTTGTGTCTTTAGATGGCACACAAGTCCAAATAAGTGGTCATACTTCTTTA
 TTCAGGGTCTCAGCTGCCTGTACACCTGCTGCCTACATCTTCTTGGCAACAAAGTTACCT
 GCCACAGGCTCTGCTGAGCCTAGTTCTTGGTCAGTAATAACTGAACAGTGCAATTTGGCT
 TTGGATGTGTCTGTGGACAAGCTTGCTGAGTTTCTCTACCATATTCTGAGCACACGGTCT
 CTTTGTCTTAATTTTCTGCTTCACTGACACTGGGTTGAGCACTACTGTATGTGGAGGGTT
 TGGTGATTGGGAATGGATGGGGGACAGTGAGGAGGACACACCAGCCATTAGTTGTTAAT
 15 CATCAATCACATCTGATTGTTGAAGGTTATTAAATTAAAGAAAGATCATTTGTAACATA
 CTCTTTGTATATATTTATTATATGAAAGGTGCAATATTTTATTTTGTACAGTATGTAATA
 AAGACATGGGACATATATTTTCTTATTAACAAAATTTTATATTAATGCTTCACTTTG
 TATTTAAAGTTAAAGTTACTATTTTCTATTTGCTATTGTACTTTTATTGTTGTCTTCA
 20 ATTGACATTCCTGTGTACTGTATTTTACTACTGTTTTTATAACATGAGAGTTAATGTTTC
 TGTTTCATGATCCTTATGTAATTAGAAATAAATTTACTTTGATTATTAGTGGCATCCT
 TAT (SEQ ID NO: 57)

MPYDHFQPLPRWEHNPWTACSVSCGGGIQRRSFVCEESMHGEILQVEEWKCMYAPKPKVMQTCNLFDCPKWIAME
 WSQCTVTCGRGLRYRVVLCINHRGEHVGGCNPQLKHLHKEECVPIPCYKPKKESPVAKLPWLKQAQEELEETRIA
 25 TEEPTFIPEPWSACSTTCGPGVQVREVKCRVLLFTTQTETELPEEECEGPKLPETERPCLLEACDESPASRELDIPL
 PEDSETTYDWEYAGFTPCTATCVGGHQAIAVCLHIQTQOTVNDSLCDMVHRPPAMSQACNTEPCPPRWHVGSWGP
 CSATCGVGIIQTRDVYCLHPGETPAPPEECRDEKPHALQACNQFDCPPGWHIEEWQCSRTCGGGTQNRRTVTCRQLL
 TDGSFLNLSDELQCGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQRRKQVCQRLAAKGRRIPLEMMCRDL
 PGFPLVRSCQMPESKIKSEMKTGLGEQGPQILSVQRVYIQTREEKRINLTIGSRAYLLPNTSVIIKCPVRRFQKS
 30 LIQWEKDGRCLQNSKRLGITKSGSLKIHGLAAPDIGVYRCIAGSAQETVVLKLGTDNRLIARPALREPMREYPGM
 DHSEANSLGVTWHKMRQMWNNKNDLYLDDDHISNQPFRLALLGHCSNSAGSTNSWELKNKQFEAAVKQGAYSMDTA
 QFDELIRNMSQLMETGEVSDDLASQLIYQLVAELAKAQPTHMQWRGIEETPPAAQLRGETGSVSQSSHAKNSGKL
 TFKPKGPVLMRQSQPPSISFNKTINSRIGNTVYITKRTEVINILCDLITPSEATYTTWKDGTLLQPSVKIILDGTG
 KIQIQNPTRKEQGIYECVANHLGSDVESSSVLYAEPVILSVERNITKPEHNHLSVVVGIVAEALGANVTIRCP
 35 VKGVQPQNI TWLKRGGSLSGNVSLLEFNGSLLLQNVSLNEGTYVCIATNALGKAVATSVLHLLERRWPESRIVFLQ
 GHKKYILQATNTRTNSNDPTGEPFPQEPFWEPPGNWSHCSATCGHLGARIQRPQCVMANQEVSEALCDHLQKPLAG
 FEPCNIRDCPARWFTSVWSQCSVSCGEGYHSRQVTCRKTKANGTVQVVS PRACAPKDRPLGRKPCFGHPVQWEPG
 NRCPGRCMGRAVRMQQRHTACQHNSSDSNCDRKRPTLRRNCTSGACDVCWHTGPWKPC TAACGRGFQSRKVDCIH
 TRSCKPVAKRHCVCQKKKPISWRHCLGPSCDRCDTDTTHYCMFVKHLNLCSLDRYKQRCQSCQEG (SEQ ID
 40 NO: 5)

Table 9 shows a multiple sequence alignment of NOV-1, NOV-2a, and NOV-2b
 polypeptides with a KIAA1233 protein (GenBank Accession No: BAA86547), that
 demonstrates the homology between disclosed sequences according to the invention and a
 45 known member of the protein family.

TABLE 9

5 KIAA1233 -----
NOV1 -----
NOV2b -----
NOV2a MASWTSPPWWVLIGVMFMSPLPQTAEKSPGAYFLPEFALSPQGSFLEDTTGEQFLTYRY

10 KIAA1233 -----
NOV1 -----
NOV2b -----
NOV2a DDQTSRNTRSEDEKDGNDWDGWDSDCSRTCGGGASYSLRRCLTGRNCEGQNI RYKTC SN

15 KIAA1233 -----
NOV1 -----
NOV2b -----
NOV2a HDCPPDAEDFRAQQCSAYNDVQYQGHYYEWLPRYNDPAAPCALKCHAQGNLVVELAPKV

20 KIAA1233 -----
NOV1 -----
NOV2b -----
NOV2a LDGTRCNTDSLDMCISGICQAVGCDRQLGSSNAKEDNCGVCAGDGSTCRLVRGQSKSHVSP

25 KIAA1233 -----
NOV1 -----
NOV2b -----
NOV2a EKREENVIAVPLGSRSVRITVKGPAHLFIESKTLQGSKEHSFNSPGVFVVENTTVEFOR

30 KIAA1233 -----
NOV1 -----
NOV2b -----
NOV2a GSERQTFKIPGPLMADFIFKTRYTAAKDSVVQFFFYQPI SHQWRQTDFFPCTVTCGGGYQ

35 KIAA1233 -----
NOV1 -----MPYDHFQPLP
NOV2b -----MPYDHFQPLP
NOV2a LNSAECVDIRLKRVPDPHYCHYYPENVKPKPKLKECSMDPCPSSDGFKEIMPYDHFQPLP

40 KIAA1233 -----
NOV1 RWEHNPWTACSVSCGGGIQRRSFVCVEESMHGEILQVEEWKCMYAPKPKVMQTCNLFDCP
NOV2b RWEHNPWTACSVSCGGGIQRRSFVCVEESMHGEILQVEEWKCMYAPKPKVMQTCNLFDCP
NOV2a RWEHNPWTACSVSCGGGIQRRSFVCVEESMHGEILQVEEWKCMYAPKPKVMQTCNLFDCP

45 KIAA1233 -----
NOV1 KWIAMWSQCTVTTCGRGLRYRVVLCINHRGEHVGGCNPQLKLHIKEECVPIPCYKPKKEK
NOV2b KWIAMWSQCTVTTCGRGLRYRVVLCINHRGEHVGGCNPQLKLHIKEECVPIPCYKPKKEK
NOV2a KWIAMWSQCTVTTCGRGLRYRVVLCINHRGEHVGGCNPQLKLHIKEECVPIPCYKPKKEK

50 KIAA1233 -----
NOV1 SPVEAKLPWLKQAELEETRIATEEPTFIPEPWSACSTTCGPGVQVREVKCRVLLTFTQT
NOV2b SPVEAKLPWLKQAELEETRIATEEPTFIPEPWSACSTTCGPGVQVREVKCRVLLTFTQT
NOV2a SPVEAKLPWLKQAELEETRIATEEPTFIPEPWSACSTTCGPGVQVREVKCRVLLTFTQT

55 KIAA1233 -----
NOV1 ETELPEEECEGPKLPTERPCLLEACDESPASRELDIPLPEDSETTYDWEYAGFTPCTATC
NOV2b ETELPEEECEGPKLPTERPCLLEACDESPASRELDIPLPEDSETTYDWEYAGFTPCTATC
NOV2a ETELPEEECEGPKLPTERPCLLEACDESPASRELDIPLPEDSETTYDWEYAGFTPCTATC

60 KIAA1233 -----AVCLHIQTQQTVNDSLCDMVHRPPAMSQACNTEPCPPRWHVGSWGPCSATCG
NOV1 VGGHQEAI AVCLHIQTQQTVNDSLCDMVHRPPAMSQACNTEPCPPRWHVGSWGPCSATCG
NOV2b VGGHQEAI AVCLHIQTQQTVNDSLCDMVHRPPAMSQACNTEPCPPRWHVGSWGPCSATCG
NOV2a VGGHQEAI AVCLHIQTQQTVNDSLCDMVHRPPAMSQACNTEPCPPRWHVGSWGPCSATCG

KIAA1233 VGIQTRDVYCLHPGETPAPPEECRDEKPHALQACNQFDCPPGWHIEEWQCSRTCGGGTQ
NOV1 VGIQTRDVYCLHPGETPAPPEECRDEKPHALQACNQFDCPPGWHIEEWQCSRTCGGGTQ
NOV2b VGIQTRDVYCLHPGETPAPPEECRDEKPHALQACNQFDCPPGWHIEEWQCSRTCGGGTQ

NOV2a VGIQTRDVYCLHPGETPAPPEECRDEKPHALQACNQFDCPPGWHIEEWQOCSRTCGGGTQ

5 KIAA1233 NRRVTCRQLLTDGSFLNLSDELCOGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQ
NOV1 NRRVTCRQLLTDGSFLNLSDELCOGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQ
NOV2b NRRVTCRQLLTDGSFLNLSDELCOGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQ
NOV2a NRRVTCRQLLTDGSFLNLSDELCOGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQ

10 KIAA1233 RRKQVCQRLAAKGRRIPLEMMCRDLPGLPLVRSCOMPECSKIKSEMKTCLGEQGPQILS
NOV1 RRKQVCQRLAAKGRRIPLEMMCRDLPGLPLVRSCOMPECSKIKSEMKTCLGEQGPQILS
NOV2b RRKQVCQRLAAKGRRIPLEMMCRDLPGLPLVRSCOMPECSKIKSEMKTCLGEQGPQILS
NOV2a RRKQVCQRLAAKGRRIPLEMMCRDLPGLPLVRSCOMPECSKIKSEMKTCLGEQGPQILS

15 KIAA1233 VQRVYIQTREEKRINLTIGSRAYLLPNTSVIICKPVRRFQKSLIQWEKDGRCLQNSKRLG
NOV1 VQRVYIQTREEKRINLTIGSRAYLLPNTSVIICKPVRRFQKSLIQWEKDGRCLQNSKRLG
NOV2b VQRVYIQTREEKRINLTIGSRAYLLPNTSVIICKPVRRFQKSLIQWEKDGRCLQNSKRLG
NOV2a VQRVYIQTREEKRINLTIGSRAYLLPNTSVIICKPVRRFQKSLIQWEKDGRCLQNSKRLG

20 KIAA1233 ITKSGSLKIHGLAAPDIGVYRCIAGSAQETVVLKLGTDNRLIARPALREPMREYPGMDH
NOV1 ITKSGSLKIHGLAAPDIGVYRCIAGSAQETVVLKLGTDNRLIARPALREPMREYPGMDH
NOV2b ITKSGSLKIHGLAAPDIGVYRCIAGSAQETVVLKLGTDNRLIARPALREPMREYPGMDH
NOV2a ITKSGSLKIHGLAAPDIGVYRCIAGSAQETVVLKLGTDNRLIARPALREPMREYPGMDH

25 KIAA1233 SEANSLGVTWHKMRQMWNKNKNDLYLDDDHISNQPFRLALLGHCSNSAGSTNSWELKNKQF
NOV1 SEANSLGVTWHKMRQMWNKNKNDLYLDDDHISNQPFRLALLGHCSNSAGSTNSWELKNKQF
NOV2b SEANSLGVTWHKMRQMWNKNKNDLYLDDDHISNQPFRLALLGHCSNSAGSTNSWELKNKQF
NOV2a SEANSLGVTWHKMRQMWNKNKNDLYLDDDHISNQPFRLALLGHCSNSAGSTNSWELKNKQF

30 KIAA1233 EAAVKQGAYSMDTAQFDELIRNMSQLMETGEVSDDLASQLIYQLVAELAKAQPTHMQWRG
NOV1 EAAVKQGAYSMDTAQFDELIRNMSQLMETGEVSDDLASQLIYQLVAELAKAQPTHMQWRG
NOV2b EAAVKQGAYSMDTAQFDELIRNMSQLMETGEVSDDLASQLIYQLVAELAKAQPTHMQWRG
NOV2a EAAVKQGAYSMDTAQFDELIRNMSQLMETGEVSDDLASQLIYQLVAELAKAQPTHMQWRG

35 KIAA1233 IQEETPPAAQLRGETGSVSQSSHAKNSGKLTFFKPKGPVLMRQSQPPSISFNKTINSRIGN
NOV1 IQEETPPAAQLRGETGSVSQSSHAKNSGKLTFFKPKGPVLMRQSQPPSISFNKTINSRIGN
NOV2b IQEETPPAAQLRGETGSVSQSSHAKNSGKLTFFKPKGPVLMRQSQPPSISFNKTINSRIGN
NOV2a IQEETPPAAQLRGETGSVSQSSHAKNSGKLTFFKPKGPVLMRQSQPPSISFNKTINSRIGN

40 KIAA1233 TVYITKRTEVINILCDLITPSEATYTWTKDGTLLQPSVKIILDGTGKIQIQNPTRKEQGI
NOV1 TVYITKRTEVINILCDLITPSEATYTWTKDGTLLQPSVKIILDGTGKIQIQNPTRKEQGI
NOV2b TVYITKRTEVINILCDLITPSEATYTWTKDGTLLQPSVKIILDGTGKIQIQNPTRKEQGI
NOV2a TVYITKRTEVINILCDLITPSEATYTWTKDGTLLQPSVKIILDGTGKIQIQNPTRKEQGI

45 KIAA1233 YECVANHLGSDVESSSVLYAEAPVILSVERNITKPEHNHLSVVVGIVEAALGANVTIR
NOV1 YECVANHLGSDVESSSVLYAEAPVILSVERNITKPEHNHLSVVVGIVEAALGANVTIR
NOV2b YECVANHLGSDVESSSVLYAEAPVILSVERNITKPEHNHLSVVVGIVEAALGANVTIR
NOV2a YECVANHLGSDVESSSVLYAEAPVILSVERNITKPEHNHLSVVVGIVEAALGANVTIR

50 KIAA1233 CPVKGVPPQPNITWLKRGGSLSGNVSLLFNGSLLLQNVSLNEGTYVCIATNALGKAVATS
NOV1 CPVKGVPPQPNITWLKRGGSLSGNVSLLFNGSLLLQNVSLNEGTYVCIATNALGKAVATS
NOV2b CPVKGVPPQPNITWLKRGGSLSGNVSLLFNGSLLLQNVSLNEGTYVCIATNALGKAVATS
NOV2a CPVKGVPPQPNITWLKRGGSLSGNVSLLFNGSLLLQNVSLNEGTYVCIATNALGKAVATS

55 KIAA1233 CPVKGVPPQPNITWLKRGGSLSGNVSLLFNGSLLLQNVSLNEGTYVCIATNALGKAVATS
NOV1 CPVKGVPPQPNITWLKRGGSLSGNVSLLFNGSLLLQNVSLNEGTYVCIATNALGKAVATS
NOV2b CPVKGVPPQPNITWLKRGGSLSGNVSLLFNGSLLLQNVSLNEGTYVCIATNALGKAVATS
NOV2a CPVKGVPPQPNITWLKRGGSLSGNVSLLFNGSLLLQNVSLNEGTYVCIATNALGKAVATS

60 KIAA1233 CPVKGVPPQPNITWLKRGGSLSGNVSLLFNGSLLLQNVSLNEGTYVCIATNALGKAVATS
NOV1 CPVKGVPPQPNITWLKRGGSLSGNVSLLFNGSLLLQNVSLNEGTYVCIATNALGKAVATS
NOV2b CPVKGVPPQPNITWLKRGGSLSGNVSLLFNGSLLLQNVSLNEGTYVCIATNALGKAVATS
NOV2a CPVKGVPPQPNITWLKRGGSLSGNVSLLFNGSLLLQNVSLNEGTYVCIATNALGKAVATS

KIAA1233 VLHLLERRWPESRIVFLQGHKKYILQATNTRTNSNDPTGEPPPQEPFWEPEGNWSHCSATC
 NOV1 VLHLLERRWPESRIVFLQGHKKYILQATNTRTNSNDPTGEPPPQEPFWEPEGNWSHCSATC
 NOV2b VLHLLERRWPESRIVFLQGHKKYILQATNTRTNSNDPTGEPPPQEPFWEPEGNWSHCSATC
 NOV2a VFHLLERRWPESRIVFLQGHKKYILQATNTRTNSNDPTGEPPPQEPFWEPEGNWSHCSATC
 * : *****

KIAA1233 GHLGARIQRPQCVMANQEVSEALCDHLQKPLAGFEPNIRDPCARWFTSVWSQCSVSCG
 NOV1 GHLGARIQRPQCVMANQEVSEALCDHLQKPLAGFEPNIRDPCARWFTSVWSQCSVSCG
 NOV2b GHLGARIQRPQCVMANQEVSEALCDHLQKPLAGFEPNIRDPCARWFTSVWSQCSVSCG
 NOV2a GHLGARIQRPQCVMANQEVSEALCDHLQKPLAGFEPNIRDPCARWFTSVWSQCSVSCG

KIAA1233 EGYHSRQVTCKRTKANGTVQVVSPRACAPKDRPLGRKPCFGHPCVQWEPGNRCPGRCMGR
 NOV1 EGYHSRQVTCKRTKANGTVQVVSPRACAPKDRPLGRKPCFGHPCVQWEPGNRCPGRCMGR
 NOV2b EGYHSRQVTCKRTKANGTVQVVSPRACAPKDRPLGRKPCFGHPCVQWEPGNRCPGRCMGR
 NOV2a EGYHSRQVTCKRTKANGTVQVVSPRACAPKDRPLGRKPCFGHPCVQWEPGNRCPGRCMGR

KIAA1233 AVRMQQRHTACQHNSSDSNCDDKRPTLRRNCTSGACDVCWHTGPWKPCTAACGRGFQSR
 NOV1 AVRMQQRHTACQHNSSDSNCDDKRPTLRRNCTSGACDVCWHTGPWKPCTAACGRGFQSR
 NOV2b AVRMQQRHTACQHNSSDSNCDDKRPTLRRNCTSGACDVCWHTGPWKPCTAACGRGFQSR
 NOV2a AVRMQQRHTACQHNSSDSNCDDKRPTLRRNCTSGACDVCWHTGPWKPCTAACGRGFQSR

KIAA1233 KVDCIHTRSCKPVAKRHCVQKKKPISWRHCLGPSCDRDCTDTTHYCMFVKHLNLCSLDY
 NOV1 KVDCIHTRSCKPVAKRHCVQKKKPISWRHCLGPSCDRDCTDTTHYCMFVKHLNLCSLDY
 NOV2b KVDCIHTRSCKPVAKRHCVQKKKPISWRHCLGPSCDRDCTDTTHYCMFVKHLNLCSLDY
 NOV2a KVDCIHTRSCKPVAKRHCVQKKKPISWRHCLGPSCDRDCTDTTHYCMFVKHLNLCSLDY

KIAA1233 KQRCCQSCQEG (SEQ ID NO: 28)
 NOV1 KQRCCQSCQEG (SEQ ID NO: 2)
 NOV2b KQRCCQSCQEG (SEQ ID NO: 5)
 NOV2a KQRCCQSCQEG (SEQ ID NO: 4)

Consensus key

- * - single, fully conserved residue
- : - conservation of strong groups
- . - conservation of weak groups - no consensus

Based the relatedness of the disclosed NOV-2b to the disclosed NOV-1, the disclosed NOV-2a, and KIAA1233 sequences, which as noted are related to lacunin, thrombospondins, proteinases, semaphorins, ADAM-TS and properdin family members, the nucleic acids and proteins of the invention can have similar functions as proteins belonging to these families.

Thus, the invention is implicated in the following diseases and processes and has therapeutic uses in these diseases and processes: (i) inflammation, (ii) cancer, (iii) neuronal development and axonal guidance, (iv) angiogenesis and vasculogenesis – in cancer as well as for ischemia, and (v) tissue regeneration *in vivo* and *in vitro*, and (vi) and other diseases and disorders.

Functional roles attributed to this family of proteins include cell attachment, spreading, motility, and proliferation, cytoskeletal organization, wound healing, and angiogenesis. Moreover, these proteins are expressed in the nervous systems during development and are thought to play roles in neuronal growth and patterning. In particular, the thrombospondin,

METH-1 and ADAMTS families of proteins are potent inhibitors of angiogenesis. The ADAMTS proteins have also been implicated in cleavage of proteoglycans and the control of organ shape during development. In addition, the thrombospondins have been implicated in the activation of both transforming growth factor-beta (TGF- β) precursors and TGF- β in a variety of disease states. Furthermore, semaphorin proteins have shown expression in undifferentiated neuroepithelium, suggesting that these proteins are actors in axonal guidance.

The novel nucleic acids of the invention encoding human proteins includes the nucleic acids whose sequences are provided as NOV-1, NOV-2a, and NOV-2b, respectively, or fragments thereof. The invention also includes mutant or variant nucleic acids any of whose bases may be changed from the corresponding bases shown as NOV-1, NOV-2a, and NOV-2b, while still encoding a protein that maintains its human KIAA1233-like proteins activities and physiological functions, or a fragment of such nucleic acids. The invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of non-limiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as anti-sense binding nucleic acids in therapeutic applications in a subject.

The novel proteins of the invention includes the human KIAA1233-like proteins whose sequences are provided as NOV-1, NOV-2a, and NOV-2b, respectively. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residues shown as NOV-1, NOV-2a, and NOV-2b, while still encoding a protein that maintains its human KIAA1233-like protein activities and physiological functions, or a functional fragment thereof.

The invention further encompasses antibodies and antibody fragments, such as F_{ab} or $(F_{ab})_2$, that bind immunospecifically to any of the proteins of the invention.

The expression pattern, and protein similarity information for the invention suggest that NOV-1, NOV-2a and NOV-2b may function as human KIAA1233-like proteins. Therefore, the nucleic acid and protein of the invention are useful in potential therapeutic applications implicated, for example but not limited to, (i) inflammation, (ii) cancer, (iii) neuronal development and axonal guidance, (iv) angiogenesis and vasculogenesis – in cancer as well as for ischemia, and (v) tissue regeneration *in vivo* and *in vitro*, (vi) and other diseases

and disorders. The homology to antigenic secreted and membrane proteins also suggests that antibodies directed against the novel genes may be useful in treatment and prevention of (i) inflammation, (ii) cancer, (iii) neuronal development and axonal guidance, (iv) angiogenesis and vasculogenesis – in cancer as well as for ischemia, and (v) tissue regeneration *in vivo* and *in vitro*, and (vi) other diseases and disorders.

Potential therapeutic uses for the invention(s) are, for example but not limited to, the following: (i) protein therapeutic, (ii) small molecule drug target, (iii) antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) diagnostic and/or prognostic marker, (v) gene therapy (gene delivery/gene ablation), (vi) research tools, and (vii) tissue regeneration *in vitro* and *in vivo* (regeneration for all these tissues and cell types composing these tissues and cell types derived from these tissues).

NOV-3: A Novel STE20 Protein Kinase

The NOV-3 sequences (NOV-3a, NOV-3b, NOV-3c, and NOV-3d) according to the invention are splice variants related to STE20 protein kinases. The differences between the four sequences relate to the four ways of independently combining two deletions arising from two splice variants in the mRNAs.

Splice variants are sequences that occur naturally within the cells and tissues of individuals. The physiological activity of splice variant products and the original protein, from which they are varied, may be the same (although perhaps at a different level), opposite, or completely different and unrelated. In addition, variants may have no activity at all. When a variant and the original sequence have the same or opposite activity, they may differ in various properties not directly connected to biological activity, such as stability, clearance rate, tissue and cellular localization, temporal pattern of expression, up or down regulation mechanisms, and responses to agonists or antagonists. The presence or level of specific splice variants may be the cause, and/or indicative of, a disease, disorder, pathological or normal condition.

Because a drug may be effective against one variant but not another, or may cause side effects because it targets all splice variants, an effective drug needs to target the particular splice variant. Because soluble variants with therapeutic or disease-related functions may be naturally occurring in specific tissues, they may be optimal candidates for drug targets or protein therapeutics. Variants may have no activity at all and may thus serve as dominant negative natural inhibitors. Thus, splice variants useful in generating new drug targets, protein therapeutics and markers for diagnostics.

NOV-3 sequences according to the invention encode polypeptides related to STE20 protein kinases, whose subgroups include GCK, SLK, and PSK proteins. Therefore, the nucleic acids and proteins of the invention can have similar functions as proteins belonging to these subgroups.

5 Functional roles attributed to STE20 proteins include cytoskeletal organization, apoptosis, and signal transduction pathways. Thus, the NOV-3 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in disorders associated with, *e.g.*, metabolic and endocrine disorders, cancer, bone disorders, and tissue/cell growth regulation disorders.

10 NOV-3 sequences were initially identified by searching CuraGen's Human SeqCalling database for DNA sequences that translate into proteins with similarity to the STE20 protein kinase family. The SeqCalling assembly for NOV-3 was analyzed further to identify open reading frame(s) encoding for novel full length protein(s) and novel splice variants of these genes. This was done by extending the SeqCalling assembly using additional SeqCalling
15 assemblies, publicly available EST sequences and public genomic sequence. Public ESTs and additional CuraGen SeqCalling assemblies were identified by the CuraTools program SeqExtend. They were included in the DNA sequence extension for SeqCalling assembly 18552586 when extended overlaps were found.

SeqCalling is a differential expression and sequencing procedure that normalizes
20 mRNA species in a sample, and is disclosed in U.S. Ser. No. 09/417,386 filed October 13, 1999, which is incorporated herein by reference in its entirety.

A genomic clone of NOV-3 was analyzed by GenscanTM and GrailTM to identify exons and putative coding sequences/open reading frames. The NOV-3 clone was also analyzed by TblastN, BlastX and other homology programs to identify regions translating to proteins with
25 similarity to the original protein/protein family of interest.

The results of these analyses were integrated and manually corrected for apparent inconsistencies, thereby obtaining the sequences encoding the full-length proteins. When necessary, the process to identify and analyse cDNAs/ESTs and genomic clones was reiterated to derive the full-length sequence. The full-length DNA sequences as well as their splice
30 forms, and the full-length protein sequences that they encode, are disclosed herein.

NOV-3 was mapped to chromosome 17.

Based on the CuraGen SeqCalling database information, the NOV-3 is expressed in heart tissue. Moreover, based on the expression of STE-20 family members, the following tissues are also likely to express the invention: brain (especially hippocampus and cerebral

5 cardiovascular disorders, diabetes, leukemia/lymphoma, cancer, musculoskeletal disorders, muscular generation, reproductive health, metabolic and endocrine disorders, gastrointestinal disorders, immune and autoimmune disorders, respiratory disorders, bone disorders, and tissue/cell growth regulation disorders.

Additional utilities for NOV-3 nucleic acids and polypeptides according to the

A NOV-3a sequence according to the invention is a nucleic acid sequence encoding a polypeptide related to STE20 family of protein kinases. A disclosed NOV-3a nucleic acid and encoded polypeptide includes the sequences shown in Table 10. The disclosed nucleic acid (SEQ ID NO: 6) is 3999 nucleotides in length and contains an open reading frame (ORF) that starts with an ATG initiation codon at nucleotides 1-3 and ends with a TGA stop codon at nucleotides 3996-3999. The start and stop codons are shown in bold font. The respective ORF encodes a 1332 amino acid polypeptide (SEQ ID NO: 7).

ATGGGCGACCCAGCCCCCGCCGACGCTGGACGACATCGACCTGTCCGCCCTGCGGGACCTGCTGGGATCTTTGAGCT
TGTGGAGGTGGTCGGCAATGGAACCTACGGACAGGTGTACAAGGTTCGGCATGTCAAGACGGGGCAGCTGGCTGCCATCA
AGGTCATGGATGTCACGGAGGACGAGGAGGAAGAGATCAAACAGGAGATCAACATGCTGAAAAAGTACTCTCACCACCGC
AACATCGCCACCTACTACGGAGCCTTCATCAAGAAGAGCCCCCGGGAAACGATGACCAGCTCTGGCTGGTGATGGAGTT
CTGTGGTGCTGGTTCACTGACTGACCTGGTAAAGAACACAAAGGCAACGCCCTGAAGGAGGACTGTATCGCCTATATCT
GCAGGGAGATCCTCAGGGGTCTGGCCCATCTCCATGCCACAAAGGTGATCCATCGAGACATCAAGGGGCAGAATGTGCTG
CTGACAGAGAATGCTGAGGTCAAGCTAGTGGATTTTGGGGTGAGTGCTCAGCTGGACCGCACCGTGGGCAGACGGAAACAC
TTTCATTGGGACTCCCTACTGGATGGCTCCAGAGGTCATCGCCTGTGATGAGAACCTGATGCCACCTATGATTACAGGA
GTGATATTTGGTCTCTAGGAATCACAGCCATCGAGATGGCAGAGGGAGCCCCCCTCTGTGTGACATGCACCCCATGCGA
GCCCTCTTCCTCATTCTCGGAACCTCCGCCAGGCTCAAGTCCAAGAAGTGTTCTAAGAAGTTCATTGACTTCATTGA
CACATGTCTCATCAAGACTTACCTGAGCCGCCACCCACGGAGCAGCTACTGAAGTTTCCCTTCATCCGGGACAGCCCA
CGGAGCGGCAGGTCCGCATCCAGCTTAAGGACCACATTGACCGATCCCGGAAGAAGCGGGGTGAGAAAGAGGAGACAGAA
TATGAGTACAGCGGCAGCGAGGAGGAAGATGACAGCCATGGAGAGGAAGGAGAGCCAAGCTCCATCATGAACGTGCCTGG
AGAGTCGACTCTACCGCGGAGTTTCTCCGGCTCCAGCAGGAAAATAAGAGCAACTCAGAGGCTTTAAACAGCAGCAGC
AGCTGCAGCAGCAGCAGCAGCGAGACCCCGAGGCACACATCAAACACCTGCTGCACCAGCGGCAGCGGGCGCATAGAGGAG
CAGAAGGAGGAGCGGCGCCGCTGGAGGAGCAACAGCGCGGGAGCGGGAGCAGCGGAAGCTGCAGGAGAAGGAGCAGCA
GCGGCGGCTGGAGGACATGCAGGCTCTGCGGCGGGAGGAGGAGCGGCGGAGCGGAGCGCAGCAGGAATATATTCTGTC
ACAGGCTAGAGGAGGAGCAGCGACAGCTCGAGATCCTTCAGCAACAGCTGCTCCAGGAACAGGCCTGCTGCTGGAATAA

AAGCGGAAGCAGCTGGAGGAGCAGCGGCAGT CAGAACGTCTCCAGAGGCAGCTGCAGCAGGAGCATGCCTACCTCAAGTC
CCTGCAGCAGCAGCAACAGCAGCAGCAGCTT CAGAAACAGCAGCAGCAGCAGCTCCTGCCTGGGGACAGGAAGCCCCTGT
ACCATATGGTGGGGGCATGAATCCCGCTGACAAACAGCCTGGGCCCCGAGAGGTAGAAGAGAGAACAAGGATGAACAAG
CAGCAGAACTCTCCCTTGGCCAAGAGCAAGCCAGGCAGCACGGGGCCTGAGCCCCCATCCCCAGGCCCTCCCCAGGGCC
5 CCCAGGACCCCTTTCCCAGACTCCTCCTATGCAGAGGCCGGTGGAGCCCCAGGAGGGACCGACAAGAGCCTGGTGGCAC
ACCGGGTCCCACTGAAGCCATATGCAGCACCTGTACCCCGATCCAGTCCCTGCAGGACCAGCCACCCGAAACCTGGCT
GCCTTCCCAGCCTCCCATGACCCCGACCCTGCCATCCCCGCACCCACTGCCACGCCAGTGCCCGAGGAGCTGTCATCCG
CCAGAATTGAGACCCACCTCTGAAGGACCTGGCCCCAGCCGAATCCCCAGCCTGGGTCCGCCAGATAACGAGGGCCC
CACCCAAGGTGCCTCAGAGGACCTCATCTATCGCCACTGCCCTTAACACCACTGGGGCCGAGGGTCCCGGCCAGCCCAG
10 GCAGTCCGTGCCAGTAACCCGACCTCAGGAGGAGCGACCCTGGCTGGGAACGCTCGGACAGCGTCTTCCAGCCTCTCA
CGGGCACCTCCCCAGGCTGGCTCACTGGAGCGGAACCGCTGGGAGTCTCTCCAAACCGGACAGCTCCCCTGTGCTCT
CCCCTGGGAATAAAGCCAAGCCCGACGACCACCGCTCACGGCCAGGCCCGCCCGCAAGCTATAAGCGAGCAATTGGTGAG
GACTTTGTGTTGCTGAAAGAGCGGACTCTGGACGAGGCCCTCGGCCTCCCAAGAAGGCCATGGACTACTCGTCTGTCAG
15 CGAGGAGGTGGAAGCAGTGAGGACGACGAGGAGGAAGGCGAAGCGGGCCAGCAGAGGGGAGCAGAGATACCCCTGGGG
GCCGCAGCGATGGGGATACAGACAGCGTCAGCACCATGGTGGTCCAGCAGCTCGAGGAGATCACCGGGACCCAGCCCCCA
TACGGGGGGCGGCACCATGGTGGTCCAGCGCACCCCTGAAGAGGAGCGGAACCTGCTGCATGCTGACAGCAATGGGTACAC
AAACCTGCCTGACGTGGTCCAGCCCAGCCACTCACCCACCGAGAACAGCAAAGGCCAAAGCCCACCTCGAAGGATGGGA
GTGGTGACTACAGTCTCGTGGGCTGGTAAAGGCCCTGGCAAGAGCTCGTTACAGATGTTTGTGGATCTAGGGATCTAC
20 CAGCCTGGAGGCAGTGGGGACAGCATCCCCATCACAGCCCTAGTGGGTGGAGAGGGCACTCGGCTCGACCAGTGCAGTA
CGACGTGAGGAAGGGTTCTGTGGTCAACGTGAATCCCACCAACACCCGGGCCACAGTGAGACCCCTGAGATCCGGAAGT
ACAAGAAGCGATTCAACTCCGAGATCCTCTGTGCAGCCCTTTGGGGGTCAACCTGCTGGTGGGCACGAGAACGGGCTG
ATGTTGCTGGACCGAAGTGGGCAGGCAAGGTGTATGGACTCATTTGGGCGGCGACGCTTCCAGCAGATGGATGTGCTGGA
GGGGCTCAACCTGCTCATCACCATCTCAGGGAAAAGGAACAACTGCGGGTGTATTACCTGTCTGGCTCCGGAACAAGA
25 TTCTGCACAATGACCCAGAAGTGGAGAAGAAGCAGGGCTGGACCACCGTGGGGGACATGGAGGGCTCGGGGCACTACCGT
GTTGTGAATACGAGCGGATTAAGTTCTTGGTTCATCGCCCTCAAGAGCTCCGTGGAGGTGTATGCCTGGGCCCCAAACC
CTACCACAAATTATGGCCTTCAAGTCTTTGCCGACCTCCCCACCGCCCTCTGCTGGTGCACCTGACAGTAGAGGAGG
GGCAGCGGTCAAGGTCTATGGCTCCAGTGTGGCTTCCATGCTGTGGATGTGACTCGGGGAACAGCTATGACATC
TACATCCCTGTGCACATCCAGAGCCAGATCACGCCCCATGCCATCATCTCCTCCCAACACCGAGGCATGGAGATGCT
30 GCTGTGCTACGAGGACGAGGTGTCTACGTCAACACGTACGGGCGCATCATTAAGGATGTGGTGTGCTGAGTGGGGGAGA
TGCTACTTCTGTGGCCTACATCTGTCCAACCAGATAATGGGCTGGGGTGAGAAAGCCATTGAGATCCGCTCTGTGGAG
ACGGGCCACCTCGACGGGGTCTTATGCACAAACGAGCTCAGAGGCTCAAGTTCTGTGTGAGCGGAATGACAAGGTGTT
TTTTGCCTCAGTCCGCTCTGGGGGCAGCAGCCAAGTTACTTCTGACTCTGAACCGTAAGTGCATCATGAAGTGGTGA
(SEQ ID NO: 6)

MGDPAPARSLDDIDLALRDPAGIFELVEVVNGTYGVYKGRHVKTGQLAAIKVMDVTEDEEEIKQEIINMLKYSHHR
NIATYYGAFIKKSPPGNDQLWLVMEFCGAGSVTDLVKNTKGNALKEDCIAIYICREILRGLAHLHAHKVIHRDIKQNVL
LTENAEVKLVDFGVSQQLDRTVGRNTFIGTPYWMAPVIACDENPDATYDYSIDIWSLGITAIEMAEGAPPLCDMHPMR
ALFLIPRNPPLKSKKWSKFFIDFIDTCLIKTYLSRPTEQLLKFPFIRDQPTERQVRIQLKDHDIRSRRKRGEEETE
YEYSGEEDDSHGEEGEPSSIMNVPGESTLRREFLRLQENKSNSEALKQQQQLQQQQQDPEAHIKHLLHQRORRIEE
40 QKEERRRVEEQRREREQRKLQEQEQRRLEDQMALRREERROAEREQEYIRHRLLEEQRQLEILOQQLLEQALLLEY
KRKQLEEQRQSERLQROLQEHAYLKSLOQQQQQQQLKQOQQQLPGDRKPLYHYGRGMNPADKPAWAREVEERTMKN
QONSPLAKSKPGSTGPEPPIQASPGPPGPLSQTPPMQRPVEPQEGPHKSLVAHRVPLKPYAAPVPRSQSLQDQPTRNLA
AFPASHDPDAIPAPTATPSARGAVIRQNSDPTSEGPSPNPAPWVRPDNEAPPKVPORTSSIATLNTSGAGGSRAQ
AVRASNPDLRRSDPGWERSDSVLPASHGHLPOAGSLERNRVGVSSKPDSSPVLSPGNKAKPDHRSRFRGPASYKRAIGE
45 DFVLLKERTLDEAPRPKKAMDYSSSSSEEVESSEDEEEGEGGPAEGSRDTPGGRSDGDTDSVSTMVVDVEEITGTQPP
YGGGTMVVQRTPEEERNLLHADSNGYTNLPDVVQPSHSPTENSKGQSPPSKDGSGDYQSRGLVKAPGKSSFTMFVDLGIY

QPGGSGDSIPITALVGGEGTRLDQLQYDVRKGSVVNVNPTNTRAHSETPEIRKYKKRFNSEILCAALWGVNLLVGTENGL
 MLLDRSGQGKVGVLIGRRRFQOMDVLEGLNLLITISGKRNLKRVYLSWLRNKILHNDPEVEKKQGTTVGDMEGCGHYR
 VVKYERIKFLVIALKSSVEVYAWAPKPYHKFMAFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDSDGNSYDI
 YIPVHIQSQITPHAIIFLPNTDGMEMLLCYEDEGVYVNTYGRIIKDVVLQWGEMPTSVAYICSNQIMGWGEKATEIRSVE
 5 TGHLDGVMHKRAORLKLFLCERNDKVFFASVRSGGSSQVYFMTLNRNCIMNW (SEQ ID NO: 7)

The disclosed NOV-3a nucleic acid sequence has homology (73% identity) to a mouse mRNA for a NIK protein (NIK) (GenBank Accession No: MMU88984), as shown in Table 11. NIK proteins are a subgroup of the STE20 family of protein kinases. As indicated by the "Expect" value, the probability of this alignment occurring by chance alone is 4.3e-298, which is an incredibly low probability score. Moreover, the disclosed, encoded amino acid sequence has 1095 of 1332 amino acid residues (82%) identical to a human NIK-related protein (GenBank Accession No: BAA90753), as shown in Table 12. As indicated by the "Expect" value, the probability of this alignment occurring by chance alone is 0, the lowest probability score.

TABLE 11

Score = 3892 (584.0 bits), Expect = 4.3e-298, Sum P(2) = 4.3e-298
 Identities = 1224/1657 (73%), Positives = 1224/1657 (73%), Strand = Plus / Plus

NOV3a:	4	GGCGACCCAGCC-CCCGCCCGCAGCCTGGACGACATCGACCTGTCCGCCCTGCGGGACCC	62
		GGCGA C A C CCCGC AGCCTGG GACAT GACCTGTC CCCTGCGGGACCC	
NIK :	3	GGCGAACGACTCTCCCGCAAGAGCCTGGTGGACATTGACCTGTCGTCCCTGCGGGACCC	62
NOV3a:	63	TGCTGGGATCTTTGAGCTTGTGGAGGTGGTCGGCAATGGAACCTACGGACAGGTGTACAA	
122		TGCTGGGAT TTTGAGCT GTGGA GTGGT GG AATGG ACCTA GGACA GT TA AA	
NIK :	63	TGCTGGGATTTTGTAGCTGGTGGAAAGTGGTGGAAATGGCACCTATGGACAAGTCTATAA	
122			
NOV3a:	123	GGGTCGGCATGTCAAGACGGGGCAGCTGGCTGCCATCAAGGTCATGGATGTCACGGAGGA	
182		GGGTCG CATGT AA ACGG CA CTG C GCCATCAAGGT ATGGA GTCAC GAGGA	
NIK :	123	GGGTCGACATGTTAAACGGT-CA-CTGCC-GCCATCAAGGTATGGACGTCACCGAGGA	
179			
NOV3a:	183	CGAGGAGGAAGAGATCAAACAGGAGATCAACATGCTGAAAAAGTACTCTCACCACCGCAA	
242		GA GAGGAAGA ATCA AC GGAGAT AA ATGCTGAA AAGTA TCTCA CA CG AA	
NIK :	180	TGAAGAGGAAGAAATCACACTGGAGATAAATATGCTGAAGAAGTATTCTCATCATCGAAA	
239			
NOV3a:	243	CATCGCCACCTACTACGGAGCCTTCATCAAGAAGAGCCCCCGGAAACGATGACCAGCT	
302		AT GCCAC TACTA GG GC TTCAT AAGAAGAGCCC CC GGA A GATGACCA CT	
NIK :	240	TATTGCCACGTACTATGGTGCTTTTCATTAAGAAGAGCCCTCAGGACATGATGACCACT	
299			

NOV3a: 303 CTGGCTGGTGATGGAGTTCTGTGGTGCTGGTTCAGTGACTGACCTGGTAAAGAACACAAA
 362
 CTGGCT GT ATGGAGTT TGTGG GCTGG TC T AC GACCT GT AAGAACAC AA
 5 NIK : 300 CTGGCTTGTATGGAGTTTTGTGGGGCTGGGTCCATCACAGACCTTGTGAAGAACACCAA
 359
 NOV3a: 363 AGGCAACGCCCTGAAGGAGGACTGTATCGCCTATATCTGCAGGGAGATCCTCAGGGGTCT
 422
 AGG AAC C CT AA GA GACTG AT GC TA ATCT CAGGGA ATCCTCAGGGG T
 10 NIK : 360 AGGGAACACTCTCAAAGAAGACTGGATTGCTTACATCTCCAGGGAAATCCTCAGGGGATT
 419
 NOV3a: 423 GGCCCATCTCCATGCCACAAAGGTGATCCATCGAGACATCAAGGGGCAGAATGTGCTGCT
 482
 GGC CATCTCCAT CAC A GT AT CA CGAGA ATCAAGGG CA AATGTGCTGCT
 15 NIK : 420 GGCACATCTCCATATTACCACGTTATTACCAGAGATATCAAGGGCCAAAATGTGCTGCT
 479
 NOV3a: 483 GACAGAGAATGCTGAGGTCAAGCTAGTGGATTTTGGGGTGAGTGCTCAGCTGGACCGCAC
 542
 GAC GAGAAATGCTGAGGT AA CT GT GATTTTGG GT AG GCTCAGCTGGAC G AC
 NIK : 480 GACCGAGAATGCTGAGGTGAAACTTGTGATTTTGGTGTAAGCGCTCAGCTGGACAGGAC
 539
 20 NOV3a: 543 CGTGGG-CAGACGGAACACTTTCATTGGGACTCCCTACTGGATGGCTCCAGAGGTCATCG
 601
 GT GG C GA G AA AC TTCAT GG AC CCCTACTGGATGGCTCCAGAGGTCATCG
 NIK : 540 GGTGGACGGA-GAAATACGTTTCATAGGCACACCCTACTGGATGGCTCCAGAGGTCATCG
 598
 30
 NOV3a: 602 CCTGTGATGAGAACCCTGATGCCACCTATGATTACAGGAGTGATATTTGGTCTCTA-GGA
 660
 CCTGTGATGAGAACC GA GCCAC TA GA TACAG AGTGA T TGGTC CT GG
 35 NIK : 599 CCTGTGATGAGAACCAGACGCCACTTACGACTACAGAAGTGACCTCTGGTC-CTGTGGC
 657
 NOV3a: 661 ATCACAGCCATCGAGATGGCAGAGGGAGCCCCCTCTGTGTGACATGCACCCCATGCGA
 720
 ATCACAGCCATCGAGATGGC GA GG G CCCCCCTCT TGTGACATGCA CC ATG GA
 40 NIK : 658 ATCACAGCCATCGAGATGGCTGAAGGGGGCCCCCTCTCTGTGACATGCATCCAATGAGA
 717
 NOV3a: 721 GCCCTCTTCCTCATTCCTCGGAACCCTCCGCCCAGGCTCAAGTCCAAGAAGTGGTCTAAG
 780
 GC CT TT CTCAT CC G AACCCTCC CCCAGGCT AAGTC AA AA TGGTC AAG
 NIK : 718 GCGCTGTTTCTCATCCCCAGAAACCCTCCTCCAGGCTGAAGTCAAAAAAATGGTCAAAG
 777
 45
 NOV3a: 781 AAGTTCATTGA-CTTCATTGACACATGTCTCATCAAGACTTACCTG-AGCCGCCCACCCA
 838
 AA TT TT A CTT AT GA TGTCT T AAGA TTAC TG AGC GCCC C A
 NIK : 778 AAATTT-TTCAGCTTTATAGAAGGCTGTCTGGTGAAGAATTACATGCAGCGGCCCTCT-A
 835
 55
 NOV3a: 839 CGGAGCAGCTACTGAAGTTTCCCTTCATCCGGGACCAGCCCACGGAGCGGCAGGTCCGCA
 898
 C GAGCA CT T AA CC TTCAT GGGG CAGCCCA GA GGCAGGT CG A
 NIK : 836 CAGAGCAACTTTTAAACACCCTTTCATAAGGGATCAGCCCAATGAAAGGCAGGTTCGAA
 895
 60
 NOV3a: 899 TCCAGCTTAAGGACCACATTGACCGATCCCGGAAGAAGCGGGGTGAGAAAGAGGAGACAG
 958

TCCAGCTTAAGGA CACAT GACCG CC G AAGAAG G GG GAGAAAGA GAGAC G
 NIK : 896 TCCAGCTTAAGGATCACATAGACCGGACCAGAAAGAAGAGAGGCGAGAAAGATGAGACGG
 955

5 NOV3a: 959 AATATGAGTACAGCGGCAGCGAGGAGGAAGATGAC-A-GC-CATGGAG-AGGAAGGAGAG
 1014
 A TA GAGTACAGCGG AGCGAGGAGGA GA GA A G C TG AG AGGA GGAGAG
 NIK : 956 AGTACGAGTACAGCGGGAGCGAGGAGGAGGAGGAAGTGCCTG-AGCAGGAGGGAGAG
 1014

10 NOV3a: 1015 CCAAGCTCCATCATGAACGTGCCTGGAGAGTCTGACTCTACGCCGGGAGTTTCTCCGGCTC
 1074
 CCAAG TCCATC T AA GTGCCTGGAGAGTC ACTCT CG CG GA TT CT G CT
 NIK : 1015 CCAAGTTCCATCGTCAATGTGCCTGGAGAGTCAACTCTGCGACGTGATTTCTGAGACTG
 1074

15 NOV3a: 1075 CAGCAGGAAAATAAG-AGCAACTCAGAGGCTTTAAACAG-CAGCAGCAGCTGCAGCAGC
 1132
 CAGCAGGA AA AAG AGC TC GAGGCT T AG CAGCAGC CTGCAG AGC
 NIK : 1075 CAGCAGGAGAACAAGGAGCGG-TCTGAGGCTCTGCGG-AGACAGCAGCTTCTGCAGGAGC
 1132

20 NOV3a: 1133 AGCAGCAGCGAGACCCCGAGGCACACATCAAACACCTGCTGCACCAGCGGCAGCGGCGCA
 1192
 AGCAGC CG GA C GAGG A A A CA CTGCTG AG GGCAG GCG A
 NIK : 1133 AGCAGCTCCGGGAGCAGGAGGAGTATAAGAGGCAGCTGCTGGCTGAGAGGCAGAAGCGGA
 1192

25 NOV3a: 1193 TAGAGGAGCAGAAGGAGGAGCGGCGCCGCTGGAGGAGCAACAGCGGCGGGAGCGGGA-G
 1251
 T GA AGCAGAA GA AG GG G CG TGGA GAGCAACA G G GA CGGGA G
 NIK : 1193 TTGAACAGCAGAAAGAACAGAGGAGGCGGCTGGAAGAGCAACAAAGAAGAGAACGGGAAG
 1252

30 NOV3a: 1252 CAGCGGAAGCTGCAGGAGAAGGAGCAGCAGCGGCG-G--CTGGAGGACATGCAGGC-TCT
 1307
 C GGA GC GCAGGAG GAGCAGC GCGGCG G C GAGGA A G AGGC TCT
 NIK : 1253 CCA-GGAGGCAGCAGGAGCGTGAGCAGCGGCGGCGTGAACAAGAGGAGAAG-AGGCGTCT
 1310

40 NOV3a: 1308 GCGGCGGGA--GGAGGAGCGGCGGCGAGCGGAGCAGGAATATATTCGTACAGG
 1365
 CG GG A GGA GCGGCG A G GAG GAG AGGA A C A AGG
 NIK : 1311 -CGA-GGAACTGGAAGGCGGCGTAAAGAAGAGGAAGAG-AGGAG-ACGGGCAGAAGAGG
 1366

45 NOV3a: 1366 CTA-GAGGAG-GAGCAGCGACAGCTCGAGATCCTTCAGCAACAGCTGCTCCAGGAACAGG
 1423
 A GAGGAG G G AG G A C GAG T C TCAG C GC GCT AGGA AG
 NIK : 1367 AGAAGAGGAGAGTGGAGAGGGAACAGGAG-TACATCAGG--CGGCAGCTAGAGGAGGAGC
 1423

50 NOV3a: 1424 CCCTGCTGCTGGA-ATACA--AGCGGAAGCAGCTGGAGGAGCAGCGGCA-GTCAGAACGT
 1479
 C GC CTGGA AT C AGC G AGC GCT AGGAGCAG G CA GT A C
 NIK : 1424 AGCGGCACCTGGAGATCCTGCAGCAGCAGCTGCTCCAGGAGCAG-GCCATGTTACTGCAC
 1482

60 NOV3a: 1480 CTCCAGAGGCAGCTGCA-GCAGGAGCATGCCTACCTCAAGTCCCTGCAGCAGCAGCAACA
 1538
 CCA AGG GC GCA GCA AGCA GC CC C G CCC GCAGCAGCAG A CA

NIK : 1483 GACCACAGGAGGCCGCACGCAC-AGCA-GCAG-CCGCC-GCCCCCGCAGCAGCAGGA-CA
1537

5 NOV3a: 1539 GCAGCAG--C-AGCTT-CA-GAAACAGCAGCAGCAGCAGCTCC-TG-CC-TGGGGACAGG
1590

G AGCA C AGCTT CA G CAG AGC AGC C C TG CC TG GACAG
NIK : 1538 GGAGCAAACCGAGCTTTCATGCTCCAG-AGCCCAAGCCTCACTATGACCTGCTGACAG-
1595

10 NOV3a: 1591 AAGCCCCTGTACCATTATGGTCGGGGCATGAATCCCGCT-GA-CAAAC-CAGCCTGGGCC
1647

AGC C G A TGGTC C G ATC C C GA CAA C CC G C
NIK : 1596 -AGCTCGGGAGGTACAGTGGTCCACCTGGCATCTCTCAAGAACAATGTCTCCCTGTCT
1654

15 NOV3a: 1648 CGAGA 1652 (SEQ ID NO:62)
CGAGA

NIK : 1655 CGAGA 1659 (SEQ ID NO: 29)

20

TABLE 12

25 Score = 2104 bits (5451), Expect = 0.0
Identities = 1095/1332 (82%), Positives = 1095/1332 (82%), Gaps = 37/1332
(2%)

30 NOV3a: 1 MGD PAPARSLDDIDLSALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTX 60
MGDPAPARSLDDIDLSALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVT
NIK : 1 MGD PAPARSLDDIDLSALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTE 60

NOV3a: 61 XXXXXIKQEINMLKKYSHRNIATYYGAFIKKSPPGNDDQLWLVMEFCGAGSVTDLVKNT 120
IKQEINMLKKYSHRNIATYYGAFIKKSPPGNDDQLWLVMEFCGAGSVTDLVKNT
35 NIK : 61 DEEEEIKQEINMLKKYSHRNIATYYGAFIKKSPPGNDDQLWLVMEFCGAGSVTDLVKNT 120

NOV3a: 121 KGNALKEDCIAYICREILRGLAHLHAHKVIHRDIKGQNVLLTENA EVKLVD FGVSAQLDR 180
KGNALKEDCIAYICREILRGLAHLHAHKVIHRDIKGQNVLLTENA EVKLVD FGVSAQLDR
40 NIK : 121 KGNALKEDCIAYICREILRGLAHLHAHKVIHRDIKGQNVLLTENA EVKLVD FGVSAQLDR 180

NOV3a: 181 TVGRRNTFIGTPYWMAPEVIACDENPDATYDYS DIWSLGITAEIEMAEGAPPLCDMHPMR 240
TVGRRNTFIGTPYWMAPEVIACDENPDATYDYS DIWSLGITAEIEMAEGAPPLCDMHPMR
NIK : 181 TVGRRNTFIGTPYWMAPEVIACDENPDATYDYS DIWSLGITAEIEMAEGAPPLCDMHPMR 240

45 NOV3a: 241 ALFLIPRNPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPT EQLLKFPFIRDQPTERQVRI 300
ALFLIPRNPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPT EQLLKFPFIRDQPTERQVRI
NIK : 241 ALFLIPRNPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPT EQLLKFPFIRDQPTERQVRI 300

50 NOV3a: 301 QLKDHIXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX PSSIMNVPGESTLRREFLRLQQ 360
QLKDH I PSSIMNVPGESTLRREFLRLQQ
NIK : 301 QLKDHIDRSRKRGRGEKEETEYEGSSEEDDSHGEEGEPSSIMNVPGESTLRREFLRLQQ 360

NOV3a: 361 ENKSNSEALKXXXXXXXXXXRDPEAHIKHLLHXXXXXXXXXXXXXXXXXXXXXXXXXXXX 420
ENKSNSEALK RDPEAHIKHLLH
55 NIK : 361 ENKSNSEALKQQQQQLQQQQQRPDPEAHIKHLLHQRRRIEEQKEERRRVEEQRREREQRK 420

NOV3a: 421 XXXXXXXXXXXXDMQALXXXXXXXXXXXXXXXXXXYIRHXXXXXXXXXXXXXXXXXXXXX 480
DMQAL Y

60 NIK : 421 LQEKQQRRLEDMQAL-----RREEERRQAEREQEY 451

NOV3a: 481 KRKXXXXXXXXXXXXXXXXXXHAYLKSXXXXXXXXXXXXXXXXXXPGDRKPLYHYGRGM 540
KRK HAYLKS PGDRKPLYHYGRGM

NIK : 452 KRKQLEEQRQSERLQORQLQOEHA YLKS LQOQOQOQOQLQKQOQOQLLPQDRKPLYHYGRGM 511
 NOV3a: 541 NPADKPAWAREVEERTRMNKQONSPLAKSKPGSTXXXXXXXXXXXXXXXXXXXXXXXXXMQRP 600
 NPADKPAWAREVEERTRMNKQONSPLAKSKPGST MQRP
 5 NIK : 512 NPADKPAWAREVEERTRMNKQONSPLAKSKPGSTGPEPPIQASPGPPGPLSQTPPMQRP 571
 NOV3a: 601 VEPQEGPHKSLVAHRVPLKPYAAPVPRSQSLQDQPTRNLAAFPASHXXXXXXXXXXXXXXXXX 660
 VEPQEGPHKSLVAHRVPLKPYAAPVPRSQSLQDQPTRNLAAFPASH
 10 NIK : 572 VEPQEGPHKSLVAHRVPLKPYAAPVPRSQSLQDQPTRNLAAFPASHDPPAIPAPTATPS 631
 NOV3a: 661 XRGAVIRQNSDPTSEGGPSPNPPAWVRPDNEAPPKVPQRTSSIALNTSGAGGSRPAQ 720
 RGAVIRQNSDPTSEGGPSPNPPAWVRPDNEAPPKVPQRTSSIALNTSGAGGSRPAQ
 NIK : 632 ARGAVIRQNSDPTSEGGPSPNPPAWVRPDNEAPPKVPQRTSSIALNTSGAGGSRPAQ 691
 15 NOV3a: 721 AVRASNPD LRRSDPGWERSDSVLPASHGHL PQAGSLERNRVGVSSKPDSSPVLSPGNKAK 780
 AVRASNPD LRRSDPGWERSDSVLPASHGHL PQAGSLERNRVGVSSKPDSSPVLSPGNKAK
 NIK : 692 AVRASNPD LRRSDPGWERSDSVLPASHGHL PQAGSLERNRVGVSSKPDSSPVLSPGNKAK 751
 NOV3a: 781 PDDHRSRPGRPASYKRAIGEDFVLLKERTLDEAPRPPKKAMDYXXXXXXXXXXXXXXXXX 840
 PDDHRSRPGRPA DFVLLKERTLDEAPRPPKKAMDY
 20 NIK : 752 PDDHRSRPGRPA-----DFVLLKERTLDEAPRPPKKAMDYSSSSEEVESEDDEEEG 803
 NOV3a: 841 XXXXXXXXRDTPGGRSDGDTDSVSTMVVDVEEITGTQPPYGGGT MVVQRTPEEERNLLH 900
 RDTPGGRSDGDTDSVSTMVVDVEEITGTQPPYGGGT MVVQRTPEEERNLLH
 25 NIK : 804 EGGPAEGSRDTPGGRSDGDTDSVSTMVVDVEEITGTQPPYGGGT MVVQRTPEEERNLLH 863
 NOV3a: 901 ADSNGYTNLPDVVQPSHSPTENSKGQSPPSKDGSGDYQSRGLVKAPGKSFTMFVDLGIY 960
 ADSNGYTNLPDVVQPSHSPTENSKGQSPPSKDGSGDYQSRGLVKAPGKSFTMFVDLGIY
 30 NIK : 864 ADSNGYTNLPDVVQPSHSPTENSKGQSPPSKDGSGDYQSRGLVKAPGKSFTMFVDLGIY 923
 NOV3a: 961 QPGGSGDSIPITALVGGEGRDQLQYDVRKGSVVVNPTNTRAHSETPEIRKYKKRFNS 1020
 QPGGSGDSIPITALVGGEGRDQLQYDVRKGSVVVNPTNTRAHSETPEIRKYKKRFNS
 35 NIK : 924 QPGGSGDSIPITALVGGEGRDQLQYDVRKGSVVVNPTNTRAHSETPEIRKYKKRFNS 983
 NOV3a: 1021 EILCAALWGVNLLVGTENGLMLLDRSGQGVYGLIGRRRFQOMDVLEGLNLLITISGKR 1080
 EILCAALWGVNLLVGTENGLMLLDRSGQGVYGLIGRRRFQOMDVLEGLNLLITISGKR
 40 NIK : 984 EILCAALWGVNLLVGTENGLMLLDRSGQGVYGLIGRRRFQOMDVLEGLNLLITISGKR 1043
 NOV3a: 1081 KLRVYYLSWLRNKILHNDPEVEKKQGWTTVGDMEGCGHYRVVKYERIKFLVIALKSSVE 1140
 KLRVYYLSWLRNKILHNDPEVEKKQGWTTVGDMEGCGHYRVVKYERIKFLVIALKSSVE
 45 NIK : 1044 KLRVYYLSWLRNKILHNDPEVEKKQGWTTVGDMEGCGHYRVVKYERIKFLVIALKSSVE 1103
 NOV3a: 1141 YAWAPKPYHKFMAFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDVDSGNSYDI 1200
 YAWAPKPYHKFMAFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDVDSGNSYDI
 50 NIK : 1104 YAWAPKPYHKFMAFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDVDSGNSYDI 1163
 NOV3a: 1201 YIPVHIQSQITPHAIIFLPNTDGMEMLLCYEDEGVYVNTYGR I IKDVVLQWGEMPTSVAY 1260
 YIPVHIQSQITPHAIIFLPNTDGMEMLLCYEDEGVYVNTYGR I IKDVVLQWGEMPTSVAY
 55 NIK : 1164 YIPVHIQSQITPHAIIFLPNTDGMEMLLCYEDEGVYVNTYGR I IKDVVLQWGEMPTSVAY 1223
 NOV3a: 1261 ICSNQIMGWGEKAIEIRSVETGHL DGVFMHKRAQRLKFLCERN DKVFFASVRSGGSSQVY 1320
 ICSNQIMGWGEKAIEIRSVETGHL DGVFMHKRAQRLKFLCERN DKVFFASVRSGGSSQVY

NIK : 1224 ICSNQIMGWGEKAIEIRSVETGHLDGVMHKRAQRLKFLCERNDKVFFASVRSGSSQVY
1283

NOV3a: 1321 FMTLNRNCIMNW 1332 (SEQ ID NO: 63)

FMTLNRNCIMNW

NIK : 1284 FMTLNRNCIMNW 1295 (SEQ ID NO: 30)

Based on its relatedness to known members of the STE20 family of protein kinases, NOV3a provides new diagnostic and therapeutic compositions useful in the treatment of disorders associated with alterations in the expression of members of the STE20 family of protein kinases. Nucleic acids, polypeptides, antibodies, and other compositions of the present invention are useful in the treatment and diagnosis of a variety of diseases and pathologies, including, by way of nonlimiting example, those involving metabolic and endocrine disorders, cancer, bone disorders, and tissue/cell growth regulation disorders.

NOV-3b

A NOV-3b sequence according to the invention is a nucleic acid sequence encoding a polypeptide related to STE20 family of protein kinases. A disclosed NOV-3b nucleic acid and its encoded polypeptide includes the sequences shown in Table 13. The disclosed nucleic acid (SEQ ID NO: 8) is 3912 nucleotides in length and contains an open reading frame (ORF) that begins with an ATG initiation codon at nucleotides 1-3 and ends with a TGA stop codon at nucleotides 3910-3912. The start and stop codons are shown in bold font. The respective ORF encodes a 1303 amino acid polypeptide (SEQ ID NO: 9).

TABLE 13

ATGGGCGACCCAGCCCCCGCCCGCAGCCTGGACGACATCGACCTGTCCGCCCTGCCGGACCCCTGCTGGGATCTTTGAGCT
TGTGGAGGTGGTTCGGCAATGGAACCTACGGACAGGTGTACAAGGGTCGGCATGTCAAGACGGGGCAGCTGGCTGCCATCA
AGGTCATGGATGTCACGGAGGACGAGGAGGAAGAGATCAAACAGGAGATCAACATGCTGAAAAAGTACTCTCACCACCGC
AACATCGCCACCTACTACGGAGCCTTCATCAAGAAGAGCCCCCGGGAACGATGACCAGCTCTGGCTGGTGTGAGGTT
CTGTGGTGTGTTTCAGTGACTGACCTGGTAAGAACAACAAAGGCAACGCCCTGAAGGAGGACTGTATCGCCTATATCT
GCAGGGAGATCCTCAGGGGTCTGGCCCATCTCCATGCCCAAGGTGATCCATCGAGACATCAAGGGGCAGAATGTGCTG
CTGACAGAGAATGCTGAGGTCAAGCTAGTGGATTTTGGGGTGAGTGCTCAGCTGGACCGCACCGTGGGCAGACGGAACAC
TTTCATTGGGACTCCCTACTGGATGGCTCCAGAGGTTCATCGCCTGTGATGAGAACCCTGATGCCACCTATGATTACAGGA
GTGATATTTGGTCTCTAGGAATCACAGCCATCGAGATGGCAGAGGGAGCCCCCTCTGTGTGACATGCACCCCATGCGA
GCCCTCTTCCTCATTCCTCGGAACCTCCGCCAGGCTCAAGTCCAAGAAGTGGTCTAAGAAGTTTCATTGACTTCATTGA
CACATGTCTCATCAAGACTTACCTGAGCCGCCACCCAGGAGCAGCTACTGAAGTTTCCCTTCATCCGGGACCAGCCCA
CGGAGCGGCAGGTCCGCATCCAGCTTAAGGACCACATTGACCGATCCCGGAAGAAGCGGGGTGAGAAAGAGGAGACAGAA
TATGAGTACAGCGGCAGCGAGGAGGAAGATGACAGCCATGGAGAGGAAGGAGAGCCAAGCTCCATCATGAACGTGCCTGG
AGAGTCGACTCTACGCCGGGAGTTTCTCCGGCTCCAGCAGGAAATAAGAGCAACTCAGAGGCTTTAAACAGCAGCAGC
AGCTGCAGCAGCAGCAGCAGGAGACCCGAGGCACACATCAAACACCTGCTGCACCAGCGGCAGCGGCGCATAGAGGAG
CAGAAGGAGGAGCGCGCCGCTGGAGGAGCAACAGCGCGGGAGCGGGAGCAGCGGAAGCTGCAGGAGAAGGAGCAGCA

NO: 8)

MGDPAPARSLDDIDLALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTEDEEEETKQEIINMLKKYSHHR
NIATYYGAFIKKSPPGNDQLWLVMFCGAGSVTDLVKNTKGNALKEDCIAIYICREILRGLAHLHAHKVVIHRDIKQONVL
LTENAEVKLVDFGVSAQLDRTVGRNRTFIGTPYWMAPEVIACDENPDATYDYRSDIWSLGITAIEMAEGAPPLCDMHMPMR
ALFLIPRNPPLRLKSKKWSKKFIDFIDTCLIKTYLSRPTEQLLKFPFIRDOPTERQVRIQLKDHIHRSRKKRGEKEETE
YEYSGSEEDDSHGEEGEPSSIMNVPGESTLRREFRLRQENKSNSEALKQQQQQLQQQQORDPEAHIKHLLHQRORRIEE
QKEERRRVEEQRRREREQRKLOEKEQORRLIEDMQALRREEERRQAEREQEYIRHRLEEQRQSERLQROLQQEHAYLKSLO
QQQQQQQLQKQQQQQLPGDRKPLYHYGRGMNPADKPAWAREVEERTRMNKQONSFLAKSKPGSTGPEPPIQASPGGPG
PLSQTPPMQRPVEPQEGPHKSLVAHRVPLKPYAAPVPRSQSLQDQPTRNLAAFPASHDPDAIPAPTATPSARGAVIRQN
SDPTSEGPGPSPNPPAWVRPDNEAPPKVPQRTSSIATAINTSGAGGSRPAQAVRASNPDLRRSDPGWERSDSVLPASHGH
LPQAGSLERNRVGVSSKPDSSPVLSPGNKAKPDDHRSRPGRPASYSKRAIGEDFVLLKERTLDEAPRPPKKAMDYSSSSEE
VESSEDEEEEGEGGPAEGSRDTPGGRSDGDTDSVSTMVVDHVEEITGTOPPYGGGTMMVORTPEERENLLHADSNGYTNL

PDVVQPSHSPTEENSKGQSPPSKDGSGDYQSRGLVKAPGKSSFTMFVDLGIYQPGSGDSIPITALVGGEGTRLDQLQYDV
 RKGSVVNVNPTNTRAHSETPEIRKYKKRFNSEILCAALWGVNLLVGTENGLMLLDRSGQCKVYGLIGRRRFQOMDVLEGL
 NLLITISGKRNLKRVYLSWLRNKLHNDPEVEKKQGWTTVGDMEGCGHYRVVKYERIKFLVIALKSSVEVYAWAPKPYH
 KFMAFKSFADLPHRPLLDLTVEEGQRLKVIYGSAGFHAVDSDGNSYDIYIPVHIQSQITPHAIIFLNTDGMEMLLC
 YEDEGVYVNTYGRILKDVVLQWEMPTSVAYICSNQIMGWGEKAIEIRSVETGHLDGVMHKRAQRLKFLCERNDKVFFA
 SVRSGGSSQVYFMTLNRNCIMNW (SEQ ID NO: 9)

The disclosed NOV-3b nucleic acid sequence has homology (75% identity) to a mouse mRNA for a NIK protein (NIK) (GenBank Accession No: MMU88984), as shown in Table

14. NIK proteins are a subgroup of the STE20 family of protein kinases. As indicated by the "Expect" value, the probability of this alignment occurring by chance alone is $3.3e-295$, which is an incredibly low probability score. Moreover, the disclosed, encoded amino acid sequence has 1093 of 1303 amino acid residues (83%) identical to a human NIK-related protein (GenBank Accession No: BAA90753), as shown in Table 15. As indicated by the "Expect" value, the probability of this alignment occurring by chance alone is 0.0, the lowest probability score.

TABLE 14

Score = 3828 (574.4 bits); Expect = $3.3e-295$, Sum P(2) = $3.3e-295$

Identities = 1128/1488 (75%), Positives = 1128/1488 (75%), Strand = Plus / Plus

NOV3b:	4	GGCGACCCAGCC-CCCGCCCGCAGCCTGGACGACATCGACCTGTCCGCCCTGCGGGACCC	62
NIK :	3	GGCGA C A C CCCGC AGCCTGG GACAT GACCTGTC CCCTGCGGGACCC	62
NOV3b:	63	TGCTGGGATCTTTGAGCTTGTGGAGGTGGTTCGGCAATGGAACCTACGGACAGGTGTACAA	122
NIK :	63	TGCTGGGAT TTTGAGCT GTGGA GTGGT GG AATGG ACCTA GGACA GT TA AA	122
NOV3b:	123	GGGTCGGCATGTCAAGACGGGGCAGCTGGCTGCCATCAAGGTCATGGATGTCACGGAGGA	182
NIK :	123	GGGTCG CATGT AA ACGG CA CTG C GCCATCAAGGT ATGGA GTCAC GAGGA	179
NOV3b:	183	CGAGGAGGAAGAGATCAAACAGGAGATCAACATGCTGAAAAAGTACTCTCACCACCGCAA	242
NIK :	180	GA GAGGAAGA ATCA AC GGAGAT AA ATGCTGAA AAGTA TCTCA CA CG AA	239
NOV3b:	243	CATCGCCACCTACTACGGAGCCTTCATCAAGAAGAGCCCCCGGGAAACGATGACCAGCT	302
NIK :	240	AT GCCAC TACTA GG GC TTCAT AAGAAGAGCCC CC GGA A GATGACCA CT	299

NOV3b: 303 CTGGCTGGTGATGGAGTTCTGTGGTGGTTCAGTGAAGTACCTGGTAAAGAACACAAA
 362
 CTGGCT GT ATGGAGTT TGTGG GCTGG TC T AC GACCT GT AAGAACAC AA
 5 NIK : 300 CTGGCTTGTATGGAGTTTTGTGGGGCTGGGTCCATCACAGACCTTGTGAAGAACACCAA
 359
 NOV3b: 363 AGGCAACGCCCTGAAGGAGGACTGTATCGCCTATATCTGCAGGGAGATCCTCAGGGGTCT
 422
 AGG AAC C CT AA GA GACTG AT GC TA ATCT CAGGGA ATCCTCAGGGG T
 10 NIK : 360 AGGGAACACTCTCAAAGAAGACTGGATTGCTTACATCTCCAGGGAAATCCTCAGGGGATT
 419
 NOV3b: 423 GGCCCATCTCCATGCCACACAAGGTGATCCATCGAGACATCAAGGGGCAGAATGTGCTGCT
 482
 GGC CATCTCCAT CAC A GT AT CA CGAGA ATCAAGGG CA AATGTGCTGCT
 15 NIK : 420 GGCACATCTCCATATTCACCACGTTATTCACCGAGATATCAAGGGCCAAATGTGCTGCT
 479
 NOV3b: 483 GACAGAGAATGCTGAGGTCAAGCTAGTGGATTTTGGGGTGAGTGCTCAGCTGGACCGCAC
 542
 GAC GAGAATGCTGAGGT AA CT GT GATTTTGG GT AG GCTCAGCTGGAC G AC
 NIK : 480 GACCGAGAATGCTGAGGTGAAACTTGTGATTTTGGTGTAAAGCGCTCAGCTGGACAGGAC
 539
 20
 NOV3b: 543 CGTGGG-CAGACGGAACACTTTCATTGGGACTCCCTACTGGATGGCTCCAGAGGTCATCG
 601
 GT GG C GA G AA AC TTCAT GG AC CCCTACTGGATGGCTCCAGAGGTCATCG
 NIK : 540 GGTGGACGGA-GAAATACGTTTCATAGGCACACCCCTACTGGATGGCTCCAGAGGTCATCG
 598
 30
 NOV3b: 602 CCTGTGATGAGAACCCTGATGCCACCTATGATTACAGGAGTGATATTTGGTCTCTA-GGA
 660
 CCTGTGATGAGAACCC GA GCCAC TA GA TACAG AGTGA T TGGTC CT GG
 35 NIK : 599 CCTGTGATGAGAACCCAGACGCCACTTACGACTACAGAAGTGACCTCTGGTC-CTGTGGC
 657
 NOV3b: 661 ATCACAGCCATCGAGATGGCAGAGGGAGCCCCCTCTGTGTGACATGCACCCCATGCGA
 720
 ATCACAGCCATCGAGATGGC GA GG G CCCCCCTCT TGTGACATGCA CC ATG GA
 40 NIK : 658 ATCACAGCCATCGAGATGGCTGAAGGGGGCCCCCTCTCTGTGACATGCATCCAATGAGA
 717
 NOV3b: 721 GCCCTCTTCCTCATTCTCGGAACCTCCGCCCAGGCTCAAGTCCAAGAAGTGGTCTAAG
 780
 GC CT TT CTCAT CC G AACCTCC CCCAGGCT AAGTC AA AA TGGTC AAG
 NIK : 718 GCGCTGTTCTCATCCCCAGAAACCTCCTCCAGGCTGAAGTCAAAAAAATGGTCAAAG
 777
 45
 NOV3b: 781 AAGTTCATTGA-CTTCATTGACACATGTCTCATCAAGACTTACCTG-AGCCGCCCACCCA
 838
 AA TT TT A CTT AT GA TGTCT T AAGA TTAC TG AGC GCCC C A
 NIK : 778 AAATTT-TTCAGCTTTATAGAAGGCTGTCTGGTGAAGAATTACATGCAGCGGCCCTCT-A
 835
 55
 NOV3b: 839 CGGAGCAGCTACTGAAGTTTCCTTCATCCGGGACCAGCCCACGGAGCGGCAGGTCCGCA
 898
 C GAGCA CT T AA CC TTCAT GGGG CAGCCCA GA GGCAGGT CG A
 NIK : 836 CAGAGCAACTTTTAAACACCCCTTTCATAAGGGATCAGCCCAATGAAAGGCAGGTTCGAA
 895
 60
 NOV3b: 899 TCCAGCTTAAGGACCACATTGACCGATCCCGGAAGAAGCGGGGTGAGAAAGAGGAGACAG
 958

TCCAGCTTAAGGA CACAT GACCG CC G AAGAAG G GG GAGAAAGA GAGAC G
 NIK : 896 TCCAGCTTAAGGATCACATAGACCGGACCAGAAAGAAGAGAGGCGAGAAAGATGAGACGG
 955

5 NOV3b: 959 AATATGAGTACAGCGGCAGCGAGGAGGAAGATGAC-A-GC-CATGGAG-AGGAAGGAGAG
 1014
 A TA GAGTACAGCGG AGCGAGGAGGA GA GA A G C TG AG AGGA GGAGAG
 NIK : 956 AGTACGAGTACAGCGGGAGCGAGGAGGAGGAGGAAGTGCCTG-AGCAGGAGGGAGAG
 1014

10 NOV3b: 1015 CCAAGCTCCATCATGAACGTGCCTGGAGAGTCTGACTCTACGCCGGGAGTTTCTCCGGCTC
 1074
 CCAAG TCCATC T AA GTGCCTGGAGAGTC ACTCT CG CG GA TT CT G CT
 NIK : 1015 CCAAGTTCCATCGTCAATGTGCCTGGAGAGTCAACTCTGCGACGTGATTTCTGAGACTG
 1074

15 NOV3b: 1075 CAGCAGGAAAATAAG-AGCAACTCAGAGGCTTTAAACAG-CAGCAGCAGCTGCAGCAGC
 1132
 CAGCAGGA AA AAG AGC TC GAGGCT T AG CAGCAGC CTGCAG AGC
 20 NIK : 1075 CAGCAGGAGAACAAGGAGCGG-TCTGAGGCTCTGCGG-AGACAGCAGCTTCTGCAGGAGC
 1132

NOV3b: 1133 AGCAGCAGCGAGACCCCGAGGCACACATCAAACACCTGCTGCACCAGCGGCAGCGGCGCA
 1192
 AGCAGC CG GA C GAGG A A A CA CTGCTG AG GGCAG GCG A
 25 NIK : 1133 AGCAGCTCCGGGAGCAGGAGGAGTATAAGAGGCAGCTGCTGGCTGAGAGGCAGAAGCGGA
 1192

NOV3b: 1193 TAGAGGAGCAGAAGGAGGAGCGGCGCCGCTGGAGGAGCAACAGCGGCGGGAGCGGGA-G
 1251
 T GA AGCAGAA GA AG GG G CG TGGG GAGCAACA G G GA CGGGA G
 NIK : 1193 TTGAACAGCAGAAAGAACAGAGGAGGCGGCTGGAAGAGCAACAAAGAAGAGAACGGGAAG
 1252

30 NOV3b: 1252 CAGCGGAAGCTGCAGGAGAAGGAGCAGCAGCGGCG-G--CTGGAGGACATGCAGGC-TCT
 1307
 C GGA GC GCAGGAG GAGCAGC GCGGCG G C GAGGA A G AGGC TCT
 NIK : 1253 CCA-GGAGGCAGCAGGAGCGTGAGCAGCGGCGGCTGAACAAGAGGAGAAG-AGGCGTCT
 1310

40 NOV3b: 1308 GCGGCGGGA--GGAGGAGCGGCGGCAGGCGGAGCGGAGCAGGAATATATTTCGTACAGG
 1365
 CG GG A GGA GCGGCG A G GAG GAG AGGA A C A AGG
 45 NIK : 1311 -CGA-GGAACTGGAAAGGCGGCGTAAAGAAGAGGAAGAG-AGGAG-ACGGGCAGAAGAGG
 1366

NOV3b: 1366 CTA-GAGGAGCAGCGGC-AGT---CAGAACGT-CTCCAGA-GGCAGCTGCAGCAGGAGCA
 1418
 A GAGGAG AG GG AG CAG A GT C CAG GGCAGCT AG AGGAGCA
 50 NIK : 1367 AGAAGAGGAG-AGTGGAGAGGGAACAGGA-GTACATCAGGCGGCAGCTAGAGGAGGAGCA
 1424

NOV3b: 1419 T-GCCTACCTCAAGTCCCTGCAGCAGCAGCAACAGCAGCAGCAGCTTCA-GAAACAGCAG
 1476
 G C ACCT AG CCTGCAGCAGCAGC C CAG AGCAG CA G AC GCA
 55 NIK : 1425 GCGGC-ACCTGGAGATCCTGCAGCAGCAGCTGCTCCAGGAGCAGGC-CATGTTACTGCAC
 1482

NOV3b: 1477 CAGCAGCAG 1485 (SEQ ID NO: 64)
 A CA CAG
 60 NIK : 1483 GACCA-CAG 1490 (SEQ ID NO: 31)

TABLE 15

Score = 2114 bits (5478), Expect = 0.0

Identities = 1093/1303 (83%), Positives = 1093/1303 (83%), Gaps = 8/1303 (0%)

5	NOV3b: 1	MGDPAPARSLDDIDLSALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTX	60
	NIK : 1	MGDPAPARSLDDIDLSALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVT	60
10	NOV3b: 61	XXXXXIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDQDLWLVMFCGAGSVTDLVKNT	120
	NIK : 61	DEEEEIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDQDLWLVMFCGAGSVTDLVKNT	120
15	NOV3b: 121	KGNALKEDCIAIYICREILRGLAHLHAHKVIHRDIKGQNVLLTENA EVKLVD FGVSAQLDR	180
	NIK : 121	KGNALKEDCIAIYICREILRGLAHLHAHKVIHRDIKGQNVLLTENA EVKLVD FGVSAQLDR	180
20	NOV3b: 181	TVGRRNTFIGTPYWMapeviACDENPDATYDYSdiwSLGITAIEMAEGAPPLCDMHPMR	240
	NIK : 181	TVGRRNTFIGTPYWMapeviACDENPDATYDYSdiwSLGITAIEMAEGAPPLCDMHPMR	240
25	NOV3b: 241	ALFLIPRNPPPRLKSKKWSKKFIDFIDTCLIKTYLSRPTEQLLKFPFIRDQPTERQVRI	300
	NIK : 241	ALFLIPRNPPPRLKSKKWSKKFIDFIDTCLIKTYLSRPTEQLLKFPFIRDQPTERQVRI	300
	NOV3b: 301	QLKDHIXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX PSSIMNVPGESTLRREFLRLQQ	360
	NIK : 301	QLKDHIDRSRKKRGEKEETEYEGSGSEEDDSHGEEGEPSSIMNVPGESTLRREFLRLQQ	360
30	NOV3b: 361	ENKSNSEALKXXXXXXXXXXRDPEAHIKHLLHXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	420
	NIK : 361	ENKSNSEALKXXXXXXXXXXRDPEAHIKHLLHXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	420
35	NOV3b: 421	XXXXXXXXXXDMQALXXXXXXXXXXXXXXXXXXYIRHXXXXXXXXXXXXXXXXXXHAYLKSXX	480
	NIK : 421	LQEKEQORRLED MQALRREERRQAEREQEYKRKQLEEQRQSERLQRQLQEHAYLKS LQ	480
40	NOV3b: 481	XXXXXXXXXXXXXXXXXXPGDRKPLYHYGRGMNPADKPAWAREVEERTRMNKQONSPLAKS	540
	NIK : 481	QOQOQOQLKQOQOQLLPGDRKPLYHYGRGMNPADKPAWAREVEERTRMNKQONSPLAKS	540
45	NOV3b: 541	KPGSTXXXXXXXXXXXXXXXXXXXXXXXXXMRPVEPQEGPHKSLVAHRVPLKPYAAPVPRSQ	600
	NIK : 541	KPGSTGPEPPI PQASPGPPGPLSQTPPMQRPVEPQEGPHKSLVAHRVPLKPYAAPVPRSQ	600
50	NOV3b: 601	SLQDQPTRNLAAFPASHXXXXXXXXXXXXXXXXXRGAVIRQNSDPTSEGPSPNPPAWVRP	660
	NIK : 601	SLQDQPTRNLAAFPASHDPDAIPAPTATPSARGAVIRQNSDPTSEGPSPNPPAWVRP	660
55	NOV3b: 721	LPQAGSLERNRVGVSSKPDSSPVLSPGNKAKPDDHRSRPGRPASYPKRAIGEDFVLLKERT	780
	NIK : 721	LPQAGSLERNRVGVSSKPDSSPVLSPGNKAKPDDHRSRPGRPA-----DFVLLKERT	772
60	NOV3b: 781	LDEAPRPPKKAMDYXXXXXXXXXXXXXXXXXXXXXXXXXRDTPGGRSDGDTDSVSTMVH	840
	NIK : 773	LDEAPRPPKKAMDYSSSSEEVESSEDEEEGEGGPAEGSRDTPGGRSDGDTDSVSTMVH	832
	NOV3b: 841	DVEEITGTQPPYGGGTMMVQRTPEEERNLLHADSNGYTNPDPVQPSHSPTENSKGQSPP	900

		DVEEITGTQPPYGGGTMVVQRTPEEERNLLHADSNGYTNLPDVVQPSHSPTENSKGQSPP	
	NIK : 833	DVEEITGTQPPYGGGTMVVQRTPEEERNLLHADSNGYTNLPDVVQPSHSPTENSKGQSPP	892
5	NOV3b: 901	SKDGSGDYQSRGLVKAPGKSSFTMFVDLGIYQPGGSGDSIPITALVGGEGRDLQLOYDV	960
		SKDGSGDYQSRGLVKAPGKSSFTMFVDLGIYQPGGSGDSIPITALVGGEGRDLQLOYDV	
	NIK : 893	SKDGSGDYQSRGLVKAPGKSSFTMFVDLGIYQPGGSGDSIPITALVGGEGRDLQLOYDV	952
	NOV3b: 961	RKGSVVNVNPTNTRAHSETPEIRKYKRFNSEILCAALWGVNLLVGTENGLMLLDRSGQG	
	1020		
10		RKGSVVNVNPTNTRAHSETPEIRKYKRFNSEILCAALWGVNLLVGTENGLMLLDRSGQG	
	NIK : 953	RKGSVVNVNPTNTRAHSETPEIRKYKRFNSEILCAALWGVNLLVGTENGLMLLDRSGQG	
	1012		
	NOV3b: 1021	KVYGLIGRRRFQQMDVLEGLNLLITISGKRNLRVYYLSWLRNKILHNDPEVEKKQGWT	
	1080		
		KVYGLIGRRRFQQMDVLEGLNLLITISGKRNLRVYYLSWLRNKILHNDPEVEKKQGWT	
	NIK : 1013	KVYGLIGRRRFQQMDVLEGLNLLITISGKRNLRVYYLSWLRNKILHNDPEVEKKQGWT	
	1072		
20	NOV3b: 1081	VGDMEGCGHYRVVKYERIKFLVIALKSSVEVYAWAPKPYHKFMAFKSFADLPHRPLLVDL	
	1140		
		VGDMEGCGHYRVVKYERIKFLVIALKSSVEVYAWAPKPYHKFMAFKSFADLPHRPLLVDL	
	NIK : 1073	VGDMEGCGHYRVVKYERIKFLVIALKSSVEVYAWAPKPYHKFMAFKSFADLPHRPLLVDL	
	1132		
25	NOV3b: 1141	TVEEGQRLKVIYGSSAGFHAVDSDSGNSYDIYIPVHIQSQITPHAIIFLNTDGMEMLLC	
	1200		
		TVEEGQRLKVIYGSSAGFHAVDSDSGNSYDIYIPVHIQSQITPHAIIFLNTDGMEMLLC	
	NIK : 1133	TVEEGQRLKVIYGSSAGFHAVDSDSGNSYDIYIPVHIQSQITPHAIIFLNTDGMEMLLC	
30	1192		
	NOV3b: 1201	YEDEGVYVNTYGRIIKDVVLQWGEMPTSVAYICSNQIMGWGEKAIEIRSVETGHLDGVM	
	1260		
		YEDEGVYVNTYGRIIKDVVLQWGEMPTSVAYICSNQIMGWGEKAIEIRSVETGHLDGVM	
35	NIK : 1193	YEDEGVYVNTYGRIIKDVVLQWGEMPTSVAYICSNQIMGWGEKAIEIRSVETGHLDGVM	
	1252		
	NOV3b: 1261	HKRAQRLKFLCERNDKVFFASVRS GGSSQVYFMTLNRNCIMNW	1303 (SEQ ID NO: 65)
		HKRAQRLKFLCERNDKVFFASVRS GGSSQVYFMTLNRNCIMNW	
40	NIK : 1253	HKRAQRLKFLCERNDKVFFASVRS GGSSQVYFMTLNRNCIMNW	1295 (SEQ ID NO: 32)

Based on its relatedness to known members of the STE20 family of protein kinases, NOV3b provides new diagnostic and therapeutic compositions useful in the treatment of disorders associated with alterations in the expression of members of the STE20 family of protein kinases. Nucleic acids, polypeptides, antibodies, and other compositions of the present invention are useful in the treatment and diagnosis of a variety of diseases and pathologies, including, by way of nonlimiting example, those involving metabolic and endocrine disorders, cancer, bone disorders, and tissue/cell growth regulation disorders.

NOV-3c

A NOV-3c sequence according to the invention is a nucleic acid sequence encoding a polypeptide related to STE20 family of protein kinases. A disclosed NOV-3c nucleic acid and

its encoded polypeptide includes the sequences shown in Table 16. The disclosed nucleic acid (SEQ ID NO: 10) is 3822 nucleotides in length and contains an open reading frame (ORF) that begins with an ATG initiation codon at nucleotides 1-3 and ends with a TGA stop codon at nucleotides 3820-3822. The start and stop codons are shown in bold font. A respective ORF
 5 encodes a 1273 amino acid polypeptide (SEQ ID NO: 11).

TABLE 16

ATGGGCGACCCAGCCCCCGCCGACGCTGGACGACATCGACCTGTCCGCCCTGCGGGACCCCTGCTGGGATCTTTGAGCT
 TGTGGAGGTGGTTCGGCAATGGAACCTACGGACAGGTGTACAAGGGTCGGCATGTCAAGACGGGGCAGCTGGCTGCCATCA
 10 AGGTCATGGATGTACGGAGGACGAGGAGGAAGAGATCAACAGGAGATCAACATGCTGAAAAAGTACTCTCACCACCGC
 AACATCGCCACCTACTACGGAGCCTTCATCAAGAAGAGCCCCCGGAAACGATGACCAGCTCTGGCTGGTGATGGAGTT
 CTGTGGTGCTGGTTCAGTGACTGACCTGGTAAAGAACACAAAAGGCAACGCCCTGAAGGAGGACTGTATCGCCTATATCT
 GCAGGGAGATCCTCAGGGGTCTGGCCCATCTCCATGCCACAAGGTGATCCATCGAGACATCAAGGGGCAGAATGTGCTG
 CTGACAGAGAATGCTGAGGTCAAGCTAGTGGATTTTGGGGTGAGTGCTCAGCTGGACCGCACCGTGGGCAGACGGAACAC
 15 TTTTATTGGGACTCCCTACTGGATGGCTCCAGAGGTATCGCCTGTGATGAGAACCCTGATGCCACCTATGATTACAGGA
 GTGATATTTGGTCTCTAGGAATCACAGCCATCGAGATGGCAGAGGGAGCCCCCTCTGTGTGACATGCACCCCATGCGA
 GCCCTCTTCTCATTCTCGGAACCTCCGCCAGGCTCAAGTCCAAGAAGTGGTCTAAGAAGTTTATTGACTTCATTGA
 CACATGTCTCATCAAGACTTACCTGAGCCGCCACCCACGGAGCAGCTACTGAAGTTTCCCTTCATCCGGGACCGAGCCCA
 CGGAGCGGCAGGTCCGCATCCAGCTTAAGGACCACATTGACCGATCCCGGAAGAAGCGGGGTGAGAAAGAGGAGACAGAA
 20 TATGAGTACAGCGGCAGCGAGGAGGAAGATGACAGCCATGGAGAGGAAGGAGAGCCAAGCTCCATCATGAACGTGCCTGG
 AGAGTCGACTCTACGCCGGGAGTTTCTCCGGCTCCAGCAGGAAAATAAGAGCAACTCAGAGGCTTTAAACAGCAGCAGC
 AGCTGCAGCAGCAGCAGCAGCAGACCCGAGGCACACATCAACACCTGCTGCACAGCGGCAGCGCGCATAGAGGAG
 CAGAAGGAGGAGCGGCGCCGCTGGAGGAGCAACAGCGCGGGAGCGGGAGCAGCGGAAGCTGCAGGAGAAGGAGCAGCA
 GCGGCGGCTGGAGGACATGCAGGCTCTGCGGCGGGAGGAGGAGCGGCGGAGCGGAGCAGGAATATATTCTGTC
 25 ACAGGCTAGAGGAGGAGCAGCGACAGCTCGAGATCCTTCAGCAACAGCTGCTCCAGGAACAGGCCCTGCTGCTGGAATAC
 AAGCGGAAGCAGCTGGAGGAGCAGCGCAGTCAGAACGTCTCCAGAGGCAGCTGCAGCAGGAGCATGCCCTACCTCAAGTC
 CCTGCAGCAGCAGCAACAGCAGCAGCAGCTTCAGAAACAGCAGCAGCAGCAGCTCCTGCCTGGGGACAGGAAGCCCCTGT
 ACCATTATGGTTCGGGGCATGAATCCCGCTGACAAACAGCCTGGGCCCGAGAGGTAGTGGCACACCGGGTCCCCTGAAG
 CCATATGCAGCACCTGTACCCGATCCAGTCCCTGCAGGACCAGCCACCCGAAACCTGGCTGCCTTCCCAGCCTCCCA
 30 TGACCCCGACCTGCCATCCCCGACCCACTGCCACGCCAGTGCCCGAGGAGCTGTATCCGCCAGAATTGAGCCCCA
 CCTCTGAAGGACCTGGCCCCAGCCCCAATCCCCAGCCTGGGTCCGCCAGATAACGAGGCCCCACCAAGGTGCCTCAG
 AGGACCTCATCTATCGCCACTGCCCTTAACACCAAGTGGGGCCGAGGGTCCCGCCAGCCAGGCAGTCCGTGCCAGTAA
 CCCCAGCTCAGGAGGAGCGACCTGGCTGGGAACGCTCGGACAGCGTCTTCCAGCCTCTACGGGCACCTCCCCCAGG
 CTGGCTCACTGGAGCGGAACCGCTGGGAGTCTCCTCCAAACCGGACAGCTCCCTGTGCTCTCCCTGGGAATAAAGCC
 35 AAGCCCGACGACCACCGCTCAGGCCAGGCCGGCCCGCAAGCTATAAGCGAGCAATTGGTGAGGACTTTGTGTTGCTGAA
 AGAGCGGACTCTGGACGAGGCCCTCGGCCTCCCAAGAAGGCCATGGACTACTCGTCGTCCAGCGAGGAGGTGGAAAGCA
 GTGAGGACGACGAGGAGGAAGGCGAAGGCGGCCAGCAGAGGGAGCAGAGATACCCCTGGGGGCGCAGCGATGGGGAT
 ACAGACAGCGTCAGCACCATGGTGGTCCACGACGTGAGGAGATACCGGGACCCAGCCCCATACGGGGGCGGCACCAT
 GGTGGTCCAGCGCACCCCTGAAGAGGAGCGGAACCTGCTGCATGCTGACAGCAATGGGTACAAACCTGCCTGACGTGG
 40 TCCAGCCAGCCACTCACCACCGAGAACAGCAAAGGCCAAAGCCACCCTCGAAGGATGGGAGTGGTGACTACCACTCT
 CGTGGGCTGGTAAAGGCCCTGGCAAGAGCTCGTTACGATGTTTGTGGATCTAGGGATCTACCAGCCTGGAGGCAGTGG
 GGACAGCATCCCCATCACAGCCCTAGTGGGTGGAGAGGGCACTCGGCTCGACCAGCTGCAGTACGACGTGAGGAAGGGTT
 CTGTGGTCAACGTGAATCCCAACACCCGGGCCACAGTGAGACCCCTGAGATCCGGAAGTACAAGAAGCGATTCAAC
 TCCGAGATCCTCTGTGCAGCCCTTTGGGGGGTCAACCTGCTGGTGGGCACGGAGAACGGGCTGATGTTGCTGGACCGAAG

TGGGCAGGGCAAGGTGTATGGACTCATTGGGCGGCGACGCTTCCAGCAGATGGATGTGCTGGAGGGGCTCAACCTGCTCA
 TCACCATCTCAGGGAAAGGAACAACTGCGGGTGTATTACCTGTCTGGCTCCGGAACAAGATTCTGCACAATGACCCA
 GAAGTGAGAGAAGCAGGGCTGGACCACCGTGGGGGACATGGAGGGCTGCGGGCACTACCGTGTGTGAAATACGAGCG
 GATTAAGTTCCTGGTCATCGCCCTCAAGAGCTCCGTGGAGGTGTATGCCTGGGCCCCCAAACCTACCACAAATTCATGG
 5 CCTTCAAGTCCTTTGCCGACCTCCCCACCGCCCTCTGCTGGTCGACCTGACAGTAGAGGAGGGGAGCGGCTCAAGGTC
 ATCTATGGCTCCAGTGTGGCTTCCATGCTGTGGATGTGACTCGGGGAACAGCTATGACATCTACATCCCTGTGCACAT
 CCAGAGCCAGATCACGCCCATGCCATCATCTTCTCCCCAACACCGACGGCATGGAGATGCTGCTGTGCTACGAGGACG
 AGGGTGTCTACGTCAACACGTACGGGCGCATCATTAAAGATGTGGTGTGCTGAGTGGGGGAGATGCCTACTTCTGTGGCC
 TACATCTGCTCCAACCAGATAATGGGCTGGGGTGAGAAAGCCATTGAGATCCGCTCTGTGGAGACGGGCCACCTCGACGG
 10 GGTCTTCATGCACAAACGAGCTCAGAGGCTCAAGTTCCTGTGTGAGCGGAATGACAAGGTGTTTTTGCCTCAGTCCGCT
 CTGGGGGACAGCCAAAGTTTACTTTCATGACTCTGAACCGTAACCTGCATCATGAAGTGGTGA (SEQ ID NO: 10)

MGDPAPARSLDDIDLALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTEDEEEEIKQEINMLKKYSHHR
 NIATYYGAFIKKSPPGNDQLWLVMEFCGAGSVTDLVKNTKGNALKEDCIAYICREILRGLAHLHAHKVIHRDIKQNVL
 15 LTENAELVLVDFGVSAQLDRTVGRNNTFIGTPYMAPEVIACDENPDATYDYRSDIWSLGITAIEMAEAPPLCDMHPMR
 ALFLIPRNPPLRLKSKKWSKKFIDFIDTCLIKTYLSRPTEQLLKFFPFIHQPTERQVRIQLKDHIDRSRKKRGEKEETE
 YEYSGSEEDDSDHGEPESSIMNVPGESTLRRREFRLQENKSNSEALKQQQQQLQQQQQORDPEAHIKHLLHQRQRRIEE
 QKEERRRVVEEQORREREQRKLQEKEQORRLEDMLALRREERROAEREQEYIRHRLEEEQRQLEILQQQLQEALLEY
 KRKQLEEQQRSERLQRLQEHAYLKSLOQQQQQQLOKQQQQQLPGDRKPLYHYGRGMNPADKPAWAREVVAHRVPLK
 20 PYAAPVPRSQSLQDQPTRNLAAFPASHDPDPAIPAPTATPSARGAVIRONSDPTSEGPGSPENPPAWVRPDNEAPPKVPQ
 RTSSIATALNTSGAGGSRPAQAVRASNPDLRRSDPGWERSDSVLPASHGHLFPAGSLERNRVGVSSKPDSSPVLSPGNKA
 KPDDHRSRPRGPASYKRAIGEDFVLLKERTLDEAPRPKKAMDYSSSSEEVESSEDEEEGEGGPAEGSRDTPGGRSDGD
 TDSVSTMVVDHVEEITGTQPPYGGGTVMVQRTPEEERNLLHADSNGYTNLPDVVQPSHSPTENSKQSPSPSKDGSQDYQS
 RGLVKAPGKSSFTMFVLDLGIYQPGSGDSIPITALVGEGGTRLDQLQYDVRKGSVVNVNPTNTRAHSETPEIRKYKKRFN
 25 SEILCAALWGVNLLVGTENGIMLLDRSGQGKVGYLIGRRRFQQMDVLEGLNLLITISGKRNLRVYYLSWLRNKLHNDP
 EVEKKQGWTTVGDMEGCGHYRVVKYERIKFLVIALKSSVEVYAWAPKPYHKFMAFKSFADLPHRPLLVDLTVEEGQRLKV
 IYGSAGFHAVDVGNSYDIYIPVHIQSQITPHAIIFLNTDGMEMLLCYEDEGVYVNTYGRIKIDVVLQWGMPTSA
 YICSNQIMGWGEKAIEIRSVETGHLDGVMHKRAQRLKFLCERNDKVFFASVRSGSSQVYFMTINRNCIMNW (SEQ
 ID NO: 11)

The disclosed NOV-3c nucleic acid sequence has homology (72% identity) to a mouse mRNA for a NIK protein (NIK) (GenBank Accession No: MMU88984), as shown in Table 17. NIK proteins are a subgroup of the STE20 family of protein kinases. As indicated by the "Expect" value, the probability of this alignment occurring by chance alone is 9.1e-299.

Moreover, the disclosed, encoded amino acid sequence has 1048 of 1332 amino acid residues (78%) identical to a human NIK-related protein (GenBank Accession No: BAA90753), shown in Table 18. Furthermore, the encoded amino acid sequence also has homology (79% identity) to a human GCK kinase (GenBank Accession No: BAA94838), another subgroup of the STE20 kinase family, as shown in Table 19. As indicated by the "Expect" value, the probability of these amino acid alignments occurring by chance alone are both 0.0, the lowest probability score.

TABLE 17

Score = 3907 (586.2 bits), Expect = 9.1e-299, Sum P(2) = 9.1e-299
 Identities = 1297/1788 (72%), Positives = 1297/1788 (72%), Strand = Plus / Plus

5	NOV3c:	4	GGCGACCCAGCC-CCCGCCCGCAGCCTGGACGACATCGACCTGTCCGCCCTGCGGGACCC	62
			GGCGA C A C CCCGC AGCCTGG GACAT GACCTGTC CCCTGCGGGACCC	
10	NIK :	3	GGCGAACGACTCTCCCGCGAAGAGCCTGGTGGACATTGACCTGTCTCCCTGCGGGACCC	62
	NOV3c:	63	TGCTGGGATCTTTGAGCTTGTGGAGGTGGTCGGCAATGGAACCTACGGACAGGTGTACAA	
		122	TGCTGGGAT TTTGAGCT GTGGA GTGGT GG AATGG ACCTA GGACA GT TA AA	
15	NIK :	63	TGCTGGGATTTTGTGAGCTGGTGGAAAGTGGTGGAAATGGCACCTATGGACAAGTCTATAA	
		122		
	NOV3c:	123	GGGTCGGCATGTCAAGACGGGGCAGCTGGCTGCCATCAAGGTCATGGATGTCACGGAGGA	
		182	GGGTCG CATGT AA ACGG CA CTG C GCCATCAAGGT ATGGA GTCAC GAGGA	
20	NIK :	123	GGGTCGACATGTTAAACGGT-CA-CTGCC-GCCATCAAGGTTATGGACGTCACCGAGGA	
		179		
	NOV3c:	183	CGAGGAGGAAGAGATCAAACAGGAGATCAACATGCTGAAAAAGTACTCTCACCACCGCAA	
		242	GA GAGGAAGA ATCA AC GGAGAT AA ATGCTGAA AAGTA TCTCA CA CG AA	
25	NIK :	180	TGAAGAGGAAGAAATCACACTGGAGATAAATATGCTGAAGAAGTATTCTCATCATCGAAA	
		239		
	NOV3c:	243	CATCGCCACCTACTACGGAGCCTTCATCAAGAAGAGCCCCCGGAAACGATGACCAGCT	
		302	AT GCCAC TACTA GG GC TTCAT AAGAAGAGCCC CC GGA A GATGACCA CT	
30	NIK :	240	TATTGCCACGTACTATGGTGCCTTTCATTAAGAAGAGCCCTCCAGGACATGATGACCAACT	
		299		
35	NOV3c:	303	CTGGCTGGTGATGGAGTTCTGTGGTGGTTCAGTGACTGACCTGGTAAAGAACACAAA	
		362	CTGGCT GT ATGGAGTT TGTGG GCTGG TC T AC GACCT GT AAGAACAC AA	
	NIK :	300	CTGGCTTGTATGGAGTTTTGTGGGGCTGGGTCCATCACAGACCTTGTGAAGAACACCAA	
		359		
40	NOV3c:	363	AGGCAACGCCCTGAAGGAGGACTGTATCGCCTATATCTGCAGGGAGATCCTCAGGGGTCT	
		422	AGG AAC C CT AA GA GACTG AT GC TA ATCT CAGGGA ATCCTCAGGGG T	
45	NIK :	360	AGGGAACACTCTCAAAGAAGACTGGATTGCTTACATCTCCAGGGAAATCCTCAGGGGATT	
		419		
	NOV3c:	423	GGCCCATCTCCATGCCACAAAGGTGATCCATCGAGACATCAAGGGGCAGAATGTGCTGCT	
		482	GGC CATCTCCAT CAC A GT AT CA CGAGA ATCAAGGG CA AATGTGCTGCT	
50	NIK :	420	GGCACATCTCCATATTCACCACGTTATTCACCGAGATATCAAGGGCCAAAATGTGCTGCT	
		479		
	NOV3c:	483	GACAGAGAATGCTGAGGTCAAGCTAGTGGATTTTGGGGTGAGTGCTCAGCTGGACCGCAC	
		542	GAC GAGAATGCTGAGGT AA CT GT GATTTTGG GT AG GCTCAGCTGGAC G AC	
55	NIK :	480	GACCGAGAATGCTGAGGTGAACTTGTGATTTTGGTGTAAAGCGCTCAGCTGGACAGGAC	
		539		
	NOV3c:	543	CGTGGG-CAGACGGAACACTTTTCATTGGGACTCCCTACTGGATGGCTCCAGAGGTCATCG	
60		601	GT GG C GA G AA AC TTCAT GG AC CCCTACTGGATGGCTCCAGAGGTCATCG	

NIK : 540 GGTGGACGGA-GAAATACGTTTCATAGGCACACCCTACTGGATGGCTCCAGAGGTCATCG
 598
 5 NOV3c: 602 CCTGTGATGAGAACCTGATGCCACCTATGATTACAGGAGTGATATTTGGTCTCTA-GGA
 660
 CCTGTGATGAGAACCC GA GCCAC TA GA TACAG AGTGA T TGGTC CT GG
 NIK : 599 CCTGTGATGAGAACCCAGACGCCACTTACGACTACAGAAGTGACCTCTGGTC-CTGTGGC
 657
 10 NOV3c: 661 ATCACAGCCATCGAGATGGCAGAGGGAGCCCCCTCTGTGTGACATGCACCCCATGCGA
 720
 ATCACAGCCATCGAGATGGC GA GG G CCCCCCTCT TGTGACATGCA CC ATG GA
 NIK : 658 ATCACAGCCATCGAGATGGCTGAAGGGGGCCCCCTCTGTGTGACATGCATCCAATGAGA
 717
 15 NOV3c: 721 GCCCTCTTCCTCATTCCTCGGAACCTCCGCCCAGGCTCAAGTCCAAGAAGTGGTCTAAG
 780
 GC CT TT CTCAT CC G AACCTCC CCCAGGCT AAGTC AA AA TGGTC AAG
 NIK : 718 GCGCTGTTTCTCATCCCCAGAAACCTCCTCCCAGGCTGAAGTCAAAAAATGGTCAAAG
 777
 20 NOV3c: 781 AAGTTCATTGA-CTTCATTGACACATGTCTCATCAAGACTTACCTG-AGCCGCCCCACCCA
 838
 AA TT TT A CTT AT GA TGTCT T AAGA TTAC TG AGC GCCC C A
 25 NIK : 778 AAATTT-TTCAGCTTTATAGAAGGCTGTCTGGTGAAGAATTACATGCAGCGGCCCTCT-A
 835
 NOV3c: 839 CGGAGCAGCTACTGAAGTTTCCCTTCATCCGGGACCAGCCACGGAGCGGCAGGTCCGCA
 898
 30 C GAGCA CT T AA CC TTCAT GGA CAGCCCA GA GGCAGGT CG A
 NIK : 836 CAGAGCAACTTTTAAACACCTTTTCATAAGGGATCAGCCCAATGAAAGCAGGTTCGAA
 895
 NOV3c: 899 TCCAGCTTAAGGACCACATTGACCGATCCCGGAAGAAGCGGGGTGAGAAAGAGGAGACAG
 958
 35 TCCAGCTTAAGGA CACAT GACCG CC G AAGAAG G GG GAGAAAGA GAGAC G
 NIK : 896 TCCAGCTTAAGGATCACATAGACCGGACCAGAAAGAAGAGAGGCGAGAAAGATGAGACGG
 955
 40 NOV3c: 959 AATATGAGTACAGCGGCAGCGAGGAGGAAGATGAC-A-GC-CATGGAG-AGGAAGGAGAG
 1014
 A TA GAGTACAGCGG AGCGAGGAGGA GA GA A G C TG AG AGGA GGAGAG
 NIK : 956 AGTACGAGTACAGCGGGAGCGAGGAGGAGGAGGAAGTGCCTG-AGCAGGAGGGAGAG
 1014
 45 NOV3c: 1015 CCAAGCTCCATCATGAACGTGCCTGGAGAGTCGACTCTACGCCGGGAGTTTCTCCGGCTC
 1074
 CCAAG TCCATC T AA GTGCCTGGAGAGTC ACTCT CG CG GA TT CT G CT
 NIK : 1015 CCAAGTCCATCGTCAATGTGCCTGGAGAGTCAACTCTGCGACGTGATTCTCTGAGACTG
 1074
 50 NOV3c: 1075 CAGCAGGAAAATAAG-AGCAACTCAGAGGCTTTAAACAG-CAGCAGCAGCTGCAGCAGC
 1132
 CAGCAGGA AA AAG AGC TC GAGGCT T AG CAGCAGC CTGCAG AGC
 55 NIK : 1075 CAGCAGGAGAACAAGGAGCGG-TCTGAGGCTCTGCGG-AGACAGCAGCTTCTGCAGGAGC
 1132
 NOV3c: 1133 AGCAGCAGCGAGACCCCGAGGCACACATCAAACACCTGCTGCACCAGCGGCAGCGGCGCA
 1192
 60 AGCAGC CG GA C GAGG A A A CA CTGCTG AG GGCAG GCG A
 NIK : 1133 AGCAGCTCCGGGAGCAGGAGGAGTATAAGAGGCAGCTGCTGGCTGAGAGGCAGAAGCGGA
 1192

NOV3c: 1193 TAGAGGAGCAGAAGGAGGAGCGGCGCCGCTGGAGGAGCAACAGCGGCGGGAGCGGGA-G
1251
T GA AGCAGAA GA AG GG G CG TGGAGAGCAACA G G GA CGGGA G
5 NIK : 1193 TTGAACAGCAGAAAGAACAGAGGAGGCGGCTGGAAGAGCAACAAAGAAGAGAACGGGAAG
1252

NOV3c: 1252 CAGCGGAAGCTGCAGGAGAAGGAGCAGCAGCGGCG-G--CTGGAGGACATGCAGGC-TCT
1307
C GGA GC GCAGGAG GAGCAGC GCGGCG G C GAGGA A G AGGC TCT
10 NIK : 1253 CCA-GGAGGCAGCAGGAGCGTGAGCAGCGGCGGCTGAACAAGAGGAGAAG-AGGCGTCT
1310

NOV3c: 1308 GCGGCGGGA--GGAGGAGCGGCGGAGGCGGAGCGGAGCAGGAATATATTCGTACAGG
1365
CG GG A GGA GCGGCG A G GAG GAG AGGA A C A AGG
15 NIK : 1311 -C&A-GGAAGTGGAAAGGCGGCGTAAAGAAGAGGAAGAG-AGGAG-ACGGGCAGAAGAGG
1366

NOV3c: 1366 CTA-GAGGAG-GAGCAGCGACAGCTCGAGATCCTTCAGCAACAGCTGCTCCAGGAACAGG
1423
A GAGGAG G G AG G A C GAG T C TCAG C GC GCT AGGA AG
20 NIK : 1367 AGAAGAGGAGAGTGGAGAGGGAACAGGAG-TACATCAGG--CGGCAGCTAGAGGAGGAGC
1423

NOV3c: 1424 CCCTGCTGCTGGA-ATACA--AGCGGAAGCAGCTGGAGGAGCAGCGGCA-GTCAGAACGT
1479
C GC CTGGA AT C AGC G AGC GCT AGGAGCAG G CA GT A C
25 NIK : 1424 AGCGGCACCTGGAGATCCTGCAGCAGCAGCTGCTCCAGGAGCAG-GCCATGTTACTGCAC
1482

NOV3c: 1480 CTCCAGAGGCAGCTGCA-GCAGGAGCATGCCTACCTCAAGTCCCTGCAGCAGCAGCAACA
1538
CCA AGG GC GCA GCA AGCA GC CC C G CCC GCAGCAGCAG A CA
30 NIK : 1483 GACCACAGGAGGCCGACGCAC-AGCA-GCAG-CCGCC-GCCCCGCAGCAGCAGGA-CA
1537

NOV3c: 1539 GCAGCAG--C-AGCTT-CA-GAAACAGCAGCAGCAGCAGCTCC-TG-CC-TGGGGACAGG
1590
G AGCA C AGCTT CA G CAG AGC AGC C C TG CC TG GACAG
40 NIK : 1538 GGAGCAAACCGAGCTTTTCATGCTCCAG-AGCCCAAGCCTCACTATGACCCTGCTGACAG-
1595

NOV3c: 1591 AAGCCCCTGTACCATTATGGTCGGGGCATGAATCCCGCT-GA-CAAAC-CAGCCTGGGCC
1647
AGC C G A TGGTC C G ATC C C GA CAA C CC G C
45 NIK : 1596 -AGCTCGGGAGGTACAGTGGTCCCACCTGGCATCTCTCAAGAACAATGTCTCCCCGTCT
1654

NOV3c: 1648 CGAGAGGTAGTGGCACACCGGGTCCCACTGAAGCCATAT--GCAGCACCTGTACC-CCGA
1704
CGAGA T C C G G CCC T CCA AT GCA CACC A C CCG
50 NIK : 1655 CGAGATCCCATTCTT-CAGTGACCCT-TCTC-CCAAATTCGCA-CACCACCATCTCCGC
1710

NOV3c: 1705 TCCCAGTCCCTGCAGGACCAGCCCACCCGAAACCTGGCTGCCTTCCCAGCCTCCCATGAC
1764
TC CAG CC CA G CCA CC CCCG A GG GC CAG C C TGAC
55 NIK : 1711 TCTCAGGACC--CATGTCCA-CCTTCCCGCAGTGAGGG-GCTCAGTCAGAG-CTC-TGAC
1764

NOV3c: 1765 CCCGACCCTGCCATCCCCGCACCCAC 1790 (SEQ ID NO: 66)
C A C G T CCCG CCCAC
60 NIK : 1765 TCTAAGTCGGAGGTGCCCCGAGCCCAC 1790 (SEQ ID NO: 33)

TABLE 18

Score = 1985 bits (5143), Expect = 0.0

Identities = 1048/1332 (78%), Positives = 1051/1332 (78%), Gaps = 96/1332 (7%)

5	NOV3c: 1	MGDPAPARSLDDIDLSALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTX	60
	NIK : 1	MGDPAPARSLDDIDLSALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVT	60
10	NOV3c: 61	XXXXXXIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDQLWLVMFCGAGSVTDLVKNT	120
	NIK : 61	DEEEEIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDQLWLVMFCGAGSVTDLVKNT	120
15	NOV3c: 121	KGNALKEDCIAIYICREILRGLAHLHAHKVIHRDIKGQNVLLTENA EVKLVD FGVSAQLDR	180
	NIK : 121	KGNALKEDCIAIYICREILRGLAHLHAHKVIHRDIKGQNVLLTENA EVKLVD FGVSAQLDR	180
20	NOV3c: 181	TVGRRNTFIGTPYWMAPEVIACDENPDATYDYRS DIWSLGITAEIEMAEGAPPLCDMHPMR	240
	NIK : 181	TVGRRNTFIGTPYWMAPEVIACDENPDATYDYRS DIWSLGITAEIEMAEGAPPLCDMHPMR	240
25	NOV3c: 241	ALFLIPRNP PRLKSKKWSKKFIDFIDTCLIKTYLSRPTEQLLKFPFIRDQPTERQVRI	300
	NIK : 241	ALFLIPRNP PRLKSKKWSKKFIDFIDTCLIKTYLSRPTEQLLKFPFIRDQPTERQVRI	300
30	NOV3c: 301	QLKDHIXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX PSSIMNVPGESTLRREFLRLOQ	360
	NIK : 301	QLKDHIDRSRKRGRGEKEETEYEGSGSEEDDSHGEEGEPSSIMNVPGESTLRREFLRLOQ	360
35	NOV3c: 361	ENKSNSEALKXXXXXXXXXXXXRDEPAHIKHLHXXXXXXXXXXXXXXXXXXXXXXXXXXXX	420
	NIK : 361	ENKSNSEALKQOQQQLQOQQQRDEPAHIKHLHQRRRIEEQKEERRRVEEQORREREQRK	420
40	NOV3c: 421	XXXXXXXXXXXXDMQALXXXXXXXXXXXXXXYYIRHXXXXXXXXXXXXXXXXXXXXXXXXXX	480
	NIK : 421	LQEKEQQRRLDMQAL-----RREEERRQAEREQEY	451
45	NOV3c: 481	KRKXXXXXXXXXXXXXXXXXXHAYLKSXXXXXXXXXXXXXXXXXXPGDRKPLYHYGRGM	540
	NIK : 452	KRKQLEEQRQSERLQRLQOEHAYLKS LQOQQOQQQLQKQOQQQLPGDRKPLYHYGRGM	511
50	NOV3c: 541	NPADKPAWAREVVAH-----RVP	558
	NIK : 512	NPADKPAWAREVEERTRMNKQONSPLAKSKPGSTGPEPPPIQASPGPPGPLSQT PPMQRP	571
55	NOV3c: 559	LKPYAAP-----VPRSQSLQDQPTRNLAAFPASHXXXXXXXXXXXXXXXXXX	601
	NIK : 572	VEPQEGPHKSLVAHRVPLKPYAAPVPRSQSLQDQPTRNLAAFPASHDPDPAIPAPTATPS	631
60	NOV3c: 602	XRGAVIRQNSDPTSEGPGSPNPPAWVRPDNEAPPKVPQRTSS IATALNTSGAGGSRAQ	661
	NIK : 632	ARGAVIRQNSDPTSEGPGSPNPPAWVRPDNEAPPKVPQRTSS IATALNTSGAGGSRAQ	691
65	NOV3c: 662	AVRASNPDLRRSDPGWERSDSVLPASHGHLPOAGSLERNRVGVSSKPDSSPVLSPGNKAK	721
	NIK : 692	AVRASNPDLRRSDPGWERSDSVLPASHGHLPOAGSLERNRVGVSSKPDSSPVLSPGNKAK	751
70	NOV3c: 722	PDDHRSRPGRPASYKRAIGEDFVLLKERTLDEAPRPPKKAMDYXXXXXXXXXXXXXXXXXX	781
	NIK : 752	PDDHRSRPGRPA-----DFVLLKERTLDEAPRPPKKAMDYSSSSEEVESEDDEEEG	803

5	NOV3c: 782	XXXXXXXXRDTPGGRSDGDTDSVSTMVVDHVEEITGTQPPYGGGTMMVVQRTPEEERNLLH	841
	NIK : 804	EGGPAEGSRDTPGGRSDGDTDSVSTMVVDHVEEITGTQPPYGGGTMMVVQRTPEEERNLLH	863
10	NOV3c: 842	ADSNGYTNLPDVVQPSHSPTENSKGQSPPSKDGSGDYQSRGLVKAPGKSSFTMFVDLGIY	901
	NIK : 864	ADSNGYTNLPDVVQPSHSPTENSKGQSPPSKDGSGDYQSRGLVKAPGKSSFTMFVDLGIY	923
15	NOV3c: 902	QPGGSGDSIPITALVGGEGRDLQYDVRKGSVVNVNPTNTRAHSETPEIRKYKKRFNS	961
	NIK : 924	QPGGSGDSIPITALVGGEGRDLQYDVRKGSVVNVNPTNTRAHSETPEIRKYKKRFNS	983
20	NOV3c: 962	EILCAALWGVNLLVGTENGLMLLDRSGQGKVYGLIGRRRFQOMDVLEGLNLLITISGKR	1021
	NIK : 984	EILCAALWGVNLLVGTENGLMLLDRSGQGKVYGLIGRRRFQOMDVLEGLNLLITISGKR	1043
25	NOV3c: 1022	KLRVYYLSWLRNKILHNDPEVEKKQGWTTVGDMEGCGHYRVVKYERIKFLVIALKSSVEV	1081
	NIK : 1044	KLRVYYLSWLRNKILHNDPEVEKKQGWTTVGDMEGCGHYRVVKYERIKFLVIALKSSVEV	1103
30	NOV3c: 1082	YAWAPKPYHKFMAFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDSDGNSYDI	1141
	NIK : 1104	YAWAPKPYHKFMAFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDSDGNSYDI	1163
35	NOV3c: 1142	YIPVHIQSQITPHAIIFLPNTDGMEMLLCYEDEGVYVNTYGRIIKDVVLQWGEMPTSVAY	1201
	NIK : 1164	YIPVHIQSQITPHAIIFLPNTDGMEMLLCYEDEGVYVNTYGRIIKDVVLQWGEMPTSVAY	1223
40	NOV3c: 1202	ICSNQIMGWGEKAIEIRSVETGHLDGVMHKRAQRLKFLCERNDKVFFASVRSGGSSQVY	1261
	NIK : 1224	ICSNQIMGWGEKAIEIRSVETGHLDGVMHKRAQRLKFLCERNDKVFFASVRSGGSSQVY	1283
45	NOV3c: 1262	FMTLNRNCIMNW 1273 (SEQ ID NO: 67)	
	NIK : 1284	FMTLNRNCIMNW 1295 (SEQ IS NO: 34)	

TABLE 19

Score = 2007 bits (5201), Expect = 0.0

Identities = 1056/1332 (79%), Positives = 1059/1332 (79%), Gaps = 88/1332 (6%)

50	NOV3c: 1	MGDPAPARSLDDIDLSALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTX	60
	GCK : 1	MGDPAPARSLDDIDLSALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVT	60
55	NOV3c: 61	XXXXXXIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFEFCGAGSVTDLVKNT	120
	GCK : 61	DEEEEIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFEFCGAGSVTDLVKNT	120
60	NOV3c: 121	KGNALKEDCIAAYICREILRGLAHLHAHKVHRDIKGQNVLLTENA EVKLVD FGVSAQLDR	180

GCK : 121 KGNALKEDCIAIYICREILRGLAHLHAHKVIHRDIKGQNVLLTENAIEVKLVDFGVSAQLDR 180
 NOV3c: 181 TVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSDIWSLGITAIEMAEGAPPLCDMHPMR 240
 5 GCK : 181 TVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSDIWSLGITAIEMAEGAPPLCDMHPMR 240
 NOV3c: 241 ALFLIPRNPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPTEQLLKFPFIRDQPTERQVRI 300
 10 GCK : 241 ALFLIPRNPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPTEQLLKFPFIRDQPTERQVRI 300
 NOV3c: 301 QLKDHIXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX PSSIMNVPGESTLRREFLRLOQ 360
 QLKDHI PSSIMNVPGESTLRREFLRLOQ
 15 GCK : 301 QLKDHIDRSRKRGEEKEETEYEYSGSEEDDSHGEEGEPSSIMNVPGESTLRREFLRLOQ 360
 NOV3c: 361 ENKSNSEALKXXXXXXXXXXRDPEAHIKHLLHXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 420
 ENKSNSEALK RDPEAHIKHLLH
 GCK : 361 ENKSNSEALKQQQQLOQQQORDPEAHIKHLLHQRRRIEQKEERRRVEEQRREREQRK 420
 20 NOV3c: 421 XXXXXXXXXXXXDMQALXXXXXXXXXXXXXXXXXXYIRHRXXXXXXXXXXXXXXXXXXXXX 480
 DMQAL Y
 GCK : 421 LOEKEQRRLEDQAL-----RREEERRQAEREQEY 451
 NOV3c: 481 KRKXXXXXXXXXXXXXXXXXXXXHAYLKSXXXXXXXXXXXXXXXXXXXXPGDRKPLYHYGRGM 540
 KRK HAYLKS PGDRKPLYHYGRGM
 25 GCK : 452 KRKQLEEQRQSERLQRQLQEHAYLKSLOQQQQQQLOKQQQQQLLPGDRKPLYHYGRGM 511
 NOV3c: 541 NPADKPAWAREVVAH-----RVP 558
 NPADKPAWAREV + P
 30 GCK : 512 NPADKPAWAREVEERTRMNKQONSPLAKSKPGSTGPEPPIPQASPGPPGPLSQTPPMQRP 571
 NOV3c: 559 LKPYAAP-----VPRSQSLQDQPTRNLAAFPASHXXXXXXXXXXXXXXXXX 601
 ++P P VPRSQSLQDQPTRNLAAFPASH
 35 GCK : 572 VEPQEGPHKSLVAHRVPLKPYAAPVPRSQSLQDQPTRNLAAFPASHDPDPAIPAPTATPS 631
 NOV3c: 602 XRGAVIRQNSDPTSEGPGSPNPAPWVRPDNEAPPKVPQRTSSIALNTSGAGGSRPAQ 661
 RGAVIRQNSDPTSEGPGSPNPAPWVRPDNEAPPKVPQRTSSIALNTSGAGGSRPAQ
 GCK : 632 ARGAVIRQNSDPTSEGPGSPNPAPWVRPDNEAPPKVPQRTSSIALNTSGAGGSRPAQ 691
 40 NOV3c: 662 AVRASNPDLRSDPGWERSDSVLPASHGHLPOAGSLERNRVGVSSKPDSSPVLSPGNKAK 721
 AVRASNPDLRSDPGWERSDSVLPASHGHLPOAGSLERNRVGVSSKPDSSPVLSPGNKAK
 GCK : 692 AVRASNPDLRSDPGWERSDSVLPASHGHLPOAGSLERNRVGVSSKPDSSPVLSPGNKAK 751
 NOV3c: 722 PDDHRSRPGRPASYKRAIGEDFVLLKERTLDEAPRPPKKAMDYXXXXXXXXXXXXXXXXX 781
 PDDHRSRPGRPASYKRAIGEDFVLLKERTLDEAPRPPKKAMDY
 45 GCK : 752 PDDHRSRPGRPASYKRAIGEDFVLLKERTLDEAPRPPKKAMDYSSSSEEVESSEDDEEEG 811
 NOV3c: 782 XXXXXXXXRDTPGGRSDGDTDSVSTMVVDVEEITGTQPPYGGGTMOVVQRTPEEERNLLH 841
 RDTPGGRSDGDTDSVSTMVVDVEEITGTQPPYGGGTMOVVQRTPEEERNLLH
 50 GCK : 812 EGGPAEGSRDTPGGRSDGDTDSVSTMVVDVEEITGTQPPYGGGTMOVVQRTPEEERNLLH 871
 NOV3c: 842 ADSNGYTNLDPVVQPSHSPTENSKGQSPPSKDGSGDYQSRGLVKAPGKSSFTMFVDLGIY 901
 ADSNGYTNLDPVVQPSHSPTENSKGQSPPSKDGSGDYQSRGLVKAPGKSSFTMFVDLGIY
 55 GCK : 872 ADSNGYTNLDPVVQPSHSPTENSKGQSPPSKDGSGDYQSRGLVKAPGKSSFTMFVDLGIY 931
 NOV3c: 902 QPGGSGDSIPITALVGEGTRLDQLQYDVRKGSVVNVNPTNTRAHSETPEIRKYKKRFNS 961
 QPGGSGDSIPITALVGEGTRLDQLQYDVRKGSVVNVNPTNTRAHSETPEIRKYKKRFNS
 GCK : 932 QPGGSGDSIPITALVGEGTRLDQLQYDVRKGSVVNVNPTNTRAHSETPEIRKYKKRFNS 991
 60 NOV3c: 962 EILCAALWGVNLLVGTENGLMLLDRSGQGKQVYGLIGRRRFQOMDVLEGLNLLITISGKRN 1021
 EILCAALWGVNLLVGTENGLMLLDRSGQGKQVYGLIGRRRFQOMDVLEGLNLLITISGKRN

GCK : 992 EILCAALWGVNLLVGTENGLMLLLDRSGQGKVYGLIGRRRFQQMDVLEGLNLLITISGKRN
1051

5 NOV3c: 1022 KLRVYYLSWLRNKILHNDPEVEKKQGWTTVGDMEGCGHYRVVKYERIKFLVIALKSSVEV
1081
KLRVYYLSWLRNKILHNDPEVEKKQGWTTVGDMEGCGHYRVVKYERIKFLVIALKSSVEV
GCK : 1052 KLRVYYLSWLRNKILHNDPEVEKKQGWTTVGDMEGCGHYRVVKYERIKFLVIALKSSVEV
1111

10 NOV3c: 1082 YAWAPKPYHKFMAFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDVDSGNSYDI
1141
YAWAPKPYHKFMAFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDVDSGNSYDI
GCK : 1112 YAWAPKPYHKFMAFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDVDSGNSYDI
1171

15 NOV3c: 1142 YIPVHIQSQITPHAIIFLPNTDGMEMLLCYEDEGVYVNTYGRIIKDVVLQWGEMPTSVAY
1201
YIPVHIQSQITPHAIIFLPNTDGMEMLLCYEDEGVYVNTYGRIIKDVVLQWGEMPTSVAY
GCK : 1172 YIPVHIQSQITPHAIIFLPNTDGMEMLLCYEDEGVYVNTYGRIIKDVVLQWGEMPTSVAY
20 1231

NOV3c: 1202 ICSNQIMGWGEKAIEIRSVETGHLDGVMHKRAQRLKFLCERNDKVFFASVRSGGSSQVY
1261
ICSNQIMGWGEKAIEIRSVETGHLDGVMHKRAQRLKFLCERNDKVFFASVRSGGSSQVY
25 GCK : 1232 ICSNQIMGWGEKAIEIRSVETGHLDGVMHKRAQRLKFLCERNDKVFFASVRSGGSSQVY
1291

NOV3c: 1262 FMTLNRNCIMNW 1273 (SEQ ID No: 68)
FMTLNRNCIMNW
30 GCK : 1292 FMTLNRNCIMNW 1303 (SEQ ID NO: 35)

Based on its relatedness to known members of the STE20 family of protein kinases,
NOV3b provides new diagnostic and therapeutic compositions useful in the treatment of
35 disorders associated with alterations in the expression of members of the STE20 family of
protein kinases. Nucleic acids, polypeptides, antibodies, and other compositions of the present
invention are useful in the treatment and diagnosis of a variety of diseases and pathologies,
including, by way of nonlimiting example, those involving metabolic and endocrine disorders,
cancer, bone disorders, and tissue/cell growth regulation disorders.

NOV-3d

A NOV-3d sequence according to the invention is a nucleic acid sequence encoding a
polypeptide related to STE20 family of protein kinases. A disclosed NOV-3d nucleic acid and
its encoded polypeptide includes the sequences shown in Table 20. The disclosed nucleic acid
45 (SEQ ID NO: 12) is 3735 nucleotides in length and contains an open reading frame (ORF) that
begins with an ATG initiation codon at nucleotides 1-3 and ends with a TGA stop codon at
nucleotides 3733-3735. The start and stop codons are shown in bold font. The disclosed,
respective ORF encodes a 1244 amino acid polypeptide (SEQ ID NO: 13).

TABLE 20[illegible]

GCTCCAACCAGATAATGGGCTGGGGTGAGAAAGCCATTGAGATCCGCTCTGTGGAGACGGGCCACCTCGACGGGGTCTTC
 ATGCACAAACGAGCTCAGAGGCTCAAGTTCTGTGTGAGCGGAATGACAAGGTGTTTTTGCCTCAGTCCGCTCTGGGGG
 CAGCAGCCAAGTTTACTTCATGACTCTGAACCGTAACTGCATCATGAACTGGTGA (SEQ ID NO: 12)

5 MGDPAPARSLDDIDLALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTEDEEEEIKQEIINMLKKYSHHR
 NIATYYGAFIKKSPPGNDDQLWLVMFCGAGSVTDLVKNTKGNALKEDCIAYICREILRGLAHLHAHKVIHRDIKGQNVL
 LTENAEVKLVDFGSAQLDRTVGRNRTFIGTPYWMAPEVIACDENPDATYDYSIDIWSLGITAEIEMAGAPPLCDMHPMR
 ALFLIPRNPPLRLKSKKWSKKFIDFIDTCLIKTYLSRPTEQLLKFPFIRDQPTERQVRIQLKDHIDRSRKKRGEKEETE
 YEYSGSEEEEDSHGEEGEPSSIMNVPGESTLRREFLRLQENKSNSEALKQQQQQQQQORDPEAHIKHLLHQRRRIEE
 10 QKEERRRVEEQORREREQRKLQEKQORRLDMQALRREERRQAEREQEIYRHRLEEQRQSERLQRLQOEHAHYLKSLO
 QQQQQQQQLKQKQQQQLLPGRKPLYHYGRGMNPADKPAWAREVVAHRVPLKPYAAPVVERSSQLQDQPTNRNLAFFASHDP
 DPAIPAPTATPSARGAVIRONSDPTSEGPGSPNPPAWVRPDNEAPPKVPQRTSSIALNTSGAGGSRPAQAVRASNP
 LRRSDPGWERSDSVLPASHGLPQAGSLERNRVGVSSKPDSSPVLSPGNKAKPDDHRSRPGRPASYKRAIGEDFVLLKER
 TLDEAPRPKKAMDYSSSSEVESEDEDEEGEGGPAEGSRDTPGGRSDGDTDSVSTMVVDVEEITGTQPPYGGGTMOV
 15 QRTPEEERNLLHADSNYTNLPDVVQPSHSPTENSKSGSPSKDGSQDYQSRGLVKAPGKSSFTMFVDLGIYQPGSGDS
 IPITALVGEGGTRLDQLQYDVRKGSVVNPNPTNTRAHSETPEIRKYKRFNSEILCAALWGVNLLVGTENGLMLLDRSGQ
 GKVYGLIGRRRFRQQMDVLEGLNLLITISGKRNKLRVYYLSWLRNKLHNDPEVEKKQGWTTVGDMECGHYRVVKYERIK
 FLVIALKSSVEVYAWAPKPYHKFMAFKSFADLPHRPLLVDLTVEEGQRLKVIYGSAGFHAVDSDGNSYDIYIPVHIQS
 QITPHAIIFLPNTDGMEMLLCYEDEGVYVNTYGRIIKDVVLQWGEMPTSVAYICSNQIMGWGEKAIEIRSVETGHLGDFV
 20 MHKRAORLKFCLCERNKDVFFASVRSVSGSSQVYFMTLNRNCIMNW (SEQ ID NO: 13)

The disclosed NOV-3d nucleic acid sequence has homology (73% identity) to a mouse
 mRNA for a NIK protein (NIK) (GenBank Accession No: MMU88984), as shown in Table
 21. NIK proteins are a subgroup of the STE20 family of protein kinases. As indicated by the
 25 "Expect" value, the probability of this alignment occurring by chance alone is 2.2e-295.
 Moreover, the disclosed, encoded amino acid sequence has 1046 of 1303 amino acid residues
 (80%) identical to a human NIK-related protein (GenBank Accession No: BAA90753), shown
 in Table 22. Furthermore, the disclosed, encoded amino acid sequence also has homology
 (80% identity) to a human GCK kinase (GenBank Accession No: BAA94838), another
 30 subgroup of the STE20 kinase family, as shown in Table 23. As indicated by the "Expect"
 value, the probability of these amino acid alignments occurring by chance alone are both 0.0,
 the lowest probability score.

TABLE 21

Score = 3832 (575.0 bits), Expect = 2.2e-295, Sum P(2) = 2.2e-295
 Identities = 1260/1725 (73%), Positives = 1260/1725 (73%), Strand = Plus / Plus

5	NOV3d:	4	GGCGACCCAGCC-CCCGCCCGCAGCCTGGACGACATCGACCTGTCCGCCCTGCGGGACCC	62
	NIK :	3	GGCGA C A C CCCGC AGCCTGG GACAT GACCTGTC CCCTGCGGGACCC	62
10	NOV3d:	63	TGCTGGGATCTTTGAGCTTGTGGAGGTGGTCCGCAATGGAACCTACGGACAGGTGTACAA	
	122		TGCTGGGAT TTTGAGCT GTGGA GTGGT GG AATGG ACCTA GGACA GT TA AA	
	NIK :	63	TGCTGGGATTTTGTAGCTGGTGGAAAGTGGTGGAAATGGCACCTATGGACAAGTCTATAA	
	122			
15	NOV3d:	123	GGGTCGGCATGTCAAGACGGGGCAGCTGGCTGCCATCAAGGTCATGGATGTCACGGAGGA	
	182		GGGTCG CATGT AA ACGG CA CTG C GCCATCAAGGT ATGGA GTCAC GAGGA	
20	NIK :	123	GGGTCGACATGTTAAACGGT-CA-CTGCC-GCCATCAAGGTTATGGACGTCACCGAGGA	
	179			
	NOV3d:	183	CGAGGAGGAAGAGATCAAACAGGAGATCAACATGCTGAAAAAGTACTCTCACCACCGCAA	
	242		GA GAGGAAGA ATCA AC GGAGAT AA ATGCTGAA AAGTA TCTCA CA CG AA	
25	NIK :	180	TGAAGAGGAAGAAATCACACTGGAGATAAATATGCTGAAGAAGTATTCTCATCATCGAAA	
	239			
	NOV3d:	243	CATCGCCACCTACTACGGAGCCTTCATCAAGAAGAGCCCCCGGGAAACGATGACCAGCT	
	302		AT GCCAC TACTA GG GC TTCAT AAGAAGAGCCC CC GGA A GATGACCA CT	
30	NIK :	240	TATTGCCACGTACTATGGTGCTTTCATTAAGAAGAGCCCTCCAGGACATGATGACCACT	
	299			
	NOV3d:	303	CTGGCTGGTGATGGAGTTCTGTGGTGCTGGTTCAGTGACTGACCTGGTAAAGAACACAAA	
35	362		CTGGCT GT ATGGAGTT TGTGG GCTGG TC T AC GACCT GT AAGAACAC AA	
	NIK :	300	CTGGCTTGTATGGAGTTTTGTGGGGCTGGGTCCATCACAGACCTTGTGAAGAACACCAA	
	359			
40	NOV3d:	363	AGGCAACGCCCTGAAGGAGGACTGTATCGCCTATATCTGCAGGGAGATCCTCAGGGGTCT	
	422		AGG AAC C CT AA GA GACTG AT GC TA ATCT CAGGGA ATCCTCAGGGG T	
	NIK :	360	AGGGAACACTCTCAAAGAAGACTGGATTGCTTACATCTCCAGGGAAATCCTCAGGGGATT	
	419			
45	NOV3d:	423	GGCCCATCTCCATGCCACAAAGGTGATCCATCGAGACATCAAGGGGCAGAATGTGCTGCT	
	482		GGC CATCTCCAT CAC A GT AT CA CGAGA ATCAAGGG CA AATGTGCTGCT	
50	NIK :	420	GGCACATCTCCATATTCACCACGTTATTCACCGAGATATCAAGGGCCAAAATGTGCTGCT	
	479			
	NOV3d:	483	GACAGAGAATGCTGAGGTCAAGCTAGTGGATTTTGGGGTGAGTGCTCAGCTGGACCGCAC	
	542		GAC GAGAATGCTGAGGT AA CT GT GATTTTGG GT AG GCTCAGCTGGAC G AC	
55	NIK :	480	GACCGAGAATGCTGAGGTGAACTTGTGATTTTGGTGTAAGCGCTCAGCTGGACAGGAC	
	539			
	NOV3d:	543	CGTGGG-CAGACGGAACACTTTCATTGGGACTCCCTACTGGATGGCTCCAGAGGTCATCG	
	601		GT GG C GA G AA AC TTCAT GG AC CCCTACTGGATGGCTCCAGAGGTCATCG	
60	NIK :	540	GGTTGGACGGA-GAAATACGTTTCATAGGCACACCCCTACTGGATGGCTCCAGAGGTCATCG	
	598			

NOV3d: 602 CCTGTGATGAGAACCCTGATGCCACCTATGATTACAGGAGTGATATTTGGTCTCTA-GGA
 660
 5 NIK : 599 CCTGTGATGAGAACCCAGACGCCACTTACGACTACAGAAGTGACCTCTGGTC-CTGTGGC
 657
 NOV3d: 661 ATCACAGCCATCGAGATGGCAGAGGGAGCCCCCTCTGTGTGACATGCACCCCATGCGA
 720
 10 NIK : 658 ATCACAGCCATCGAGATGGCTGAAGGGGGCCCCCTCTGTGTGACATGCATCCAATGAGA
 717
 NOV3d: 721 GCCCTCTTCCTCATTCTCGGAACCCTCCGCCCAGGCTCAAGTCCAAGAAGTGGTCTAAG
 780
 15 NIK : 718 GCGCTGTTTCTCATCCCCAGAAACCCTCCTCCCAGGCTGAAGTCAAAAAATGGTCAAAG
 777
 NOV3d: 781 AAGTTCATTGA-CTTCATTGACACATGTCTCATCAAGACTTACCTG-AGCCGCCCACCCA
 838
 NIK : 778 AAATTT-TTCAGCTTTATAGAAGGCTGTCTGGTGAAGAATTACATGCAGCGGCCCTCT-A
 835
 25 NOV3d: 839 CGGAGCAGCTACTGAAGTTTCCCTTCATCCGGGACCAGCCCACGGAGCGGCAGGTCCGCA
 898
 NIK : 836 CAGAGCAACTTTTAAACACCCTTTCATAAGGGATCAGCCCAATGAAAGGCAGGTTCGAA
 895
 30 NOV3d: 899 TCCAGCTTAAGGACCACATTGACCGATCCCGGAAGAAGCGGGGTGAGAAAGAGGAGACAG
 958
 NIK : 896 TCCAGCTTAAGGATCACATAGACCGGACCAGAAAGAAGAGAGGCGAGAAAGATGAGACGG
 955
 35 NOV3d: 959 AATATGAGTACAGCGGCAGCGAGGAGGAAGATGAC-A-GC-CATGGAG-AGGAAGGAGAG
 1014
 NIK : 956 AGTACGAGTACAGCGGGAGCGAGGAGGAGGAGGAGGAAGTGCCTG-AGCAGGAGGGAGAG
 1014
 40 NOV3d: 1015 CCAAGCTCCATCATGAACGTGCCTGGAGAGTGCAGTCTACGCCGGGAGTTTCTCCGGCTC
 1074
 NIK : 1015 CCAAGTTCCATCGTCAATGTGCCTGGAGAGTCAACTCTGCGACGTGATTCCTGAGACTG
 1074
 45 NOV3d: 1075 CAGCAGGAAAATAAG-AGCAACTCAGAGGCTTTAAACAG-CAGCAGCAGCTGCAGCAGC
 1132
 NIK : 1075 CAGCAGGAGAACAAGGAGCGG-TCTGAGGCTCTGCGG-AGACAGCAGCTTCTGCAGGAGC
 1132
 55 NOV3d: 1133 AGCAGCAGCGAGACCCCGAGGCACACATCAACACCTGCTGCACCAGCGGCAGCGGCGCA
 1192
 NIK : 1133 AGCAGCTCCGGGAGCAGGAGGAGTATAAGAGGCAGCTGCTGGCTGAGAGGCAGAAGCGGA
 1192
 60 NOV3d: 1193 TAGAGGAGCAGAAGGAGGAGCGGCGCCGCTGGAGGAGCAACAGCGGCGGGAGCGGGA-G
 1251

T GA AGCAGAA GA AG GG G CG TGA GAGCAACA G G GA CGGGA G
 NIK : 1193 TTGAACAGCAGAAAGAACAGAGGAGCGGCTGGAAGAGCAACAAAGAAGAGAACGGGAAG
 1252

5 NOV3d: 1252 CAGCGGAAGCTGCAGGAGAAGGAGCAGCAGCGGCG-G--CTGGAGGACATGCAGGC-TCT
 1307
 C GGA GC GCAGGAG GAGCAGC GCGGCG G C GAGGA A G AGGC TCT
 NIK : 1253 CCA-GGAGGCAGCAGGAGCGTGAGCAGCGGCGCGTGAACAAGAGGAGAAG-AGGCGTCT
 1310

10 NOV3d: 1308 GCGGCGGGA--GGAGGAGCGGCGGCAGGCGGAGCGGAGCAGGAATATATTCGTCACAGG
 1365
 CG GG A GGA GCGGCG A G GAG GAG AGGA A C A AGG
 NIK : 1311 -CGA-GGAACTGGAAGGCGGCGTAAAGAAGAGGAAGAG-AGGAG-ACGGGCAGAAGAGG
 1366

15 NOV3d: 1366 CTA-GAGGAGCAGCGGC-AGT---CAGAACGT-CTCCAGA-GGCAGCTGCAGCAGGAGCA
 1418
 A GAGGAG AG GG AG CAG A GT C CAG GGCAGCT AG AGGAGCA
 20 NIK : 1367 AGAAGAGGAG-AGTGGAGAGGGAACAGGA-GTACATCAGGCGGCAGCTAGAGGAGGAGCA
 1424

NOV3d: 1419 T-GCCTACCTCAAGTCCCTGCAGCAGCAGCAACAGCAGCAGCAGCTTCA-GAAACAGCA-
 1475
 25 G C ACCT AG CCTGCAGCAGCAGC C CAG AGCAG CA G AC GCA
 NIK : 1425 GCGGC-ACCTGGAGATCCTGCAGCAGCAGCTGCTCCAGGAGCAGGC-CATGTTACTGCAC
 1482

NOV3d: 1476 G-CAGCAGCAGCTCCTGCCTGGGGA-CAGGAAGCCCCTGTACCATTATGGTCGGGGCATG
 1533
 30 G C CAG AG CC GC G A CAG A GCC C G CC A G C G CA G
 NIK : 1483 GACCACAGGAGG-CC-GCACGCACAGCAGCA-GCCGCCGCCCGCA--G-CAG--CAGG
 1534

35 NOV3d: 1534 AATCCCGCTGACAAACC-AGCCTGG--GCCCGAGAGGTAGTGGCACACCGGGTCCCA-CT
 1589
 A C G G CAAACC AGC T GC C AGAG G C CAC G CCC CT
 NIK : 1535 A--CAGGA-G-CAAACCGAGCTTTCATGCTCCAGAGCCCAAGCCTCACTATGACCCTGCT
 1590

40 NOV3d: 1590 GA-AGCCATATGCAGC-ACC-TGTACCCGATCCCAGTCCCTGCAGGACCAGCCCACCCG
 1646
 GA AG T G AG AC TG CCC T CA TC CT AG AC A C CCC
 45 NIK : 1591 GACAGAGCTCGGGAGGTACAGTGGTCCCACCTGGCA-TCTCTCAAGAACAATGTCTCCCC
 1649

NOV3d: 1647 AAACCTG-GCTGCC-TTCC--CAGCCTCCCATGACCCCGACCCTGC-CATCCCCGCACCC
 1701
 C G G T CC TTCC CAG CCC T CCC A C GC CA C CC CC
 50 NIK : 1650 TGTCTCGAGATCCCATTCCCTTCAGTGACCCTTCTCCCAAATTC-GCACACCACCATCTCC
 1708

NOV3d: 1702 ACTGCCACG-CCCAGTGCCC 1720 (SEQ ID NO: 69)
 CT CA G CCA TG CC
 55 NIK : 1709 GCTCTCAGGACCCA-TGTCC 1727 (SEQ ID NO: 36)

TABLE 22

Score = 1995 bits (5170), Expect = 0.0

Identities = 1046/1303 (80%), Positives = 1049/1303 (80%), Gaps = 67/1303 (5%)

5	NOV3d: 1	MGDPAPARSLLDDIDLSALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTX	60
	NIK : 1	MGDPAPARSLLDDIDLSALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVT	60
10	NOV3d: 61	XXXXXXIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFCGAGSVTDLVKNT	120
	NIK : 61	DEEEEIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFCGAGSVTDLVKNT	120
15	NOV3d: 121	KGNALKEDCIAYICREILRGLAHLHAHKVIHRDIKQNVLLTENA EVKLVDGVSQAQLDR	180
	NIK : 121	KGNALKEDCIAYICREILRGLAHLHAHKVIHRDIKQNVLLTENA EVKLVDGVSQAQLDR	180
20	NOV3d: 181	TVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSDIWSLGITAIEMAEGAPPLCDMHPMR	240
	NIK : 181	TVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSDIWSLGITAIEMAEGAPPLCDMHPMR	240
25	NOV3d: 241	ALFLIPRNPPPRLLKSKKWSKKFIDFIDTCLIKTYLSRPTEQLLKFPFIRDQPTERQVRI	300
	NIK : 241	ALFLIPRNPPPRLLKSKKWSKKFIDFIDTCLIKTYLSRPTEQLLKFPFIRDQPTERQVRI	300
	NOV3d: 301	QLKDHIXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX PSSIMNVPGESTLRREFLRLOQ	360
	NIK : 301	QLKDHIDRSRKRGEKEETEYEGSSEEDDSHGEEGEPSSIMNVPGESTLRREFLRLOQ	360
30	NOV3d: 361	ENKSNSEALKXXXXXXXXXXXXRDPEAHIKHLLHXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	420
	NIK : 361	ENKSNSEALKXXXXXXXXXXXXRDPEAHIKHLLHXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	420
35	NOV3d: 421	XXXXXXXXXXXXDMQALXXXXXXXXXXXXXYIRHXXXXXXXXXXXXXXXXXXXXHAYLKSXX	480
	NIK : 421	LOEKEQORRLEDMQALRREERROAEREQEYKRKQLEEQRQSERLQRLQOE HAYLKSLO	480
40	NOV3d: 481	XXXXXXXXXXXXXXXXXXXXPGDRKPLYHYGRGMNPADKPAWAREVVAH-----	526
	NIK : 481	QOQOQOQLQKQOQOQLPGDRKPLYHYGRGMNPADKPAWAREVEERTRMNKQONSPLAKS	540
45	NOV3d: 527	-----RVPLKPYAAP-----VPRSQ	541
	NIK : 541	KPGSTGPEPPIPQASPGPPGPLSQTPPMQRPVEPQEGPHKSLVAHRVPLKPYAAPVPRSQ	600
50	NOV3d: 542	SLQDQPTRNLAAFPASHXXXXXXXXXXXXXXXXXRGAVIRQNSDPTSEGPGPSNPPAWVRP	601
	NIK : 601	SLQDQPTRNLAAFPASHDPDAIPAPTATPSARGAVIRQNSDPTSEGPGPSNPPAWVRP	660
55	NOV3d: 662	LPOAGSLERNRVGVSSKPDSSPVLSPGNKAKPDDHRSRPGRPASYKRAIGEDFVLLKERT	721
	NIK : 721	LPOAGSLERNRVGVSSKPDSSPVLSPGNKAKPDDHRSRPGRPADVFLLKERT	772
60	NOV3d: 722	LDEAPRPPKKAMDYXXXXXXXXXXXXXXXXXXXXXRDTPGGRSDGDTDSVSTMVH	781
	NIK : 773	LDEAPRPPKKAMDYSSSSEEVESSEDDEEEGEGGPAEGSRDTPGGRSDGDTDSVSTMVH	832
	NOV3d: 782	DVEEITGTQPPYGGGTMVVQRTPEEERNLLHADSNGYTNLPDVVQPSHSPTENSKGQSPP	841

	NIK : 833	DVEEITGTQPPYGGGTMMVQRTPEEERNLLHADSNGYTNLPDVVQPSHSPTENSKGQSPP DVEEITGTQPPYGGGTMMVQRTPEEERNLLHADSNGYTNLPDVVQPSHSPTENSKGQSPP	892
5	NOV3d: 842	SKDGS GDYQSRGLVKAPGKSSFTMFVDLGIYQPGGSGDSIPITALVGGEGRDLQDYDV SKDGS GDYQSRGLVKAPGKSSFTMFVDLGIYQPGGSGDSIPITALVGGEGRDLQDYDV	901
	NIK : 893	SKDGS GDYQSRGLVKAPGKSSFTMFVDLGIYQPGGSGDSIPITALVGGEGRDLQDYDV	952
	NOV3d: 902	RKGSVVNVNPTNTRAHSETPEIRKYKRFNSEILCAALWGVNLLVGTENGLMLLDRSGQG RKGSVVNVNPTNTRAHSETPEIRKYKRFNSEILCAALWGVNLLVGTENGLMLLDRSGQG	961
10	NIK : 953	RKGSVVNVNPTNTRAHSETPEIRKYKRFNSEILCAALWGVNLLVGTENGLMLLDRSGQG	1012
	NOV3d: 962	KVYGLIGRRRFQQMDVLEGLNLLITISGKRNLRVYYLSWLRNKILHNDPEVEKKQGWT 1021	
15	NIK : 1013	KVYGLIGRRRFQQMDVLEGLNLLITISGKRNLRVYYLSWLRNKILHNDPEVEKKQGWT 1072	
	NOV3d: 1022	VGDMEGCGHYRVVKYERIKFLVIALKSSVEVYAWAPKPYHKFMAFKSFADLPHRPLLVDL 1081	
20	NIK : 1073	VGDMEGCGHYRVVKYERIKFLVIALKSSVEVYAWAPKPYHKFMAFKSFADLPHRPLLVDL 1132	
	NOV3d: 1082	TVEEGQRLKVIYGSSAGFHAVDSDGNSYDIYIPVHIQSQITPHAIIFLPNTDGMEMLLC 1141	
25	NIK : 1133	TVEEGQRLKVIYGSSAGFHAVDSDGNSYDIYIPVHIQSQITPHAIIFLPNTDGMEMLLC 1192	
30	NOV3d: 1142	YEDEGVYVNTYGRIIKDVLQWEMPTSVAYICSNQIMGWGEKAIEIRSVETGHLDGVFM 1201	
	NIK : 1193	YEDEGVYVNTYGRIIKDVLQWEMPTSVAYICSNQIMGWGEKAIEIRSVETGHLDGVFM 1252	
35	NOV3d: 1202	HKRAQRLKFLCERNDKVFFASVRSGSSQVYFMTLNRNCIMNW 1244 (SEQ ID NO: 70) HKRAQRLKFLCERNDKVFFASVRSGSSQVYFMTLNRNCIMNW	
40	NIK : 1253	HKRAQRLKFLCERNDKVFFASVRSGSSQVYFMTLNRNCIMNW 1295 (SEQ ID NO: 37)	

TABLE 23

Score = 2018 bits (5228), Expect = 0.0

Identities = 1054/1303 (80%), Positives = 1057/1303 (80%), Gaps = 59/1303 (4%)

	NOV3d: 1	MGDPAPARSLDDIDLSALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTX	60
	GCK : 1	MGDPAPARSLDDIDLSALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVT	60
50	NOV3d: 61	XXXXXIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFCGAGSVTDLVKNT IKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFCGAGSVTDLVKNT	120
	GCK : 61	DEEEEIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFCGAGSVTDLVKNT	120
55	NOV3d: 121	KGNALKEDCIAYICREILRGLAHLHAHKVIHRDIKGQNVLLTENAEVKLVDFGVSAQLDR KGNALKEDCIAYICREILRGLAHLHAHKVIHRDIKGQNVLLTENAEVKLVDFGVSAQLDR	180
	GCK : 121	KGNALKEDCIAYICREILRGLAHLHAHKVIHRDIKGQNVLLTENAEVKLVDFGVSAQLDR	180
60	NOV3d: 181	TVGRRNTFIGTPYWMAPEVIACDENPDATYDYSDIWSLGITAIEMAEGAPPLCDMHPMR TVGRRNTFIGTPYWMAPEVIACDENPDATYDYSDIWSLGITAIEMAEGAPPLCDMHPMR	240
	GCK : 181	TVGRRNTFIGTPYWMAPEVIACDENPDATYDYSDIWSLGITAIEMAEGAPPLCDMHPMR	240

NOV3d: 241 ALFLIPRNPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPTQLLKFPFIRDQPTERQVRI 300
 ALFLIPRNPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPTQLLKFPFIRDQPTERQVRI
 GCK : 241 ALFLIPRNPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPTQLLKFPFIRDQPTERQVRI 300

5 NOV3d: 301 QLKDHIXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXPSIMNVPGESTLRREFLRLQQ 360
 QLKDHI PSSIMNVPGESTLRREFLRLQQ
 GCK : 301 QLKDHIDRSRKKRGEKEETEYEYSGSEEDDSHGEEGEPSSIMNVPGESTLRREFLRLQQ 360

10 NOV3d: 361 ENKSNSEALKXXXXXXXXXXRDPEAHIKHLLHXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 420
 ENKSNSEALK RDPEAHIKHLLH
 GCK : 361 ENKSNSEALKQQQQQLQQQQQORDPEAHIKHLLHQRRRIEEQKEERRRVVEQQRREREQRK 420

NOV3d: 421 XXXXXXXXXXXXDMQALXXXXXXXXXXXXXXXXXIRHXXXXXXXXXXXXXXXXXXXXHAYLKSXX 480
 DMQAL Y R HAYLKS
 15 GCK : 421 LQEKEQQRLEDMQALRREEERRQAEREQEYKRRKQLEEQRQSERLQRLQOEHAYLKSLO 480

NOV3d: 481 XXXXXXXXXXXXXXXXXXXXPGDRKPLYHYGRGMNPADKPAWAREVVAH----- 526
 PGDRKPLYHYGRGMNPADKPAWAREV
 20 GCK : 481 QQQQQQQLQKQQQQQLLPGRKPLYHYGRGMNPADKPAWAREVEERTRMNKQONSPLAKS 540

NOV3d: 527 -----RVPLKPYAAP-----VPRSQ 541
 + P++P P VPRSQ
 GCK : 541 KPGSTGPEPPIPQASPGPPGPLSQTPPMQRPVEPQEGPHKSLVAHRVPLKPYAAPVPRSQ 600

25 NOV3d: 542 SLQDQPTRNLAAFPASHXXXXXXXXXXXXXXXXXRGAVIRQNSDPTSEGPGSPNPPAWVRP 601
 SLQDQPTRNLAAFPASH RGAVIRQNSDPTSEGPGSPNPPAWVRP
 GCK : 601 SLQDQPTRNLAAFPASHDPDAIPAPTATPSARGAVIRQNSDPTSEGPGSPNPPAWVRP 660

NOV3d: 602 DNEAPPKVPQRTSSIALNTSGAGGSRAQAVRASNPDLRRSDPGWERSDSVLPASHGH 661
 DNEAPPKVPQRTSSIALNTSGAGGSRAQAVRASNPDLRRSDPGWERSDSVLPASHGH
 30 GCK : 661 DNEAPPKVPQRTSSIALNTSGAGGSRAQAVRASNPDLRRSDPGWERSDSVLPASHGH 720

NOV3d: 662 LPQAGSLERNRVGVSSKPDSSPVLSPGNKAKPDDHRSRPGRPASYKRAIGEDFVLLKERT 721
 LPQAGSLERNRVGVSSKPDSSPVLSPGNKAKPDDHRSRPGRPASYKRAIGEDFVLLKERT
 35 GCK : 721 LPQAGSLERNRVGVSSKPDSSPVLSPGNKAKPDDHRSRPGRPASYKRAIGEDFVLLKERT 780

NOV3d: 722 LDEAPRPPKKAMDYXXXXXXXXXXXXXXXXXXXXXXXXXRDTPGGRSDGDTDSVSTMVH 781
 LDEAPRPPKKAMDY RDTPGGRSDGDTDSVSTMVH
 40 GCK : 781 LDEAPRPPKKAMDYSSSSEEVESSEDEEEEGGPAEGSRDTPGGRSDGDTDSVSTMVH 840

NOV3d: 782 DVEEITGTQPPYGGGTMMVQRTPEEERNLLHADSNGYTNLPDVVQPSHSPTENSKGQSPP 841
 DVEEITGTQPPYGGGTMMVQRTPEEERNLLHADSNGYTNLPDVVQPSHSPTENSKGQSPP
 GCK : 841 DVEEITGTQPPYGGGTMMVQRTPEEERNLLHADSNGYTNLPDVVQPSHSPTENSKGQSPP 900

45 NOV3d: 842 SKDGS GDYQSRGLVKAPGKSSFTMFVDLGIYQPGGSGDSIPITALVGGEGRDLQDQYDV 901
 SKDGS GDYQSRGLVKAPGKSSFTMFVDLGIYQPGGSGDSIPITALVGGEGRDLQDQYDV
 GCK : 901 SKDGS GDYQSRGLVKAPGKSSFTMFVDLGIYQPGGSGDSIPITALVGGEGRDLQDQYDV 960

NOV3d: 902 RKGSVNVNPTNTRAHSETPEIRYKKRFNSEILCAALWGVNLLVGTENGLMLLDRSGQG 961
 RKGSVNVNPTNTRAHSETPEIRYKKRFNSEILCAALWGVNLLVGTENGLMLLDRSGQG
 50 GCK : 961 RKGSVNVNPTNTRAHSETPEIRYKKRFNSEILCAALWGVNLLVGTENGLMLLDRSGQG 1020

NOV3d: 962 KVGGLIGRRRFQQMDVLEGLNLLITISGKRNLRVYYLSWLRNKILHNDPEVEKKQGWT 1021
 KVGGLIGRRRFQQMDVLEGLNLLITISGKRNLRVYYLSWLRNKILHNDPEVEKKQGWT
 55 GCK : 1021 KVGGLIGRRRFQQMDVLEGLNLLITISGKRNLRVYYLSWLRNKILHNDPEVEKKQGWT 1080

NOV3d: 1022 VGDMEGCGHYRVVKYERIKFLVIALKSSVEVYAWAPKPYHKFMAFKSFADLPHRPLLVDL 1081
 VGDMEGCGHYRVVKYERIKFLVIALKSSVEVYAWAPKPYHKFMAFKSFADLPHRPLLVDL
 60

GCK : 1081 VGDMEGCGHYRVVKYERIKFLVIALKSSVEVYAWAPKPYHKFMAFKSFADLPHRPLLVDL
1140

NOV3d: 1082 TVEEGQRLKVIYGSSAGFHAVDSDSGNSYDIYIPVHIQSQITPHAIIFLPNTDGMEMLLC
1141

TVEEGQRLKVIYGSSAGFHAVDSDSGNSYDIYIPVHIQSQITPHAIIFLPNTDGMEMLLC

GCK : 1141 TVEEGQRLKVIYGSSAGFHAVDSDSGNSYDIYIPVHIQSQITPHAIIFLPNTDGMEMLLC
1200

NOV3d: 1142 YEDEGVYVNTYGRIIKDVVLQWGEMPTSVAYICSNQIMGWGEKAIEIRSVETGHLDGVMF
1201

YEDEGVYVNTYGRIIKDVVLQWGEMPTSVAYICSNQIMGWGEKAIEIRSVETGHLDGVMF

GCK : 1201 YEDEGVYVNTYGRIIKDVVLQWGEMPTSVAYICSNQIMGWGEKAIEIRSVETGHLDGVMF
1260

NOV3d: 1202 HKRAQRLKFLCERNDKVFFASVRSQVYFMTLNRNCIMNW 1244 (SEQ ID NO: 71)
HKRAQRLKFLCERNDKVFFASVRSQVYFMTLNRNCIMNW

GCK : 1261 HKRAQRLKFLCERNDKVFFASVRSQVYFMTLNRNCIMNW 1303 (SEQ ID NO: 38)

Based on its relatedness to known members of the STE20 family of protein kinases, NOV3d provides new diagnostic and therapeutic compositions useful in the treatment of disorders associated with alterations in the expression of members of the STE20 family of protein kinases. Nucleic acids, polypeptides, antibodies, and other compositions of the present invention are useful in the treatment and diagnosis of a variety of diseases and pathologies, including, by way of nonlimiting example, those involving metabolic and endocrine disorders, cancer, bone disorders, and tissue/cell growth regulation disorders.

Table 24 shows a multiple sequence alignment of the disclosed NOV-3 polypeptides with a STE20 protein (GenBank Accession No: BAA90753), indicating the homology between the present invention and a known member of the protein family.

TABLE 24

STE20	MGDPAPARSLDDIDLSALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTE
NOV3b	MGDPAPARSLDDIDLSALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTE
NOV3a	MGDPAPARSLDDIDLSALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTE
NOV3d	MGDPAPARSLDDIDLSALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTE
NOV3c	MGDPAPARSLDDIDLSALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTE

STE20	DEEEEIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFEFCGAGSVTDLVKNT
NOV3b	DEEEEIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFEFCGAGSVTDLVKNT
NOV3a	DEEEEIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFEFCGAGSVTDLVKNT
NOV3d	DEEEEIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFEFCGAGSVTDLVKNT
NOV3c	DEEEEIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFEFCGAGSVTDLVKNT

STE20	KGNALKEDCIAYICREILRGLAHLHAHKVIHRDIKGQNVLLTENA EVKLVD FGVSAQLDR
NOV3b	KGNALKEDCIAYICREILRGLAHLHAHKVIHRDIKGQNVLLTENA EVKLVD FGVSAQLDR
NOV3a	KGNALKEDCIAYICREILRGLAHLHAHKVIHRDIKGQNVLLTENA EVKLVD FGVSAQLDR
NOV3d	KGNALKEDCIAYICREILRGLAHLHAHKVIHRDIKGQNVLLTENA EVKLVD FGVSAQLDR
NOV3c	KGNALKEDCIAYICREILRGLAHLHAHKVIHRDIKGQNVLLTENA EVKLVD FGVSAQLDR

	STE20	TVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSDIWSLGITAEMAEGAPPLCDMHMPMR
	NOV3b	TVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSDIWSLGITAEMAEGAPPLCDMHMPMR
	NOV3a	TVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSDIWSLGITAEMAEGAPPLCDMHMPMR
5	NOV3d	TVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSDIWSLGITAEMAEGAPPLCDMHMPMR
	NOV3c	TVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSDIWSLGITAEMAEGAPPLCDMHMPMR

	STE20	ALFLIPRNPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPTQQLKFPFIRDQPTERQVRI
10	NOV3b	ALFLIPRNPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPTQQLKFPFIRDQPTERQVRI
	NOV3a	ALFLIPRNPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPTQQLKFPFIRDQPTERQVRI
	NOV3d	ALFLIPRNPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPTQQLKFPFIRDQPTERQVRI
	NOV3c	ALFLIPRNPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPTQQLKFPFIRDQPTERQVRI

15	STE20	QLKDHIDRSRKKRGEKEETEYEYSGSEEDDSHGEEGEPSSIMNVPGESTLRREFLRLQQ
	NOV3b	QLKDHIDRSRKKRGEKEETEYEYSGSEEDDSHGEEGEPSSIMNVPGESTLRREFLRLQQ
	NOV3a	QLKDHIDRSRKKRGEKEETEYEYSGSEEDDSHGEEGEPSSIMNVPGESTLRREFLRLQQ
	NOV3d	QLKDHIDRSRKKRGEKEETEYEYSGSEEDDSHGEEGEPSSIMNVPGESTLRREFLRLQQ
20	NOV3c	QLKDHIDRSRKKRGEKEETEYEYSGSEEDDSHGEEGEPSSIMNVPGESTLRREFLRLQQ

	STE20	ENKSNSEALKQQQQQLQQQQQORDPEAHIKHLLHQRRRIEEQKEERRRVEEQRREREQRK
25	NOV3b	ENKSNSEALKQQQQQLQQQQQORDPEAHIKHLLHQRRRIEEQKEERRRVEEQRREREQRK
	NOV3a	ENKSNSEALKQQQQQLQQQQQORDPEAHIKHLLHQRRRIEEQKEERRRVEEQRREREQRK
	NOV3d	ENKSNSEALKQQQQQLQQQQQORDPEAHIKHLLHQRRRIEEQKEERRRVEEQRREREQRK
	NOV3c	ENKSNSEALKQQQQQLQQQQQORDPEAHIKHLLHQRRRIEEQKEERRRVEEQRREREQRK

30	STE20	LQEKEQQRRLQEDMQALRREEERRQAEREQEYKRKQLEE-----
	NOV3b	LQEKEQQRRLQEDMQALRREEERRQAEREQEYIRHRLEE-----
	NOV3a	LQEKEQQRRLQEDMQALRREEERRQAEREQEYIRHRLEEEQROLEILQQQLLQEQALLLEY
	NOV3d	LQEKEQQRRLQEDMQALRREEERRQAEREQEYIRHRLEE-----
	NOV3c	LQEKEQQRRLQEDMQALRREEERRQAEREQEYIRHRLEEEQROLEILQQQLLQEQALLLEY
35		***** *.:***
	STE20	-----QRQSERLQROLQQEHAYLKSLOQQQQQQQLQKQQQQQLLPGDRKPLYHYGRGM
40	NOV3b	-----QRQSERLQROLQQEHAYLKSLOQQQQQQQLQKQQQQQLLPGDRKPLYHYGRGM
	NOV3a	KRKQLEEQRQSERLQROLQQEHAYLKSLOQQQQQQQLQKQQQQQLLPGDRKPLYHYGRGM
	NOV3d	-----QRQSERLQROLQQEHAYLKSLOQQQQQQQLQKQQQQQLLPGDRKPLYHYGRGM
	NOV3c	KRKQLEEQRQSERLQROLQQEHAYLKSLOQQQQQQQLQKQQQQQLLPGDRKPLYHYGRGM

	STE20	NPADKPAWAREVEERTRMNKQONSPLAKSKPGSTGPEPPIPOASPGPPGPLSQTPPMQRP
45	NOV3b	NPADKPAWAREVEERTRMNKQONSPLAKSKPGSTGPEPPIPOASPGPPGPLSQTPPMQRP
	NOV3a	NPADKPAWAREVEERTRMNKQONSPLAKSKPGSTGPEPPIPOASPGPPGPLSQTPPMQRP
	NOV3d	NPADKPAWAREV-----
	NOV3c	NPADKPAWAREV-----

50	STE20	VEPQEGPHKSLVAHRVPLKPYAAPVPRSQSLQDQPTRNLAAFPASHDPDAIPAPTATPS
	NOV3b	VEPQEGPHKSLVAHRVPLKPYAAPVPRSQSLQDQPTRNLAAFPASHDPDAIPAPTATPS
	NOV3a	VEPQEGPHKSLVAHRVPLKPYAAPVPRSQSLQDQPTRNLAAFPASHDPDAIPAPTATPS
	NOV3d	-----VAHRVPLKPYAAPVPRSQSLQDQPTRNLAAFPASHDPDAIPAPTATPS
55	NOV3c	-----VAHRVPLKPYAAPVPRSQSLQDQPTRNLAAFPASHDPDAIPAPTATPS

	STE20	ARGAVIRQNSDPTSEGPSPNPPAWVRPDNEAPPKVPQRTSSIATALNTSGAGGSRPAQ
60	NOV3b	ARGAVIRQNSDPTSEGPSPNPPAWVRPDNEAPPKVPQRTSSIATALNTSGAGGSRPAQ
	NOV3a	ARGAVIRQNSDPTSEGPSPNPPAWVRPDNEAPPKVPQRTSSIATALNTSGAGGSRPAQ
	NOV3d	ARGAVIRQNSDPTSEGPSPNPPAWVRPDNEAPPKVPQRTSSIATALNTSGAGGSRPAQ
	NOV3c	ARGAVIRQNSDPTSEGPSPNPPAWVRPDNEAPPKVPQRTSSIATALNTSGAGGSRPAQ

5 STE20 AVRASNPDLRRSDPGWERSDVL PASHGHL PQAGSLERNRVGVSSKPDSSPVLSPGNKAK
NOV3b AVRASNPDLRRSDPGWERSDVL PASHGHL PQAGSLERNRVGVSSKPDSSPVLSPGNKAK
NOV3a AVRASNPDLRRSDPGWERSDVL PASHGHL PQAGSLERNRVGVSSKPDSSPVLSPGNKAK
NOV3d AVRASNPDLRRSDPGWERSDVL PASHGHL PQAGSLERNRVGVSSKPDSSPVLSPGNKAK
NOV3c AVRASNPDLRRSDPGWERSDVL PASHGHL PQAGSLERNRVGVSSKPDSSPVLSPGNKAK

10 STE20 PDDHRSRPGRPA-----DFVLLKERTLDEAPRPPKKAMDYSSSSEEVESSEDDEEEG
NOV3b PDDHRSRPGRPASYPKRAIGEDFVLLKERTLDEAPRPPKKAMDYSSSSEEVESSEDDEEEG
NOV3a PDDHRSRPGRPASYPKRAIGEDFVLLKERTLDEAPRPPKKAMDYSSSSEEVESSEDDEEEG
NOV3d PDDHRSRPGRPASYPKRAIGEDFVLLKERTLDEAPRPPKKAMDYSSSSEEVESSEDDEEEG
NOV3c PDDHRSRPGRPASYPKRAIGEDFVLLKERTLDEAPRPPKKAMDYSSSSEEVESSEDDEEEG

15 STE20 EGGPAEGSRDTPGGRSDGDTDSVSTMVVDVEEITGTQPPYGGGTMMVQRTPEEERNLLH
NOV3b EGGPAEGSRDTPGGRSDGDTDSVSTMVVDVEEITGTQPPYGGGTMMVQRTPEEERNLLH
NOV3a EGGPAEGSRDTPGGRSDGDTDSVSTMVVDVEEITGTQPPYGGGTMMVQRTPEEERNLLH
NOV3d EGGPAEGSRDTPGGRSDGDTDSVSTMVVDVEEITGTQPPYGGGTMMVQRTPEEERNLLH
20 NOV3c EGGPAEGSRDTPGGRSDGDTDSVSTMVVDVEEITGTQPPYGGGTMMVQRTPEEERNLLH

25 STE20 ADSNGYTNLPDVVQPSHSPTENSKGQSPPSKDGSGDYQSRGLVKAPGKSSFTMFVDLGIY
NOV3b ADSNGYTNLPDVVQPSHSPTENSKGQSPPSKDGSGDYQSRGLVKAPGKSSFTMFVDLGIY
NOV3a ADSNGYTNLPDVVQPSHSPTENSKGQSPPSKDGSGDYQSRGLVKAPGKSSFTMFVDLGIY
NOV3d ADSNGYTNLPDVVQPSHSPTENSKGQSPPSKDGSGDYQSRGLVKAPGKSSFTMFVDLGIY
NOV3c ADSNGYTNLPDVVQPSHSPTENSKGQSPPSKDGSGDYQSRGLVKAPGKSSFTMFVDLGIY

30 STE20 QPGGSGDSIPITALVGGEGRDLQDQYDVRKGSVVNVNPTNTRAHSETPEIRKYKKRFS
NOV3b QPGGSGDSIPITALVGGEGRDLQDQYDVRKGSVVNVNPTNTRAHSETPEIRKYKKRFS
NOV3a QPGGSGDSIPITALVGGEGRDLQDQYDVRKGSVVNVNPTNTRAHSETPEIRKYKKRFS
NOV3d QPGGSGDSIPITALVGGEGRDLQDQYDVRKGSVVNVNPTNTRAHSETPEIRKYKKRFS
NOV3c QPGGSGDSIPITALVGGEGRDLQDQYDVRKGSVVNVNPTNTRAHSETPEIRKYKKRFS
35 *****

40 STE20 EILCAALWGVNLLVGTENGLMLLDRSGQGKVYGLIGRRRFQOMDVLEGLNLLITISGKRN
NOV3b EILCAALWGVNLLVGTENGLMLLDRSGQGKVYGLIGRRRFQOMDVLEGLNLLITISGKRN
NOV3a EILCAALWGVNLLVGTENGLMLLDRSGQGKVYGLIGRRRFQOMDVLEGLNLLITISGKRN
NOV3d EILCAALWGVNLLVGTENGLMLLDRSGQGKVYGLIGRRRFQOMDVLEGLNLLITISGKRN
NOV3c EILCAALWGVNLLVGTENGLMLLDRSGQGKVYGLIGRRRFQOMDVLEGLNLLITISGKRN

45 STE20 KLRVYYLSWLRNKKILHNDPEVEKKQGWTTVGDMEGCGHYRVVKYERIKFLVIALKSSVEV
NOV3b KLRVYYLSWLRNKKILHNDPEVEKKQGWTTVGDMEGCGHYRVVKYERIKFLVIALKSSVEV
NOV3a KLRVYYLSWLRNKKILHNDPEVEKKQGWTTVGDMEGCGHYRVVKYERIKFLVIALKSSVEV
NOV3d KLRVYYLSWLRNKKILHNDPEVEKKQGWTTVGDMEGCGHYRVVKYERIKFLVIALKSSVEV
NOV3c KLRVYYLSWLRNKKILHNDPEVEKKQGWTTVGDMEGCGHYRVVKYERIKFLVIALKSSVEV
50 *****

55 STE20 YAWAPKPYHKFMAFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDSDGNSYDI
NOV3b YAWAPKPYHKFMAFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDSDGNSYDI
NOV3a YAWAPKPYHKFMAFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDSDGNSYDI
NOV3d YAWAPKPYHKFMAFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDSDGNSYDI
NOV3c YAWAPKPYHKFMAFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDSDGNSYDI

60 STE20 YIPVHIQSQITPHAIIFLPNTDGMEMLLCYEDEGVYVNTYGRIIKDVVLQWGEMPTSVAY
NOV3b YIPVHIQSQITPHAIIFLPNTDGMEMLLCYEDEGVYVNTYGRIIKDVVLQWGEMPTSVAY
NOV3a YIPVHIQSQITPHAIIFLPNTDGMEMLLCYEDEGVYVNTYGRIIKDVVLQWGEMPTSVAY
NOV3d YIPVHIQSQITPHAIIFLPNTDGMEMLLCYEDEGVYVNTYGRIIKDVVLQWGEMPTSVAY
NOV3c YIPVHIQSQITPHAIIFLPNTDGMEMLLCYEDEGVYVNTYGRIIKDVVLQWGEMPTSVAY

5 STE20 ICSNQIMGWGEKAIEIRSVETGHLDGVMHKRAQRLKFLCERNDKVFFASVRSGGSSQVY
 NOV3b ICSNQIMGWGEKAIEIRSVETGHLDGVMHKRAQRLKFLCERNDKVFFASVRSGGSSQVY
 NOV3a ICSNQIMGWGEKAIEIRSVETGHLDGVMHKRAQRLKFLCERNDKVFFASVRSGGSSQVY
 NOV3d ICSNQIMGWGEKAIEIRSVETGHLDGVMHKRAQRLKFLCERNDKVFFASVRSGGSSQVY
 NOV3c ICSNQIMGWGEKAIEIRSVETGHLDGVMHKRAQRLKFLCERNDKVFFASVRSGGSSQVY

10 STE20 FMTLNRNCIMNW (SEQ ID NO: 39)
 NOV3b FMTLNRNCIMNW (SEQ ID NO: 9)
 NOV3a FMTLNRNCIMNW (SEQ ID NO: 7)
 NOV3d FMTLNRNCIMNW (SEQ ID NO: 13)
 NOV3c FMTLNRNCIMNW (SEQ ID NO: 11)

15 **Consensus key**
 * - single, fully conserved residue
 : - conservation of strong groups
 . - conservation of weak groups
 - no consensus

20

Based on the relatedness between NOV-3 and STE20 kinases, the disclosed NOV3 proteins are novel members of the STE20 protein kinase family. Therefore, the nucleic acids and proteins of the inventions are useful in potential therapeutic applications implicated in various pathologies and disorders described and other pathologies and disorders related to aberrant function or aberrant expression of these STE20-protein kinases.

Potential therapeutic uses for the nucleic acids and proteins of the invention include, by way of nonlimiting example, protein therapeutic, small molecule drug target, antibody target (including therapeutic, diagnostic, or drug targeting/cytotoxic antibodies), diagnostic and/or prognostic marker, gene therapy (gene delivery/gene ablation), research tools, and tissue regeneration *in vitro* and *in vivo* (regeneration for all these tissues and cell types composing these tissues and cell types derived from these tissues).

The nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various names of pathologies/disorders described above, as well as other pathologies or disorders. For example, a cDNA encoding the STE20 protein kinase-like protein may be useful in gene therapy, and the STE20 protein kinase-like protein may be useful when administered to a subject in need thereof. By way of nonlimiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from the pathologies described above. The novel nucleic acids encoding the STE20 protein kinase-like proteins, and the STE20 protein kinase-like proteins of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. These materials are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods.

NOV-4: A Novel Trypsin Inhibitor-like protein

The NOV-4 sequences (NOV-4a, NOV-4b, NOV-4c, NOV-4d, and NOV-4e) according to the invention are nucleotide sequences encoding respective polypeptides related to trypsin inhibitor proteins.

The disclosed NOV-4 sequences are splice variants. Splice variants occur naturally. When a variant and the original sequence have the same or opposite activity, they may differ in various properties not directly connected to biological activity. A certain variant may be expressed mainly in one tissue, while the original sequence from which it has been varied, or another variant derived from the same sequence, may be expressed mainly in another tissue. The presence or level of specific splice variants may be the cause, and/or indicative of, a disease, disorder, pathological or normal condition.

Because a drug may be effective against one variant but not another, or may cause side effects because it targets all splice variants, an effective drug needs to target the particular splice variant. Because soluble variants with therapeutic or disease-related functions may be naturally occurring in specific tissues, they may be optimal candidates for drug targets or protein therapeutics. Variants may have no activity at all and may serve as dominant negative natural inhibitors. Thus, splice variants useful in generating new drug targets, protein therapeutics and markers for diagnostics.

NOV-4 sequences according to the invention encode polypeptides related to trypsin inhibitor proteins that are expressed in brain tumors, polypeptides related to sperm coat glycoproteins, and polypeptides related to glioma pathogenesis related proteins. *See Yamakawa et al., 1998, Biochim Biophys Acta 1395(2):202-8; Murphy et al., 1995, Gene 159(1): 131-5.* In addition, similarities were found between NOV-4 and insect allergens in wasps, hornets, fire ants, and secreted/membrane proteins in nematode pathogens. *See J Allergy Clin Immunol 1990, 85(6):988-96.* Therefore, the nucleic acids and proteins of the NOV-4 splice variants described in this invention can have similar functions as these proteins.

NOV-4 proteins are expressed in the following tissues: pituitary gland, mammary gland, adrenal gland, thalamus, and fetal lung.

Functional roles attributed to trypsin inhibitor proteins include sperm coat maturation, immunological responses, glioma pathogenesis, and signal transduction pathways. Thus, NOV-4 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in disorders associated with, e.g., reproductive disorders, immunological disorders, cancer, and metabolic disorders.

Additional utilities for NOV-4 nucleic acids and polypeptides according to the invention are disclosed herein.

NOV-4a

A NOV-4a sequence according to the invention is a nucleic acid sequence that encodes a polypeptide related to trypsin inhibitor proteins. A disclosed NOV-4a nucleic acid and its encoded polypeptide is included in Table 25. The disclosed nucleic acid (SEQ ID NO: 14) is 2305 nucleotides in length and contains an open reading frame (ORF) that begins with an ATG initiation codon at nucleotide 453, and ends with a TGA stop codon at nucleotide 1602. A disclosed, representative ORF encodes a 383 amino acid polypeptide (SEQ ID NO: 15). NOV-4a is missing one exon in the 5' nucleotide region compared to other splice variants (NOV-4b and NOV-4c), resulting in an alternative methionine start codon and a Kozak sequence.

TABLE 25

```
CTCTGACTGCTCCTATTGAGCTGTCTGCTCGCTGTGCCGCTGTGCCTGCTGTGCCCGCG
CTGTGCGCGCTGCTACCGCTCTACTGGACGCGGGAGACGCCAGCGAGCTGGTGATTGGA
GCCCTGCGGAGAGCTCAAGCGCCAGCTCTGCCCCAGGAGCCAGGCTGCCCCGTGAGTC
CCATAGTTGCTACAGGAGTGGAGCCATGAGCTGCGTCTGGGTGGTGTATCCCTTGGG
GCTGCTGTTCTGGTCCGCGGATCCCAAGGCTACCTCCTGCCCAACGTCACTCTCTTAGA
GGAGCTGCTCAGCAAATACCAGCACAAACGAGTCTCACTCCCGGGTCCGCAGAGCCATCCC
CAGGGAGGACAAGGAGGAGATCCTCATGCTGCACAACAAGCTTCGGGGCCAGGTGCAGCC
TCAGGCCCTCCAACATGGAGTACATGACCTGGGATGACGAACTGGGGCAGGTATCGCTCTC
CGGGGTTCATGTGCAGTCTGGTATGACGAGGTGAAGGACTACACCTACCCCTACCCGA
GCGAGTGCAACCCCTGGTGTCCAGAGAGGTGCTCGGGCCATGTGCACGCACTACACAC
AGATAGTTTGGGCCACCACCAACAAGATCGGTTGTGCTGTGAACACCTGCCGGAAGATGA
CTGTCTGGGGAGAAGTTTGGGAGAACGCGGTCTACTTTGTCTGCAATTATTCTCCAAAGG
GGAACCTGGATTGGAGAAGCCCCCTACAAGAATGGCCGGCCCTGCTCTGAGTGCCACCCA
GCTATGGAGGCAGCTGCAGGAACAACCTTGTGTTACCGAGAAGAACTACACTCCAAAAC
CTGAAACGGACGAGATGAATGAGGTGGAACGGCTCCCATTCCTGAAGAAAACCATGTTT
GGCTCCAACCGAGGGTGATGAGACCCACCAAGCCCAGAAAACCTCTGCGGTCAACTACA
TGACCCAAGTCGTGAGATGTGACACCAAGATGAAGGACAGGTGCAAAGGGTCCACGTGTA
ACAGGTACAGTGCCAGCAGGCTGCCTGAACCACAAGGCGAAGATCTTTGGAACCTCTGT
TCTATGAAAGCTCGTCTAGCATATGCCGCGCCGCCATCCACTACGGGATCCTGGATGACA
AGGGAGGCCTGGTGGATATCACCAGGAACGGGAAGTCCCCTTCTTCGTGAAGTCTGAGA
GACACGGCGTGAGTCCCTCAGCAAATACAAACCTTCCAGCTCATTGATGGTGTCAAAG
TGAAAGTGCAGGATTTGGACTGCTACACGACCGTTGCTCAGCTGTGCCGTTTGAAAAGC
CAGCAACTCACTGCCCCAAGAATCCATTGTCCGGCACACTGCAAAGACGAACCTTCCTACT
GGGCTCCGGTGTGTTGGAACCAACATCTATGCAGATACCTCAAGCATCTGCAAGACAGCCG
TGCACGCGGGAGTCATCAGCAACGAGAGTGGGGGTGACGTGGACGTGATGCCCGTGGATA
AAAAGAAGACCTACGTGGGCTCGCTCAGGAATGGAGTTCAGTCTGAAAGCCTGGGGACTC
```

CTCGGGATGGAAAGCCTTCCGGATCTTTGCTGTCAGGCAGTGAATTTCCAGCACCAGGG
 GAGAAGGGGCGTCTTCAGGAGGGCTTCGGGGTTTGGCTTTTATTTTATTTTGTGATTGC
 GGGGTATATGGAGAGTCAGGAACTTCTTTGACTGATGTTTCACTGTCCATCACTTTGTG
 GCCTGTGGGTGAGGTGACATCTCATCCCTCACTGAAGCAACAGCATCCCAAGGTGCTCA
 5 GCCGGACTCCCTGGTGCCTGATCCTGCTGGGGCCCGGGGGTCTCCATCTGGACGTCTCT
 CTCTTTTAGAGATCTGAGCTGTCTCTTAAAGGGGACAGTTGCCCAAAATGTTCTTGCTA
 TGTGTTCTTCTGTTGGTGGAGGAAGTTGATTTCAACCTCCCTGCCAAAAGAACAAACCAT
 TTGAAGCTCACAATTGTGAAGCATTACGGCGTCGGAAGAGGCCTTTTGAGCAAGCGCCA
 ATGAGTTTCAGGAATGAAGTAGAAGGTAGTTATTTAAAAATAAAAAACACAGTCCGTCCC
 10 TACCAATAGAGGAAAATGGTTTAAATGTTTGGTGGTCAACAGACAAATGGGCTAGAGTA
 AGAGGGCTCGGGGTATGAGAGACCCCGGCTCCGCCCTGGCACGTGTCTTGCTGGCGGCC
 CGCCACAGGCCCCCTCAATGGCCGATTCAAGATGGCTCTATACACAGCAGTGTGGTT
 TATGTAAAGTTCAGCAGTCACTTCA (SEQ ID NO: 14)

MTNWGRYRSPGFHVQSWYDEVKDYTYPPSECNPWCPERCSPGPMCTHYTQIVWATTN
 KIGCAVNTCRKMTVWGEVWENAVYFVCNYSKGNWIGEAPYKNGRPCSECPPSYGGS
 CRNNLCYREETYTPKPKETDEMNEVETAPIPEENHVWLQPRVMRPTKPKKTSAVNYMT
 QVVRCDTKMKDRCKGSTCNRYQCPAGCLNHKAKIFGTLFYESSSSICRAAIHYGILD
 DKGGLVDITRNGKVPFFVKSERHGVQSLSKYKPSSEFMVSKVKVQDLDCYTTVAQLC
 20 PFEKPATHCPRIHCPAHCKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGD
 VDMPVDKKKTYVGSRLRNGVQSESLGTPRDGKAFRIFAVRQ (SEQ ID NO: 15)

The disclosed NOV-4a amino acid sequence has a high level of homology (99% identity, 99% similarity) to a human trypsin inhibitor-like protein (GenBank Accession No: CAB66795), shown in Table 26. Moreover, the NOV-4a amino acid sequence has homology (72% identity, 82% similarity) to a known human trypsin inhibitor (TREMBL ACC No: 043692), also shown in Table 26. As indicated by the "Expect" values, the probability of these alignments occurring by chance alone is 0.0 and 5.3e-51, respectively.

TABLE 26

- Score = 786 bits (2031), Expect = 0.0
 Identities = 380/381 (99%), Positives = 381/381 (99%)

NOV4a: 3 NWGRYRSPGFHVQSWYDEVKDYTYPPSECNPWCPERCSPGPMCTHYTQIVWATTNKIGCA 62
 +WGRYRSPGFHVQSWYDEVKDYTYPPSECNPWCPERCSPGPMCTHYTQIVWATTNKIGCA
 35 TRYP : 117 HWGRYRSPGFHVQSWYDEVKDYTYPPSECNPWCPERCSPGPMCTHYTQIVWATTNKIGCA 176

NOV4a: 63 VNTCRKMTVWGEVWENAVYFVCNYSKGNWIGEAPYKNGRPCSECPPSYGGGSCRNNLCYR 122
 VNTCRKMTVWGEVWENAVYFVCNYSKGNWIGEAPYKNGRPCSECPPSYGGGSCRNNLCYR
 40 TRYP : 177 VNTCRKMTVWGEVWENAVYFVCNYSKGNWIGEAPYKNGRPCSECPPSYGGGSCRNNLCYR 236

NOV4a: 123 EETYPKPKETDEMNEVETAPIPEENHVWLQPRVMRPTKPKKTSAVNYMTQVVRCDTKMKD 182
 EETYPKPKETDEMNEVETAPIPEENHVWLQPRVMRPTKPKKTSAVNYMTQVVRCDTKMKD
 45 TRYP : 237 EETYPKPKETDEMNEVETAPIPEENHVWLQPRVMRPTKPKKTSAVNYMTQVVRCDTKMKD 296

NOV4a: 183 RCKGSTCNRYQCPAGCLNHKAKIFGTLFYESSSSICRAAIHYGILDDKGGLVDITRNGKV 242
 RCKGSTCNRYQCPAGCLNHKAKIFGTLFYESSSSICRAAIHYGILDDKGGLVDITRNGKV
 TRYP : 297 RCKGSTCNRYQCPAGCLNHKAKIFGTLFYESSSSICRAAIHYGILDDKGGLVDITRNGKV 356

NOV4a: 243 PFFVKSERHGVQSLSKYKPSSSFMVSKVKVQDLDCYTTVAQLCPFEKPATHCPRIHCPAH 302
 PFFVKSERHGVQSLSKYKPSSSFMVSKVKVQDLDCYTTVAQLCPFEKPATHCPRIHCPAH
 TRYP : 357 PFFVKSERHGVQSLSKYKPSSSFMVSKVKVQDLDCYTTVAQLCPFEKPATHCPRIHCPAH 416

NOV4a: 303 CKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDVMPVDKKKTYVGSRLNGV 362
 CKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDVMPVDKKKTYVGSRLNGV
 TRYP : 417 CKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDVMPVDKKKTYVGSRLNGV 476

NOV4a: 363 QSESLGTPRDGKAFRIFAVRQ 383 (SEQ ID NO: 72)
 QSESLGTPRDGKAFRIFAVRQ

TRYP : 477 QSESLGTPRDGKAFRIFAVRQ 497 (SEQ ID NO: 40)

- Score = 530 (186.6 bits), Expect = 5.3e-51, P = 5.3e-51
 Identities = 85/117 (72%), Positives = 97/117 (82%)

NOV4a: 5 GRYRSPGFHVQSWYDEVKDYTYYPSECNPWCPERCSPGPMCTHYTQIVWATTNKIGCAVN 64
 GRYRS V+ WYDEVKDY +PYP +CNP CP RC GPMCTHYTQ+VWAT+N+IGCA++
 TRYP : 130 GRYRSILQLVKPWWYDEVKDYAFFYPQDCNPRCPMRCFGPMCTHYTQMWWATSNRIGCAIH 189

NOV4a: 65 TCRKMTVWGEVWENAVYFVCNYSKGNWIGEAPYKNGRPCSECPPSYGGSCRNNLCY 121 (SEQ
 ID NO: 73)

TC+ M VWG VW AVY VCNY+PKGNWIGEAPYK G PCS CPPSYGGSC +NLC+

TRYP : 190 TCQNMNVWGSVWRRAYLVLCNYAPKGNWIGEAPYKVGVPCCSCPPSYGGSCDTNLCF 246 (SEQ
 ID NO: 41)

Furthermore, a PROSITE database search of protein families and domains confirmed that a NOV-4a polypeptide is a member of the trypsin inhibitor family. One of the conserved regions found in trypsin inhibitors is a SCP domain, located at the C-terminal half. The pattern of this conserved domain is: [LIVMFYH]-[LIVMFY]-x-C-[NQRHS]-Y-x-[PARH]-x-[GL]-N-[LIVMFYWDN] (SEQ ID NO: 56). This pattern is found in amino acids 81-92 of SEQ ID NO: 15.

PSORT analyses indicate that that NOV-4a is likely located in the nucleus (certainty = 0.3000). The predicted molecular weight of NOV-4a is 43185.7 daltons.

Based on its relatedness to known members of the trypsin inhibitor family of proteins, NOV4a provides new diagnostic and therapeutic compositions useful in the treatment of disorders associated with alterations in the expression of members of the trypsin inhibitor protein family. Nucleic acids, polypeptides, antibodies, and other compositions of the present invention are useful in the treatment and diagnosis of a variety of diseases and pathologies, including, by way of nonlimiting example, those involving reproductive disorders, immunological disorders, cancer, and metabolic disorders.

NOV-4b

A disclosed NOV-4b sequence according to the invention is a nucleic acid sequence that encodes a polypeptide related to trypsin inhibitor proteins. A disclosed NOV-4b nucleic acid and its encoded polypeptide are included in Table 27. The disclosed nucleic acid (SEQ ID NO: 16) is 2400 nucleotides in length and contains an open reading frame (ORF) that

begins with an ATG initiation codon at nucleotide 205, and ends with a TGA stop codon at nucleotide 1697. A disclosed, representative ORF encodes a 497 amino acid polypeptide (SEQ ID NO: 17).

5 TABLE 27

CTCTGACTGCTCCTATTGAGCTGTCTGCTCGCTGTGCCCCGCTGTGCTGTGCCCCGCTGTGCCCCGCTGTACCGCG
TCTACTGGACGCGGGAGACGCCAGCGAGCTGGTGATTGGAGCCCTGCGGAGAGCTCAAGCGCCAGCTGTGCCCCGAGGAG
CCCAGGCTGCCCCGTGAGTCCCATAGTTGCTGCAGGAGTGGAGCCATGAGCTGCGTCTGGGTGGTGTATCCCCCTGGG
GCTGTGTTCTCTGGTCCGCGGATCCCAAGGCTACCTCCTGCCAACGTCACTCTCTTAGAGGAGCTGCTCAGCAAATACC
10 AGCACAACGAGTCTCACTCCCGGGTCCGAGAGCCATCCCAGGGAGGACAAGGAGGAGATCCTCATGCTGCACAACAAG
CTTCGGGGCCAGGTGCAGCCTCAGGCCTCCAACATGGAGTACATGACCTGGGATGACGAACTGGAGAAGTCTGCTGCAGC
GTGGGCCAGTCAGTGCATCTGGGAGCACGGGCCCACCGTCTGCTGGTGTCCATCGGGCAGAACCTGGGCGCTCACTGGG
GCAGTATCGCTCTCCGGGGTTCATGTGCAGTCTGGTATGACGAGGTGAAGGACTACACCTACCCCTACCCGAGCGAG
TGCAACCCCTGGTGTCCAGAGAGGTGCTCGGGGCTATGTGCACGCACTACACACAGATAGTTTGGGCCACCACCAACAA
15 GATCGGTTGTGCTGTGAACACCTGCCGAAGATGACTGTCTGGGAGAAGTTTGGGAGAACGCGGTCTACTTTGTCTGCA
ATTATTCTCCAAAGGGGAACGGATTGGAGAAGCCCCCTACAAGATGGCCGGCCCTGCTCTGAGTGCCCAACCGAGTAT
GGAGGCAGCTGCAGGAACAACCTGTGTACCGAGAAGAAACCTACACTCCAAAACCTGAAACGGACGAGATGAATGAGGT
GGAAACGGCTCCCATTCCTGAAGAAAACCATGTTTGGCTCCAACCGAGGGTGATGAGACCCACCAAGCCCAAGAAAACCT
CTGCGGTCAACTACATGACCCAGTCCGTGAGATGTGACACCAAGATGAAGGACAGGTGCAAGGGTCCACGTGTAACAGG
20 TACAGTGCCCAAGCAGGCTGCCTGAACCAAGCGAAGATCTTTGGAAGTCTGTTCTATGAAAGCTCGTCTAGCATATG
CCGCGCCGCCATCCACTACGGGATCCTGGATGACAAGGGAGGCCTGGTGGATATCACCAGGAACGGGAAGGTCCCTTCT
TCGTGAAGTCTGAGAGACACGGCGTGCAGTCCCTCAGCAATACAAACCTTCAGCTCATTGATGTTCAAAAGTGAAG
GTGCAGGATTGGACTGCTACACGACCGTTGCTCAGCTGTGCCCCGTTTGAAGGCCAGCAACTCACTGCCCAAGAATCCA
TTGTCCGGCACACTGCAAGACGAACCTTCCTACTGGGCTCCGGTGTGTTGGAACCAACATCTATGCAGATACCTCAAGCA
25 TCTGCAAGACAGCCGTGCACGCGGGAGTCATCAGCAACGAGAGTGGGGGTGACGTGGACGTGATGCCCGTGGATAAAAG
AAGACCTACGTGGGCTCGCTCAGGAATGGAGTTCAGTCTGAAAGCTGGGGACTCCTCGGGATGGAAAGGCCCTCCGGAT
CTTTGCTGTGAGGCAGTGAATTTCCAGCACAGGGGAGAAGGGGCGTCTTCAGGAGGGCTTCGGGGTTTGTCTTTATT
TTATTTTGTGATTGCGGGGTATATGGAGAGTCAGGAACTTCCTTTGACTGATGTTTCACTGTCCATCACTTTGTGGCCTG
TGGGTGAGGTGACATCTCATCCCTCACTGAAGCAACAGCATCCCAAGGTGCTCAGCCGGACTCCCTGGTGCCTGATCCT
30 GCTGGGGCCCGGGGTCTCCATCTGGACGTCTCTCTCCTTTAGAGATCTGAGCTGTCTCTTAAAGGGGACAGTTGCCCA
AAATGTTCTTGTATGTGTTCTTCTGTTGGTGGAGGAAGTTGATTTCACCTCCCTGCCAAAAGAACAAACCATTTGAA
GCTCACAATTGTGAAGCATTACGGCGTCCGGAAGAGGCCTTTTGAAGCAAGCGCAATGAGTTTCAGGAATGAAGTAGAAG
GTAGTTATTTAAAAATAAAAAACAGTCCGTCCCTACCAATAGAGGAAATGGTTTAAATGTTTGTGGTGTGAGACAGAC
AAATGGGCTAGAGTAAGAGGGCTGCGGGTATGAGAGACCCGGCTCCGCCCTGGCAGCTGTCTTGTGGCGGCCGCCA
35 CAGGCCCCCTCAATGGCCGCAATTGAGATGGCTCTATACACAGCAGTGTGGTTTATGTAAGTTTCAGCAGTCACTTCA
(SEQ ID NO: 16)

MSCVLGGVIFLGLLFLVRGSQGYLLPNVTLLEELLSKYQHNEHSRVRRAIPREDKEEILMLHNKLRGQVQPQASNM
EYMTWDDLEKSAAWASQCIWEHGPTGLLVSIGQNLGAHWGRYRSPGFHVQSWYDEVKDYTPYPSECNPWCPERC
40 SGPMCTHYTQIVWATTNKIGCAVNTCRKMTVWGEVWENAVYFVCNYSKGNWIGEAPYKNRCPCECPPSYGGGSCRN
NLCYREETYTPKPEDMENVEETAPIPEENHVWLQPRVMRPTPKPKTSAVNYMTQVVRCDTKMKDRCKGSTCNRYQC
PAGCLNHKAKIFGSLFYESSSSICRAAIHYGILDGKGLVDITRNGKVPFFVKSERHGVQSLSKYKPSSEFMVSKVK
VQDLDCYTTVAQLCPFEKPATHCPRIHCPAHCKDEPSYAWPVFGTNIYADTSSICKTAVHAGVISNESGGDQVDMVPV
DKKKTYYVGSRLNGVQSESLGTPRDGKAFRIFAVRQ (SEQ ID NO: 17)

The disclosed NOV-4b amino acid sequence has 124 of 191 amino acid residues (64%) identical to, and 148 of 191 (77%) similar to, a known human trypsin inhibitor (TREMBL ACC No: 043692), as shown in Table 28. As indicated by the "Expect" value, the probability of this alignment occurring by chance alone is $6.1e-73$, which is a very low probability score.

TABLE 28

Score = 737 (259.4 bits), Expect = $6.1e-73$, P = $6.1e-73$
Identities = 124/191 (64%), Positives = 148/191 (77%)

10	NOV4b:	45	SRVRRRAIPREDKEEILMLHNKLRGQVQPQASNM EYMTWDDLEKSAAAWASQCIWEHGPT	104
			+R +R I + D IL HN++RG+V P A+NMEYM WD+ L KSA ANA+ CIW+HGP+	
	TRYP :	56	ARRKRYISQNDMTAILDYHNQVRGKVFPPAANMEYMVWDENLAKSARAWAATCIWDHGPS	115
15	NOV4b:	105	GLLVSIGQNLGAHWGRYRSPGFHVQSWYDEVKDYTYYPSECNPWCPERCSGPMCTHTYTQ	164
			LL +GQNL GRYRS V+ WYDEVKDY +PYP +CNP CP RC GPMCTHTYTQ	
	TRYP :	116	YLLRFLGQNL SVRTGRYRSILQLVKPWYDEVKDYAFYPQDCNPRCPMRCFGPMCTHTYTQ	175
20	NOV4b:	165	IVWATTNKIGCAVNTCRKMTVWGEVWENAVYFVCNYSKGNWIGEAPYKNGRPCSECPPS	224
			+VWAT+N+IGCA++TC+ M VWG VW AVY VCNY+PKGNWIGEAPYK G PCS CPPS	
	TRYP :	176	MVWATSNRIGCAIHTCQNMNVWGSVWRRRAVYLVCNYAPKGNWIGEAPYKVGVPSCSCPPS	235
	NOV4b:	225	YGGSCRNNLCY	235 (SEQ ID NO: 74)
			YGGSC +NLC+	
25	TRYP :	236	YGGSCDNLCF	246 (SEQ ID NO: 42)

Furthermore, a PROSITE database search of protein families and domains confirmed that NOV-4a is a member of the trypsin inhibitor family. One of the conserved regions found in trypsin inhibitors is a SCP domain, located at the C-terminal half. The pattern of this conserved domain is: [LIVMFYH]-[LIVMFY]-x-C-[NQRHS]-Y-x-[PARH]-x-[GL]-N-[LIVMFYWDN] (SEQ ID NO: 56). This pattern is found in amino acids 195-206 of SEQ ID NO: 17.

SignalPep and PSORT analyses indicate that that NOV-4b is likely located outside of the cell (certainty = 0.6950), and is likely to have a cleavable N-terminal signal sequence with a cleavage site between positions 22 and 23: SQG-YL. The predicted molecular weight of NOV-4b is 55928.2 daltons.

Based on its relatedness to known members of the trypsin inhibitor family of proteins, NOV4b provides new diagnostic and therapeutic compositions useful in the treatment of disorders associated with alterations in the expression of members of the trypsin inhibitor protein family. Nucleic acids, polypeptides, antibodies, and other compositions of the present invention are useful in the treatment and diagnosis of a variety of diseases and pathologies, including, by way of nonlimiting example, those involving reproductive disorders, immunological disorders, cancer, and metabolic disorders.

NOV-4c

A NOV-4c sequence according to the invention is a nucleic acid sequence that encodes a polypeptide related to trypsin inhibitor proteins. A disclosed NOV-4c nucleic acid and its encoded polypeptide are included in Table 29. The disclosed nucleic acid (SEQ ID NO: 18) is 1669 nucleotides in length and contains an open reading frame (ORF) that begins with an ATG initiation codon at nucleotide 205, and ends with a TAG stop codon at nucleotide 1636. The representative ORF encodes a 205 amino acid polypeptide (SEQ ID NO: 19).

TABLE 29

TCTGACTGCTCCTATTGAGCTGTCTGCTCGCTGTGCCCGCTGTGCCTGCTGTGCCCGCGC
 TGTGCGCGCTGCTACCGCGTCTACTGGACGCGGGAGACGCCAGCGAGCTGGTGATTGGAG
 CCCTGCCGAGAGCTCAAGCGCCAGCTCTGCCCGAGGAGCCAGGCTGCCCGTGAGTCC
 CATAGTTGCTGCAGGAGTGAGCCATGAGCTGCGTCTGGGTGGTGTATCCCTTGGGG
 CTGCTGTTCTGGTCTGCGGATCCCAAGGCTACCTCCTGCCCAACGTCACTCTCTTAGAG
 GAGCTGCTCAGCAAATACCAGCACACGAGTCTCACTCCCGGGTCCGCAGAGCCATCCCC
 AGGGAGGACAAGGAGGAGATCCTCATGCTGCACAACAAGCTTCGGGGCCAGGTGCAGCCT
 CAGGCCCTCAACATGGAGTACATGACCTGGGATGACGAAGTGGAGAAGTCTGCTGCAGCG
 TGGGCCAGTCAGTGCATCTGGGAGCACGGGCCACCGGTCTGCTGGTGTCCATCGGGCAG
 AACCTGGGCGCTCACTGGGGCAGGTATCGCTCTCCGGGGTTCATGTGCAGTCTGGTAT
 GACGAGGTGAAGGACTACACCTACCCCTACCCGAGCGAGTGCAACCCCTGGTGTCCAGAG
 AGGTGCTCGGGGCTATGTGCAGCACTACACACAGATAGTTTGGGCCACCACCAACAAG
 ATCGGTTGTGCTGTGAACACCTGCCGGAAGATGACTGTCTGGGGAGAAGTTGGGAGAAC
 GCGGTCTACTTTGTCTGCAATTATTCTCAAAGGGGAAGTGGATTGGAGAAGCCCCCTAC
 AAGAAATGGCCGCGCCCTGCTCTCAGTGCCCAACCAGCTATGGAGGCAGCTGCAGGAACAAC
 TTGTGTTACCGAGAAGAAACCTACACTCCAAAACCTGAAACGGACGAGATGAATGAGGTG
 GAAACGGCTCCCATTCCTGAAGAAAACCATGTTTGGCTCCAACCGAGGGTGATGAGACCC
 ACCAAGCCCAAGAAAACCTCTTCGGTCAACTACATGACCCAAGTCGTCTTATGTGACACC
 AAGATGAAGGACAGGTGCAAAGGGTCCACGTGTAACAGGTACCACTGCCAGCAGGCTGC
 CTGAACCACAAGGCGAAGATCTTTGGAAGTCTGTTCTATGAAAGCTCGTCTAGCATATGC
 CGCGCGCCATCCACTACGGGATCCTGGATGACAAGGGAGGCCTGGTGGATATCACCAGG
 AACGGGAAGGTCCCCTTCTTCGTGAAGTCTGAGAGACACGGCGTGCAGTCCCTCAGCAAA
 TACAAACCTTCCAGCTCATTATGGTGTCAAAAGTGAAAGTGCAGGATTGGACTGCTAC
 ACGACCGTTGCTCAGCTGTGCCCGTTTGAAAAGCCAGCAACTCACTGCCCAAGAATCCAT
 TGTCCGGCACACTGCAAAGACGAACCTTCCTACTGGGCTCEGGTGTGTTGGAACCAACATC
 TATGCAGATACCTCAAGCATCTGCAAGACAGCCGTGCACGCGGGAGTCATCAGCAACGAG
 AGTGGGGGTGACGTGGACGTGATGCCCGTGGATAAAAAGAAGACCTACACCTGCCCGGCA
 GCCGCTCGAGCCCTATAGTGTAACCGATTTCGCAGCACACTGGCGCCGT (SEQ ID

NO: 18)

MSCVLGGVIPLGLLFLVCGSQGYLLPNVTLLLEELLSKYQHNEHSRVRRAIP
 REDKEEILMLHNKLRGQVQPQASNMEYMTWDELEKSAAAWASQCIWEHGPT

GLLVSIQNLGAHWGRYRSPGFHVQSWYDEVKDYTYPPSECNPWCPERCSG
 PMCTHYTQIVWATTNKIGCAVNTCRKMTVWGEVWENAVYFVCNYSKGNWIG
 EAPYKNGRPCSQCPPSYGGSCRNNLCYREETYTPKPKETDEMNEVETAPIPEE
 NHVWLQPRVMRPTKPKKTSSVNYMTQVVLCDTKMKDRCKGSTCNRYQCPAGC
 5 LNHKAKIFGTLFYESSSSICRAAIHYGILDDKGGLVDITRNGKVPFFVKSER
 HGVQSLSKYKPSSSFMVSKVKVQDLDCYTTVAQLCPFEPATHCPRIHCPAH
 CKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVMVPVDKKKTY
 TCPAAARAL (SEQ ID NO: 19)

- 10 The disclosed NOV-4c amino acid sequence has a high level of homology (97% identity, 97% similarity) to a human trypsin inhibitor-like protein (GenBank Accession No: CAB66795), shown in Table 30. As indicated by the "Expect" value, the probability of this alignment occurring by chance alone is 0.0, the lowest probability score.

15 **TABLE 30**

Score = 948 bits (2452), Expect = 0.0

Identities = 458/468 (97%), Positives = 460/468 (97%)

20	NOV4c: 1	MSCVLGGVIPLGLLFLVCGSQGYLLPNVTXXXXXXSKYQHNESSHRSVRRRAIPREDKEEIL	60
		MSCVLGGVIPLGLLFLVCGSQGYLLPNVT SKYQHNESSHRSVRRRAIPREDKEEIL	
	TRYP : 1	MSCVLGGVIPLGLLFLVCGSQGYLLPNVTLLLELLSKYQHNESSHRSVRRRAIPREDKEEIL	60
	NOV4c: 61	MLHNKLRGQVQPQASNMEYMTWDDELEKSAAAWASQCIWEHGPTGLLVSIQNLGAHWGR	120
25		MLHNKLRGQVQPQASNMEYMTWDDELEKSAAAWASQCIWEHGPT LLVSIQNLGAHWGR	
	TRYP : 61	MLHNKLRGQVQPQASNMEYMTWDDELEKSAAAWASQCIWEHGPTSLLVSIQNLGAHWGR	120
	NOV4c: 121	YRSPGFHVQSWYDEVKDYTYPPSECNPWCPERCSGPMCTHYTQIVWATTNKIGCAVNTC	180
30		YRSPGFHVQSWYDEVKDYTYPPSECNPWCPERCSGPMCTHYTQIVWATTNKIGCAVNTC	
	TRYP : 121	YRSPGFHVQSWYDEVKDYTYPPSECNPWCPERCSGPMCTHYTQIVWATTNKIGCAVNTC	180
	NOV4c: 181	RKMTVWGEVWENAVYFVCNYSKGNWIGEAPYKNGRPCSQCPPSYGGSCRNNLCYREETY	240
		RKMTVWGEVWENAVYFVCNYSKGNWIGEAPYKNGRPCS+CPPSYGGSCRNNLCYREETY	
	TRYP : 181	RKMTVWGEVWENAVYFVCNYSKGNWIGEAPYKNGRPCSECPPSYGGSCRNNLCYREETY	240
35	NOV4c: 241	TPKPKETDEMNEVETAPIPEENHVWLQPRVMRPTKPKKTSSVNYMTQVVLCDTKMKDRCKG	300
		TPKPKETDEMNEVETAPIPEENHVWLQPRVMRPTKPKKTS+VNYMTQVV CDTMKMKDRCKG	
	TRYP : 241	TPKPKETDEMNEVETAPIPEENHVWLQPRVMRPTKPKKTSVNYMTQVVRCDTKMKDRCKG	300
40	NOV4c: 301	STCNRYQCPAGCLNHKAKIFGTLFYESSSSICRAAIHYGILDDKGGLVDITRNGKVPFFV	360
		STCNRYQCPAGCLNHKAKIFGTLFYESSSSICRAAIHYGILDDKGGLVDITRNGKVPFFV	
	TRYP : 301	STCNRYQCPAGCLNHKAKIFGTLFYESSSSICRAAIHYGILDDKGGLVDITRNGKVPFFV	360
	NOV4c: 361	KSERHGVQSLSKYKPSSSFMVSKVKVQDLDCYTTVAQLCPFEPATHCPRIHCPAHCKDE	420
45		KSERHGVQSLSKYKPSSSFMVSKVKVQDLDCYTTVAQLCPFEPATHCPRIHCPAHCKDE	
	TRYP : 361	KSERHGVQSLSKYKPSSSFMVSKVKVQDLDCYTTVAQLCPFEPATHCPRIHCPAHCKDE	420
	NOV4c: 421	PSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVMVPVDKKKTY	468 (SEQ ID NO: 75)
50		PSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVMVPVDKKKTY	
	TRYP : 421	PSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVMVPVDKKKTY	468 (SEQ ID NO: 43)

5 [LIVMFYWDN] (SEQ ID NO: 56). This pattern is found in amino acids 81-92 of SEQ ID NO: 19.

10 molecular weight of NOV-4c is 53587.7 daltons.

15 family. Nucleic acids, polypeptides, antibodies, and other compositions of the present invention are useful in the treatment and diagnosis of a variety of diseases and pathologies, including, by way of nonlimiting example, those involving reproductive disorders, immunological disorders, cancer, and metabolic disorders.

20 NOV-4d

25 ATG initiation codon at nucleotide 206, and ends with a TGA stop codon at nucleotide 1700.
A disclosed, representative ORF encodes a 498 amino acid polypeptide (SEQ ID NO: 21).

TABLE 31

30 TCTACTGGACGCGGGGAGACGCCAGCGAGCTGGTGATTGGAGCCCTGCGGAGAGCTCAAGCGCCAGCTCTGCCCGAGGAG
CCCAGGCTGCCCCGTGAGTCCCATAGTTGCTGCAGGAGTGGAGCCATGAGCTGCGTCTGGGTGGTGTATCCCCCTGGG
GCTGCTGTTCTCTGGTCCGCGGATCCCAAGGCTACCTCCTGCCCAACGCTCACTCTCTTAGAGGAGCTGCTCAGCAAATACC
AGCACAAAGAGTCTCACT'CCCGGGTCCGCAGAGCCATCCCCAGGGAGGACAAGGAGGAGATCCTCATGCTGCACAACAAG
CTTCGGGGCCAGGTGCAGCCTCAGGCCTCCAACATGGAGTACATGACCTGGGATGACGAACTGGAGAAGTCTGCTGCAGC
35 GTGGGCCAGTCAGTGCATCTGGGAGCACGGGCCCACCACTCTGCTGGTGTCCATCGGGCAGAACCTGGGCGCTCACTGGG
GCAGGAGGTATCGCTCTCCGGGTTCCATGTGAGTCTGGTATGACGAGGTGAAGGACTACACCTACCCCTACOCGAGC
GAGTGCAACCCCTGGTGTCCAGAGAGGTGCTCGGGGCCATGTGCACGCACTACACACAGATAGTTTGGGCCACCAACA

CAAGATCGGTTGTGCTGTGAACACCTGCCGGAAGATGACTGTCTGGGAGAGTTTGGGAGAACCGGCTCTACTTTGTCT
 GCAATTATTCTCAAAGGGGAACTGGATTGGAGAAGCCCCCTACAAGAATGGCCGGCCCTGCTCTGAGTGCCCAACCAGC
 TATGGAGGCAGCTGCAGGAACAACCTTGTGTTACCGAGAAGAAACCTACACTCCAAAACCTGAAACGGACGAGATGAATGA
 GGTGGAACCGGCTCCCATTCCTGAAGAAAACCATGTTTGGCTCCAACCGAGGGTGATGAGACCCACCAAGCCCAAGAAA
 5 CCTCTGCGGTCAACTACATGACCCAACTCGTCAGATGTGACACCAAGATGAAGGACAGGTGCAAAGGGTCCACGTGTAAC
 AGGTACCAGTGCCAGCAGGCTGCCTGAACCACAAGGCGAAGATCTTTGGAAGTCTGTTCTATGAAAGCTCGTCTAGCAT
 ATGCCGCGCCGCATCCACTACGGGATCCTGGATGACAAGGGAGGCCCTGGTGGATATCACCAGGAACGGGAAGGTCCCT
 TCTTCGTGAAGTCTGAGAGACACGGCGTGCAGTCCCTCAGCAAATACAAACCTTCAGCTCATTCTGTTGTCAAAAGTG
 AAAGTGACAGATTTGGACTGCTACACGACCGTTGCTCAGCTGTGCCCGTTTGAAAAGCCAGCAACTCACTGCCCAAGAA
 10 CCATTGTCCGGCACACTGCAAAGACGAACCTTCTACTGGGCTCCGGTGTGTTGGAACCAACATCTATGCAGATACCTCAA
 GCATCTGCAAGACAGCCGTGCACGCGGGAGTCATCAGCAACGAGAGTGGGGTGACGTGGACGTGATGCCCGTGGATAAA
 AAGAAGACCTACGTGGGCTCGCTCAGGAATGGAGTTCAGTCTGAAAGCCTGGGGACTCCTCGGGATGAAAGCCCTTCCG
 GATCTTTGCTGTGAGGCAGTGAATTTCCAGCACCAGGGGAGAAGGGCGTCTTCAGGAGGGCTTCGGGGTTTTGCTTTTA
 TTTTATTTTGTGCTATGCGGGTATATGGAGAGTCAGGAACTTCCTTTGACTGATGTTTCACTGTCCATCACTTTGTGGC
 15 CTGTGGGTGAGGTGACATCTCATCCCCCTCACTGAAGCAACAGCATCCCAAGGTGCTCAGCCGGAAGTCCCTGGTGCCTGAT
 CCTGCTGGGGCCCGGGGTCTCCATCTGGAGCTCCTCTCTCTTTAGAGATCTGAGCTGTCTCTTAAGGGGACAGTTGC
 CCAAATGTTCTTGCTATGTGTTCTTCTGTTGGTGGAGGAAGTTGATTTCAACCTCCCTGCCAAAAGAACAAACATTT
 GAAGCTCACAATTGTGAAGCATTACGGCGTGGGAAGAGGCCCTTTGAGCAAGCGCAATGAGTTTCAGGAATGAAGTAG
 AAGGTAGTTATTTAAAAATAAAAAACACAGTCCGTCCCTACCAATAGAGGAAATGGTTTAAATGTTTGTGCTGGTCAGACA
 20 GACAAATGGGCTAGAGTAAGAGGGCTGCGGGTATGAGAGACCCCGGCTCCGCCCTGGCACGTGCTCTGCTGGCGGCCG
 CCACAGGCCCTTCAATGGCCGATTGAGGATGGCTCTATACACAGCAGTGTGTTTATGTAAAGTTGAGCAGTCACT
 TCA (SEQ ID NO: 20)

MSCVLGGVPLGLLFLVRGSGQYLLPNVTLLLELLSKYQHNEHSRVRRAIPREDKEEILMLHNKLRQV
 25 QPOASNMEYMTWDELEKSAAAWASQCIWEHGPTSLLVSIGQNLGAHWGRRYRSPGFHVQSWYDEVKDYT
 YPYPSECNPWCPCRCGPMCTHYTQIVWATTNKIGCAVNTCRKMTVWGEVWENAVYFVCNYSKPGNWIGE
 APYKNGRPCSECPPSYGGSCRNNLCYREETYTPKPETDEMNEVETAPIPEENHVWLQPRVMRPTKPKKTS
 AVNYMTQVVRCDTKMKDRCKGSTCNRYQCPAGCLNHKAKIFGSLFYESSSSICRAAIHYGILDDKGLVD
 ITRNGKVPFFVKSERHGVQSLSKYPSSSFMVSKVKVQDLDCYTTVAQLCPFEKPATHCPRIHCPAHCKD
 30 EPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDVMPVDKKKTYVGSRLRNGVQSESGLTPRDGKA
 FRIFAVRQ (SEQ ID NO: 21)

The disclosed NOV-4d amino acid sequence has a high level of homology (98%
 identity, 98% similarity) to a human trypsin inhibitor-like protein (GenBank Accession No:
 35 CAB66795), as shown in Table 32. As indicated by the "Expect" value, the probability of this
 alignment occurring by chance alone is 0.0, the lowest probability score.

TABLE 32

Score = 1007 bits (2605), Expect = 0.0
 Identities = 489/498 (98%), Positives = 490/498 (98%), Gaps = 1/498 (0%)
 40
 NOV4d: 1 MSCVLGGVPLGLLFLVRGSGQYLLPNVTXXXXXSKYQHNEHSRVRRAIPREDKEEIL 60
 MSCVLGGVPLGLLFLV GSQYLLPNVT SKYQHNEHSRVRRAIPREDKEEIL
 TRYP : 1 MSCVLGGVPLGLLFLVCGSQYLLPNVTLLLELLSKYQHNEHSRVRRAIPREDKEEIL 60

5	NOV4d: 61	MLHNKLRGQVQPQASNMEYMTWDDELEKSAAAWASQCIWEHGPTSLVLSIGQNLGAHWGR	120
	TRYP : 61	MLHNKLRGQVQPQASNMEYMTWDDELEKSAAAWASQCIWEHGPTSLVLSIGQNLGAHWG-	119
10	NOV4d: 121	RYRSPGFHVQSWYDEVKDYTYYPYSECNPWCPCRCSGPMCTHYTQIVWATTNKIGCAVNT	180
	TRYP : 120	RYRSPGFHVQSWYDEVKDYTYYPYSECNPWCPCRCSGPMCTHYTQIVWATTNKIGCAVNT	179
15	NOV4d: 181	CRKMTVWGEVWENAVYFVCNYSKGNWIGEAPYKNGRPCSECPPSYGGSCRNNLCYREET	240
	TRYP : 180	CRKMTVWGEVWENAVYFVCNYSKGNWIGEAPYKNGRPCSECPPSYGGSCRNNLCYREET	239
20	NOV4d: 241	YTPKPEDEMNEVETAPIPEENHVWLQPRVMRPTKPKKTSAVNYMTQVVRCDTKMKDRCK	300
	TRYP : 240	YTPKPEDEMNEVETAPIPEENHVWLQPRVMRPTKPKKTSAVNYMTQVVRCDTKMKDRCK	299
25	NOV4d: 301	GSTCNRYQCPAGCLNHKAKIFGSLFYESSSSICRAAIHYGILDDKGGLVDITRNGKVPFF	360
	TRYP : 300	GSTCNRYQCPAGCLNHKAKIFGSLFYESSSSICRAAIHYGILDDKGGLVDITRNGKVPFF	359
30	NOV4d: 361	VKSERHGVQSLSKYKPSSEFMVSKVKVQDLDCYTTVAQLCFEKPATHCPRHCPAHCKD	420
	TRYP : 360	VKSERHGVQSLSKYKPSSEFMVSKVKVQDLDCYTTVAQLCFEKPATHCPRHCPAHCKD	419
35	NOV4d: 421	EPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDMPVDKKKTYVGSRLRNGVQSE	480
	TRYP : 420	EPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDMPVDKKKTYVGSRLRNGVQSE	479
40	NOV4d: 481	SLGTPRDGKAFRIFAVRQ	498 (SEQ ID NO: 76)
	TRYP : 480	SLGTPRDGKAFRIFAVRQ	497 (SEQ ID NO: 44)

A PROSITE database search of protein families and domains confirmed that a NOV-4c polypeptide is a member of the trypsin inhibitor family. One of the conserved regions found in trypsin inhibitors is a SCP domain, located at the C-terminal half. The pattern of this conserved domain is: [LIVMFYH]-[LIVMFY]-x-C-[NQRHS]-Y-x-[PARH]-x-[GL]-N-[LIVMFYWDN] (SEQ ID NO: 56). This pattern is found in amino acids 196-207 of SEQ ID NO: 21.

Based on the relatedness between NOV-4d and the conserved trypsin inhibitor proteins, NOV-4d is a novel member of the trypsin inhibitor family. NOV-4d provides new diagnostic and therapeutic compositions useful in the treatment of disorders associated with alterations in the expression of members of the trypsin inhibitor protein family. Nucleic acids, polypeptides, antibodies, and other compositions of the present invention are useful in the treatment and diagnosis of a variety of diseases and pathologies, including, by way of nonlimiting example, those involving reproductive disorders, immunological disorders, cancer, and metabolic disorders.

In addition, SignalPep and PSORT analyses indicate that that NOV-4d is likely located outside of the cell (certainty = 0.6950), and is likely to have a cleavable N-terminal signal

sequence with a cleavage site between positions 22 and 23: SQG-YL. The predicted molecular weight of NOV-4b is 56114.4 daltons.

5 NOV-4e

A NOV-4e sequence according to the invention is a nucleic acid sequence that encodes a polypeptide related to trypsin inhibitor proteins. A disclosed NOV-4e nucleic acid and its encoded polypeptide are included in Table 33. The disclosed nucleic acid (SEQ ID NO: 22) is 2412 nucleotides in length and contains an open reading frame (ORF) that begins with an
 10 ATG initiation codon at nucleotide 206, and ends with a TGA stop codon at nucleotide 1709. A disclosed, representative ORF encodes a 501 amino acid polypeptide (SEQ ID NO: 23).

TABLE 33

CTCTGACTGCTCCTATTGAGCTGTCTGCTCGCTGTGCCCGCTGTGCCTGCTGTGCCCCG
 15 CGCTGTGCGCCGCTGCTACCGCGTCTACTGGACGCGGGAGACGCCAGCGAGCTGGTGAT
 TGGAGCCCTGCGGAGAGCTCAAGCGCCAGCTCTGCCCGAGGAGCCAGGCTGCCCCG
 TGAGTCCCATAGTTGCTGCAGGAGTGGAGCCATGAGCTGCGTCCTGGGTGGTGTGTCATC
 CCCTTGGGGTGTGTTCTTCTGGTCCGCGGATCCCAAGGCTACCTCCTGCCCAACGTCA
 CTCTCTTAGAGGAGCTGCTCAGCAAATACCAGCACACGAGTCTCACTCCCGGGTCCG
 20 CAGAGCCATCCCCAGGGAGGACAAGGAGGAGATCCTCATGCTGCACAACAAGCTTCGG
 GGCCAGGTGCAGCCTCAGGCCCTCCAACATGGAGTACATGACCTGGGATGACGAACTGG
 AGAAGTCTGCTGCAGCGTGGGCCAGTCAGTGCATCTGGGAGCACGGGGCCACCGGTCT
 GCTGGTGTCCATCGGGCAGAACCTGGGCGCTCACTGGGGCAGGTATCGCTCTCCGGGG
 TTCCATGTGCAGTCTTGGTATGACGAGGTGAAGGACTACACCTACCCCTACCCGAGCG
 25 AGTGCAACCCCTGGTGTCCAGAGAGGTGCTCGGGGCCATGTGCACGCACTACACACA
 GGTAACCTCAGATAGTTTGGGCCACCACCAACAAGATCGGTTGTGCTGTGAACACCTGC
 CGGAAGATGACTGTCTGGGGAGAAGTTTGGGAGAACGCGGTCTACTTTGTCTGCAATT
 ATTCTCCAAAGAGGGGGAACCTGGATTGGAGAAGCCCCCTACAAGAATGGCCGGCCCTG
 CTCTGAGTGCCCAACCAGCTATGGAGGCAGCTGCAGGAACAACCTTGTGTTACCGAGAA
 30 GAAACCTACACTCCAAAACCTGAAACGGACGAGATGAATGAGGTGGAAACGGCTCCCA
 TTCCTGAAGAAAACCATGTTTGGCTCCAACCGAGGGTGATGAGACCCACCAAGCCCAA
 GAAAACCTCTGCGGTCAACTACATGACCCAAGTCGTGAGATGTGACACCAAGATGAAG
 GACAGGTGCAAAGGGTCCACGTGTAACAGGTACCAGTGCCAGCAGGCTGCCTGAACC
 ACAAGGCGAAGATCTTTGGAAGTCTGTTCTATGAAAGCTCGTCTAGCATATGCCGCGC
 35 CGCCATCCACTACGGGATCCTGGATGACAAGGGAGGCCTGGTGGATATCACCAGGAAC
 GGGAAAGTCCCCTTCTTCGTGAAGTCTGAGAGACACGGCGTGAGTCCCTCAGCAAAT
 ACAAACCTTCCAGCTCATTCATGGTGTCAAAAGTGAAAGTGCAGGATTTGGACTGCTA
 CACGACCGTTGCTCAGCTGTGCCCGTTTGAAGCCAGCAACTCACTGCCCAAGAATC
 CATTGTCCGGCACACTGCAAAGACGAACCTTCTACTGGGCTCCGGTGTGTTGGAACCA

ACATCTATGCAGATACCTCAAGCATCTGCAAGACAGCCGTGCACGCGGGAGTCATCAG
 CAACGAGAGTGGGGGTGACGTGGACGTGATGCCCCTGGATAAAAAGAAGACCTACGTG
 GGCTCGCTCAGGAATGGAGTTCAGTCTGAAAGCCTGGGGACTCCTCGGGATGGAAAGG
 CCTTCCGGATCTTTGCTGTCAGGCAGTGAATTTCCAGCACCAGGGGAGAAGGGGCGTC
 5 TTCAGGAGGGCTTCGGGGTTTTGCTTTTATTTTATTTTGTTCATTGCGGGGTATATGG
 AGAGTCAGGAAACTTCCTTTGACTGATGTTTCAGTGTCCATCACTTTGTGGCCTGTGGG
 TGAGGTGACATCTCATCCCCTCACTGAAGCAACAGCATCCCAAGGTGCTCAGCCGGAC
 TCCCTGGTGCCTGATCCTGCTGGGGCCCGGGGTCTCCATCTGGACGTCCTCTCTCCT
 TTAGAGATCTGAGCTGTCTCTTAAAGGGGACAGTTGCCCAAATGTTCTTGCTATGT
 10 GTTCTTCTGTTGGTGGAGGAAGTTGATTTCAACCTCCCTGCCAAAAGAACAAACCATT
 TGAAGCTCACAATTGTGAAGCATTACGGCGTCGGAAGAGGCCTTTTGAGCAAGCGCC
 AATGAGTTTCAGGAATGAAGTAGAAGGTAGTTATTTAAAAATAAAAAACACAGTCCGT
 CCCTACCAATAGAGGAAATGGTTTTAATGTTTGCTGGTCAGACAGACAAATGGGCTA
 GAGTAAGAGGGCTGCGGGTATGAGAGACCCCGGCTCCGCCCTGGCACGTGCTCTTGCT
 15 GCGGCCCCGCCACAGGCCCCCTTCAATGGCCGATTAGGATGGCTCTATACACAGCA
 GTGCTGGTTTTATGTAAAGTTCAGCAGTCACTTCA (SEQ ID NO: 22)

MSCVLGGV IPLGLLFLVRGSQGYLLPNVTLLLELLSKYQHNESH SRVRRRAIPREDKEE
 ILMHLNKL RGQVQPQASNMEYMTWDELEKSAAAWASQCIWEHGPTGLLV SIGQNLGA
 20 HWGRYRSPGFHVQSWYDEVKDYTPYPSECNPWC PERCSGPMCTHYTQVTQIVWATTN
 KIGCAVNTCRKMTVWGEVWENAVYFVCNYS PKRGNWIGEAPYKNGRPCSECP PSYGGG
 CRNNLCYREETYTPK PETDEMNEVETAPIPEENHVWLQPRVMRPTKPKKTS AVNYMTQ
 VVRCDTKMKDRCKGSTCNRYPQCPAGCLNHKAKIFGSLFYESSSSICRAAIHYGILDDK
 GGLVDITRNGKVPFFVKSERHGVQSLSKYKPSSSFMSKVKVQDLDCYTTVAQLCPFE
 25 KPATHCPRIHCPAHCKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGD VDM
 PVDKKKTYVGSRLRNGVQSESLGTPRDGKA FRIFAVRQ (SEQ ID NO: 23)

The disclosed NOV-4e amino acid sequence has a high level of homology (97%
 identity, 97% similarity) to a human trypsin inhibitor-like protein (GenBank Accession No:
 30 CAB66795), shown in Table 34. As indicated by the "Expect" value, the probability of this
 alignment occurring by chance alone is 0.0, the lowest probability score.

TABLE 34

Score = 1001 bits (2588), Expect = 0.0
 35 Identities = 488/501 (97%), Positives = 489/501 (97%), Gaps = 4/501 (0%)

NOV4e: 1	MSCVLGGV IPLGLLFLVRGSQGYLLPNVTXXXXXXSKYQHNESH SRVRRRAIPREDKEEIL	60
	MSCVLGGV IPLGLLFLV GSQGYLLPNVT SKYQHNESH SRVRRRAIPREDKEEIL	
40 TRYP : 1	MSCVLGGV IPLGLLFLVCGSQGYLLPNVTLLLELLSKYQHNESH SRVRRRAIPREDKEEIL	60
NOV4e: 61	MLHNKL RGQVQPQASNMEYMTWDELEKSAAAWASQCIWEHGPTGLLV SIGQNLGAHWGR	120
	MLHNKL RGQVQPQASNMEYMTWDELEKSAAAWASQCIWEHGPT LLV SIGQNLGAHWGR	
TRYP : 61	MLHNKL RGQVQPQASNMEYMTWDELEKSAAAWASQCIWEHGPTSLLV SIGQNLGAHWGR	120

NOV4e: 121 YRSPGFHVQSWYDEVKDYTPYPSECNPWCPERCSPGMCTHYTQVTQIVWATTNKIGCAV 180
 YRSPGFHVQSWYDEVKDYTPYPSECNPWCPERCSPGMCTHY TQIVWATTNKIGCAV
 5 TRYP : 121 YRSPGFHVQSWYDEVKDYTPYPSECNPWCPERCSPGMCTHY---TQIVWATTNKIGCAV 177
 NOV4e: 181 NTCRKMTVWGEVWENAVYFVCNYSKPGNWNWIGEAPYKNGRPCSECPPSYGGSCRNNLCYR 240
 NTCRKMTVWGEVWENAVYFVCNYSKPGNWNWIGEAPYKNGRPCSECPPSYGGSCRNNLCYR
 TRYP : 178 NTCRKMTVWGEVWENAVYFVCNYSKPGNWNWIGEAPYKNGRPCSECPPSYGGSCRNNLCYR 236
 10 NOV4e: 241 EETYPKPKPETDEMNEVETAPIPEENHVWLQPRVMRPTKPKKTSAVNYMTQVVRCDTKMKD 300
 EETYPKPKPETDEMNEVETAPIPEENHVWLQPRVMRPTKPKKTSAVNYMTQVVRCDTKMKD
 TRYP : 237 EETYPKPKPETDEMNEVETAPIPEENHVWLQPRVMRPTKPKKTSAVNYMTQVVRCDTKMKD 296
 15 NOV4e: 301 RCKGSTCNRYQCPAGCLNHHKAKIFGSLFYESSSSICRAAIHYGILDDKGGLVDITRNGKV 360
 RCKGSTCNRYQCPAGCLNHHKAKIFG+LFYESSSSICRAAIHYGILDDKGGLVDITRNGKV
 TRYP : 297 RCKGSTCNRYQCPAGCLNHHKAKIFGTLFYESSSSICRAAIHYGILDDKGGLVDITRNGKV 356
 NOV4e: 361 PFFVKSERHGVQSLSKYKPSSSFMVSKVKVQDLDCYTTVAQLCPFEKPATHCPRIHCPAH 420
 PFFVKSERHGVQSLSKYKPSSSFMVSKVKVQDLDCYTTVAQLCPFEKPATHCPRIHCPAH
 20 TRYP : 357 PFFVKSERHGVQSLSKYKPSSSFMVSKVKVQDLDCYTTVAQLCPFEKPATHCPRIHCPAH 416
 NOV4e: 421 CKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDVMPVDKKKTYVGSRLNGV 480
 CKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDVMPVDKKKTYVGSRLNGV
 25 TRYP : 417 CKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDVMPVDKKKTYVGSRLNGV 476
 NOV4e: 481 QSESLGTPRDGKAFRIFAVRQ 501 (SEQ ID NO: 77)
 QSESLGTPRDGKAFRIFAVRQ
 TRYP : 477 QSESLGTPRDGKAFRIFAVRQ 497 (SEQ ID NO: 45)

30 In addition, SignalPep and PSORT analyses indicate that that NOV-4e is likely located
 outside of the cell (certainty = 0.6950), and is likely to have a cleavable N-terminal signal
 sequence with a cleavage site between positions 22 and 23: SQG-YL. The predicted
 molecular weight of NOV-4b is 56412.8 daltons.

Based on the relatedness between NOV-4e and the conserved trypsin inhibitor
 35 proteins, the NOV-4e protein is a novel member of the trypsin inhibitor family. NOV-4e
 provides new diagnostic and therapeutic compositions useful in the treatment of disorders
 associated with alterations in the expression of members of the trypsin inhibitor protein
 family. Nucleic acids, polypeptides, antibodies, and other compositions of the present
 invention are useful in the treatment and diagnosis of a variety of diseases and pathologies,
 40 including, by way of nonlimiting example, those involving reproductive disorders,
 immunological disorders, cancer, and metabolic disorders.

Table 35 shows a sequence alignment between the NOV-4 polypeptides according to
 the invention and a human trypsin inhibitor-like protein (GenBank Accession No:
 CAB66795), indicating the homology between the present invention and the trypsin inhibitor
 45 family. Moreover, the PROSITE conserved SCP region found in trypsin inhibitors is found in
 sequences 151-162 of the trypsin inhibitor-like protein shown (shown in bold font).

TABLE 35

5	NOV4e	MSCVLGGV IPLGLLFLVRGSQGYLLPNVTLLLEELL SKYQHNE SHSRVRRRAIPREDKEEIL
	NOV4a	-----
	NOV4b	MSCVLGGV IPLGLLFLVRGSQGYLLPNVTLLLEELL SKYQHNE SHSRVRRRAIPREDKEEIL
	NOV4d	MSCVLGGV IPLGLLFLVRGSQGYLLPNVTLLLEELL SKYQHNE SHSRVRRRAIPREDKEEIL
	NOV4c	MSCVLGGV IPLGLLFLVCGSQGYLLPNVTLLLEELL SKYQHNE SHSRVRRRAIPREDKEEIL
	TRYP	-----ARRKRYISQNDMIAIL
10	NOV4e	MLHNKLRGQVQPQASNMEYMTWDDLEKSAAAWASQCIWEHGPTGLLVSIGQNLGAHWG-
	NOV4a	-----MTNWG-
	NOV4b	MLHNKLRGQVQPQASNMEYMTWDDLEKSAAAWASQCIWEHGPTGLLVSIGQNLGAHWG-
	NOV4d	MLHNKLRGQVQPQASNMEYMTWDDLEKSAAAWASQCIWEHGPTSLLVSIGQNLGAHWGR
	NOV4c	MLHNKLRGQVQPQASNMEYMTWDDLEKSAAAWASQCIWEHGPTGLLVSIGQNLGAHWG-
15	TRYP	DYHNQVRGKVFP PPAANMEYMW DENLAKSAEAWAATCIWDHGPSYLLRFLGQNL SVRTG- .. *
20	NOV4e	RYRSPGFHVQSWYDEVKDYTYPPSECNPWCPERC SGPMCTHYTQVTQIVWATTNKIGCA
	NOV4a	RYRSPGFHVQSWYDEVKDYTYPPSECNPWCPERC SGPMCTHY---TQIVWATTNKIGCA
	NOV4b	RYRSPGFHVQSWYDEVKDYTYPPSECNPWCPERC SGPMCTHY---TQIVWATTNKIGCA
	NOV4d	RYRSPGFHVQSWYDEVKDYTYPPSECNPWCPERC SGPMCTHY---TQIVWATTNKIGCA
	NOV4c	RYRSPGFHVQSWYDEVKDYTYPPSECNPWCPERC SGPMCTHY---TQIVWATTNKIGCA
25	TRYP	RYRSILQLVKPWYDEVKDYAFPPQDCNPRCPMRCFGPMCTHY---TQMVWATSNRIGCA **** *:*****:***:*** ** * ***** **:****:****
30	NOV4e	VNTRKMTVWGEVWENAVYFVCNYS PKRGNWIGEAPYKNGRPCSECPPSYGGSCRNNLCY
	NOV4a	VNTRKMTVWGEVWENAVYFVCNYS PK-GNWIGEAPYKNGRPCSECPPSYGGSCRNNLCY
	NOV4b	VNTRKMTVWGEVWENAVYFVCNYS PK-GNWIGEAPYKNGRPCSECPPSYGGSCRNNLCY
	NOV4d	VNTRKMTVWGEVWENAVYFVCNYS PK-GNWIGEAPYKNGRPCSECPPSYGGSCRNNLCY
	NOV4c	VNTRKMTVWGEVWENAVYFVCNYS PK-GNWIGEAPYKNGRPCSQCPPSYGGSCRNNLCY
	TRYP	IHTCQNMNVWGSVWRRAYVLVCNYPK-GNWIGEAPYKVGVPCCSSCPPSYGGSCDNLCLF ::***:*.***.***.***:***:***:*** ***** * ***.*****:***:
35	NOV4e	REETYTPKPETDEMNEVETAPI PEENHVWLQPRVMRPTKPKKTS AVNYMTQVVRCDTKMK
	NOV4a	REETYTPKPETDEMNEVETAPI PEENHVWLQPRVMRPTKPKKTS AVNYMTQVVRCDTKMK
	NOV4b	REETYTPKPETDEMNEVETAPI PEENHVWLQPRVMRPTKPKKTS AVNYMTQVVRCDTKMK
	NOV4d	REETYTPKPETDEMNEVETAPI PEENHVWLQPRVMRPTKPKKTS AVNYMTQVVRCDTKMK
	NOV4c	REETYTPKPETDEMNEVETAPI PEENHVWLQPRVMRPTKPKKTS SVNYMTQVVLCDTKMK
40	TRYP	-----
45	NOV4e	DRCKGSTCNRYQCPAGCLNHKAKIFGSLFYESSSSICRAAIHYGILDDKGGLVDITRNGK
	NOV4a	DRCKGSTCNRYQCPAGCLNHKAKIFGTLFYESSSSICRAAIHYGILDDKGGLVDITRNGK
	NOV4b	DRCKGSTCNRYQCPAGCLNHKAKIFGSLFYESSSSICRAAIHYGILDDKGGLVDITRNGK
	NOV4d	DRCKGSTCNRYQCPAGCLNHKAKIFGSLFYESSSSICRAAIHYGILDDKGGLVDITRNGK
	NOV4c	DRCKGSTCNRYQCPAGCLNHKAKIFGTLFYESSSSICRAAIHYGILDDKGGLVDITRNGK
	TRYP	-----
50	NOV4e	VPFFVKSERHGVQSLSKYKPSSEFMVSKVKVQDLDCYTTVAQLCPFEKPATHCPRIHCPA
	NOV4a	VPFFVKSERHGVQSLSKYKPSSEFMVSKVKVQDLDCYTTVAQLCPFEKPATHCPRIHCPA
	NOV4b	VPFFVKSERHGVQSLSKYKPSSEFMVSKVKVQDLDCYTTVAQLCPFEKPATHCPRIHCPA
	NOV4d	VPFFVKSERHGVQSLSKYKPSSEFMVSKVKVQDLDCYTTVAQLCPFEKPATHCPRIHCPA
	NOV4c	VPFFVKSERHGVQSLSKYKPSSEFMVSKVKVQDLDCYTTVAQLCPFEKPATHCPRIHCPA
55	TRYP	-----
60	NOV4e	HCKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGD VDVMPVDKKKTYVGS LRNG
	NOV4a	HCKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGD VDVMPVDKKKTYVGS LRNG
	NOV4b	HCKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGD VDVMPVDKKKTYVGS LRNG
	NOV4d	HCKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGD VDVMPVDKKKTYVGS LRNG

NOV4c HCKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDVMPVDKKKTYT-----
 TRYP -----

5 NOV4e VQSESLGTPRDGKAFRIFAVRQ (SEQ ID NO: 23)
 NOV4a VQSESLGTPRDGKAFRIFAVRQ (SEQ ID NO: 15)
 NOV4b VQSESLGTPRDGKAFRIFAVRQ (SEQ ID NO: 17)
 NOV4d VQSESLGTPRDGKAFRIFAVRQ (SEQ ID NO: 21)
 NOV4c -----CPAAARAL----- (SEQ ID NO: 19)
 10 TRYP ----- (SEQ ID NO: 46)

Consensus key

* - single, fully conserved residue
 : - conservation of strong groups
 . - conservation of weak groups
 - no consensus

The expression pattern, and protein similarity information for NOV-4 suggests that the human trypsin inhibitor-like proteins described in this invention may function as a trypsin inhibitor. Therefore, the nucleic acid and protein of the invention are useful in potential therapeutic applications implicated, for example but not limited to, in allergies and infectious diseases, in cancer, in metabolic disorders like obesity, hypertension and diabetes, and other diseases and disorders.

Homology to antigenic secreted and membrane proteins suggests that antibodies directed against the novel genes may be useful in treatment and prevention of allergic reactions and infectious diseases. Expression in pituitary and adrenal gland suggests therapeutic applications in metabolic disorders like obesity, hypertension and diabetes. Similarity to a brain tumor overexpressed trypsin inhibitor suggests that the splice variants of 10093872 may be involved in the pathogenesis of these cancers. Hence it could be useful as a cancer diagnostic marker or as a target for small molecule trypsin inhibitors in cancer treatment.

Potential therapeutic uses for the invention(s) include, for example, the following: (i) protein therapeutic, (ii) small molecule drug target, (iii) antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) diagnostic and/or prognostic marker, (v) gene therapy (gene delivery/gene ablation), (vi) research tools, and (vii) tissue regeneration *in vitro* and *in vivo* (regeneration for all these tissues and cell types composing these tissues and cell types derived from these tissues).

The nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies and disorders. For example, but not limited to, a cDNA encoding the human trypsin inhibitor-like protein may be useful in gene therapy, and the human trypsin inhibitor-like protein may be useful when administered to a subject in need thereof. By way of non-

limiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from, for example, but not limited to, in allergies and infectious diseases, in cancer, in metabolic disorders like obesity, hypertension and diabetes, and other diseases and disorders. The novel nucleic acid encoding the human trypsin inhibitor-like protein, and the human trypsin inhibitor-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. These materials are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods.

NOV-X Nucleic acids

The nucleic acids of the invention include those that encode a NOV-X polypeptide or protein. As used herein, the terms polypeptide and protein are interchangeable.

In some embodiments, a NOV-X nucleic acid encodes a mature NOV-X polypeptide. As used herein, a "mature" form of a polypeptide or protein described herein relates to the product of a naturally occurring polypeptide or precursor form or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, by way of nonlimiting example, the full-length gene product, encoded by the corresponding gene. Alternatively, it may be defined as the polypeptide, precursor or proprotein encoded by an open reading frame described herein. The product "mature" form arises, again by way of nonlimiting example, as a result of one or more naturally occurring processing steps that may take place within the cell in which the gene product arises. Examples of such processing steps leading to a "mature" form of a polypeptide or protein include the cleavage of the N-terminal methionine residue encoded by the initiation codon of an open reading frame, or the proteolytic cleavage of a signal peptide or leader sequence. Thus a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining after removal of the N-terminal methionine. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an N-terminal signal sequence from residue 1 to residue M is cleaved, would have the residues from residue M+1 to residue N remaining. Further as used herein, a "mature" form of a polypeptide or protein may arise from a step of post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristoylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or a combination of any of them.

Among the NOV-X nucleic acids is the nucleic acid whose sequence is provided in SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, or a fragment thereof. Additionally, the invention includes mutant or variant nucleic acids of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, or a fragment thereof, any of whose bases may be changed from the corresponding bases shown in SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, while still encoding a protein that maintains at least one of its NOV-X-like activities and physiological functions (i.e., modulating angiogenesis, neuronal development). The invention further includes the complement of the nucleic acid sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, including fragments, derivatives, analogs and homologs thereof. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications.

One aspect of the invention pertains to isolated nucleic acid molecules that encode NOV-X proteins or biologically active portions thereof. Also included are nucleic acid fragments sufficient for use as hybridization probes to identify NOV-X-encoding nucleic acids (e.g., NOV-X mRNA) and fragments for use as polymerase chain reaction (PCR) primers for the amplification or mutation of NOV-X nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

"Probes" refer to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), 100 nt, or as many as about, e.g., 6,000 nt, depending on use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are usually obtained from a natural or recombinant source, are highly specific and much slower to hybridize than oligomers. Probes may be single- or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.

An "isolated" nucleic acid molecule is one that is separated from other nucleic acid molecules that are present in the natural source of the nucleic acid. Examples of isolated nucleic acid molecules include, but are not limited to, recombinant DNA molecules contained in a vector, recombinant DNA molecules maintained in a heterologous host cell, partially or substantially purified nucleic acid molecules, and synthetic DNA or RNA molecules. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of

the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated NOV-X nucleic acid molecule can contain less than about 50 kb, 25 kb, 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention, e.g., a nucleic acid molecule having the nucleotide sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, or a complement of any of this nucleotide sequence, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, as a hybridization probe, NOV-X nucleic acid sequences can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook et al., eds., MOLECULAR CLONING: A LABORATORY MANUAL 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and Ausubel, et al., eds., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993.)

A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to NOV-X nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

As used herein, the term "oligonucleotide" refers to a series of linked nucleotide residues, which oligonucleotide has a sufficient number of nucleotide bases to be used in a PCR reaction. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise portions of a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, or a complement thereof. Oligonucleotides may be chemically synthesized and may be used as probes.

In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, or a portion of this nucleotide sequence. A nucleic acid molecule that is complementary to the nucleotide sequence shown in SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 is one that is sufficiently complementary to the nucleotide sequence shown in SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 that it can hydrogen bond with little or no mismatches to the nucleotide sequence shown in SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, thereby forming a stable duplex.

As used herein, the term "complementary" refers to Watson-Crick or Hoogsteen base pairing between nucleotide units of a nucleic acid molecule, and the term "binding" means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, Von der Waals, hydrophobic interactions, etc. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates.

Moreover, the nucleic acid molecule of the invention can comprise only a portion of the nucleic acid sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, e.g., a fragment that can be used as a probe or primer, or a fragment encoding a biologically active portion of NOV-X. Fragments provided herein are defined as sequences of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, respectively, and are at most some portion less than a full length sequence. Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice. Derivatives are nucleic acid sequences or amino acid sequences formed from the native compounds either directly or by modification or partial substitution. Analogs are nucleic acid sequences or amino acid sequences that have a structure similar to, but not identical to, the native compound but differs from it in respect to certain components or side chains. Analogs may be synthetic or from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type.

Derivatives and analogs may be full length or other than full length, if the derivative or analog contains a modified nucleic acid or amino acid, as described below. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to,

molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, 85%, 90%, 95%, 98%, or even 99% identity (with a preferred identity of 80-99%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the complement of a sequence encoding the aforementioned proteins under stringent, moderately stringent, or low stringent conditions.

See e.g. Ausubel, et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993, and below. An exemplary program is the Gap program (Wisconsin Sequence Analysis Package, Version 8 for UNIX, Genetics Computer Group, University Research Park, Madison, WI) using the default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2: 482-489, which is incorporated herein by reference in its entirety).

A "homologous nucleic acid sequence" or "homologous amino acid sequence," or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences encode those sequences coding for isoforms of a NOV-X polypeptide. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the present invention, homologous nucleotide sequences include nucleotide sequences encoding for a NOV-X polypeptide of species other than humans, including, but not limited to, mammals, and thus can include, e.g., mouse, rat, rabbit, dog, cat, cow, horse, and other organisms. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence does not, however, include the nucleotide sequence encoding human NOV-X protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23, as well as a polypeptide having NOV-X activity. Biological activities of the NOV-X proteins are described below. A homologous amino acid sequence does not encode the amino acid sequence of a human NOV-X polypeptide.

The nucleotide sequence determined from the cloning of the human NOV-X gene allows for the generation of probes and primers designed for use in identifying and/or cloning NOV-X homologues in other cell types, e.g., from other tissues, as well as NOV-X homologues from other mammals. The probe/primer typically comprises a substantially

purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400 or more consecutive sense strand nucleotide sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57; or an anti-sense strand nucleotide sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57; or of a naturally occurring mutant of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57.

Probes based on the human NOV-X nucleotide sequence can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe further comprises a label group attached thereto, e.g., the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissue which misexpress a NOV-X protein, such as by measuring a level of a NOV-X-encoding nucleic acid in a sample of cells from a subject e.g., detecting NOV-X mRNA levels or determining whether a genomic NOV-X gene has been mutated or deleted.

A "polypeptide having a biologically active portion of NOV-X" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a "biologically active portion of NOV-X" can be prepared by isolating a portion of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 that encodes a polypeptide having a NOV-X biological activity (biological activities of the NOV-X proteins are described below), expressing the encoded portion of NOV-X protein (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of NOV-X. For example, a nucleic acid fragment encoding a biologically active portion of NOV-X can optionally include an ATP-binding domain. In another embodiment, a nucleic acid fragment encoding a biologically active portion of NOV-X includes one or more regions.

NOV-X Variants

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences shown in SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 due to the degeneracy of the genetic code. These nucleic acids thus encode the same NOV-X protein as that encoded by the nucleotide sequence shown in SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 e.g., the polypeptide of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide

sequence encoding a protein having an amino acid sequence shown in SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23.

In addition to the human NOV-X nucleotide sequence shown in SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, it will be appreciated by those skilled in the art that DNA
5 sequence polymorphisms that lead to changes in the amino acid sequences of NOV-X may exist within a population (e.g., the human population). Such genetic polymorphism in the NOV-X gene may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding a NOV-X protein, preferably a mammalian NOV-
10 X protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the NOV-X gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in NOV-X that are the result of natural allelic variation and that do not alter the functional activity of NOV-X are intended to be within the scope of the invention.

Moreover, nucleic acid molecules encoding NOV-X proteins from other species, and
15 thus that have a nucleotide sequence that differs from the human sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the NOV-X cDNAs of the invention can be isolated based on their homology to the human NOV-X nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization
20 probe according to standard hybridization techniques under stringent hybridization conditions. For example, a soluble human NOV-X cDNA can be isolated based on its homology to human membrane-bound NOV-X. Likewise, a membrane-bound human NOV-X cDNA can be isolated based on its homology to soluble human NOV-X.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the
25 invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500 or 750 nucleotides in length. In another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term
30 "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.

Homologs (i.e., nucleic acids encoding NOV-X proteins derived from species other than human) or other related sequences (e.g., paralogs) can be obtained by low, moderate or

high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.

As used herein, the phrase "stringent hybridization conditions" refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at T_m , 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes, primers or oligonucleotides (e.g., 10 nt to 50 nt) and at least about 60°C for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

Stringent conditions are known to those skilled in the art and can be found in CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.

Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other.

A non-limiting example of stringent hybridization conditions is hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65°C. This hybridization is followed by one or more washes in 0.2X SSC, 0.01% BSA at 50°C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 corresponds to a naturally occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).

In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization

conditions are hybridization in 6X SSC, 5X Denhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55°C, followed by one or more washes in 1X SSC, 0.1% SDS at 37°C. Other conditions of moderate stringency that may be used are well known in the art. See, e.g., Ausubel et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY,

- 5 John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY.

In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, or fragments, analogs or derivatives thereof, under conditions of low stringency, is
10 provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40°C, followed by one or more washes in 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50°C. Other conditions of low stringency that may be
15 used are well known in the art (e.g., as employed for cross-species hybridizations). See, e.g., Ausubel et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and Weinberg, 1981, Proc Natl Acad Sci USA 78: 6789-6792.

20 Conservative mutations

In addition to naturally-occurring allelic variants of the NOV-X sequence that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, thereby leading to changes in the amino acid sequence of the encoded NOV-
25 X protein, without altering the functional ability of the NOV-X protein. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of NOV-X without altering the biological activity, whereas an "essential" amino acid
30 residue is required for biological activity. For example, amino acid residues that are conserved among the NOV-X proteins of the present invention, are predicted to be particularly unamenable to alteration.

Another aspect of the invention pertains to nucleic acid molecules encoding NOV-X proteins that contain changes in amino acid residues that are not essential for activity. Such

NOV-X proteins differ in amino acid sequence from SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 75% homologous to the amino acid sequence of SEQ ID NO: 2, 4, 6, or 8. Preferably, the protein encoded by the nucleic acid is at least about 80% homologous to SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23, more preferably at least about 90%, 95%, 98%, and most preferably at least about 99% homologous to SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23.

An isolated nucleic acid molecule encoding a NOV-X protein homologous to the protein of can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.

Mutations can be introduced into the nucleotide sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in NOV-X is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a NOV-X coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for NOV-X biological activity to identify mutants that retain activity. Following mutagenesis of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined.

In one embodiment, a mutant NOV-X protein can be assayed for (1) the ability to form protein:protein interactions with other NOV-X proteins, other cell-surface proteins, or

biologically active portions thereof, (2) complex formation between a mutant NOV-X protein and a NOV-X receptor; (3) the ability of a mutant NOV-X protein to bind to an intracellular target protein or biologically active portion thereof; (e.g., avidin proteins); (4) the ability to bind NOV-X protein; or (5) the ability to specifically bind an anti-NOV-X protein antibody.

5

Antisense NOV-X Nucleic acids

Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, or fragments, analogs or derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire NOV-X coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of a NOV-X protein of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 or antisense nucleic acids complementary to a NOV-X nucleic acid sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 are additionally provided.

In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding NOV-X. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues (e.g., the protein coding region of human NOV-X corresponds to SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23). In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding NOV-X. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding NOV-X disclosed herein (e.g., SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of NOV-X mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of NOV-X mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NOV-X mRNA. An

antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used.

Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a NOV-X protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified

such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an α -anomeric nucleic acid molecule. An α -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gaultier et al. (1987) Nucleic acids Res 15: 6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue et al. (1987) Nucleic acids Res 15: 6131-6148) or a chimeric RNA-DNA analogue (Inoue et al. (1987) FEBS Lett 215: 327-330).

Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.

NOV-X Ribozymes and PNA moieties

In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as a mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988) Nature 334:585-591)) can be used to catalytically cleave NOV-X mRNA transcripts to thereby inhibit translation of NOV-X mRNA. A ribozyme having specificity for a NOV-X-encoding nucleic acid can be designed based upon the nucleotide sequence of a NOV-X DNA disclosed herein (i.e., SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a NOV-X-encoding mRNA. See, e.g., Cech et al. U.S. Pat. No. 4,987,071; and Cech et al. U.S. Pat. No. 5,116,742. Alternatively, NOV-X mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel et al., (1993) Science 261:1411-1418.

Alternatively, NOV-X gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the NOV-X (e.g., the NOV-X promoter and/or enhancers) to form triple helical structures that prevent transcription of the NOV-X gene in target cells. See generally, Helene. (1991) *Anticancer Drug Des.* 6: 569-84; Helene. et al. (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher (1992) *Bioassays* 14: 807-15.

In various embodiments, the nucleic acids of NOV-X can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup et al. (1996) *Bioorg Med Chem* 4: 5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup et al. (1996) above; Perry-O'Keefe et al. (1996) *PNAS* 93: 14670-675.

PNAs of NOV-X can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs of NOV-X can also be used, e.g., in the analysis of single base pair mutations in a gene by, e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S1 nucleases (Hyrup B. (1996) above); or as probes or primers for DNA sequence and hybridization (Hyrup et al. (1996), above; Perry-O'Keefe (1996), above).

In another embodiment, PNAs of NOV-X can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of NOV-X can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, e.g., RNase H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup (1996) above). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996) above and Finn et al. (1996) *Nucl Acids Res* 24: 3357-63. For example, a DNA chain can be synthesized

on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e.g., 5'-(4-methoxytrityl) amino-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5' end of DNA (Mag et al. (1989) Nucl Acid Res 17:

5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric

5 molecule with a 5' PNA segment and a 3' DNA segment (Finn et al. (1996) above).

Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. See, Petersen et al. (1975) Bioorg Med Chem Lett 5: 1119-11124.

In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across

10 the cell membrane (see, e.g., Letsinger et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556; Lemaitre et al., 1987, Proc. Natl. Acad. Sci. 84:648-652; PCT Publication No.

W088/09810) or the blood-brain barrier (see, e.g., PCT Publication No. W089/10134). In

addition, oligonucleotides can be modified with hybridization triggered cleavage agents (See, e.g., Krol et al., 1988, BioTechniques 6:958-976) or intercalating agents. (See, e.g., Zon, 1988,

15 Pharm. Res. 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, etc.

NOV-X Polypeptides

20 A NOV-X polypeptide of the invention includes the NOV-X-like protein whose sequence is provided in SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 while still encoding a protein that maintains its NOV-X-like activities and physiological functions,

25 or a functional fragment thereof. In some embodiments, up to 20% or more of the residues may be so changed in the mutant or variant protein. In some embodiments, the NOV-X polypeptide according to the invention is a mature polypeptide.

In general, a NOV-X-like variant that preserves NOV-X-like function includes any variant in which residues at a particular position in the sequence have been substituted by

30 other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above.

One aspect of the invention pertains to isolated NOV-X proteins, and biologically active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-NOV-X antibodies. In one embodiment, native NOV-X proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, NOV-X proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, a NOV-X protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the NOV-X protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of NOV-X protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced.

In one embodiment, the language "substantially free of cellular material" includes preparations of NOV-X protein having less than about 30% (by dry weight) of non-NOV-X protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-NOV-X protein, still more preferably less than about 10% of non-NOV-X protein, and most preferably less than about 5% non-NOV-X protein. When the NOV-X protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of NOV-X protein in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of NOV-X protein having less than about 30% (by dry weight) of chemical precursors or non-NOV-X chemicals, more preferably less than about 20% chemical precursors or non-NOV-X chemicals, still more preferably less than about 10% chemical precursors or non-NOV-X chemicals, and most preferably less than about 5% chemical precursors or non-NOV-X chemicals.

Biologically active portions of a NOV-X protein include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequence of the

NOV-X protein, e.g., the amino acid sequence shown in SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 that include fewer amino acids than the full length NOV-X proteins, and exhibit at least one activity of a NOV-X protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the NOV-X protein. A biologically active portion of a NOV-X protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length.

A biologically active portion of a NOV-X protein of the present invention may contain at least one of the above-identified domains conserved between the NOV-X proteins, e.g. TSR modules. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native NOV-X protein.

In an embodiment, the NOV-X protein has an amino acid sequence shown in SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23. In other embodiments, the NOV-X protein is substantially homologous to SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 and retains the functional activity of the protein of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail below. Accordingly, in another embodiment, the NOV-X protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 and retains the functional activity of the NOV-X proteins of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23.

Determining homology between two or more sequence

To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in either of the sequences being compared for optimal alignment between the sequences). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity").

The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. See, Needleman and Wunsch 1970 J Mol Biol 48: 443-453. Using GCG GAP software with the following settings

for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence shown in SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57.

The term "sequence identity" refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region. The term "percentage of positive residues" is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical and conservative amino acid substitutions, as defined above, occur in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of positive residues.

Chimeric and fusion proteins

The invention also provides NOV-X chimeric or fusion proteins. As used herein, a NOV-X "chimeric protein" or "fusion protein" comprises a NOV-X polypeptide operatively linked to a non-NOV-X polypeptide. An "NOV-X polypeptide" refers to a polypeptide having an amino acid sequence corresponding to NOV-X, whereas a "non-NOV-X polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the NOV-X protein, e.g., a protein that is different from the NOV-X protein and that is derived from the same or a different organism. Within a NOV-X fusion protein the NOV-X polypeptide can correspond to all or a portion of a NOV-X protein.

In one embodiment, a NOV-X fusion protein comprises at least one biologically active portion of a NOV-X protein. In another embodiment, a NOV-X fusion protein comprises at least two biologically active portions of a NOV-X protein. Within the fusion protein, the term "operatively linked" is intended to indicate that the NOV-X polypeptide and the non-NOV-X polypeptide are fused in-frame to each other. The non-NOV-X polypeptide can be fused to the N-terminus or C-terminus of the NOV-X polypeptide.

For example, in one embodiment a NOV-X fusion protein comprises a NOV-X polypeptide operably linked to the extracellular domain of a second protein. Such fusion proteins can be further utilized in screening assays for compounds that modulate NOV-X activity (such assays are described in detail below).

In another embodiment, the fusion protein is a GST-NOV-X fusion protein in which the NOV-X sequences are fused to the C-terminus of the GST (i.e., glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant NOV-X.

In another embodiment, the fusion protein is a NOV-X-immunoglobulin fusion protein in which the NOV-X sequences comprising one or more domains are fused to sequences derived from a member of the immunoglobulin protein family. The NOV-X-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a NOV-X ligand and a NOV-X protein on the surface of a cell, to thereby suppress NOV-X-mediated signal transduction in vivo. In one nonlimiting example, a contemplated NOV-X ligand of the invention is the NOV-X receptor. The NOV-X-immunoglobulin fusion proteins can be used to affect the bioavailability of a NOV-X cognate ligand. Inhibition of the NOV-X ligand/NOV-X interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, e.g., cancer as well as modulating (e.g., promoting or inhibiting) cell survival, as well as acute and chronic inflammatory disorders and hyperplastic wound healing, e.g. hypertrophic scars and keloids. Moreover, the NOV-X-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-NOV-X antibodies in a subject, to purify NOV-X ligands, and in screening assays to identify molecules that inhibit the interaction of NOV-X with a NOV-X ligand.

A NOV-X chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate,

alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Ausubel et al. (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A NOV-X-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NOV-X protein.

NOV-X agonists and antagonists

The present invention also pertains to variants of the NOV-X proteins that function as either NOV-X agonists (mimetics) or as NOV-X antagonists. Variants of the NOV-X protein can be generated by mutagenesis, e.g., discrete point mutation or truncation of the NOV-X protein. An agonist of the NOV-X protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the NOV-X protein. An antagonist of the NOV-X protein can inhibit one or more of the activities of the naturally occurring form of the NOV-X protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the NOV-X protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the NOV-X proteins.

Variants of the NOV-X protein that function as either NOV-X agonists (mimetics) or as NOV-X antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the NOV-X protein for NOV-X protein agonist or antagonist activity. In one embodiment, a variegated library of NOV-X variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of NOV-X variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential NOV-X sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of NOV-X sequences therein. There are a variety of methods which can be used to produce libraries of potential

NOV-X variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential NOV-X sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang (1983) Tetrahedron 39:3; Itakura et al. (1984) Annu Rev Biochem 53:323; Itakura et al. (1984) Science 198:1056; Ike et al. (1983) Nucl Acid Res 11:477.

10 Polypeptide libraries

In addition, libraries of fragments of the NOV-X protein coding sequence can be used to generate a variegated population of NOV-X fragments for screening and subsequent selection of variants of a NOV-X protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a NOV-X coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal and internal fragments of various sizes of the NOV-X protein.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of NOV-X proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique that enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify NOV-X variants (Arkin and Yourvan (1992) PNAS 89:7811-7815; Delgrave et al. (1993) Protein Engineering 6:327-331).

NOV-X Antibodies

Also included in the invention are antibodies to NOV-X proteins, or fragments of NOV-X proteins. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, F_{ab} , F_{ab}' and $F_{(ab)2}$ fragments, and an F_{ab} expression library. In general, an antibody molecule obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG₁, IgG₂, and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.

An isolated NOV-X-related protein of the invention may be intended to serve as an antigen, or a portion or fragment thereof, and additionally can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein, such as an amino acid sequence shown in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, or 20, and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.

In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of NOV-X-related protein that is located on the surface of the protein, e.g., a hydrophilic region. A hydrophobicity analysis of the human NOV-X-related protein sequence will indicate which regions of a NOV-X-related protein are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art,

including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, e.g., Hopp and Woods, 1981, Proc. Nat. Acad. Sci. USA 78: 3824-3828; Kyte and Doolittle 1982, J. Mol. Biol. 157: 105-142, each of which is incorporated herein by reference in its entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.

Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference). Some of these antibodies are discussed below.

Polyclonal Antibodies

For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known

techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28).

Monoclonal Antibodies

The term "monoclonal antibody" (MAb) or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MABs thus contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.

Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.

The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas

typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, *J. Immunol.*, 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63).

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, *Anal. Biochem.*, 107:220 (1980). Preferably, antibodies having a high degree of specificity and a high binding affinity for the target antigen are isolated.

After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown *in vivo* as ascites in a mammal.

The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors,

which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison, Nature 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

Humanized Antibodies

The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin.

Humanization can be performed following the method of Winter and co-workers (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Patent No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)).

Human Antibodies

Fully human antibodies relate to antibody molecules in which essentially the entire sequences of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies", or "fully human antibodies" herein.

5 Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 Immunol Today 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by

10 using human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).

In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991);

15 Marks et al., J. Mol. Biol., 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This

20 approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (Bio/Technology 10, 779-783 (1992)); Lonberg et al. (Nature 368 856-859 (1994)); Morrison (Nature 368, 812-13 (1994)); Fishwild et al. (Nature Biotechnology 14, 845-51 (1996)); Neuberger (Nature Biotechnology 14, 826 (1996)); and Lonberg and Huszar (Intern. Rev. Immunol. 13 65-93 (1995)).

25 Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light

30 chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a

mouse, and is termed the Xenomouse™ as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively
5 from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.

10 An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Patent No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain
15 locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.

A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Patent No. 5,916,771. It includes introducing an expression vector that contains a
20 nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.

In a further improvement on this procedure, a method for identifying a clinically
25 relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.

F_{ab} Fragments and Single Chain Antibodies

30 According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of F_{ab} expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal F_{ab} fragments with the desired specificity for a protein or

derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotype to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an $F_{(ab)2}$ fragment produced by pepsin digestion of an antibody molecule; (ii) an F_{ab} fragment generated by reducing the disulfide bridges of an $F_{(ab)2}$ fragment; (iii) an F_{ab} fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F_v fragments.

Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, *Nature*, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., 1991 EMBO J., 10:3655-3659.

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., *Methods in Enzymology*, 121:210 (1986).

According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino

acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. $F(ab')_2$ bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate $F(ab')_2$ fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab' -TNB derivatives is then reconverted to the Fab' -thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab' -TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Additionally, Fab' fragments can be directly recovered from *E. coli* and chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody $F(ab')_2$ molecule. Each Fab' fragment was separately secreted from *E. coli* and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments

comprise a heavy-chain variable domain (V_H) connected to a light-chain variable domain (V_L) by a linker which is too short to allow pairing between the two domains on the same chain.

Accordingly, the V_H and V_L domains of one fragment are forced to pair with the complementary V_L and V_H domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., *J. Immunol.* 152:5368 (1994).

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., *J. Immunol.* 147:60 (1991).

Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (Fc R), such as Fc RI (CD64), Fc RII (CD32) and Fc RIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

Effector Function Engineering

It can be desirable to modify the antibody of the invention with respect to effector

function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989).

Immunoconjugates

The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include ^{212}Bi , ^{131}I , ^{131}In , ^{90}Y , and ^{186}Re .

Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-

methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

In another embodiment, the antibody can be conjugated to a "receptor" (such as streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) that is in turn conjugated to a cytotoxic agent.

NOV-X Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a NOV-X protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably-linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an in

vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).

The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., NOV-X proteins, mutant forms of NOV-X proteins, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of NOV-X proteins in prokaryotic or eukaryotic cells. For example, NOV-X proteins can be expressed in bacterial cells such as *Escherichia coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *Escherichia coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. Gene 67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse

glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amrann et al., (1988) Gene 69:301-315) and pET 11d (Studier et al., GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).

One strategy to maximize recombinant protein expression in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. See, e.g., Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E. coli (see, e.g., Wada, et al., 1992. Nucl. Acids Res. 20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the NOV-X expression vector is a yeast expression vector. Examples of vectors for expression in yeast *Saccharomyces cerevisiae* include pYepSec1 (Baldari, et al., 1987. EMBO J. 6: 229-234), pMFa (Kurjan and Herskowitz, 1982. Cell 30: 933-943), pJRY88 (Schultz et al., 1987. Gene 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.).

Alternatively, NOV-X can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, et al., 1983. Mol. Cell. Biol. 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989. Virology 170: 31-39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. Nature 329: 840) and pMT2PC (Kaufman, et al., 1987. EMBO J. 6: 187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific

regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., 1987. *Genes Dev.* 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. *Adv. Immunol.* 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. *EMBO J.* 8: 729-733) and immunoglobulins (Banerji, et al., 1983. *Cell* 33: 729-740; Queen and Baltimore, 1983. *Cell* 33: 741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989. *Proc. Natl. Acad. Sci. USA* 86: 5473-5477), pancreas-specific promoters (Edlund, et al., 1985. *Science* 230: 912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, e.g., the murine hox promoters (Kessel and Gruss, 1990. *Science* 249: 374-379) and the α -fetoprotein promoter (Campes and Tilghman, 1989. *Genes Dev.* 3: 537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to NOV-X mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see, e.g., Weintraub, et al., "Antisense RNA as a molecular tool for genetic analysis," *Reviews-Trends in Genetics*, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, NOV-X protein can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as human, Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

5 Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or
10 electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.

15 For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a
20 selectable marker can be introduced into a host cell on the same vector as that encoding NOV-X or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

25 A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) NOV-X protein. Accordingly, the invention further provides methods for producing NOV-X protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding NOV-X protein has been introduced) in a suitable medium such that NOV-X protein is produced. In another embodiment, the method further
30 comprises isolating NOV-X protein from the medium or the host cell.

Transgenic NOV-X Animals

The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which NOV-X protein-coding sequences have been introduced.

Such host cells can then be used to create non-human transgenic animals in which exogenous NOV-X sequences have been introduced into their genome or homologous recombinant animals in which endogenous NOV-X sequences have been altered. Such animals are useful for studying the function and/or activity of NOV-X protein and for identifying and/or evaluating modulators of NOV-X protein activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous NOV-X gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing NOV-X-encoding nucleic acid into the male pronuclei of a fertilized oocyte (e.g., by microinjection, retroviral infection) and allowing the oocyte to develop in a pseudopregnant female foster animal.

Sequences including SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 can be introduced as a transgene into the genome of a non-human animal. Alternatively, a non-human homologue of the human NOV-X gene, such as a mouse NOV-X gene, can be isolated based on hybridization to the human NOV-X cDNA (described further supra) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably-linked to the NOV-X transgene to direct expression of NOV-X protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan, 1986. In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the NOV-X transgene in its genome and/or expression of NOV-X mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed

additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene-encoding NOV-X protein can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a NOV-X gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the NOV-X gene. The NOV-X gene can be a human gene (e.g., the DNA of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57), but more preferably, is a non-human homologue of a human NOV-X gene. For example, a mouse homologue of human NOV-X gene of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 can be used to construct a homologous recombination vector suitable for altering an endogenous NOV-X gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous NOV-X gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector).

Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous NOV-X gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous NOV-X protein). In the homologous recombination vector, the altered portion of the NOV-X gene is flanked at its 5'- and 3'-termini by additional nucleic acid of the NOV-X gene to allow for homologous recombination to occur between the exogenous NOV-X gene carried by the vector and an endogenous NOV-X gene in an embryonic stem cell. The additional flanking NOV-X nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5'- and 3'-termini) are included in the vector. See, e.g., Thomas, et al., 1987. Cell 51: 503 for a description of homologous recombination vectors. The vector is then introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced NOV-X gene has homologously-recombined with the endogenous NOV-X gene are selected. See, e.g., Li, et al., 1992. Cell 69: 915.

The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras. See, e.g., Bradley, 1987. In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the

homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, 1991. *Curr. Opin. Biotechnol.* 2: 823-829; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.

5 In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, See, e.g., Lakso, et al., 1992. *Proc. Natl. Acad. Sci. USA* 89: 6232-6236. Another example of a recombinase system is the FLP recombinase system of
10 *Saccharomyces cerevisiae*. See, O'Gorman, et al., 1991. *Science* 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the
15 other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, et al., 1997. *Nature* 385: 810-813. In brief, a cell (e.g., a somatic cell) from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, e.g., through the use of
20 electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell (e.g., the somatic cell) is isolated.

25 **Pharmaceutical Compositions**

The NOV-X nucleic acid molecules, NOV-X proteins, and anti-NOV-X antibodies (also referred to herein as "active compounds") of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable
30 for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most

recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

The antibodies disclosed herein can also be formulated as immunoliposomes.

Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.

Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem., 257: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See Gabizon et al., J. National Cancer Inst., 81(19): 1484 (1989).

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a NOV-X protein or anti-NOV-X antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or

adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a
5 lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g.,
10 a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal
15 administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas
20 for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides,
25 polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared
30 according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit

containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see, e.g., U.S. Patent No. 5,328,470) or by stereotactic injection (see, e.g., Chen, et al., 1994. Proc. Natl. Acad. Sci. USA 91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.

Antibodies specifically binding a protein of the invention, as well as other molecules identified by the screening assays disclosed herein, can be administered for the treatment of various disorders in the form of pharmaceutical compositions. Principles and considerations involved in preparing such compositions, as well as guidance in the choice of components are provided, for example, in Remington : The Science And Practice Of Pharmacy 19th ed. (Alfonso R. Gennaro, et al., editors) Mack Pub. Co., Easton, Pa. : 1995; Drug Absorption Enhancement : Concepts, Possibilities, Limitations, And Trends, Harwood Academic Publishers, Langhorne, Pa., 1994; and Peptide And Protein Drug Delivery (Advances In Parenteral Sciences, Vol. 4), 1991, M. Dekker, New York. If the antigenic protein is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. See, e.g., Marasco et al., 1993 Proc. Natl. Acad. Sci. USA, 90: 7889-7893. The formulation herein can also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition,

the composition can comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended. The active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions.

The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules.

Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

Screening and Detection Methods

The isolated nucleic acid molecules of the invention can be used to express NOV-X protein (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect NOV-X mRNA (e.g., in a biological sample) or a genetic lesion in a NOV-X gene, and to modulate NOV-X activity, as described further, below. In addition, the NOV-X proteins can be used to screen drugs or compounds that modulate the NOV-X protein activity or expression as well as to treat disorders characterized by insufficient or excessive production of NOV-X protein or production of NOV-X protein forms that have decreased or aberrant activity compared to NOV-X wild-type protein. In addition, the anti-NOV-X antibodies of the

invention can be used to detect and isolate NOV-X proteins and modulate NOV-X activity. For example, NOV-X activity includes growth and differentiation, antibody production, and tumor growth.

5 The invention further pertains to novel agents identified by the screening assays described herein and uses thereof for treatments as described, *supra*.

Screening Assays

The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) that bind to NOV-X proteins or have a
10 stimulatory or inhibitory effect on, e.g., NOV-X protein expression or NOV-X protein activity. The invention also includes compounds identified in the screening assays described herein.

In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of a NOV-X protein or polypeptide or biologically-active portion thereof. The test compounds of the
15 invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries,
20 while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. See, e.g., Lam, 1997. *Anticancer Drug Design* 12: 145.

A "small molecule" as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be, e.g., nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates,
25 lipids or other organic or inorganic molecules. Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened with any of the assays of the invention.

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt, et al., 1993. *Proc. Natl. Acad. Sci. U.S.A.* 90: 6909; Erb, et al., 1994. *Proc. Natl. Acad. Sci. U.S.A.* 91: 11422; Zuckermann, et al., 1994. *J. Med. Chem.* 37: 2678;
30 Cho, et al., 1993. *Science* 261: 1303; Carrell, et al., 1994. *Angew. Chem. Int. Ed. Engl.* 33: 2059; Carell, et al., 1994. *Angew. Chem. Int. Ed. Engl.* 33: 2061; and Gallop, et al., 1994. *J. Med. Chem.* 37: 1233.

Libraries of compounds may be presented in solution (e.g., Houghten, 1992. *Biotechniques* 13: 412-421), or on beads (Lam, 1991. *Nature* 354: 82-84), on chips (Fodor, 1993. *Nature* 364: 555-556), bacteria (Ladner, U.S. Patent No. 5,223,409), spores (Ladner, U.S. Patent 5,233,409), plasmids (Cull, et al., 1992. *Proc. Natl. Acad. Sci. USA* 89: 1865-1869) or on phage (Scott and Smith, 1990. *Science* 249: 386-390; Devlin, 1990. *Science* 249: 404-406; Cwirla, et al., 1990. *Proc. Natl. Acad. Sci. U.S.A.* 87: 6378-6382; Felici, 1991. *J. Mol. Biol.* 222: 301-310; Ladner, U.S. Patent No. 5,233,409.).

In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of NOV-X protein, or a biologically-active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to a NOV-X protein determined. The cell, for example, can be of mammalian origin or a yeast cell. Determining the ability of the test compound to bind to the NOV-X protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the NOV-X protein or biologically-active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with ^{125}I , ^{35}S , ^{14}C , or ^3H , either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically-labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of NOV-X protein, or a biologically-active portion thereof, on the cell surface with a known compound which binds NOV-X to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOV-X protein, wherein determining the ability of the test compound to interact with a NOV-X protein comprises determining the ability of the test compound to preferentially bind to NOV-X protein or a biologically-active portion thereof as compared to the known compound.

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of NOV-X protein, or a biologically-active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the NOV-X protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOV-X or a biologically-active portion thereof can be accomplished, for example, by determining the ability of the NOV-X protein to bind to or interact with a NOV-X

target molecule. As used herein, a "target molecule" is a molecule with which a NOV-X protein binds or interacts in nature, for example, a molecule on the surface of a cell which expresses a NOV-X interacting protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. A NOV-X target molecule can be a non-NOV-X molecule or a NOV-X protein or polypeptide of the invention. In one embodiment, a NOV-X target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (e.g. a signal generated by binding of a compound to a membrane-bound NOV-X molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with NOV-X.

Determining the ability of the NOV-X protein to bind to or interact with a NOV-X target molecule can be accomplished by one of the methods described above for determining direct binding.

In one embodiment, determining the ability of the NOV-X protein to bind to or interact with a NOV-X target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (i.e. intracellular Ca^{2+} , diacylglycerol, IP_3 , etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising a NOV-X-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, e.g., luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.

In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting a NOV-X protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to bind to the NOV-X protein or biologically-active portion thereof. Binding of the test compound to the NOV-X protein can be determined either directly or indirectly as described above.

In one such embodiment, the assay comprises contacting the NOV-X protein or biologically-active portion thereof with a known compound which binds NOV-X to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOV-X protein, wherein determining the ability of the test compound to interact with a NOV-X protein comprises determining the ability of the test

compound to preferentially bind to NOV-X or biologically-active portion thereof as compared to the known compound.

In still another embodiment, an assay is a cell-free assay comprising contacting NOV-X protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to modulate (e.g. stimulate or inhibit) the activity of the NOV-X protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOV-X can be accomplished, for example, by determining the ability of the NOV-X protein to bind to a NOV-X target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of NOV-X protein can be accomplished by determining the ability of the NOV-X protein further modulate a NOV-X target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described above.

In yet another embodiment, the cell-free assay comprises contacting the NOV-X protein or biologically-active portion thereof with a known compound which binds NOV-X protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOV-X protein, wherein determining the ability of the test compound to interact with a NOV-X protein comprises determining the ability of the NOV-X protein to preferentially bind to or modulate the activity of a NOV-X target molecule.

The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of NOV-X protein. In the case of cell-free assays comprising the membrane-bound form of NOV-X protein, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of NOV-X protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton[®] X-100, Triton[®] X-114, Thesit[®], Isotridecypoly(ethylene glycol ether)_n, N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1-propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO).

In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either NOV-X protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to NOV-X protein, or interaction of

NOV-X protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-NOV-X fusion proteins or GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or NOV-X protein, and the mixture is incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described, supra. Alternatively, the complexes can be dissociated from the matrix, and the level of NOV-X protein binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the NOV-X protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated NOV-X protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well-known within the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with NOV-X protein or target molecules, but which do not interfere with binding of the NOV-X protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or NOV-X protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the NOV-X protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the NOV-X protein or target molecule.

In another embodiment, modulators of NOV-X protein expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of NOV-X mRNA or protein in the cell is determined. The level of expression of NOV-X mRNA or protein in the presence of the candidate compound is compared to the level of expression of NOV-X mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of NOV-X mRNA or protein expression

based upon this comparison. For example, when expression of NOV-X mRNA or protein is greater (i.e., statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of NOV-X mRNA or protein expression. Alternatively, when expression of NOV-X mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of NOV-X mRNA or protein expression. The level of NOV-X mRNA or protein expression in the cells can be determined by methods described herein for detecting NOV-X mRNA or protein.

In yet another aspect of the invention, the NOV-X proteins can be used as "bait proteins" in a two-hybrid assay or three hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos, et al., 1993. *Cell* 72: 223-232; Madura, et al., 1993. *J. Biol. Chem.* 268: 12046-12054; Bartel, et al., 1993. *Biotechniques* 14: 920-924; Iwabuchi, et al., 1993. *Oncogene* 8: 1693-1696; and Brent WO 94/10300), to identify other proteins that bind to or interact with NOV-X ("NOV-X-binding proteins" or "NOV-X-bp") and modulate NOV-X activity. Such NOV-X-binding proteins are also likely to be involved in the propagation of signals by the NOV-X proteins as, for example, upstream or downstream elements of the NOV-X pathway.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for NOV-X is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, in vivo, forming a NOV-X-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with NOV-X.

The invention further pertains to novel agents identified by the aforementioned screening assays and uses thereof for treatments as described herein.

Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) identify an individual from a minute biological sample (tissue typing); and (ii) aid in forensic identification of a biological sample. Some of these applications are described in the subsections, below.

Tissue Typing

The NOV-X sequences of the invention can be used to identify individuals from minute biological samples. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. The sequences of the invention are useful as additional DNA markers for RFLP ("restriction fragment length polymorphisms," described in U.S. Patent No. 5,272,057).

Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the NOV-X sequences described herein can be used to prepare two PCR primers from the 5'- and 3'-termini of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such identification sequences from individuals and from tissue. The NOV-X sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms (RFLPs).

Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in

SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

Predictive Medicine

5 The invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the invention relates to diagnostic assays for determining NOV-X protein and/or nucleic acid expression as well as NOV-X activity, in the context of a biological sample (e.g.,
10 blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant NOV-X expression or activity. Disorders associated with aberrant NOV-X expression of activity include, for example, disorders of olfactory loss, e.g. trauma, HIV illness, neoplastic growth, and neurological disorders, e.g. Parkinson's disease and Alzheimer's disease.

15 The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with NOV-X protein, nucleic acid expression or activity. For example, mutations in a NOV-X gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or
20 associated with NOV-X protein, nucleic acid expression, or biological activity.

 Another aspect of the invention provides methods for determining NOV-X protein, nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as "pharmacogenomics"). Pharmacogenomics allows for the selection of agents (e.g., drugs) for therapeutic or
25 prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)

 Yet another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOV-X in clinical trials.

30 These and other agents are described in further detail in the following sections.

Diagnostic Assays

 An exemplary method for detecting the presence or absence of NOV-X in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting NOV-X protein or nucleic acid (e.g.,

mRNA, genomic DNA) that encodes NOV-X protein such that the presence of NOV-X is detected in the biological sample. An agent for detecting NOV-X mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NOV-X mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length NOV-X nucleic acid, such as the nucleic acid of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to NOV-X mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

One agent for detecting NOV-X protein is an antibody capable of binding to NOV-X protein, preferably an antibody with a detectable label. Antibodies directed against a protein of the invention may be used in methods known within the art relating to the localization and/or quantitation of the protein (e.g., for use in measuring levels of the protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies against the proteins, or derivatives, fragments, analogs or homologs thereof, that contain the antigen binding domain, are utilized as pharmacologically-active compounds.

An antibody specific for a protein of the invention can be used to isolate the protein by standard techniques, such as immunoaffinity chromatography or immunoprecipitation. Such an antibody can facilitate the purification of the natural protein antigen from cells and of recombinantly produced antigen expressed in host cells. Moreover, such an antibody can be used to detect the antigenic protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the antigenic protein. Antibodies directed against the protein can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include

luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')_2) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect NOV-X mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of NOV-X mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of NOV-X protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of NOV-X genomic DNA include Southern hybridizations. Furthermore, in vivo techniques for detection of NOV-X protein include introducing into a subject a labeled anti-NOV-X antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

In one embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting NOV-X protein, mRNA, or genomic DNA, such that the presence of NOV-X protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of NOV-X protein, mRNA or genomic DNA in the control sample with the presence of NOV-X protein, mRNA or genomic DNA in the test sample.

The invention also encompasses kits for detecting the presence of NOV-X in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting NOV-X protein or mRNA in a biological sample; means for determining the amount

of NOV-X in the sample; and means for comparing the amount of NOV-X in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect NOV-X protein or nucleic acid.

Prognostic Assays

5 The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant NOV-X expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with NOV-X protein, nucleic acid expression or activity.

10 Such disorders include for example, disorders of olfactory loss, e.g. trauma, HIV illness, neoplastic growth, and neurological disorders, e.g. Parkinson's disease and Alzheimer's disease.

 Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for
15 identifying a disease or disorder associated with aberrant NOV-X expression or activity in which a test sample is obtained from a subject and NOV-X protein or nucleic acid (e.g., mRNA, genomic DNA) is detected, wherein the presence of NOV-X protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant NOV-X expression or activity. As used herein, a "test sample" refers to a biological
20 sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.

 Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder
25 associated with aberrant NOV-X expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant NOV-X expression or activity in which a test sample is obtained and NOV-X protein or nucleic acid is detected (e.g., wherein
30 the presence of NOV-X protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant NOV-X expression or activity).

 The methods of the invention can also be used to detect genetic lesions in a NOV-X gene, thereby determining if a subject with the lesioned gene is at risk for a disorder

characterized by aberrant cell proliferation and/or differentiation. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding a NOV-X-protein, or the misexpression of the NOV-X gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of: (i) a deletion of one or more nucleotides from a NOV-X gene; (ii) an addition of one or more nucleotides to a NOV-X gene; (iii) a substitution of one or more nucleotides of a NOV-X gene, (iv) a chromosomal rearrangement of a NOV-X gene; (v) an alteration in the level of a messenger RNA transcript of a NOV-X gene, (vi) aberrant modification of a NOV-X gene, such as of the methylation pattern of the genomic DNA, (vii) the presence of a non-wild-type splicing pattern of a messenger RNA transcript of a NOV-X gene, (viii) a non-wild-type level of a NOV-X protein, (ix) allelic loss of a NOV-X gene, and (x) inappropriate post-translational modification of a NOV-X protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in a NOV-X gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran, et al., 1988. Science 241: 1077-1080; and Nakazawa, et al., 1994. Proc. Natl. Acad. Sci. USA 91: 360-364), the latter of which can be particularly useful for detecting point mutations in the NOV-X-gene (see, Abravaya, et al., 1995. Nucl. Acids Res. 23: 675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to a NOV-X gene under conditions such that hybridization and amplification of the NOV-X gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include: self sustained sequence replication (see, Guatelli, et al., 1990. Proc. Natl. Acad. Sci. USA 87: 1874-1878), transcriptional amplification system (see, Kwoh, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 1173-1177); Q β Replicase

(see, Lizardi, et al, 1988. *BioTechnology* 6: 1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

5 In an alternative embodiment, mutations in a NOV-X gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in
10 the sample DNA. Moreover, the use of sequence specific ribozymes (see, e.g., U.S. Patent No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in NOV-X can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high-density arrays containing
15 hundreds or thousands of oligonucleotides probes. See, e.g., Cronin, et al., 1996. *Human Mutation* 7: 244-255; Kozal, et al., 1996. *Nat. Med.* 2: 753-759. For example, genetic mutations in NOV-X can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, et al., *supra*. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base
20 changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the
25 other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the NOV-X gene and detect mutations by comparing the sequence of the sample NOV-X with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert,
30 1977. *Proc. Natl. Acad. Sci. USA* 74: 560 or Sanger, 1977. *Proc. Natl. Acad. Sci. USA* 74: 5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (see, e.g., Naeve, et al., 1995. *Biotechniques* 19: 448), including sequencing by mass spectrometry (see, e.g., PCT International Publication

No. WO 94/16101; Cohen, et al., 1996. *Adv. Chromatography* 36: 127-162; and Griffin, et al., 1993. *Appl. Biochem. Biotechnol.* 38: 147-159).

Other methods for detecting mutations in the NOV-X gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes. See, e.g., Myers, et al., 1985. *Science* 230: 1242. In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type NOV-X sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S₁ nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, e.g., Cotton, et al., 1988. *Proc. Natl. Acad. Sci. USA* 85: 4397; Saleeba, et al., 1992. *Methods Enzymol.* 217: 286-295. In an embodiment, the control DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in NOV-X cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. See, e.g., Hsu, et al., 1994. *Carcinogenesis* 15: 1657-1662. According to an exemplary embodiment, a probe based on a NOV-X sequence, e.g., a wild-type NOV-X sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Patent No. 5,459,039.

In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in NOV-X genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids. See, e.g., Orita, et al., 1989. *Proc. Natl. Acad. Sci. USA*: 86: 2766; Cotton, 1993. *Mutat. Res.* 285: 125-144; Hayashi, 1992. *Genet. Anal. Tech. Appl.* 9: 73-79. Single-stranded DNA fragments of sample and control NOV-X nucleic acids will be denatured

and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility. See, e.g., Keen, et al., 1991. Trends Genet. 7: 5.

In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE). See, e.g., Myers, et al., 1985. Nature 313: 495. When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA. See, e.g., Rosenbaum and Reissner, 1987. Biophys. Chem. 265: 12753.

Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found. See, e.g., Saiki, et al., 1986. Nature 324: 163; Saiki, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 6230. Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; see, e.g., Gibbs, et al., 1989. Nucl. Acids Res. 17: 2437-2448) or at the extreme 3'-terminus of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (see, e.g., Prossner, 1993. Tibtech. 11: 238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. See, e.g., Gasparini, et al., 1992. Mol. Cell Probes 6: 1. It is anticipated that in certain embodiments

amplification may also be performed using Taq ligase for amplification. See, e.g., Barany, 1991. Proc. Natl. Acad. Sci. USA 88: 189. In such cases, ligation will occur only if there is a perfect match at the 3'-terminus of the 5' sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

5 The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a NOV-X gene.

10 Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which NOV-X is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

15 **Pharmacogenomics**

Agents, or modulators that have a stimulatory or inhibitory effect on NOV-X activity (e.g., NOV-X gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders (e.g. disorders of olfactory loss, e.g. trauma, HIV illness, neoplastic growth, and neurological disorders, e.g. Parkinson's disease and Alzheimer's disease). In conjunction with such treatment, the pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of NOV-X protein, expression of NOV-X nucleic acid, or mutation content of NOV-X genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See e.g., Eichelbaum, 1996. Clin. Exp. Pharmacol. Physiol., 23: 983-985; Linder, 1997. Clin.

Chem., 43: 254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

Thus, the activity of NOV-X protein, expression of NOV-X nucleic acid, or mutation content of NOV-X genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a NOV-X modulator, such as a modulator identified by one of the exemplary screening assays described herein.

Monitoring of Effects During Clinical Trials

Monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOV-X (e.g., the ability to modulate aberrant cell proliferation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase NOV-X gene expression, protein levels, or upregulate NOV-X activity, can be monitored in clinical trials of subjects exhibiting decreased NOV-X gene expression, protein levels, or downregulated NOV-X activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease NOV-X gene expression, protein levels, or downregulate NOV-X activity, can be monitored in clinical trials of subjects exhibiting increased NOV-X gene expression, protein levels, or upregulated NOV-X activity. In such clinical trials, the expression or activity of NOV-X and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a "read out" or markers of the immune responsiveness of a particular cell.

By way of example, and not of limitation, genes, including NOV-X, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) that modulates NOV-X activity (e.g., identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of NOV-X and other genes implicated in the disorder. The levels of gene expression (i.e., a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of NOV-X or other genes. In this manner, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of a NOV-X protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the NOV-X protein, mRNA, or genomic DNA in the

post-administration samples; (v) comparing the level of expression or activity of the NOV-X protein, mRNA, or genomic DNA in the pre-administration sample with the NOV-X protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of NOV-X to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of NOV-X to lower levels than detected, i.e., to decrease the effectiveness of the agent.

10 Methods of Treatment

The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant NOV-X expression or activity. Disorders associated with aberrant NOV-X expression include, for example, disorders of olfactory loss, e.g. trauma, HIV illness, neoplastic growth, and neurological disorders, e.g. Parkinson's disease and Alzheimer's disease.

These methods of treatment will be discussed more fully, below.

Disease and Disorders

Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that antagonize (i.e., reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (iii) nucleic acids encoding an aforementioned peptide; (iv) administration of antisense nucleic acid and nucleic acids that are "dysfunctional" (i.e., due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to "knockout" endogenous function of an aforementioned peptide by homologous recombination (see, e.g., Capecchi, 1989. Science 244: 1288-1292); or (v) modulators (i.e., inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between an aforementioned peptide and its binding partner.

Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (i.e., are agonists to) activity. Therapeutics that upregulate activity

may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; or an agonist that increases bioavailability.

Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (e.g., from biopsy tissue) and assaying it in vitro for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an aforementioned peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (e.g., by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (e.g., Northern assays, dot blots, in situ hybridization, and the like).

Prophylactic Methods

In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant NOV-X expression or activity, by administering to the subject an agent that modulates NOV-X expression or at least one NOV-X activity. Subjects at risk for a disease that is caused or contributed to by aberrant NOV-X expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the NOV-X aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending upon the type of NOV-X aberrancy, for example, a NOV-X agonist or NOV-X antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the invention are further discussed in the following subsections.

Therapeutic Methods

Another aspect of the invention pertains to methods of modulating NOV-X expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of NOV-X protein activity associated with the cell. An agent that modulates NOV-X protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of a NOV-X protein, a peptide, a NOV-X peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more NOV-X protein activity. Examples of such stimulatory agents include active NOV-X protein and a nucleic acid molecule encoding NOV-

X that has been introduced into the cell. In another embodiment, the agent inhibits one or more NOV-X protein activity. Examples of such inhibitory agents include antisense NOV-X nucleic acid molecules and anti-NOV-X antibodies. These modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g., by administering the agent to a subject). As such, the invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a NOV-X protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) NOV-X expression or activity. In another embodiment, the method involves administering a NOV-X protein or nucleic acid molecule as therapy to compensate for reduced or aberrant NOV-X expression or activity.

Stimulation of NOV-X activity is desirable in situations in which NOV-X is abnormally downregulated and/or in which increased NOV-X activity is likely to have a beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (e.g., cancer or immune associated). Another example of such a situation is where the subject has an immunodeficiency disease (e.g., AIDS).

Antibodies of the invention, including polyclonal, monoclonal, humanized and fully human antibodies, may be used as therapeutic agents. Such agents will generally be employed to treat or prevent a disease or pathology in a subject. An antibody preparation, preferably one having high specificity and high affinity for its target antigen, is administered to the subject and will generally have an effect due to its binding with the target. Such an effect may be one of two kinds, depending on the specific nature of the interaction between the given antibody molecule and the target antigen in question. In the first instance, administration of the antibody may abrogate or inhibit the binding of the target with an endogenous ligand to which it naturally binds. In this case, the antibody binds to the target and masks a binding site of the naturally occurring ligand, wherein the ligand serves as an effector molecule. Thus the receptor mediates a signal transduction pathway for which ligand is responsible.

Alternatively, the effect may be one in which the antibody elicits a physiological result by virtue of binding to an effector binding site on the target molecule. In this case the target, a receptor having an endogenous ligand which may be absent or defective in the disease or pathology, binds the antibody as a surrogate effector ligand, initiating a receptor-based signal transduction event by the receptor.

A therapeutically effective amount of an antibody of the invention relates generally to the amount needed to achieve a therapeutic objective. As noted above, this may be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target, and in other cases, promotes a physiological response. The amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen, and will also depend on the rate at which an administered antibody is depleted from the free volume other subject to which it is administered. Common ranges for therapeutically effective dosing of an antibody or antibody fragment of the invention may be, by way of nonlimiting example, from about 0.1 mg/kg body weight to about 50 mg/kg body weight. Common dosing frequencies may range, for example, from twice daily to once a week.

Determination of the Biological Effect of the Therapeutic

In various embodiments of the invention, suitable in vitro or in vivo assays are performed to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue.

In various specific embodiments, in vitro assays may be performed with representative cells of the type(s) involved in the patient's disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for in vivo testing, any of the animal model system known in the art may be used prior to administration to human subjects.

The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

EXAMPLES

Example 1: Quantitative Expression Analysis of NOV-1, NOV-2, NOV-3, and NOV-4 in various cells and tissues.

RTQ-PCR Panel Descriptions:

Panel 1

As shown in the expression data in Tables 39, 40, and 41, Panel 1 of each table is composed of RNA or cDNA isolated from various human cells or cell lines from normal and

cancerous tissue. These cells and cell lines have been extensively characterized by investigators in both academia and the commercial sector regarding their tumorigenicity, metastatic potential, drug resistance, invasive potential, and other cancer-related properties. They serve as suitable tools for pre-clinical evaluation of anti-cancer agents and promising therapeutic strategies.

Panel 2:

In Tables 39, 40, and 41, Panel 2 of each table includes 2 control wells and 94 test samples composed of RNA or cDNA isolated from human tissue procured by surgeons working in close cooperation with the National Cancer Institute's Cooperative Human Tissue Network (CHTN) or the National Disease Research Initiative (NDRI). The tissues are derived from human malignancies and in cases where indicated, many malignant tissues have "matched margins", which is non-cancerous tissue adjacent to the tumor. These are termed normal adjacent tissues and are denoted "NAT" in Tables 39, 40, and 41. The tumor tissue and the matched margins are evaluated by two independent pathologists at NDRI or CHTN. This analysis provides a gross histopathological assessment of tumor differentiation grade. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical stage of the patient. In addition, these RNA and cDNA samples were obtained from various human tissues derived from autopsies performed on elderly people or sudden death victims (accidents, etc.). These tissue were ascertained to be free of disease and were purchased from various commercial sources such as Clontech (Palo Alto, CA), Research Genetics, and Invitrogen.

RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s:18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.

Panel 3:

Panel 3 in Tables 39, 40, and 41, include samples on a 96 well plate (2 control wells, 94 test samples) composed of RNA or cDNA isolated from various human cell lines or tissues related to inflammatory conditions. Total RNA from control normal tissues such as colon and lung (Stratagene, La Jolla, CA) and thymus and kidney (Clontech) were employed. Total

RNA from liver tissue from cirrhosis patients and kidney from lupus patients was obtained from BioChain (Biochain Institute, Inc., Hayward, CA). Intestinal tissue for RNA preparation from patients diagnosed as having Crohn's disease and ulcerative colitis was obtained from the National Disease Research Interchange (NDRI) (Philadelphia, PA).

5 Astrocytes, lung fibroblasts, dermal fibroblasts, coronary artery smooth muscle cells, small airway epithelium, bronchial epithelium, microvascular dermal endothelial cells, microvascular lung endothelial cells, human pulmonary aortic endothelial cells, human umbilical vein endothelial cells were all purchased from Clonetics (Walkersville, MD) and grown in the media supplied for these cell types by Clonetics. These primary cell types were
10 activated with various cytokines or combinations of cytokines for 6 and/or 12-14 hours, as indicated. The following cytokines were used; IL-1 beta at approximately 1-5 ng/ml, TNF alpha at approximately 5-10 ng/ml, IFN gamma at approximately 20-50 ng/ml, IL-4 at approximately 5-10 ng/ml, IL-9 at approximately 5-10 ng/ml, IL-13 at approximately 5-10 ng/ml. Endothelial cells were sometimes starved for various times by culture in the basal
15 media from Clonetics with 0.1% serum.

Mononuclear cells were prepared from blood of employees at CuraGen Corporation, using Ficoll. LAK cells were prepared from these cells by culture in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco/Life Technologies, Rockville, MD), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes
20 (Gibco) and Interleukin 2 for 4-6 days. Cells were then either activated with 10-20 ng/ml PMA and 1-2 μ g/ml ionomycin, IL-12 at 5-10 ng/ml, IFN gamma at 20-50 ng/ml and IL-18 at 5-10 ng/ml for 6 hours. In some cases, mononuclear cells were cultured for 4-5 days in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco) with
25 PHA (phytohemagglutinin) or PWM (pokeweed mitogen) at approximately 5 μ g/ml. Samples were taken at 24, 48 and 72 hours for RNA preparation. MLR (mixed lymphocyte reaction) samples were obtained by taking blood from two donors, isolating the mononuclear cells using Ficoll and mixing the isolated mononuclear cells 1:1 at a final concentration of approximately 2×10^6 cells/ml in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1
30 mM sodium pyruvate (Gibco), mercaptoethanol (5.5×10^{-5} M) (Gibco), and 10 mM Hepes (Gibco). The MLR was cultured and samples taken at various time points ranging from 1- 7 days for RNA preparation.

Monocytes were isolated from mononuclear cells using CD14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet according to the manufacturer's instructions.

Monocytes were differentiated into dendritic cells by culture in DMEM 5% fetal calf serum (FCS) (Hyclone, Logan, UT), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco), 50 ng/ml GMCSF and 5 ng/ml IL-4 for 5-7 days. Macrophages were prepared by culture of monocytes for 5-7 days in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), 10 mM Hepes (Gibco) and 10% AB Human Serum or MCSF at approximately 50 ng/ml. Monocytes, macrophages and dendritic cells were stimulated for 6 and 12-14 hours with lipopolysaccharide (LPS) at 100 ng/ml. Dendritic cells were also stimulated with anti-CD40 monoclonal antibody (Pharmingen) at 10 μ g/ml for 6 and 12-14 hours.

CD4 lymphocytes, CD8 lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection columns and a Vario Magnet according to the manufacturer's instructions. CD45RA and CD45RO CD4 lymphocytes were isolated by depleting mononuclear cells of CD8, CD56, CD14 and CD19 cells using CD8, CD56, CD14 and CD19 Miltenyi beads and +ve selection. Then CD45RO beads were used to isolate the CD45RO CD4 lymphocytes with the remaining cells being CD45RA CD4 lymphocytes. CD45RA CD4, CD45RO CD4 and CD8 lymphocytes were placed in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco) and plated at 10^6 cells/ml onto Falcon 6 well tissue culture plates that had been coated overnight with 0.5 μ g/ml anti-CD28 (Pharmingen) and 3 μ g/ml anti-CD3 (OKT3, ATCC) in PBS. After 6 and 24 hours, the cells were harvested for RNA preparation. To prepare chronically activated CD8 lymphocytes, we activated the isolated CD8 lymphocytes for 4 days on anti-CD28 and anti-CD3 coated plates and then harvested the cells and expanded them in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco) and IL-2. The expanded CD8 cells were then activated again with plate bound anti-CD3 and anti-CD28 for 4 days and expanded as before. RNA was isolated 6 and 24 hours after the second activation and after 4 days of the second expansion culture. The isolated NK cells were cultured in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco) and IL-2 for 4-6 days before RNA was prepared.

To obtain B cells, tonsils were procured from NDRI. The tonsil was cut up with sterile dissecting scissors and then passed through a sieve. Tonsil cells were then spun down and

resuspended at 10^6 cells/ml in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco). To activate the cells, we used PWM at 5 μ g/ml or anti-CD40 (Pharmingen) at approximately 10 μ g/ml and IL-4 at 5-10 ng/ml. Cells were harvested for RNA preparation at 5 24, 48 and 72 hours.

To prepare the primary and secondary Th1/Th2 and Tr1 cells, six-well Falcon plates were coated overnight with 10 μ g/ml anti-CD28 (Pharmingen) and 2 μ g/ml OKT3 (ATCC), and then washed twice with PBS. Umbilical cord blood CD4 lymphocytes (Poietic Systems, German Town, MD) were cultured at 10^5 - 10^6 cells/ml in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), 10 mM Hepes (Gibco) and IL-2 (4 ng/ml). IL-12 (5 ng/ml) and anti-IL4 (1 μ g/ml) were used to direct to Th1, while IL-4 (5 ng/ml) and anti-IFN gamma (1 μ g/ml) were used to direct to Th2 and IL-10 at 5 ng/ml was used to direct to Tr1. After 4-5 days, the activated Th1, Th2 and Tr1 lymphocytes were washed once in DMEM and expanded for 4-7 15 days in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), 10 mM Hepes (Gibco) and IL-2 (1 ng/ml). Following this, the activated Th1, Th2 and Tr1 lymphocytes were re-stimulated for 5 days with anti-CD28/OKT3 and cytokines as described above, but with the addition of anti-CD95L (1 μ g/ml) to prevent apoptosis. After 4-5 days, the Th1, Th2 and Tr1 lymphocytes 20 were washed and then expanded again with IL-2 for 4-7 days. Activated Th1 and Th2 lymphocytes were maintained in this way for a maximum of three cycles. RNA was prepared from primary and secondary Th1, Th2 and Tr1 after 6 and 24 hours following the second and third activations with plate bound anti-CD3 and anti-CD28 mAbs and 4 days into the second and third expansion cultures in Interleukin 2.

The following leukocyte cells lines were obtained from the ATCC: Ramos, EOL-1, KU-812. EOL cells were further differentiated by culture in 0.1 mM dbcAMP at 5×10^5 cells/ml for 8 days, changing the media every 3 days and adjusting the cell concentration to 5×10^5 cells/ml. For the culture of these cells, we used DMEM or RPMI (as recommended by the ATCC), with the addition of 5% FCS (Hyclone), 100 μ M non essential amino acids 30 (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), 10 mM Hepes (Gibco). RNA was either prepared from resting cells or cells activated with PMA at 10 ng/ml and ionomycin at 1 μ g/ml for 6 and 14 hours. Keratinocyte line CCD106 and an airway epithelial tumor line NCI-H292 were also obtained from the ATCC. Both were cultured in

DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco).

CCD1106 cells were activated for 6 and 14 hours with approximately 5 ng/ml TNF alpha and 1 ng/ml IL-1 beta, while NCI-H292 cells were activated for 6 and 14 hours with the following
5 cytokines: 5 ng/ml IL-4, 5 ng/ml IL-9, 5 ng/ml IL-13 and 25 ng/ml IFN gamma.

For these cell lines and blood cells, RNA was prepared by lysing approximately 10^7 cells/ml using Trizol (Gibco BRL). Briefly, 1/10 volume of bromochloropropane (Molecular Research Corporation) was added to the RNA sample, vortexed and after 10 minutes at room temperature, the tubes were spun at 14,000 rpm in a Sorvall SS34 rotor. The aqueous phase
10 was removed and placed in a 15 ml Falcon Tube. An equal volume of isopropanol was added and left at -20 degrees C overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min in a Sorvall SS34 rotor and washed in 70% ethanol. The pellet was redissolved in 300 μ l of RNase-free water and 35 μ l buffer (Promega) 5 μ l DTT, 7 μ l RNasin and 8 μ l DNase were added. The tube was incubated at 37 degrees C for 30 minutes to remove contaminating
15 genomic DNA, extracted once with phenol chloroform and re-precipitated with 1/10 volume of 3 M sodium acetate and 2 volumes of 100% ethanol. The RNA was spun down and placed in RNase free water. RNA was stored at -80 degrees C.

Methods:

20 The quantitative expression of various clones was assessed using microtiter plates containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ PCR; TAQMAN[®]). RTQ PCR was performed on a Perkin-Elmer Biosystems ABI PRISM[®] 7700 Sequence Detection System. Various
25 collections of samples are assembled on the plates, and referred to as Panel 1 (containing cells and cell lines from normal and cancer sources), Panel 2 (containing samples derived from tissues, in particular from surgical samples, from normal and cancer sources), Panel 3 (containing samples derived from a wide variety of cancer sources) and Panel 3 (containing cells and cell lines from normal cells and cells related to inflammatory conditions).

First, the RNA samples were normalized to constitutively expressed genes such as β -
30 actin and GAPDH. RNA (~50 ng total or ~1 ng polyA+) was converted to cDNA using the TAQMAN[®] Reverse Transcription Reagents Kit (PE Biosystems, Foster City, CA; Catalog No. N808-0234) and random hexamers according to the manufacturer's protocol. Reactions were performed in 20 μ l and incubated for 30 min. at 48[°]C. cDNA (5 μ l) was then transferred to a separate plate for the TAQMAN[®] reaction using β -actin and GAPDH TAQMAN[®]

Assay Reagents (PE Biosystems; Catalog Nos. 4310881E and 4310884E, respectively) and TAQMAN® universal PCR Master Mix (PE Biosystems; Catalog No. 4304447) according to the manufacturer's protocol. Reactions were performed in 25 ul using the following parameters: 2 min. at 50°C; 10 min. at 95°C; 15 sec. at 95°C/1 min. at 60°C (40 cycles).

- 5 Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) using a log scale, with the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT. The percent relative expression is then obtained by taking the reciprocal of this RNA difference and multiplying by 100. The average CT values obtained for β -actin and GAPDH
10 were used to normalize RNA samples. The RNA sample generating the highest CT value required no further diluting, while all other samples were diluted relative to this sample according to their β -actin /GAPDH average CT values.

- Normalized RNA (5 ul) was converted to cDNA and analyzed via TAQMAN® using One Step RT-PCR Master Mix Reagents (PE Biosystems; Catalog No. 4309169) and gene-
15 specific primers according to the manufacturer's instructions. Probes and primers were designed for each assay according to Perkin Elmer Biosystem's *Primer Express* Software package (version I for Apple Computer's Macintosh Power PC) or a similar algorithm using the target sequence as input. Default settings were used for reaction conditions and the following parameters were set before selecting primers: primer concentration = 250 nM,
20 primer melting temperature (T_m) range = 58°-60° C, primer optimal T_m = 59° C, maximum primer difference = 2° C, probe does not have 5' G, probe T_m must be 10° C greater than primer T_m , amplicon size 75 bp to 100 bp. The probes and primers selected (see below) were synthesized by Synthesgen (Houston, TX, USA). Probes were double purified by HPLC to remove uncoupled dye and evaluated by mass spectroscopy to verify coupling of reporter and
25 quencher dyes to the 5' and 3' ends of the probe, respectively. Their final concentrations were: forward and reverse primers, 900 nM each, and probe, 200nM.

The Taqman oligonucleotide set Ag756 for NOV-1, NOV-2, and NOV-2b (*i.e.*, 10132038) include the forward probe and reverse oligomers shown below:

30 **TABLE 36**

Primers	Sequences	TM	ength	Start osition
Forward	5'-GGAGCAGTTCCTCACTTATCG-3' (SEQ ID NO: 47)	59	21	248

Probe	TET-5'-TET-5'- TGATGACCAGACCTCAAGAAACACTCG-3'-TAMRA (SEQ ID NO: 48)	68.6	27	272
Reverse	5'-CAGTTGCCATCTTTGTCTTCAT-3' (SEQ ID NO: 49)	59.2	22	304

The Taqman oligonucleotide set Ag756 for NOV-3a through NOV-3d (*i.e.*, 18552586) include the forward probe and reverse oligomers shown below:

TABLE 37

Primers	Sequences	TM	Length	Start Position
Forward	5'-AATGCTGAGGTCAAGCTAGGT-3' (SEQ ID NO: 50)	58.1	21	121
Probe	TET-5'-CTCCTTCTGAGGCTGACGAGGACCT-3'- TAMRA (SEQ ID NO: 51)	69.3	25	149
Reverse	5'-CATTCTCTGTTCTGGAGGTGAA-3' (SEQ ID NO: 52)	59.3	22	174

5

The Taqman oligonucleotide set Ag⁴756 for NOV-4a, NOV-4b, NOV-4c, NOV-4d, and NOV-4e (*i.e.*, 10093872) include the forward probe and reverse oligomers shown below:

TABLE 38

Primer	Sequences	Length
Forward	5'-GGACTCCTCGGGATGGAAAG-3' (SEQ ID NO: 53)	20
Probe	FAM-5'-CGGCCTTGGTCTCGGAGATCCC-3'- TAMRA (SEQ ID NO: 54)	23
Reverse	5'-CTCCCCTGGTGCTGGAAATT-3' (SEQ ID NO: 55)	20

10 PCR conditions:

Normalized RNA from each tissue and each cell line was spotted in each well of a 96 well PCR plate (Perkin Elmer Biosystems). PCR cocktails including two probes (a probe specific for the target clone and another gene-specific probe multiplexed with the target probe) were set up using 1X TaqManTM PCR Master Mix for the PE Biosystems 7700, with 5 mM
 15 MgCl₂, dNTPs (dA, G, C, U at 1:1:1:2 ratios), 0.25 U/ml AmpliTaq GoldTM (PE Biosystems), and 0.4 U/μl RNase inhibitor, and 0.25 U/μl reverse transcriptase. Reverse transcription was

performed at 48° C for 30 minutes followed by amplification/PCR cycles as follows: 95° C 10 min, then 40 cycles of 95° C for 15 seconds, 60° C for 1 minute.

TABLE 39: NOV-1, NOV-2, NOV-2b Taqman Results

- 5 • In panel 1 of the results, the following abbreviations are used:
- ca. = carcinoma,
 - * = established from metastasis,
 - met = metastasis,
 - 10 s cell var = small cell variant,
 - non-s = non-sm =non-small,
 - squam = squamous,
 - pl. eff = pl effusion = pleural effusion,
 - glio = glioma,
 - 15 astro = astrocytoma, and
 - neuro = neuroblastoma.
- In panel 2 of the results, the following abbreviations are used:
- Cca: Colon Cancer
 - 20 PCa: Prostate Cancer
 - Lca: Lung Cancer
 - RCC: Renal Cell Carcinoma
 - UtCa: Uterine Cancer
 - ThyCa: Thyroid Cancer
 - BrCa: Breast Cancer
 - 25 HCC: Hepatic Cell Carcinoma
 - TCC: Transitional Cell Carcinoma of the bladder
 - OvCa: Ovarian Cancer
 - GaCa: Gastric Cancer

	Panel 1					
	Run 1					
	Run 2		Panel 2		Panel 3	
		g756		ag756		
	ag756	% Rel.		6 %	ag756	
	%Rel.	Expn.		Rel.	%	
Tissue_Name	Expn.		Tissue_Name	Exp	Rel.	
				n.	Expn	
Endothelial cells	0.0	0.0	Normal Colon	78.5	93768_Secondary Th1_anti-CD28/anti-CD3	0
Endothelial cells (treated)	12.2	54.7	CCa 1	1.0	93769_Secondary Th2_anti-CD28/anti-CD3	0
Pancreas	27.6	5.4	CCa 1 Margin	7.9	93770_Secondary Tr1_anti-CD28/anti-CD3	0
Pancreatic ca.CAPAN 2	0.0	0.0	CCa 2	3.7	93573_Secondary Th1_resting day 4-6 in IL-2	0
Adrenal Gland (new lot*)	9.3	29.3	CCa 2 Margin	15.2	93572_Secondary Th2_resting day 4-6 in IL-2	0
Thyroid	8.0	6.5	CCa 3	0.4	93571_Secondary Tr1_resting day 4-6 in IL-2	0

Salivary gland	6.8	19.9	CCa 3 Margin	35.6	93568_primary Th1_anti- CD28/anti-CD3	0
Pituitary gland	3.2	7.8	CCa 4	10.1	93569_primary Th2_anti- CD28/anti-CD3	0
Brain (fetal)	3.4	18.4	CCa 4 Margin	11.6	93570_primary Tr1_anti- CD28/anti-CD3	0
Brain (whole)	6.9	27.4	CCa 5 Metastasis	7.2	93565_primary Th1_resting dy 4-6 in IL-2	0
Brain (amygdala)	2.5	13.8	CCa 5 Margin (Liver)	52.9	93566_primary Th2_resting dy 4-6 in IL-2	0
Brain (cerebellum)	2.0	28.7	CCa 6	2.5	93567_primary Tr1_resting dy 4-6 in IL-2	0
Brain (hippocampus)	3.8	20.9	CCa 6 Margin (Lung)	14.1	93351_CD45RA CD4 lymphocyte_anti- CD28/anti-CD3	0
Brain (thalamus)	3.0	11.0	Normal Prostate	10.0	93352_CD45RO CD4 lymphocyte_anti- CD28/anti-CD3	0
Cerebral Cortex	7.0	61.1	PCa 1	10.7	93251_CD8 Lymphocytes_anti- CD28/anti-CD3	0
Spinal cord	8.6	27.0	PCa 1 Margin	37.6	93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	0
CNS ca.(glio/astro) U87-MG	0.0	0.0	PCa 2	100. 0	93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	0
CNS ca.(glio/astro)U -118-MG	0.2	0.0	PCa 2 Margin	89.5	93354_CD4_none	0
CNS ca.(astro)SW1 783	0.0	0.0	Normal Lung	51.1	93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	0
CNS ca.* (neuro; met)SK-N-AS	0.0	0.0	LCa 1 Metastasis	1.0	93103_LAK cells_resting	0
CNS ca. (astro)SF-539	0.1	0.0	LCa 1 Margin (Muscle)	11.3	93788_LAK cells_IL-2	0
CNS ca. (astro)SNB-75	0.3	0.3	LCa 2	8.5	93787_LAK cells_IL-2+IL- 12	0
CNS ca. (glio)SNB-19	0.1	0.0	LCa 2 Margin	31.6	93789_LAK cells_IL-2+IFN gamma	0
CNS ca. (glio)U251	0.0	0.0	LCa 3	5.8	93790_LAK cells_IL-2+ IL- 18	0
CNS ca. (glio)SF-295	0.0	0.0	LCa 3 Margin	28.3	93104_LAK cells_PMA/Ionomycin and IL-18	0
Heart	28.5	77.9	LCa 4	1.6	93578_NK Cells IL- 2_resting	0
Skeletal Muscle (new lot*)	16.3	15.7	LCa 5	4.2	93109_Mixed Lymphocyte Reaction_Two Way MLR	0
Bone marrow	0.7	0.9	LCa 5 Margin	29.5	93110_Mixed Lymphocyte Reaction_Two Way MLR	0
Thymus	1.1	2.7	Ocular Melanoma Metastasis	15.9	93111_Mixed Lymphocyte Reaction_Two Way MLR	0
Spleen	0.9	2.1	Ocular Melanoma Margin	38.7	93112_Mononuclear Cells (PBMCs)_resting	0

			(Liver)			
Lymph node	3.6	10.2	Melanoma Metastasis	0.0	93113_Mononuclear Cells (PBMCs)_PWM	0
Colorectal	2.2	11.4	Melanoma Margin (Lung)	32.3	93114_Mononuclear Cells (PBMCs)_PHA-L	0
Stomach	11.8	34.4	Normal Kidney	56.3	93249_Ramos (B cell)_none	0
Small intestine	11.7	18.7	RCC 1	71.2	93250_Ramos (B cell)_ionomycin	0
Colon ca.SW480	0.0	0.0	RCC 1 Margin	26.1	93349_B lymphocytes_PWM	0
Colon ca.* (SW480 met)SW620	0.0	0.0	RCC 2	63.7	93350_B lymphocytes_CD40L and IL-4	0
Colon ca.HT29	0.0	0.0	RCC 2 Margin	28.3	92665_EOL-1 (Eosinophil)_dbcAMP differentiated	0
Colon ca.HCT-116	0.0	0.0	RCC 3	37.1	93248_EOL-1 (Eosinophil)_dbcAMP/PmA ionomycin	0
Colon ca.CaCo-2	0.0	0.0	RCC 3 Margin	33.7	93356_Dendritic Cells_none	0
83219 CC Well to Mod Diff (ODO3866)	0.3	1.7	RCC 4	5.7	93355_Dendritic Cells_LPS 100 ng/ml	0
Colon ca.HCC-2998	0.0	0.0	RCC 4 Margin	18.2	93775_Dendritic Cells_anti-CD40	0
Gastric ca.* (liver met) NCI-N87	0.0	0.0	RCC 5	8.5	93774_Monocytes_resting	0
Bladder	16.4	29.3	RCC 5 Margin	5.5	93776_Monocytes_LPS 50 ng/ml	0
Trachea	4.2	12.7	RCC 6	1.0	93581_Macrophages_resting	0
Kidney	5.3	14.3	RCC 6 Margin	18.7	93582_Macrophages_LPS 100 ng/ml	0
Kidney (fetal)	7.8	24.3	RCC 7	6.0	93098_HUVEC (Endothelial)_none	0
Renal ca. 786-0	0.5	2.4	RCC 7 Margin	8.5	93099_HUVEC (Endothelial)_starved	0
Renal ca.A498	0.2	0.0	RCC 8	0.3	93100_HUVEC (Endothelial)_IL-1b	0
Renal ca.RXF 393	6.0	18.6	RCC 8 Margin	14.1	93779_HUVEC (Endothelial)_IFN gamma	0.1
Renal ca.ACHN	15.0	28.7	RCC 9	6.3	93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	0.0
Renal ca.UO-31	1.2	4.2	RCC 9 Margin	19.6	93101_HUVEC (Endothelial)_TNF alpha + IL4	0.0
Renal ca.TK-10	10.3	21.2	Normal Uterus	7.0	93781_HUVEC (Endothelial)_IL-11	0.0
Liver	12.9	48.0	UtCa 1	46.0	93583_Lung Microvascular Endothelial Cells_none	37.1
Liver (fetal)	4.7	17.7	Normal Thyroid	6.1	93584_Lung Microvascular Endothelial Cells_TNFa (4 ng/ml) and IL1b (1 ng/ml)	12.9
Liver ca. (hepatoblast)	0.0	0.0	ThyCa 1	6.1	92662_Microvascular Dermal endothelium_none	81.2

HepG2						
Lung	7.4	25.4	ThyCa 2	0.8	92663_Microvascular Dermal endothelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	38.7
Lung (fetal)	9.6	19.0	ThyCa 2 Margin	22.5	93773_Bronchial epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml) **	0.0
Lung ca. (small cell) LX-1	0.0	0.0	Normal Breast	12.1	93347_Small Airway Epithelium none	0.0
Lung ca. (small cell) NCI-H69	0.0	0.0	BrCa 1	7.5	93348_Small Airway Epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.5
Lung ca. (s.cell var.) SHP-77	0.0	0.0	BrCa 2	4.0	92668_Coronary Artery SMC resting	0.6
Lung ca. (large cell)NCI-H460	0.1	0.0	BrCa 3 Metastasis	15.1	92669_Coronary Artery SMC_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.1
Lung ca. (non- sm. cell) A549	0.2	0.0	BrCa 4 Metastasis	18.4	93107_astrocytes resting	20.0
Lung ca. (non- s.cell) NCI-H23	0.4	2.4	BrCa 5	11.7	93108_astrocytes_TNFa (4 ng/ml) and IL1b (1 ng/ml)	17.0
Lung ca (non- s.cell) HOP-62	1.3	0.8	BrCa 6	3.1	92666_KU-812 (Basophil) resting	0.0
Lung ca. (non- s.cl) NCI-H522	100.0	100.0	BrCa 6 Margin	5.3	92667_KU-812 (Basophil) PMA/ionoycin	0.0
Lung ca. (squam.) SW 900	0.7	0.8	BrCa 7	6.8	93579_CCD1106 (Keratinocytes) none	0.0
Lung ca. (squam.) NCI- H596	0.0	0.0	BrCa 7 Margin	11.7	93580_CCD1106 (Keratinocytes)_TNFa and IFNg **	4.1
Mammary gland	5.0	7.5	Normal Liver	37.1	93791_Liver Cirrhosis	8.1
Breast ca.* (pl. effusion) MCF-7	2.7	12.0	HCC 1	47.0	93792_Lupus Kidney	18.1
Breast ca.* (pl.ef) MDA- MB-231	0.0	0.0	HCC 2	34.2	93577_NCI-H292	1.9
Breast ca.* (pl. effusion) T47D	0.2	0.0	HCC 3	5.2	93358_NCI-H292_IL-4	4.6
Breast ca.BT- 549	0.0	0.0	HCC 4	27.6	93360_NCI-H292_IL-9	0.9
Breast ca. MDA-N	0.0	0.0	HCC 4 Margin	3.6	93359_NCI-H292_IL-13	1.7
Ovary	5.5	18.4	HCC 5	5.3	93357_NCI-H292_IFN gamma	4.6
Ovarian ca.OVCAR-3	11.8	21.2	HCC 5 Margin	15.9	93777_HPAEC -	0.0
Ovarian ca.OVCAR-4	4.6	12.5	Normal Bladder	27.0	93778_HPAEC_IL-1 beta/TNA alpha	0.0
Ovarian ca.OVCAR-5	0.2	0.0	TCC 1	2.1	93254_Normal Human Lung Fibroblast none	0.3
Ovarian ca.OVCAR-8	4.5	21.5	TCC 2	1.1	93253_Normal Human Lung Fibroblast_TNFa (4 ng/ml) and IL-1b (1 ng/ml)	0.8
Ovarian ca.IGROV-1	4.3	5.4	TCC 3	2.1	93257_Normal Human Lung Fibroblast_IL-4	0.5
Ovarian ca.*	50.0	92.7	TCC 3	52.1	93256_Normal Human	0.3

(ascites) SK-OV-3			Margin		Lung Fibroblast_IL-9	
Uterus	7.6	24.2	Normal Ovary	7.7	93255_Normal Human Lung Fibroblast_IL-13	1.7
Placenta	17.0	31.4	OvCa 1	89.5	93258_Normal Human Lung Fibroblast_IFN gamma	10.2
Prostate	5.3	15.5	OvCa 2	45.1	93106_Dermal Fibroblasts CCD1070_resting	0.0
Prostate ca.* (bone met)PC-3	14.7	42.6	OvCa 2 Margin	8.7	93361_Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	0.3
Testis	10.2	13.1	Normal Stomach	25.7	93105_Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	0.0
Melanoma Hs688(A).T	0.0	0.0	Normal Stomach	15.6	93772_dermal fibroblast_IFN gamma	0.8
Melanoma* (met) Hs688(B).T	0.1	0.0	GaCa 1	26.6	93771_dermal fibroblast_IL-4	0.5
MelanomaUAC C-62	0.2	0.0	GaCa 1 Margin	31.0	93259_IBD Colitis 1**	19.3
Melanoma M14	0.0	0.0	GaCa 2	15.4	93260_IBD Colitis 2	6.1
Melanoma LOX IMVI	0.0	0.0	GaCa 2 Margin	5.2	93261_IBD Crohns	3.7
Melanoma* (met)SK-MEL-5	0.1	0.0	GaCa 3	13.7	735010_Colon_normal	26.1
Adipose	2.5	29.9			735019_Lung_none	90.1
					64028-1_Thymus_none	100.0
					64030-1_Kidney_none	16.0

TABLE 40: NOV-3a, NOV-3b, NOV-3c Taqman Results

	Panel 1		Panel 2		Panel 3
Tissue_Name	Ag664 %Rel. Expn.	Tissue_Name	ag664 %Rel. Expn.	Tissue_Name	ag664 %Rel. Expn.
Liver adenocarcinoma	13.6	Normal Colon	70.2	93768_Secondary Th1_anti-CD28/anti-CD3	16.4
Heart (fetal)	6.5	CCa 1	22.7	93769_Secondary Th2_anti-CD28/anti-CD3	12.9
Pancreas	6.4	CCa 1 Margin	9.0	93770_Secondary Tr1_anti-CD28/anti-CD3	18.3
Pancreatic ca. CAPAN 2	1.6	CCa 2	14.0	93573_Secondary Th1_resting day 4-6 in IL-2	22.1
Adrenal gland	10.5	CCa 2 Margin	6.5	93572_Secondary Th2_resting day 4-6 in IL-2	13.1
Thyroid	5.6	CCa 3	42.6	93571_Secondary Tr1_resting day 4-6 in IL-2	23.0
Salivary gland	4.8	CCa 3 Margin	20.2	93568_primary Th1_anti-	11.5

				CD28/anti-CD3	
Pituitary gland	14.3	CCa 4	27.6	93569_primary Th2_anti-CD28/anti-CD3	15.9
Brain (fetal)	27.6	CCa 4 Margin	10.2	93570_primary Tr1_anti-CD28/anti-CD3	16.5
Brain (whole)	22.5	CCa 5 Metastasis	38.4	93565_primary Th1_resting dy 4-6 in IL-2	73.7
Brain (amygdala)	22.7	CCa 5 Margin (Liver)	7.3	93566_primary Th2_resting dy 4-6 in IL-2	47.0
Brain (cerebellum)	13.0	CCa 6	34.4	93567_primary Tr1_resting dy 4-6 in IL-2	26.4
Brain (hippocampus)	100.0	CCa 6 Margin (Lung)	5.9	93351_CD45RA CD4 lymphocyte_anti-CD28/anti-CD3	8.5
Brain (thalamus)	22.4	Normal Prostate	20.7	93352_CD45RO CD4 lymphocyte_anti-CD28/anti-CD3	19.3
Cerebral Cortex	24.3	PCa 1	26.6	93251_CD8 Lymphocytes_anti-CD28/anti-CD3	8.0
Spinal cord	22.7	PCa 1 Margin	32.8	93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	9.9
glio/astro U87-MG	2.8	PCa 2	47.3	93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	6.7
glio/astro U-118-MG	22.7	PCa 2 Margin	36.9	93354_CD4_none	17.4
astro SW1783	5.4	Normal Lung	100.0	93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	20.7
neuro; met SK-N-AS	26.8	LCa 1 Metastasis	12.5	93103_LAK cells_resting	20.5
astro SF-539	12.8	LCa 1 Margin (Muscle)	3.8	93788_LAK cells_IL-2	19.3
astro SNB-75	5.4	LCa 2	24.2	93787_LAK cells_IL-2+IL-12	6.8
glio SNB-19	7.4	LCa 2 Margin	40.9	93789_LAK cells_IL-2+IFN gamma	16.0
glio U251	4.0	LCa 3	13.6	93790_LAK cells_IL-2+ IL-18	24.2
glio SF-295	4.5	LCa 3 Margin	7.8	93104_LAK cells_PMA/ionomycin and IL-18	1.5
Heart	2.4	LCa 4	10.4	93578_NK Cells_IL-2_resting	18.7
Skeletal muscle	0.9	LCa 5	32.3	93109_Mixed Lymphocyte Reaction_Two Way MLR	23.7
Bone marrow	17.0	LCa 5 Margin	12.1	93110_Mixed Lymphocyte Reaction_Two Way MLR	5.8
Thymus	20.3	Ocular Melanoma Metastasis	6.8	93111_Mixed Lymphocyte Reaction_Two Way MLR	10.2
Spleen	25.4	Ocular Melanoma Margin (Liver)	8.0	93112_Mononuclear Cells (PBMCs)_resting	8.6
Lymph node	29.9	Melanoma Metastasis	18.2	93113_Mononuclear Cells (PBMCs)_PWM	24.5
Colorectal	15.9	Melanoma Margin (Lung)	16.4	93114_Mononuclear Cells (PBMCs)_PHA-L	18.6
Stomach	24.8	Normal Kidney	40.9	93249_Ramos (B cell)_none	5.2
Small intestine	14.4	RCC 1	32.8	93250_Ramos (B cell)_ionomycin	17.8
Colon SW480	4.9	RCC 1 Margin	30.6	93349_B lymphocytes_PWM	26.2
Colon SW620(SW480 met)	9.3	RCC 2	63.3	93350_B lymphocytes_CD40L and IL-4	30.6
Colon HT29	6.6	RCC 2 Margin	9.7	92665_EOL-1 (Eosinophil)_dbcAMP differentiated	9.7
Colon HCT-116	3.2	RCC 3	31.2	93248_EOL-1 (Eosinophil)_dbcAMP/PmAionomycin	22.2
Colon CaCo-2	3.7	RCC 3 Margin	18.6	93356_Dendritic Cells_none	12.1
Colon Ca tissue(ODO3866)	18.7	RCC 4	4.5	93355_Dendritic Cells_LPS 100 ng/ml	20.0

Colon HCC-2998	32.5	RCC 4 Margin	12.2	93775_Dendritic Cells_anti-CD40	17.7
Gastric(liver met) NCI-N87	11.0	RCC 5	11.6	93774_Monocytes_resting	22.4
Bladder	6.9	RCC 5 Margin	3.9	93776_Monocytes_LPS 50 ng/ml	2.0
Trachea	35.6	RCC 6	15.8	93581_Macrophages_resting	11.8
Kidney	6.4	RCC 6 Margin	14.6	93582_Macrophages_LPS 100 ng/ml	3.9
Kidney (fetal)	13.7	RCC 7	9.2	93098_HUVEC (Endothelial)_none	6.0
Renal 786-0	0.0	RCC 7 Margin	5.8	93099_HUVEC (Endothelial)_starved	15.0
Renal A498	20.7	RCC 8	20.9	93100_HUVEC (Endothelial)_IL-1b	5.3
Renal RXF 393	1.5	RCC 8 Margin	10.7	93779_HUVEC (Endothelial)_IFN gamma	13.2
Renal ACHN	1.8	RCC 9	23.0	93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	9.0
Renal UO-31	1.6	RCC 9 Margin	21.0	93101_HUVEC (Endothelial)_TNF alpha + IL4	5.3
Renal TK-10	2.3	Normal Uterus	5.5	93781_HUVEC (Endothelial)_IL-11	5.5
Liver	10.5	UtCa 1	31.9	93583_Lung Microvascular Endothelial Cells_none	7.3
Liver (fetal)	21.8	Normal Thyroid	13.8	93584_Lung Microvascular Endothelial Cells_TNFa (4 ng/ml) and IL1b (1 ng/ml)	6.5
Liver (hepatoblast) HepG2	14.1	ThyCa 1	6.3	92662_Microvascular Dermal endothelium_none	8.0
Lung	48.6	ThyCa 2	7.9	92663_Microvascular Dermal endothelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	10.2
Lung (fetal)	24.3	ThyCa 2 Margin	7.0	93773_Bronchial epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml) **	12.2
Lung (small cell) LX-1	4.7	Normal Breast	36.9	93347_Small Airway Epithelium_none	4.9
Lung (small cell) NCI-H69	1.1	BrCa 1	10.7	93348_Small Airway Epithelium_TNFa (4 ng/ml) and IL1b (1 ng/ml)	32.5
Lung (s.cell var.) SHP-77	24.5	BrCa 2	11.2	92668_Coronary Artery SMC_resting	2.4
Lung (large cell) NCI-H460	1.6	BrCa 3 Metastasis	32.8	92669_Coronary Artery SMC_TNFa (4 ng/ml) and IL1b (1 ng/ml)	0.0
Lung (non-sm. cell) A549	1.4	BrCa 4 Metastasis	13.7	93107_astrocytes_resting	4.4
Lung (non-s.cell) NCI-H23	10.7	BrCa 5	19.8	93108_astrocytes_TNFa (4 ng/ml) and IL1b (1 ng/ml)	4.2
Lung (non-s.cell) HOP-62	32.3	BrCa 6	29.1	92666_KU-812 (Basophil)_resting	2.5
Lung (non-s.cl) NCI-H522	1.7	BrCa 6 Margin	17.2	92667_KU-812 (Basophil)_PMA/Ionoycin	7.2
Lung (squamous) SW 900	3.6	BrCa 7	13.9	93579_CCD1106 (Keratinocytes)_none	6.6
Lung (squamous) NCI-H596	0.9	BrCa 7 Margin	25.5	93580_CCD1106 (Keratinocytes)_TNFa and IFNg **	3.0
Mammary gland	27.2	Normal Liver	8.3	93791_Liver Cirrhosis	5.4
Breast (pl.ef) MCF-7	12.4	HCC 1	14.1	93792_Lupus Kidney	2.2
Breast (pl.ef) MDA-MB-231	18.7	HCC 2	14.5	93577_NCI-H292	41.5
Breast (pl.ef) T47D	0.4	HCC 3	7.9	93358_NCI-H292_IL-4	62.4
Breast BT-549	28.9	HCC 4	16.0	93360_NCI-H292_IL-9	53.2
Breast MDA-N	20.6	HCC 4 Margin	19.3	93359_NCI-H292_IL-13	21.3
Ovary	12.2	HCC 5	4.0	93357_NCI-H292_IFN gamma	19.9

Ovarian OVCAR-3	2.1	HCC 5 Margin	2.0	93777_HPAEC -	6.5
Ovarian OVCAR-4	0.5	Normal Bladder	44.4	93778_HPAEC_IL-1 beta/TNA alpha	9.7
Ovarian OVCAR-5	0.6	TCC 1	24.5	93254_Normal Human Lung Fibroblast_none	2.2
Ovarian OVCAR-8	6.5	TCC 2	16.4	93253_Normal Human Lung Fibroblast_TNFa (4 ng/ml) and IL-1b (1 ng/ml)	3.0
Ovarian IGROV-1	3.5	TCC 3	22.7	93257_Normal Human Lung Fibroblast_IL-4	4.0
Ovarian (ascites) SK-OV-3	2.3	TCC 3 Margin	13.4	93256_Normal Human Lung Fibroblast_IL-9	3.2
Uterus	17.2	Normal Ovary	12.7	93255_Normal Human Lung Fibroblast_IL-13	4.8
Placenta	12.9	OvCa 1	23.3	93258_Normal Human Lung Fibroblast_IFN gamma	4.0
Prostate	8.5	OvCa 2	72.2	93106_Dermal Fibroblasts CCD1070_resting	1.5
Prostate (bone met)PC-3	3.3	OvCa 2 Margin	4.1	93361_Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	42.6
Testis	4.1	Normal Stomach	20.2	93105_Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	7.3
Melanoma Hs688(A).T	0.6	Normal Stomach	5.2	93772_dermal fibroblast_IFN gamma	4.3
Melanoma (met) Hs688(B).T	0.5	GaCa 1	8.4	93771_dermal fibroblast_IL-4	10.4
Melanoma UACC-62	1.6	GaCa 1 Margin	15.9	93259_IBD Colitis 1**	3.2
Melanoma M14	0.6	GaCa 2	38.4	93260_IBD Colitis 2	0.0
Melanoma LOX IMVI	1.7	GaCa 2 Margin	4.5	93261_IBD Crohns	0.0
Melanoma (met) SK-MEL-5	6.2	GaCa 3	55.5	735010_Colon_normal	23.0
Adipose	6.0			735019_Lung_none	6.4
				64028-1_Thymus_none	21.2
				64030-1_Kidney_none	100.0

TABLE 41: NOV-4a, NOV-4b, NOV-4c, NOV-4d, and NOV-4e Taqman results

Tissue_Name	Panel 1	Tissue_Name	Panel 2
	ag538 % Rel. expn.		ag538 % Rel. expn.
Adipose	12.6	Normal Colon GENPAK 061003	9.7
Adrenal gland	19.9	83219 CC Well to Mod Diff (ODO3866)	4.3
Bladder	100.0	83220 CC NAT (ODO3866)	3.3
Bone marrow	4.8	83221 CC Gr.2 rectosigmoid (ODO3868)	2.9
Endothelial cells	0.0	83222 CC NAT (ODO3868)	2.1
Endothelial cells (treated)	4.5	83235 CC Mod Diff (ODO3920)	8.0
Liver	9.3	83236 CC NAT (ODO3920)	4.6
Liver (fetal)	4.1	83237 CC Gr.2 ascend colon (ODO3921)	3.4
Spleen	4.4	83238 CC NAT (ODO3921)	2.4
Thymus	2.3	83241 CC from Partial Hepatectomy (ODO4309)	2.8

Thyroid	14.0	83242 Liver NAT (ODO4309)	4.5
Trachea	7.6	87472 Colon mets to lung (OD04451-01)	7.0
Testis	10.4	87473 Lung NAT (OD04451-02)	17.2
Spinal cord	8.7	Normal Prostate Clontech A+ 6546-1	6.2
Salivary gland	13.7	84140 Prostate Cancer (OD04410)	13.0
Brain (amygdala)	0.2	84141 Prostate NAT (OD04410)	100.0
Brain (cerebellum)	0.8	87073 Prostate Cancer (OD04720-01)	20.2
Brain (hippocampus)	1.2	87074 Prostate NAT (OD04720-02)	6.0
Brain (substantia nigra)	7.9	Normal Lung GENPAK 061010	2.7
Brain (thalamus)	1.2	83239 Lung Met to Muscle (ODO4286)	0.5
Cerebral Cortex	1.0	83240 Muscle NAT (ODO4286)	9.8
Brain (whole)	0.4	84136 Lung Malignant Cancer (OD03126)	2.0
Brain (fetal)	0.1	84137 Lung NAT (OD03126)	3.1
CNS ca. (glio/astro) U-118-MG	1.3	84871 Lung Cancer (OD04404)	2.0
CNS ca. (astro)SF-539	0.4	84872 Lung NAT (OD04404)	13.2
CNS ca. (astro) SNB-75	1.0	84875 Lung Cancer (OD04565)	9.8
CNS ca. (astro) SW1783	4.7	85950 Lung Cancer (OD04237-01)	4.2
CNS ca. (glio) U251	0.0	85970 Lung NAT (OD04237-02)	13.3
CNS ca. (glio) SF-295	2.1	83255 Ocular Mel Met to Liver (ODO4310)	0.7
CNS ca. (glio)SNB-19	0.0	83256 Liver NAT (ODO4310)	8.7
CNS ca. (glio/astro)U87-MG	0.0	84139 Melanoma Mets to Lung (OD04321)	1.2
CNS ca.* (neuro; met) SK-N-AS	0.1	84138 Lung NAT (OD04321)	6.0
Small intestine	31.4	Normal Kidney GENPAK 061008	7.5
Colorectal	29.7	83786 Kidney Ca, Nuclear grade 2 (OD04338)	8.8
Colon ca. HT29	0.2	83787 Kidney NAT (OD04338)	16.5
Colon ca.CaCo-2	0.0	83788 Kidney Ca Nuclear grade 1/2 (OD04339)	3.9
Colon ca.HCT-15	0.4	83789 Kidney NAT (OD04339)	6.9
Colon ca.HCT-116	0.0	83790 Kidney Ca, Clear cell type (OD04340)	8.0
Colon ca. HCC-2998	0.8	83791 Kidney NAT (OD04340)	8.8
Colon ca. SW480	0.3	83792 Kidney Ca, Nuclear grade 3 (OD04348)	3.9
Colon ca.* (SW480 met)SW620	0.0	83793 Kidney NAT (OD04348)	13.3
Fetal Skeletal	16.5	87474 Kidney Cancer (OD04622-01)	5.2

Skeletal muscle	20.9	87475 Kidney NAT (OD04622-03)	9.1
Heart	33.9	85973 Kidney Cancer (OD04450-01)	4.4
Stomach	19.8	85974 Kidney NAT (OD04450-03)	11.3
Gastric ca.* (liver met) NCI-N87	2.2	Kidney Cancer Clontech 8120607	2.1
Kidney	15.8	Kidney NAT Clontech 8120608	5.0
Kidney (fetal)	8.1	Kidney Cancer Clontech 8120613	0.1
Renal ca. 786-0	3.0	Kidney NAT Clontech 8120614	3.6
Renal ca. A498	3.9	Kidney Cancer Clontech 9010320	6.5
Renal ca.ACHN	97.3	Kidney NAT Clontech 9010321	5.6
Renal ca.TK-10	0.4	Normal Uterus GENPAK 061018	8.9
Renal ca.UO-31	10.4	Uterus Cancer GENPAK 064011	6.1
Renal ca. RXF 393	6.4	Normal Thyroid Clontech A+ 6570-1**	2.3
Pancreas	13.1	Thyroid Cancer GENPAK 064010	1.0
Pancreatic ca. CAPAN 2	0.1	Thyroid Cancer INVITROGEN A302152	10.2
Ovary	23.8	Thyroid NAT INVITROGEN A302153	6.5
Ovarian ca.IGROV-1	0.0	Normal Breast GENPAK 061019	8.1
Ovarian ca.OVCAR-3	26.6	84877 Breast Cancer (OD04566)	6.0
Ovarian ca.OVCAR-4	1.4	85975 Breast Cancer (OD04590-01)	8.0
Ovarian ca.OVCAR-5	3.4	85976 Breast Cancer Mets (OD04590-03)	7.2
Ovarian ca.OVCAR-8	0.0	87070 Breast Cancer Metastasis (OD04655-05)	2.2
Ovarian ca.* (ascites) SK-OV-3	0.0	GENPAK Breast Cancer 064006	19.2
Prostate	56.3	Breast Cancer Clontech 9100266	4.0
Prostate ca.* (bone met)PC-3	0.0	Breast NAT Clontech 9100265	6.6
Placenta	66.0	Breast Cancer INVITROGEN A209073	4.7
Pituitary gland	4.5	Breast NAT INVITROGEN A2090734	9.0
Uterus	22.4	Normal Liver GENPAK 061009	4.6
		Liver Cancer GENPAK 064003	1.1
		Liver Cancer Research Genetics RNA 1025	4.5
		Liver Cancer Research Genetics RNA 1026	4.6

	Paired Liver Cancer Tissue Research Genetics RNA 6004-T	3.9
	Paired Liver Tissue Research Genetics RNA 6004-N	3.6
	Paired Liver Cancer Tissue Research Genetics RNA 6005-T	5.4
	Paired Liver Tissue Research Genetics RNA 6005-N	5.1
	Normal Bladder GENPAK 061001	10.4
	Bladder Cancer Research Genetics RNA 1023	5.7
	Bladder Cancer INVITROGEN A302173	2.5
	87071 Bladder Cancer (OD04718-01)	4.9
	87072 Bladder Normal Adjacent (OD04718-03)	11.4
	Normal Ovary Res. Gen.	3.8
	Ovarian Cancer GENPAK 064008	19.1
	87492 Ovary Cancer (OD04768-07)	2.1
	87493 Ovary NAT (OD04768-08)	23.8
	Normal Stomach GENPAK 061017	12.3
	NAT Stomach Clontech 9060359	12.2
	Gastric Cancer Clontech 9060395	8.1
	NAT Stomach Clontech 9060394	18.3
	Gastric Cancer Clontech 9060397	7.7
	NAT Stomach Clontech 9060396	8.5
	Gastric Cancer GENPAK 064005	15.4

The Taqman results are summarized in Table 42.

TABLE 42

NOVX	Internal Accession Number	Results
NOV-1	10132038.0.67	Normal adjacent tissue to colon cancer tissue showed a higher expression of the gene as compared to colon cancer tissue itself. The results also demonstrate a similar profile for lung and ocular melanoma.
NOV-2a	10132038.0.139	
NOV-2b	10132038.0.136	
NOV-3a	18552586_EXT1	High level of expression in brain and moderate expression in lung and trachea, suggesting its potential role in diseases involving these tissues. Increased expression in normal colon as compared to colon cancer tissue. Cancerous uterus and ovary tissues exhibited significantly higher expression than their normal counterparts.
NOV-3b	18552586_EXT2	
NOV-3c	18552586_EXT3	
NOV-3d	18552586_EXT4	
NOV-4a	10093872.0.107	Increased expression in normal bladder and moderate expression in prostate, heart, placenta, small intestine, and colorectal cells. Normal adjacent tissue (NAT) of prostate showed maximum expression.
NOV-4b	10093872.1	
NOV-4c	10093872.0.38	
NOV-4d	10093872.2	
NOV-4e	10093872.3	

5

OTHER EMBODIMENTS

While the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

What is claimed is:

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - a) a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23;
 - b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed;
 - c) the amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23;
 - d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; and
 - e) a fragment of any of a) through d).
2. The polypeptide of claim 1 that is a naturally occurring allelic variant of the sequence selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23.
3. The polypeptide of claim 2, wherein the variant is the translation of a single nucleotide polymorphism.
4. The polypeptide of claim 1 that is a variant polypeptide described therein, wherein any amino acid specified in the chosen sequence is changed to provide a conservative substitution.
5. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:
 - a) a mature form of the amino acid sequence given SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23;

- b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed;
 - c) the amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23;
 - d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed;
 - e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 or any variant of said polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed; and
 - f) the complement of any of said nucleic acid molecules.
6. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises the nucleotide sequence of a naturally occurring allelic nucleic acid variant.
7. The nucleic acid molecule of claim 5 that encodes a variant polypeptide, wherein the variant polypeptide has the polypeptide sequence of a naturally occurring polypeptide variant.
8. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises a single nucleotide polymorphism encoding said variant polypeptide.
9. The nucleic acid molecule of claim 5, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of
- a) the nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57;

- b) a nucleotide sequence wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed;
 - c) a nucleic acid fragment of the sequence selected from the group consisting of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57; and
 - d) a nucleic acid fragment wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed.
10. The nucleic acid molecule of claim 5, wherein said nucleic acid molecule hybridizes under stringent conditions to the nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, or a complement of said nucleotide sequence.
11. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises a nucleotide sequence in which any nucleotide specified in the coding sequence of the chosen nucleotide sequence is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides in the chosen coding sequence are so changed, an isolated second polynucleotide that is a complement of the first polynucleotide, or a fragment of any of them.
12. A vector comprising the nucleic acid molecule of claim 11.
13. The vector of claim 12, further comprising a promoter operably linked to said nucleic acid molecule.
14. A cell comprising the vector of claim 12.
15. An antibody that binds immunospecifically to the polypeptide of claim 1.

16. The antibody of claim 15, wherein said antibody is a monoclonal antibody.
17. The antibody of claim 15, wherein the antibody is a humanized antibody.
18. A method for determining the presence or amount of the polypeptide of claim 1 in a sample, the method comprising:
 - (a) providing said sample;
 - (b) introducing said sample to an antibody that binds immunospecifically to the polypeptide; and
 - (c) determining the presence or amount of antibody bound to said polypeptide, thereby determining the presence or amount of polypeptide in said sample.
19. A method for determining the presence or amount of the nucleic acid molecule of claim 5 in a sample, the method comprising:
 - (a) providing said sample;
 - (b) introducing said sample to a probe that binds to said nucleic acid molecule; and
 - (c) determining the presence or amount of said probe bound to said nucleic acid molecule, thereby determining the presence or amount of the nucleic acid molecule in said sample.
20. A method of identifying an agent that binds to the polypeptide of claim 1, the method comprising:
 - (a) introducing said polypeptide to said agent; and
 - (b) determining whether said agent binds to said polypeptide.
21. A method for identifying a potential therapeutic agent for use in treatment of a pathology, wherein the pathology is related to aberrant expression or aberrant physiological interactions of the polypeptide of claim 1, the method comprising:
 - (a) providing a cell expressing the polypeptide of claim 1 and having a property or function ascribable to the polypeptide;
 - (b) contacting the cell with a composition comprising a candidate substance; and
 - (c) determining whether the substance alters the property or function ascribable to the polypeptide;

whereby, if an alteration observed in the presence of the substance is not observed when the cell is contacted with a composition devoid of the substance, the substance is identified as a potential therapeutic agent.

22. A method for modulating the activity of the polypeptide of claim 1, the method comprising introducing a cell sample expressing the polypeptide of said claim with a compound that binds to said polypeptide in an amount sufficient to modulate the activity of the polypeptide.
23. A method of treating or preventing a pathology associated with the polypeptide of claim 1, said method comprising administering the polypeptide of claim 1 to a subject in which such treatment or prevention is desired in an amount sufficient to treat or prevent said pathology in said subject.
24. The method of claim 23, wherein said subject is a human.
25. A method of treating or preventing a pathology associated with the polypeptide of claim 1, said method comprising administering to a subject in which such treatment or prevention is desired a NOVX nucleic acid in an amount sufficient to treat or prevent said pathology in said subject.
26. The method of claim 25, wherein said subject is a human.
27. A method of treating or preventing a pathology associated with the polypeptide of claim 1, said method comprising administering to a subject in which such treatment or prevention is desired a NOVX antibody in an amount sufficient to treat or prevent said pathology in said subject.
28. The method of claim 27, wherein the subject is a human.
29. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.
30. A pharmaceutical composition comprising the nucleic acid molecule of claim 5 and a

pharmaceutically acceptable carrier.

31. A pharmaceutical composition comprising the antibody of claim 15 and a pharmaceutically acceptable carrier.
32. A kit comprising in one or more containers, the pharmaceutical composition of claim 29.
33. A kit comprising in one or more containers, the pharmaceutical composition of claim 30.
34. A kit comprising in one or more containers, the pharmaceutical composition of claim 31.
35. The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease, the disease selected from a pathology associated with the polypeptide of claim 1, wherein said therapeutic is the polypeptide of claim 1.
36. The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease, the disease selected from a pathology associated with the polypeptide of claim 1, wherein said therapeutic is a NOVX nucleic acid.
37. The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease, the disease selected from a pathology associated with the polypeptide of claim 1, wherein said therapeutic is a NOVX antibody.
38. A method for screening for a modulator of activity or of latency or predisposition to a pathology associated with the polypeptide of claim 1, said method comprising:
 - a) administering a test compound to a test animal at increased risk for a pathology associated with the polypeptide of claim 1, wherein said test animal recombinantly expresses the polypeptide of claim 1;
 - b) measuring the activity of said polypeptide in said test animal after administering the compound of step (a); and
 - c) comparing the activity of said protein in said test animal with the activity of

said polypeptide in a control animal not administered said polypeptide, wherein a change in the activity of said polypeptide in said test animal relative to said control animal indicates the test compound is a modulator of latency of, or predisposition to, a pathology associated with the polypeptide of claim 1.

39. The method of claim 38, wherein said test animal is a recombinant test animal that expresses a test protein transgene or expresses said transgene under the control of a promoter at an increased level relative to a wild-type test animal, and wherein said promoter is not the native gene promoter of said transgene.
40. A method for determining the presence of or predisposition to a disease associated with altered levels of the polypeptide of claim 1 in a first mammalian subject, the method comprising:
 - a) measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and
 - b) comparing the amount of said polypeptide in the sample of step (a) to the amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, said disease, wherein an alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to said disease.
41. A method for determining the presence of or predisposition to a disease associated with altered levels of the nucleic acid molecule of claim 5 in a first mammalian subject, the method comprising:
 - a) measuring the amount of the nucleic acid in a sample from the first mammalian subject; and
 - b) comparing the amount of said nucleic acid in the sample of step (a) to the amount of the nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease; wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.

42. A method of treating a pathological state in a mammal, the method comprising administering to the mammal a polypeptide in an amount that is sufficient to alleviate the pathological state, wherein the polypeptide is a polypeptide having an amino acid sequence at least 95% identical to a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 or a biologically active fragment thereof.
43. A method of treating a pathological state in a mammal, the method comprising administering to the mammal the antibody of claim 15 in an amount sufficient to alleviate the pathological state.